

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/00638 A2**

- (51) International Patent Classification<sup>7</sup>: **C07H**
- (21) International Application Number: **PCT/US00/16658**
- (22) International Filing Date: **16 June 2000 (16.06.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**09/342,364** **29 June 1999 (29.06.1999)** **US**
- (71) Applicant: **MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02138 (US).**
- (72) Inventors: **KIRST, Susan, J.; 12 Dana Street, Brookline, MA 02445 (US). HOLTZMAN, Douglas, A.; 821 Centre Street, No. 6, Jamaica Plain, MA 02130 (US). FRASER, Christopher, C.; 52 Grassland Street, Lexington, MA 02421 (US). SHARP, John, D.; 245 Park Avenue, Arlington, MA 02476 (US). BARNES, Thomas, S.; 22 Hanson Street #2, Boston, MA 02118 (US).**
- (74) Agents: **COLBY, Gary, D. et al.; Akin, Gump, Strauss, Hauer & Feld, L.L.P., One Commerce Square, Suite 2200, 2005 Market Street, Philadelphia, PA 19103-7086 (US).**
- (81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- Published:  
— *Without international search report and to be republished upon receipt of that report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES**

(57) Abstract: The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

WO 01/00638 A2

BEST AVAILABLE COPY

(C) 2003 Copyright Derwent Information Ltd.

5                                   **NOVEL GENES ENCODING PROTEINS HAVING**  
**DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES**

**Background of the Invention**

                                  The molecular bases underlying many human and animal  
10   physiological states (e.g., diseased and homeostatic states of various tissues) remain  
                                  unknown. Nonetheless, it is well understood that these states result from  
                                  interactions among the proteins and nucleic acids present in the cells of the relevant  
                                  tissues. In the past, the complexity of biological systems overwhelmed the ability  
15   of practitioners to understand the molecular interactions giving rise to normal and  
                                  abnormal physiological states. More recently, though, the techniques of molecular  
                                  biology, transgenic and null mutant animal production, computational biology,  
                                  pharmacogenomics, and the like have enabled practitioners to discern the role and  
                                  importance of individual genes and proteins in particular physiological states.

                                  Knowledge of the sequences and other properties of genes  
20   (particularly including the portions of genes encoding proteins) and the proteins  
                                  encoded thereby enables the practitioner to design and screen agents which will  
                                  affect, prospectively or retrospectively, the physiological state of an animal tissue in  
                                  a favorable way. Such knowledge also enables the practitioner, by detecting the  
                                  levels of gene expression and protein production, to diagnose the current  
25   physiological state of a tissue or animal and to predict such physiological states in  
                                  the future. This knowledge furthermore enables the practitioner to identify and  
                                  design molecules which bind with the polynucleotides and proteins, *in vitro*, *in*  
                                  *vivo*, or both.

                                  The present invention provides sequence information for  
30   polynucleotides derived from human genes and for proteins encoded thereby, and  
                                  thus enables the practitioner to assess, predict, and affect the physiological state of  
                                  various human tissues.

### Summary of the Invention

The present invention is based, at least in part, on the discovery of a variety of human cDNA molecules which encode proteins which are herein designated INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, 5 TANGO 325, TANGO 331, and TANGO 332. These seven proteins, fragments thereof, derivatives thereof, and variants thereof are collectively referred to herein as the polypeptides of the invention or the proteins of the invention. Nucleic acid molecules encoding polypeptides of the invention are collectively referred to as nucleic acids of the invention.

10 The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are 15 suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid 20 molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

The invention also features nucleic acid molecules which are at least 25 40% (or 50%, 60%, 70%, 80%, 90%, 95%, or 98%) identical to the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151 ("a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151"), or a 30 complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550,

650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) consecutive nucleotide residues of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 50% (or 60%, 70%, 80%, 90%, 95%, or 98%) identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

In preferred embodiments, the nucleic acid molecules have the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, the fragment including at least 8 (10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, or 200) consecutive amino acids of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151.

The invention includes nucleic acid molecules which encode a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC<sup>®</sup> PTA-147, PTA-150, 207230, and PTA-151, wherein the nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleic acid sequence encoding any of SEQ ID NOs: 1, 2, 9, 10, 33, 34,

38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 50%, preferably 60%, 75%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98.

Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 40%, preferably 50%, 75%, 85%, or 95% identical the nucleic acid sequence encoding any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule consisting of the nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92.

Also within the invention are polypeptides which are naturally occurring allelic variants of a polypeptide that includes the amino acid sequence of any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule having the nucleotide

sequence of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, or a complement thereof. In some embodiments, the isolated nucleic acid molecules encode a cytoplasmic, transmembrane, extracellular, or other domain of a polypeptide of the invention. In other embodiments, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention.

Another aspect of the invention provides vectors, e.g., recombinant expression vectors, comprising a nucleic acid molecule of the invention. In another embodiment, the invention provides isolated host cells, e.g., mammalian and non-mammalian cells, containing such a vector or a nucleic acid of the invention. The invention also provides methods for producing a polypeptide of the invention by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector encoding a polypeptide of the invention such that the polypeptide of the invention is produced.

Another aspect of this invention features isolated or recombinant proteins and polypeptides of the invention. Preferred proteins and polypeptides possess at least one biological activity possessed by the corresponding naturally-occurring human polypeptide. An activity, a biological activity, and a functional activity of a polypeptide of the invention refers to an activity exerted by a protein or polypeptide of the invention on a responsive cell as determined *in vivo*, or *in vitro*, according to standard techniques. Such activities can be a direct activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular processes mediated by interaction of the protein with a second protein.

By way of example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof exhibit the ability to affect growth, proliferation, survival, differentiation, and activity of human pancreas, skeletal muscle, heart, brain, placenta, lung, liver, and kidney cells. INTERCEPT 217 modulates cellular binding to one or more mediators, modulates activity and release of one or more pancreatic secreted digestive enzymes, and protects tissue from endogenous digestive enzymes. Thus, INTERCEPT 217 polypeptides, nucleic acids, and

modulators thereof can be used to prevent, diagnose, or treat disorders relating to aberrant endogenous digestive enzyme activity, inappropriate interaction (or non-interaction) of cells with mediators, inappropriate cellular development and proliferation, inappropriate inflammation, and inappropriate immune responses.

- 5 Exemplary disorders for which INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof are useful include immune disorders (e.g., insufficient immune responses and auto-immune disorders), infectious diseases, auto-immune disorders, pancreatic disorders (e.g., pancreatitis and pancreatic carcinoma), disorders related to mal-expression of growth factors, cancers, inflammatory disorders, acute and  
10 chronic traumas, and the like.

- Further by way of example, INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof exhibit the ability to affect growth, proliferation, survival, differentiation, and activity of human fetal cells and spleen cells and of (e.g., bacterial or fungal) cells and viruses which infect humans. Furthermore,  
15 INTERCEPT 297 modulates organization, structure, and function of biological membranes. Thus, INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to affect development and persistence of atherogenesis and arteriosclerosis, for example, or to modulate transmembrane transport processes such as ion transport across neuronal and muscle cell membranes (e.g., ion transport  
20 relating to nerve impulse conduction and muscle contraction). INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, or treat transmembrane transport disorders such as cystic fibrosis, pain, seizure, epilepsy, mental disorders, and the like. Other exemplary disorders for which INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof are  
25 useful include disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections.

- Still further by way of example, TANGO 276 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human heart, placenta, brain, lung, liver, skin,  
30 kidney, pancreas, spleen, and fetal tissues. TANGO 276 guides neuronal growth and development and modulates growth, homeostasis, and regeneration of other epithelial tissues. TANGO 276 is a secreted protein which mediates cellular

interaction with cells, molecules, and structures (e.g., extracellular matrix) in the extracellular environment. TANGO 276 is therefore involved in growth, organization, migration, and adhesion of tissues and the cells which constitute those tissues. Furthermore, TANGO 276 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells. Thus, TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used, for example, to prevent, diagnose, or treat disorders characterized by aberrant organization or development of a tissue or organ, for modulating migration and adhesion of cells (e.g., in disorders such as cancer metastasis, autoimmune disorders, and graft-versus-host disease or in normal or aberrant processes involving angiogenesis, such as tumor growth and persistence), for guiding neural axon development and regeneration, for modulating differentiation of cells of the immune system (e.g., to treat bacterial, fungal, or viral infection or to prevent, diagnose, or treat autoimmune disorders), for modulating cytokine production by cells of the immune system (e.g., to prevent, detect, or treat inflammation and pain), for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.

Yet further by way of example, TANGO 292 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human keratinocytes, including embryonic keratinocytes. TANGO 292, a transmembrane protein, is also involved in binding and uptake of calcium and other metal ions, and in responses of cells which express it to the presence and uptake of such ions. TANGO 292 polypeptides, nucleic acids, and modulators thereof can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 292 protein. These activities include, for example, bone uptake, maintenance, and deposition, formation, maintenance, and repair of cartilage and skin, formation and maintenance of extracellular matrices, movement of cells through extracellular matrices, coagulation and dissolution of blood components, and deposition of materials in and on arterial walls. TANGO 292 is also related to a variety of disorders which involve these activities. Such disorders include, for example,

various bone-related disorders such as osteoporosis, skeletal development disorders, bone fragility, traumatic bone injuries, rickets, osteomalacia, Paget's disease, and other bone disorders, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other disorders of the joints and cartilage, skin disorders such as psoriasis, eczema, scleroderma, and skin tumors (e.g., keratoses, squamous cell carcinomas, malignant melanomas, and Kaposi's sarcomas), iron deficiency anemia, hemophilia, inappropriate blood coagulation, stroke, arteriosclerosis, atherosclerosis, aneurysm, and other disorders related to blood and blood vessels, metastasis and other disorders related to inappropriate movement of cells through extracellular matrices, and the like. TANGO 292 polypeptides, nucleic acids, and modulators thereof can thus be used to prevent, diagnose, and treat one or more of these disorders. TANGO 292 is also involved in skin disorders such as psoriasis, eczema, scleroderma, skin tumors (e.g., keratoses, squamous cell carcinomas, malignant melanomas, and Kaposi's sarcomas), in placental disorders such as placenta previa and *abruptio placentae*, in liver disorders such as cirrhosis of the liver, liver fibrosis, hepatitis, and hepatic cancers, in kidney disorders such as urolithiasis, glomerulonephritis, nephrosis, renal cell carcinomas, and renal failure (both acute and chronic), in lung disorders such as cystic fibrosis, chronic obstructive pulmonary diseases (e.g., emphysema, bronchitis, and bronchiectasis), lung cancers, and asthma, in pancreatic disorders such as diabetes, pancreatitis, pancreatic cancers, and pancreatic insufficiency, in cardiac disorders such as coronary artery disease (and other ischemic heart diseases), arrhythmia, congestive heart failure, endocarditis, and pericarditis, and the like. Thus, TANGO 292 polypeptides, nucleic acids, and modulators thereof can thus be used to prevent, diagnose, and treat one or more of these disorders.

As an additional example, TANGO 325 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human tissues such as vascular endothelium, including aortic endothelium, other heart tissues, placenta, liver, kidney, and pancreas tissues. Thus, TANGO 325 polypeptides, nucleic acids, and modulators thereof can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 325 protein in tissues in which it is expressed. Such

activities include, for example, modulation of cardiac contractility and vasomotor tone, modulation of leukocyte extravasation, sensing physiological signals by the endocrine system, modulating growth, development, maintenance, and regeneration of neurons, and the like. Disorders related to these activities include, by way of  
5 example and not limitation, cardiovascular disorders such as arteriosclerosis, atherosclerosis, coronary artery disease (and other ischemic heart diseases), angina, myocardial infarction, restenotic disorders, hypertension, Buerger's disease, aneurysm, stroke, arrhythmia, congestive heart failure, endocarditis, and pericarditis, placental disorders such as placenta previa and *abruptio placentae*, liver disorders  
10 such as cirrhosis of the liver, liver fibrosis, hepatitis, and hepatic cancers, kidney disorders such as urolithiasis, glomerulonephritis, nephrosis, renal cell carcinomas, and renal failure (both acute and chronic), pancreatic disorders such as diabetes, pancreatitis, pancreatic cancers, and pancreatic insufficiency, neurological system disorders, immune and auto-immune disorders, hyperthyroidism, hypothyroidism,  
15 diabetes, goiter, growth and developmental disorders, and the like.

Further by way of example, TANGO 331 polypeptides, nucleic acids, and modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human fetal, lung, spleen, and thymus cells and tissues. As described herein, TANGO 331 is involved in physiological activities  
20 such as maintenance of epithelia, carcinogenesis, modulation and storage of protein factors and metals, lactation, and infant nutrition. TANGO 331 also modulates cellular binding and uptake of cytokines, growth factors, and metal ions. Thus, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, and treat disorders such as breast cancer, insufficient lactation,  
25 infant nutritional and growth disorders, malnutrition and mineral deficiency disorders, hemochromatosis, inappropriate calcification of body tissues, bone disorders such as osteoporosis, autoimmune disorders, insufficient or inappropriate host responses to infection, acquired immune deficiency syndrome, and the like.

As another example, TANGO 332 polypeptides, nucleic acids, and  
30 modulators thereof modulate growth, proliferation, survival, differentiation, and activity of human brain and other tissues. As described herein, TANGO 332 is involved in modulating establishment and maintenance of neural connections, cell-

to-cell adhesion, tissue and extracellular matrix invasivity, and the like. Thus, TANGO 332 polypeptides, nucleic acids, and modulators thereof can be used to prevent, diagnose, and treat disorders such as brain cancers (e.g., gliomas, astrocytomas, medulloblastomas, ependymomas, Schwannomas, pituitary adenomas, teratomas, and the like), disorders of neural connection establishment or maintenance, impaired cognitive function, dementia, senility, Alzheimer's disease, mental retardation, inflammation, immune and autoimmune responses, and the like.

In one embodiment, a polypeptide of the invention has an amino acid sequence sufficiently identical to an identified domain of a polypeptide of the invention. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.

In one embodiment, the isolated polypeptide of the invention lacks both a transmembrane and a cytoplasmic domain. In another embodiment, the polypeptide lacks both a transmembrane domain and a cytoplasmic domain and is soluble under physiological conditions.

The polypeptides of the present invention, or biologically active portions thereof, can be operably linked to a heterologous amino acid sequence to form fusion proteins. The invention further features antibody substances that specifically bind a polypeptide of the invention such as monoclonal or polyclonal antibodies, antibody fragments, single-chain antibodies, and the like. In addition, the polypeptides of the invention or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers. These antibody substances can be made, for example, by providing the polypeptide of the invention to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.

In another aspect, the present invention provides methods for detecting the presence of the activity or expression of a polypeptide of the invention in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of activity such that the presence of activity is detected in the biological sample.

In another aspect, the invention provides methods for modulating activity of a polypeptide of the invention comprising contacting a cell with an agent that modulates (inhibits or enhances) the activity or expression of a polypeptide of the invention such that activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to a polypeptide of the invention.

In another embodiment, the agent modulates expression of a polypeptide of the invention by modulating transcription, splicing, or translation of an mRNA encoding a polypeptide of the invention. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense with respect to the coding strand of an mRNA encoding a polypeptide of the invention.

The present invention also provides methods to treat a subject having a disorder characterized by aberrant activity of a polypeptide of the invention or aberrant expression of a nucleic acid of the invention by administering an agent which is a modulator of the activity of a polypeptide of the invention or a modulator of the expression of a nucleic acid of the invention to the subject. In one embodiment, the modulator is a protein of the invention. In another embodiment, the modulator is a nucleic acid of the invention. In other embodiments, the modulator is a peptide, peptidomimetic, or other small molecule.

The present invention also provides diagnostic assays for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a polypeptide of the invention, (ii) mis-regulation of a gene encoding a polypeptide of the invention, and (iii) aberrant post-translational modification of a polypeptide of the invention wherein a wild-type form of the gene encodes a polypeptide having the activity of the polypeptide of the invention.

In another aspect, the invention provides a method for identifying a compound that binds to or modulates the activity of a polypeptide of the invention. In general, such methods entail measuring a biological activity of the polypeptide in the presence and absence of a test compound and identifying those compounds which alter the activity of the polypeptide.

The invention also features methods for identifying a compound which modulates the expression of a polypeptide or nucleic acid of the invention by measuring the expression of the polypeptide or nucleic acid in the presence and absence of the compound.

In yet a further aspect, the invention provides substantially purified antibodies or fragments thereof, including non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

In various embodiments, the substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

- (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151;
- (iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a

polypeptide having an amino acid sequence comprising a sequence selected from the group consisting of

- (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;
- 5 (ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151;
- (iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;
- 10 (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- 15 (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

20 The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

In a particularly preferred embodiment, the antibody substance of the invention specifically binds with an extracellular domain of one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, 25 and TANGO 332. Preferably, the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 14-18, 37, 43, 51, 58, 63, 83, or 93.

Any of the antibodies of the invention can be conjugated with a therapeutic moiety or with a detectable substance. Non-limiting examples of 30 detectable substances that can be conjugated with the antibodies of the invention include an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred  
 5   embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

10

#### Brief Description of the Drawings

*Figure 1* comprises Figures 1A through 1M. The nucleotide sequence (SEQ ID NO: 1) of a cDNA encoding the human INTERCEPT 217 protein described herein is listed in Figures 1A through 1E. The open reading frame (ORF; residues 215 to 1579; SEQ ID NO: 2) of the cDNA is indicated by  
 15   nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 3) of human INTERCEPT 217 is listed. Figure 1F is a hydrophilicity plot of human INTERCEPT 217 protein, in which the locations of cysteine residues ("Cys") and potential N-glycosylation sites ("Ngly") are indicated by vertical bars and the predicted extracellular ("out"), intracellular ("ins"), or transmembrane ("TM")  
 20   locations of the protein backbone is indicated by a horizontal bar. An alignment of the amino acid sequences of human INTERCEPT 217 protein ("H"; SEQ ID NO: 3) and porcine ribonuclease inhibitor protein ("P"; SwissProt Accession number P10775; SEQ ID NO: 64) is shown in Figures 1G and 1H, wherein identical amino acid residues are indicated by ":" and similar amino acid residues are indicated by  
 25   ".". These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4). The nucleotide sequence (SEQ ID NO: 92) of an ORF encoding the murine INTERCEPT 217 protein described herein is listed in Figures 1I through 1K. The ORF is indicated by nucleotide triplets, beneath which the  
 30   amino acid sequence (SEQ ID NO: 93) of murine INTERCEPT 217 is listed. Figure 1L is a hydrophilicity plot of murine INTERCEPT 217 protein, in which the locations of cysteine residues ("Cys") and potential N-glycosylation sites ("Ngly")

are indicated by vertical bars and the predicted extracellular ("out"), intracellular ("ins"), or transmembrane ("TM") locations of the protein backbone is indicated by a horizontal bar. An alignment of the amino acid sequences of human INTERCEPT 217 protein ("H"; SEQ ID NO: 3) and murine INTERCEPT 217 protein ("M"; SEQ ID NO: 93) is shown in Figure 1M, wherein identical amino acid residues are indicated by "|" and similar amino acid residues are indicated by ".". These alignments were made using the BESTFIT software (BLOSUM62 scoring matrix, gap opening penalty = 12, frameshift gap penalty = 5, gap extension penalty = 4).

Figure 2 comprises Figures 2A through 2D. The nucleotide sequence (SEQ ID NO: 9) of a cDNA encoding the human INTERCEPT 297 protein described herein is listed in Figures 2A, 2B, and 2C. The open reading frame (ORF; residues 40 to 1152; SEQ ID NO: 10) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 11) of human INTERCEPT 297 is listed. Figure 2D is a hydrophilicity plot of human INTERCEPT 297 protein.

Figure 3 comprises Figures 3A through 3R. The nucleotide sequence (SEQ ID NO: 33) of a cDNA encoding the human TANGO 276 protein described herein is listed in Figures 3A to 3D. The ORF (residues 58 to 786; SEQ ID NO: 34) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 35) of human TANGO 276 is listed. Figure 3E is a hydrophilicity plot of TANGO 276 protein. An alignment of the amino acid sequences of human TANGO 276 protein ("H"; SEQ ID NO: 35) and murine protein M-Sema-F ("M"; SEQ ID NO: 65) is shown in Figures 3F to 3H. In Figures 3I through 3R, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 276 protein ("H"; SEQ ID NO: 33) and the nucleotide sequences of the cDNA encoding murine protein M-Sema-F ("M"; SEQ ID NO: 66) is shown. These alignments were made using the ALIGN software (Myers and Miller (1989) CABIOS, ver. 2.0); pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

Figure 4 comprises Figures 4A through 4M. The nucleotide sequence (SEQ ID NO: 38) of a cDNA encoding the human TANGO 292 protein described herein is listed in Figures 4A to 4C. The ORF (residues 205 to 882; SEQ

ID NO: 39) of the cDNA is indicated by nucleotide triplets, beneath which the amino acid sequence (SEQ ID NO: 40) of human TANGO 292 is listed. Figure 4D is a hydrophilicity plot of human TANGO 292 protein. The nucleotide sequence (SEQ ID NO: 81) of a cDNA encoding the gerbil TANGO 292 protein described  
 5 herein is listed in Figures 4E to 4H. The ORF (residues 89 to 763; SEQ ID NO: 82) of the cDNA is indicated by nucleotide triplets, below which the amino acid sequence (SEQ ID NO: 83) of gerbil TANGO 292 is listed. Figures 4I to 4K are an alignment of the nucleotide sequences of the ORF encoding human TANGO 292 protein ("H"; SEQ ID NO: 38) and the nucleotide sequence of the ORF encoding  
 10 gerbil TANGO 292 protein ("G"; SEQ ID NO: 81), made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), wherein identical nucleotide residues are indicated by "|". Figure 4L is an alignment of the human (H) and gerbil (G) TANGO 292 amino acid sequences, made using the same software and  
 15 parameters, wherein identical amino acid residues are indicated by "|" and similar amino acid residues are indicated by ".". Figure 4M is a hydrophilicity plot of gerbil TANGO 292 protein.

*Figure 5* comprises Figures 5A through 5Mxviii. The nucleotide sequence (SEQ ID NO: 46) of a cDNA encoding the human TANGO 325 protein  
 20 described herein is listed in Figures 5A through 5E. The ORF (residues 135 to 2000; SEQ ID NO: 47) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 48) of human TANGO 325 is listed. Figure 5F is a hydrophilicity plot of TANGO 325 protein. An alignment of the amino acid sequences of TANGO 325 ("325"; SEQ ID NO: 48) and Slit-1 protein  
 25 ("Slit"; SEQ ID NO: 67) protein is shown in Figures 5G to 5L. In Figures 5Mi to 5Mxviii, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 325 protein ("325"; SEQ ID NO: 33) and the nucleotide sequence of the cDNA encoding Slit-1 protein ("Slit"; SEQ ID NO: 68) is shown. This alignment was made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0};  
 30 pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

*Figure 6* comprises Figures 6A through 6J. The nucleotide sequence (SEQ ID NO: 54) of a cDNA encoding the human TANGO 331 protein described

herein is listed in Figures 6A, 6B, and 6C. The ORF (residues 114 to 1172; SEQ ID NO: 55) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 56) of human TANGO 331 is listed. Figure 6D is a hydrophilicity plot of TANGO 331 protein. An alignment of the amino acid sequences of human TANGO 331 protein ("H"; SEQ ID NO: 56) and Chinese hamster protein HT ("C"; SEQ ID NO: 69; GenBank Accession No. U48852) is shown in Figure 6E. In Figures 6F through 6J, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 331 protein ("H"; SEQ ID NO: 54) and the nucleotide sequence of the cDNA encoding Chinese hamster protein HT ("C"; SEQ ID NO: 70) is shown. These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

Figure 7 comprises Figures 7A through 7U. The nucleotide sequence (SEQ ID NO: 59) of a cDNA encoding the human TANGO 332 protein described herein is listed in Figures 7A through 7E. The ORF (residues 173 to 2185; SEQ ID NO: 60) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 61) of human TANGO 332 protein is listed. Figure 7F is a hydrophilicity plot of TANGO 332 protein. An alignment of the amino acid sequences of TANGO 332 protein ("332"; SEQ ID NO: 61) and BEF protein ("BEF"; SEQ ID NO: 71) is shown in Figures 7G and 7H. An alignment of the amino acid sequences of human TANGO 332 protein ("H"; SEQ ID NO: 61) and murine brevidin protein ("M"; SEQ ID NO: 72) is shown in Figures 7I to 7K. In Figures 7L through 7U, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 332 protein ("H"; SEQ ID NO: 60) and the nucleotide sequence of the cDNA encoding murine brevidin protein ("M"; SEQ ID NO: 73) is shown. These alignments were made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4).

30

#### Detailed Description of the Invention

The present invention is based, at least in part, on the discovery of a variety of human cDNA molecules which encode proteins which are herein

designated INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. These proteins exhibit a variety of physiological activities, and are included in a single application for the sake of convenience. It is understood that the allowability or non-allowability of claims directed to one of these proteins has no bearing on the allowability of claims directed to the others. The characteristics of each of these proteins and the cDNAs encoding them are now described separately.

#### INTERCEPT 217

A cDNA clone (designated jthqc035f08) encoding at least a portion of human INTERCEPT 217 protein was isolated from a human prostate cDNA library. The human INTERCEPT 217 protein is predicted by structural analysis to be a transmembrane protein. In addition, cDNA clones (including those designated jtmca047g07, jTmob373b05, and jambd078d12) encoding at least a portion of murine INTERCEPT 217 protein were isolated from murine cDNA libraries.

The full length of the cDNA encoding human INTERCEPT 217 protein (Figure 1; SEQ ID NO: 1) is 2895 nucleotide residues. The ORF of this cDNA, nucleotide residues 215 to 1579 of SEQ ID NO: 1 (i.e., SEQ ID NO: 2), encodes a 455-amino acid transmembrane protein (Figure 1; SEQ ID NO: 3). The murine ORF (Figure 1; SEQ ID NO: 92) comprises at least 962 nucleotide residues. The protein encoded by the murine ORF comprises at least 320 amino acid residues (i.e., SEQ ID NO: 93), and is also a transmembrane protein.

The invention also includes purified human INTERCEPT 217 protein, both in the form of the immature 455 amino acid residue protein (SEQ ID NO: 3) and in the form of the mature, approximately 435 amino acid residue protein (SEQ ID NO: 5). Mature human INTERCEPT 217 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature INTERCEPT 217 protein and cleaving the signal sequence therefrom.

The invention thus includes purified murine INTERCEPT 217 protein, both in the immature form comprising the 320 amino acid residues of SEQ ID NO: 93 and in the mature form comprising the approximately 305 carboxyl

terminal amino acid residues of SEQ ID NO: 93 (i.e., comprising SEQ ID NO: 95).

Mature murine INTERCEPT 217 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature INTERCEPT 217 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human and murine INTERCEPT 217 proteins, the invention includes fragments, derivatives, and variants of these INTERCEPT 217 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as INTERCEPT 217 polypeptides of the invention or INTERCEPT 217 proteins of the invention.

The invention also includes nucleic acid molecules which encode an INTERCEPT 217 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 1, in SEQ ID NO: 92 (i.e., the murine ORF), or in some portion of either of these, such as the portion which encodes mature human INTERCEPT 217 protein, immature human INTERCEPT 217 protein, or a domain of human INTERCEPT 217 protein. These nucleic acids are collectively referred to as INTERCEPT 217 nucleic acids of the invention.

INTERCEPT 217 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. Each of these molecules is included in the invention. As used herein, the term "family" is intended to mean two or more proteins or nucleic acid molecules having a common or similar domain structure and having sufficient amino acid or nucleotide sequence identity as defined herein. Family members can be from either the same or different species. For example, a family can comprise two or more proteins of human origin, or can comprise one or more proteins of human origin and one or more of non-human origin (e.g., the human and murine INTERCEPT 217 proteins described herein).

A common domain present in INTERCEPT 217 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-

bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid  
5 residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a INTERCEPT 217 protein contains a signal sequence corresponding to about amino acid residues 1 to 20 of SEQ ID NO: 3 (SEQ ID NO: 4). The signal  
10 sequence is cleaved during processing of the mature protein.

INTERCEPT 217 proteins can include an extracellular domain. As used herein, an "extracellular domain" refers to a portion of a protein which is localized to the non-cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. The human INTERCEPT 217 protein  
15 extracellular domain is located from about amino acid residue 21 to about amino acid residue 383 of SEQ ID NO: 3 (SEQ ID NO: 6). The murine INTERCEPT 217 protein extracellular domain is located from about amino acid residue 17 to about amino acid residue 213 of SEQ ID NO: 93 (SEQ ID NO: 96).

In addition, INTERCEPT 217 includes a transmembrane domain.  
20 As used herein, a "transmembrane domain" refers to an amino acid sequence which is at least about 20 to 25 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine. In a preferred embodiment, a transmembrane domain contains at least about 15 to 30 amino acid residues,  
25 preferably about 20-25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues. Thus, in one embodiment, an INTERCEPT 217 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 384 to 403 of SEQ ID NO: 3 (SEQ ID NO: 7) or to about amino acid residues 214 to 233 of SEQ  
30 ID NO: 93 (SEQ ID NO: 97).

The present invention includes INTERCEPT 217 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal

cytoplasmic domain. As used herein, a "cytoplasmic domain" refers to a portion of a protein which is localized to the cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. The human INTERCEPT 217 cytoplasmic domain is located from about amino acid residue 404  
5 to amino acid residue 455 of SEQ ID NO: 3 (SEQ ID NO: 8). The murine INTERCEPT 217 cytoplasmic domain is located from about amino acid residue 234 to amino acid residue 320 of SEQ ID NO: 93 (SEQ ID NO: 98).

In one embodiment, the amino acid residues of human INTERCEPT 217 corresponding to SEQ ID NO: 8 are part of an extracellular domain, and the  
10 amino acid residues corresponding to SEQ ID NO: 6 are part of a cytoplasmic domain. In another embodiment, the amino acid residues of murine INTERCEPT 217 corresponding to SEQ ID NO: 98 are part of an extracellular domain, and the amino acid residues corresponding to SEQ ID NO: 96 are part of a cytoplasmic domain.

15 INTERCEPT 217 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables IA (for human INTERCEPT 217) and IB (for murine INTERCEPT 217), as predicted by computerized sequence analysis of INTERCEPT 217 proteins using amino acid sequence comparison software  
20 (comparing the amino acid sequence of INTERCEPT 217 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, or 10 or more of the post-translational modification sites listed in Tables IA and IB.

25

Table IA

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 3	Amino Acid Sequence
N-glycosylation site	107 to 110	NASG
	272 to 275	NCSS
	301 to 304	NTSV
	362 to 365	NQTH
	368 to 371	NVSV
Protein kinase C phosphorylation site	120 to 122	TLR
	192 to 194	SNR
	295 to 297	SLR
Casein kinase II phosphorylation site	199 to 202	SVPE
	440 to 443	TPPD
Tyrosine Kinase Phosphorylation Site	282 to 289	KRPEEHLY
N-myristoylation site	8 to 13	GTLLCM
	19 to 24	GTPDSE
	103 to 108	GVFVNA
	179 to 184	GLSATH
	323 to 328	GSRDGS
	348 to 353	GLFVCL
	390 to 395	GCAVGL
	449 to 454	GQASTS
Leucine zipper pattern	45 to 66	See Fig. 1
Leucine rich repeat amino terminal domain (LLRNT)	33 to 61	See Fig. 1

Table 1A (Continued)

Leucine rich repeat (LRR) Domain	62 to 85	See Fig. 1
	86 to 109	See Fig. 1
	110 to 133	See Fig. 1
	134 to 157	See Fig. 1
	158 to 181	See Fig. 1
	184 to 207	See Fig. 1
Leucine rich repeat carboxyl terminal (LLRCT) domain	219 to 274	See Fig. 1

Table 1B

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 93	Amino Acid Sequence
N-glycosylation site	102 to 105	NCSV
	131 to 134	NTSV
	192 to 195	NQTL
	198 to 201	NVSV
cAMP- and cGMP-dependent protein kinase site	280 to 283	RKAS
Protein kinase C phosphorylation site	125 to 127	SLR
	143 to 145	SPK
	279 to 281	SRK
Casein kinase II phosphorylation site	29 to 32	SIPE
	273 to 276	TPPD
N-myristoylation site	9 to 14	GLGLTR
	178 to 183	GVFVCL
	220 to 225	GCIVGL
	239 to 244	GCCHCC

Table IB (Continued)

Amidation Site	293 to 296	PGKK
Immunoglobulin Domain	14 to 37	See Fig. 1
Leucine rich repeat (LRR) Domain	49 to 104	See Fig. 1
Leucine rich repeat carboxyl terminal (LLRCT) domain	123 to 184	See Fig. 1

Among the domains that occur in INTERCEPT 217 proteins are

5 LRR domains, LRRNT domains, LLRCT domains, and immunoglobulin domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In other embodiments, the protein has at least

10 one of each of the LRR, LRRNT, and LLRCT domains described herein in Tables IA and IB. In other embodiments, the protein has at least one LRRNT domain, at least one LLRCT domain, and a plurality of (e.g., 2, 3, 4, or more) LRR domains.

One or more LRR domains are present in a variety of proteins involved in protein-protein interactions. Such proteins include, for example,

15 proteins involved in signal transduction, cell-to-cell adhesion, cell-to-extracellular matrix adhesion, cell development, DNA repair, RNA processing, and cellular molecular recognition processes. Specialized LRR domains, designated LRR amino terminal (LRRNT) domains and LRR carboxyl terminal (LLRCT) domains often occur near the amino and carboxyl, respectively, ends of a series of LRR

20 domains. Human INTERCEPT 217 protein has eight clustered LRR domains, including (from the amino terminus toward the carboxyl terminus of INTERCEPT 217) an LRRNT domain, six LRR domains, and an LLRCT domain.

The organization of LRR domains in human INTERCEPT 217 protein closely mirrors the organization of LRR domains in human platelet

25 glycoprotein IB alpha chain precursor (GP-IB $\alpha$ ), which also has eight clustered

LRR domains from about amino acid residue 19 to about amino acid residue 281 thereof. The eight LRR domains of GP-IB $\alpha$  include an LRRNT domain at the end of the cluster nearest the amino terminus of GP-IB $\alpha$  and an LRRCT domain at the end of the cluster nearest the carboxyl terminus of GP-IB $\alpha$ . GP-IB $\alpha$  is a membrane-bound protein of human platelets that is involved in binding of von Willebrand's factor and in aggregation of platelets during thrombus formation. Thus, INTERCEPT 217 is involved in both normal and aberrant physiological activities involving blood clotting and thrombus formation. Examples of disorders involving such activities include, for example, stroke, embolism (e.g., cerebral, renal, and pulmonary emboli), hemophilia, restenotic injury, prosthesis-associated thrombogenesis, atherosclerosis, and arteriosclerosis.

INTERCEPT 217 is involved in one or more physiological processes in which these other LRR domain-containing proteins are involved, namely binding of cells with extracellular proteins such as soluble extracellular proteins and cell surface proteins of other cells.

Human INTERCEPT 217 comprises a leucine zipper region at about amino acid residue 45 to about amino acid residue 66 (i.e., 45 LsctglgLqdvpaELpaa tadL 66). Leucine zipper regions are known to be involved in dimerization of proteins. Leucine zipper regions interact with one another, leading to formation of homo- or hetero-dimers between proteins, depending on their identity. The presence in INTERCEPT 217 of a leucine zipper region is a further indication that this protein is involved in protein-protein interactions.

The amino acid sequence of human INTERCEPT 217 protein includes multiple potential proline-rich Src homology 3 (SH3) domain binding sites in the cytoplasmic portion of the protein. SH3 domains mediate specific assembly of protein complexes, presumably by interacting with proline-rich protein domains (Morton and Campbell (1994) *Curr. Biol.* 4:615-617). SH3 domains also mediate interactions between proteins involved in transmembrane signal transduction. Coupling of proteins mediated by SH3 domains has been implicated in a variety of physiological systems, including those involving regulation of cell growth and proliferation, endocytosis, and activation of respiratory burst.

SH3 domains have been described in the art (e.g., Mayer et al. (1988) *Nature* 332:272-275; Musacchio et al. (1992) *FEBS Lett.* 307:55-61; Pawson and Schlessinger (1993) *Curr. Biol.* 3:434-442; Mayer and Baltimore (1993) *Trends Cell Biol.* 3:8-13; Pawson (1993) *Nature* 373:573-580), and occur in a variety of cytoplasmic proteins, including several (e.g., protein tyrosine kinases) involved in transmembrane signal transduction. Among the proteins in which one or more SH3 domains occur are protein tyrosine kinases such as those of the Src, Abl, Bkt, Csk and ZAP70 families, mammalian phosphatidylinositol-specific phospholipases C-gamma-1 and -2, mammalian phosphatidylinositol 3-kinase regulatory p85 subunit, mammalian Ras GTPase-activating protein (GAP), proteins which mediate binding of guanine nucleotide exchange factors and growth factor receptors (e.g., vertebrate GRB2, *Caenorhabditis elegans* sem-5, and *Drosophila* DRK proteins), mammalian Vav oncoprotein, guanidine nucleotide releasing factors of the CDC 25 family (e.g., yeast CDC25, yeast SCD25, and fission yeast ste6 proteins), MAGUK proteins (e.g., mammalian tight junction protein ZO-1, vertebrate erythrocyte membrane protein p55, *C. elegans* protein lin-2, rat protein CASK, and mammalian synaptic proteins SAP90/PSD-95, CHAPSYN-110/PSD-93, SAP97/DLG1, and SAP102), proteins which interact with vertebrate receptor protein tyrosine kinases (e.g., mammalian cytoplasmic protein Nck and oncoprotein Crk), chicken Src substrate p80/85 protein (cortactin), human hemopoietic lineage cell specific protein Hs1, mammalian dihydropyridine-sensitive L-type calcium channel beta subunit, human myasthenic syndrome antigen B (MSYB), mammalian neutrophil cytosolic activators of NADPH oxidase (e.g., p47 {NCF-1}, p67 {NCF-2}, and *C. elegans* protein B0303.7), myosin heavy chains (MYO3) from amoebae, from slime molds, and from yeast, vertebrate and *Drosophila* spectrin and fodrin alpha chain proteins, human amphiphysin, yeast actin-binding proteins ABP1 and SLA3, yeast protein BEM1, fission yeast protein scd2 (ral3), yeast BEM1-binding proteins BOI2 (BEB1) and BOB1 (BOI1), yeast fusion protein FUS1, yeast protein RSV167, yeast protein SSU81, yeast hypothetical proteins YAR014c, YFR024c, YHL002w, YHR016c, YJL020C, and YHR114w, hypothetical fission yeast protein SpAC12C2.05c, and *C. elegans* hypothetical protein F42H10.3. Of these proteins, multiple SH3 domains occur in vertebrate GRB2 protein, *C. elegans* sem-5 protein,

*Drosophila* DRK protein, oncoprotein Crk, mammalian neutrophil cytosolic activators of NADPH oxidase p47 and p67, yeast protein BEM1, fission yeast protein scd2, yeast hypothetical protein YHR114w, mammalian cytoplasmic protein Nck, *C. elegans* neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1. Of these proteins, three or more SH3 domains occur in mammalian cytoplasmic protein Nck, *C. elegans* neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1. The presence of SH3 domain binding sites in INTERCEPT 217 indicates that INTERCEPT 217 interacts with one or more of these and other SH3 domain-containing proteins and is thus involved in physiological processes in which one or more of these or other SH3 domain-containing proteins are involved.

Human INTERCEPT 217 exhibits amino acid sequence similarity to porcine ribonuclease inhibitor, a protein which binds with high affinity to pancreatic ribonucleases and inhibits their activity. INTERCEPT 217 thus is involved with similar physiological processes in humans. An alignment of the amino acid sequences of human INTERCEPT 217 and porcine ribonuclease inhibitor protein (SwissProt Accession number P10775) is shown in Figure 1G. In this alignment (made using the ALIGN software (Myers and Miller (1989) CABIOS, ver. 2.0); pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 20.5% identical. An alignment of human (SEQ ID NO: 3) and murine INTERCEPT 217 amino acid sequences (SEQ ID NO: 93; made using BESTFIT software, BLOSUM62 scoring matrix, gap opening penalty = 12, frameshift gap penalty = 5, gap extension penalty = 4). In this alignment, the human and murine amino acid sequences are 71.3% identical in the overlapping region. Alignment of human and murine INTERCEPT 217 ORFs indicated 79.9% nucleotide sequence identity in the overlapping region.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human INTERCEPT 217 protein includes an approximately 20 (i.e., 18, 19, 20, 21, or 22) amino acid residue signal peptide (amino acid residues 1 to 20 of SEQ ID NO: 3; SEQ ID NO: 4) preceding the mature INTERCEPT 217 protein (i.e., approximately amino acid residues 21 to 455 of SEQ ID NO: 3; SEQ ID NO: 5). In one embodiment, human INTERCEPT

217 protein includes an extracellular domain (amino acid residues 21 to 383 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 384 to 403 of SEQ ID NO: 3; SEQ ID NO: 7); and a cytoplasmic domain (amino acid residues 404 to 455 of SEQ ID NO: 3; SEQ ID NO: 8). In an alternative  
 5 embodiment, human INTERCEPT 217 protein includes a cytoplasmic domain (amino acid residues 21 to 383 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 384 to 403 of SEQ ID NO: 3; SEQ ID NO: 7); and an extracellular domain (amino acid residues 404 to 455 of SEQ ID NO: 3; SEQ ID NO: 8).

10 The SIGNALP program predicted that murine INTERCEPT 217 protein includes an approximately 15 (i.e., 13, 14, 15, 16, or 17) amino acid residue signal peptide (amino acid residues 1 to 16 of SEQ ID NO: 93; SEQ ID NO: 94) preceding the mature INTERCEPT 217 protein (i.e., approximately amino acid residues 16 to 320 of SEQ ID NO: 93; SEQ ID NO: 95). In one embodiment,  
 15 murine INTERCEPT 217 protein includes an extracellular domain (amino acid residues 16 to 213 of SEQ ID NO: 93; SEQ ID NO: 96); a transmembrane domain (amino acid residues 214 to 233 of SEQ ID NO: 93; SEQ ID NO: 97); and a cytoplasmic domain (amino acid residues 234 to 320 of SEQ ID NO: 93; SEQ ID NO: 98). In an alternative embodiment, murine INTERCEPT 217 protein includes  
 20 a cytoplasmic domain (amino acid residues 16 to 213 of SEQ ID NO: 93; SEQ ID NO: 96); a transmembrane domain (amino acid residues 214 to 233 of SEQ ID NO: 93; SEQ ID NO: 97); and an extracellular domain (amino acid residues 234 to 320 of SEQ ID NO: 93; SEQ ID NO: 98).

Figure 1F depicts a hydrophilicity plot of human INTERCEPT 217  
 25 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 20 of SEQ ID NO: 3 is the signal sequence of human INTERCEPT 217 (SEQ ID NO: 4). The hydrophobic region which corresponds to amino acid residues 384 to 403 of SEQ  
 30 ID NO: 3 is the transmembrane domain of human INTERCEPT 217 (SEQ ID NO: 7). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective

immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human INTERCEPT 217 protein from about amino acid residue 355 to about amino acid residue 380 appears to be located at or near the surface of the protein, while the region from about amino acid residue 190 to about amino acid residue 210 appears not to be located at or near the surface. Figure 1L depicts a hydrophilicity plot of murine INTERCEPT 217 protein.

The predicted molecular weight of human INTERCEPT 217 protein without modification and prior to cleavage of the signal sequence is about 49.8 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 217 protein without modification and after cleavage of the signal sequence is about 47.4 kilodaltons.

The predicted molecular weight of murine INTERCEPT 217 protein, without modification and prior to cleavage of the signal sequence is about 35.5 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 217 protein without modification and after cleavage of the signal sequence is about 33.8 kilodaltons.

Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding INTERCEPT 217 is expressed in two forms, one having an apparent approximate size of about 6 kilobases and another having an apparent approximate size of about 3 kilobases (i.e., corresponding to the size of the INTERCEPT 217 cDNA). These experiments indicated that INTERCEPT 217 is expressed in the tissues listed in Table II, wherein "++" indicates strong expression, "+" indicates lower expression, and "+/-" indicates still lower expression.

Table II

Animal	Tissue	Relative Level of Expression
Human	pancreas	++
	skeletal muscle	+
	heart	+/-
	brain	+/-
	placenta	+/-
	lung	+/-
	liver	+/-
	kidney	+/-

An assay to detect possible secretion of INTERCEPT 217 protein was negative. This assay was performed as follows. About  $8 \times 10^5$  293T cells were  
 5 incubated at 37°C in wells containing growth medium (Dulbecco's modified Eagle's medium {DMEM} supplemented with 10% fetal bovine serum) under a 5% (v/v) CO<sub>2</sub>, 95% air atmosphere to about 60-70% confluence. The cells were then transfected using a standard transfection mixture comprising 2 micrograms of DNA and 10 microliters of LIPOFECTAMINE™ (GIBCO/BRL Catalog no. 18342-012)  
 10 per well. The transfection mixture was maintained for about 5 hours, and then replaced with fresh growth medium and maintained in an air atmosphere. Each well was gently rinsed twice with DMEM which did not contain methionine or cysteine (DMEM-MC; ICN Catalog no. 16-424-54). About 1 milliliter of DMEM-MC and about 50 microcuries of TRANS-<sup>35</sup>S™ reagent (ICN Catalog no. 51006) were added  
 15 to each well. The wells were maintained under the 5% CO<sub>2</sub> atmosphere described above and incubated at 37°C for a selected period. Following incubation, 150 microliters of conditioned medium was removed, centrifuged to remove floating cells and debris, and combined with 150 microliters of 2× SDS sample buffer. The sample was boiled at 100°C for 5 minutes, and about 40 microliters of sample was  
 20 loaded onto a NOVEX™ 4-20% (w/v) SDS-containing polyacrylamide gel. Following electrophoresis, the gel was stained for protein and dried according to the

NOVEX™ procedure. The dried gel was exposed to radiation-sensitive film in order to detect the position of secreted proteins.

Biological function of INTERCEPT 217 proteins, nucleic acids encoding  
5 them, and modulators of these molecules

INTERCEPT 217 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that INTERCEPT 217 is expressed in pancreas, skeletal muscle, heart, brain, placenta, lung, liver, and kidney  
10 tissue, INTERCEPT 217 protein is involved in one or more biological processes which occur in these tissues. In particular, INTERCEPT 217 is involved in modulating binding of cells of one or more of these tissues with proteins of other cells or with secreted proteins which occur in the extracellular environment of one or more of these tissues. INTERCEPT 217 is especially implicated in disorders of  
15 skeletal muscle (e.g., protection of skeletal muscle cells during ischemia and in bruised tissue), and more especially those involving the pancreas (e.g., diabetes, pancreatitis, and the like).

Structural similarity of human INTERCEPT 217 protein with human GP-IB $\alpha$  indicates that INTERCEPT 217 is involved in binding extracellular  
20 proteins and other ligands. INTERCEPT 217 protein is involved in binding of proteins which induce release of pancreatic digestive enzymes (e.g., amylases, lipases, proteases, and nucleases) from pancreatic cells, and in disorders associated with insufficient or inappropriate release of such enzymes. INTERCEPT 217 protein is also involved in binding of secreted pancreatic digestive enzymes in  
25 pancreatic tissue, thereby protecting pancreatic tissue from autodigestion. Thus, INTERCEPT 217 protein is involved in disorders such as diabetes, pancreatitis, and pancreatic carcinoma which involve acute and chronic autodigestive damage to pancreatic tissues. Homology of INTERCEPT 217 protein with porcine ribonuclease inhibitor protein is a further indication of this involvement.

30 The presence of LRR domains in human INTERCEPT 217 protein and detection of its expression in a variety of tissues indicate that the tissue protective functions of INTERCEPT 217 are not limited to pancreatic tissues, but

are involved in protection of other tissues as well (e.g., skeletal muscle, heart, brain, placenta, lung, liver, prostate, and kidney tissues). INTERCEPT 217 is therefore involved in protection of these (and likely other tissues) from the effects of inflammation, autoimmunity, infection, and acute and chronic traumas.

5                    Presence in INTERCEPT 217 protein of multiple SH3 domain binding sites indicates that INTERCEPT 217 protein interacts with one or more SH3 domain-containing proteins. Thus, INTERCEPT 217 protein mediates binding of proteins (i.e., binding of proteins to INTERCEPT 217 and to one another to form protein complexes) in cells in which it is expressed. INTERCEPT 217 is also  
10 involved in transduction of signals between the exterior environment of cells (i.e., including from other cells) and the interior of cells in which it is expressed. INTERCEPT 217 mediates regulation of cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with which INTERCEPT 217 interacts.

15                    INTERCEPT 217-related molecules can be used to modulate one or more of the activities in which INTERCEPT 217 is involved and can also be used to prevent, diagnose, or treat one or more of the disorders in which INTERCEPT 217 is involved.

                    INTERCEPT 217 polypeptides, nucleic acids, and modulators  
20 thereof, can, for example, be used to treat pancreatic disorders, such as pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and  
25 gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

                    In another example, INTERCEPT 217 polypeptides, nucleic acids,  
30 and modulators thereof, can be used to treat disorders of skeletal muscle, such as muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy,

facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies (e.g., dermatomyositis and polymyositis), myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (e.g., phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmityl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because INTERCEPT 217 exhibits expression in heart tissue, INTERCEPT 217 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders (e.g., ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection, toxins, or drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain. INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used

to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous  
5 abortion. INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids,  
10 and modulators thereof, can be used to treat pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's  
15 syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors (e.g., bronchogenic carcinoma, bronchioloalveolar  
20 carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, INTERCEPT 217 polypeptides, nucleic acids,  
25 and modulators thereof, can be used to treat cardiovascular disorders, such as ischemic heart disease (e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease), hypertensive heart disease, pulmonary heart disease, valvular heart disease (e.g., rheumatic fever and rheumatic heart disease, endocarditis, mitral valve prolapse, and aortic valve stenosis), congenital heart  
30 disease (e.g., valvular and vascular obstructive lesions, atrial or ventricular septal defect, and patent ductus arteriosus), and myocardial disease (e.g., myocarditis, congestive cardiomyopathy, and hypertrophic cardiomyopathy). INTERCEPT 217

polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In yet another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Najjar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis), hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis), cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In still another example, INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). INTERCEPT 217 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

INTERCEPT 297

A cDNA clone (designated jthsa085g01) encoding at least a portion of human INTERCEPT 297 protein was isolated from a human fetal spleen cDNA library. The human INTERCEPT 297 protein is predicted by structural analysis to be a transmembrane protein.

The full length of the cDNA encoding human INTERCEPT 297 protein (Figure 2; SEQ ID NO: 9) is 1518 nucleotide residues. The ORF of this cDNA, nucleotide residues 40 to 1152 of SEQ ID NO: 9 (i.e., SEQ ID NO: 10), encodes a 371-amino acid transmembrane protein (Figure 2; SEQ ID NO: 11).

The invention thus includes purified human INTERCEPT 297 protein, both in the form of a 371 amino acid residue protein (SEQ ID NO: 11) in which the 'signal sequence' (i.e., the portion of INTERCEPT 297 protein corresponding to amino acid residues 1 to 18) described in this section is not cleaved and in the form of a 353 amino acid residue protein (SEQ ID NO: 13) in which the 'signal sequence' is cleaved. Human INTERCEPT 297 protein can exist with or without the signal sequence polypeptide at the amino terminus thereof. It is likely that the 'signal sequence' is not cleaved, but is instead a transmembrane domain of the protein.

In addition to full length human INTERCEPT 297 proteins, the invention includes fragments, derivatives, and variants of these INTERCEPT 297 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as INTERCEPT 297 polypeptides of the invention or INTERCEPT 297 proteins of the invention.

The invention also includes nucleic acid molecules which encode an INTERCEPT 297 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 9 or some portion thereof, such as the portion which encodes mature INTERCEPT 297 protein, immature INTERCEPT 297 protein, or a domain of INTERCEPT 297 protein. These nucleic acids are collectively referred to as INTERCEPT 297 nucleic acids of the invention.

INTERCEPT 297 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.

A common domain present in INTERCEPT 297 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a INTERCEPT 297 protein contains a signal sequence corresponding to about amino acid residues 1 to 18 of SEQ ID NO: 11 (SEQ ID NO: 12). The signal sequence can be cleaved during processing of the mature protein, but it is likely that amino acid residues 1 to 18 of SEQ ID NO: 11 represent a (non-cleaved) transmembrane region of the protein.

INTERCEPT 297 proteins can include one or more extracellular domains. In one embodiment of the human INTERCEPT 297 protein, extracellular domains are located from about amino acid residues 19 to 47, from about amino acid residues 110 to 118, from about amino acid residues 162 to 175, from about amino acid residues 234 to 260, and from about amino acid residues 313 to 319 of SEQ ID NO: 11 (SEQ ID NOs: 14-18, respectively). In an alternative embodiment, extracellular domains are located from about amino acid residue 69 to 88, from about amino acid residue 138 to 144, from about amino acid residue 193 to 215, from about amino acid residue 284 to 292, and from about amino acid residue 337 to 371 of SEQ ID NO: 11 (SEQ ID NOs: 28-32, respectively).

In addition, INTERCEPT 297 includes one or more transmembrane domains. In one embodiment, a INTERCEPT 297 protein of the invention contains transmembrane domains corresponding to about amino acid residues 48 to 68, about amino acid residues 89 to 109, about amino acid residues 119 to 137, about amino

acid residues 145 to 161, about amino acid residues 176 to 192, about amino acid residues 216 to 233, about amino acid residues 261 to 283, about amino acid residues 293 to 312, and about amino acid residues 320 to 336 of SEQ ID NO: 11 (SEQ ID NOs: 19-27, respectively). As indicated above, it is likely that the 'signal  
5 sequence' of INTERCEPT 297 is an additional (and non-cleaved) transmembrane region.

The present invention includes INTERCEPT 297 proteins having one or more cytoplasmic domains. In one embodiment of the human INTERCEPT  
297 protein, cytoplasmic domains are located from about amino acid residue 69 to  
10 88, from about amino acid residue 138 to 144, from about amino acid residue 193 to 215, from about amino acid residue 284 to 292, and from about amino acid residue 337 to 371 of SEQ ID NO: 11 (SEQ ID NOs: 28-32, respectively). In an alternative embodiment, cytoplasmic domains are located from about amino acid residues 19 to  
15 47, from about amino acid residues 110 to 118, from about amino acid residues 162 to 175, from about amino acid residues 234 to 260, and from about amino acid residues 313 to 319 of SEQ ID NO: 11 (SEQ ID NOs: 14-18, respectively).

INTERCEPT 297 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table III, as predicted by computerized sequence analysis  
20 of INTERCEPT 297 proteins using amino acid sequence comparison software (comparing the amino acid sequence of INTERCEPT 297 with the information in the PROSITE database (rel. 12.2; Feb, 1995) and the Hidden Markov Models database (Rel. PFAM 3.3)). In certain embodiments, a protein of the invention has  
25 at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table III.

Table III

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 11	Amino Acid Sequence
N-glycosylation site	110 to 113	NMTS
	269 to 272	NISS
Protein kinase C phosphorylation site	24 to 26	SAK
	290 to 292	TTR
	297 to 299	SLR
Casein kinase II phosphorylation site	78 to 81	SSVD
	165 to 168	SKHD
	245 to 248	TLED
	354 to 357	SEQE
N-myristoylation site	18 to 23	GSINTL
	35 to 40	GCGGSK
	53 to 58	GMFLGE
	74 to 79	GQSDSS
	147 to 152	GILATI
	236 to 241	GSFSGN
	268 to 273	GNISSI
	280 to 285	GISVTK
Amidation site	136 to 139	LGRR
DUF6 domain	44 to 171	See Fig. 2

Among the domains that occur in INTERCEPT 297 protein is a DUF6 domain. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to this DUF6 domain.

The DUF6 domain is a transmembrane domain that is highly conserved among eukaryote, prokaryote, and archae kingdoms. This high degree of domain sequence conservation indicates that proteins of the class which includes INTERCEPT 297 are involved in fundamental membrane physiology of living cells. INTERCEPT 297 protein is therefore involved in disorders which are associated with aberrant membrane function including, for example, disorders involving abnormal membrane fluidity, disorders involving aberrant transmembrane transport, disorders involving abnormal membrane organization, disorders involving abnormal membrane synthesis, disorders involving aberrant cell division, and the like.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human INTERCEPT 297 protein includes an approximately 18 (i.e., 16, 17, 18, 19, or 20) amino acid residue signal peptide (amino acid residues 1 to 18 of SEQ ID NO: 11; SEQ ID NO: 12) preceding the mature INTERCEPT 297 protein (i.e., approximately amino acid residues 19 to 371 of SEQ ID NO: 11; SEQ ID NO: 13). In one embodiment, human INTERCEPT 297 protein includes about five extracellular domains (amino acid residues 19 to 47, 110 to 118, 162 to 175, 234 to 260, and 313 to 319 of SEQ ID NO: 11); about nine transmembrane domains (amino acid residues 48 to 68, 89 to 109, 119 to 137, 145 to 161, 176 to 192, 216 to 233, 261 to 283, 293 to 312, and 320 to 326 of SEQ ID NO: 11); and about five cytoplasmic domains (amino acid residues 69 to 88, 138 to 144, 193 to 215, 284 to 292, and 337 to 371 of SEQ ID NO: 11). In an alternative embodiment, human INTERCEPT 297 protein includes about five cytoplasmic domains (amino acid residues 19 to 47, 110 to 118, 162 to 175, 234 to 260, and 313 to 319 of SEQ ID NO: 11); about nine transmembrane domains (amino acid residues 48 to 68, 89 to 109, 119 to 137, 145 to 161, 176 to 192, 216 to 233, 261 to 283, 293 to 312, and 320 to 326 of SEQ ID NO: 11); and about five extracellular domains (amino acid residues 69 to 88, 138 to 144, 193 to 215, 284 to 292, and 337 to 371 of SEQ ID NO: 11).

Figure 2D depicts a hydrophilicity plot of human INTERCEPT 297 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. Hydrophobic

region corresponding to the signal sequence and the transmembrane domains are observed in this figure. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.

- 5 For example, the region of human INTERCEPT 297 protein from about amino acid residue 165 to about amino acid residue 175 appears to be located at or near the surface of the protein.

- The predicted molecular weight of human INTERCEPT 297 protein without modification and prior to cleavage of the signal sequence is about 40.2  
10 kilodaltons. The predicted molecular weight of the mature human INTERCEPT 297 protein without modification and after cleavage of the signal sequence is about 38.2 kilodaltons.

Biological function of INTERCEPT 297 proteins, nucleic acids encoding  
15 them, and modulators of these molecules

- INTERCEPT 297 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that INTERCEPT 297 is expressed in human fetal spleen, INTERCEPT 297 protein is involved in one or  
20 more biological processes which occur in fetal and spleen tissues. In particular, INTERCEPT 297 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, spleen and fetal cells of the animal in which it is normally expressed. Thus, INTERCEPT 297 has a role in disorders which affect these cells and their growth, proliferation, survival,  
25 differentiation, and activity (e.g., hematologic and immune disorders). Expression of INTERCEPT 297 in an animal is also involved in modulating growth, proliferation, survival, differentiation, and activity of cells and viruses which are foreign to the host (i.e., bacterial, fungal, and viral infections).

- INTERCEPT 297 bears amino acid sequence similarity to  
30 *Caenorhabditis elegans* protein C2G12.12, and therefore exhibits one or more activities analogous to that protein.

INTERCEPT 297 nucleic acids, proteins, and modulators thereof can be used to modulate the proliferation, differentiation, or function of cells of the spleen (e.g., cells of the splenic connective tissue, splenic smooth muscle cells, and endothelial cells of the splenic blood vessels). INTERCEPT 297 nucleic acids, proteins, and modulators thereof can also be used to modulate the proliferation, differentiation, and function of cells that are processed within the spleen (e.g., regenerated or phagocytized within the spleen, erythrocytes, B and T lymphocytes, and macrophages). Thus, INTERCEPT 297 nucleic acids, proteins, and modulators thereof can be used to treat disorders of the spleen (including disorders of the fetal spleen). Examples of splenic disorders include, splenic lymphoma, splenomegaly, and phagocytotic disorders (e.g., those in which macrophage engulfment of bacteria and viruses in the bloodstream is inhibited). INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Structural analysis of INTERCEPT 297 and the presence of a DUF6 domain therein indicate that INTERCEPT 297 is involved in disorders which affect membrane structure and function. INTERCEPT 297 can be used to affect development and persistence of disorders involving inappropriate membrane structure and function, such as atherogenesis, arteriosclerosis, and various transmembrane transport disorders. Other exemplary disorders for which INTERCEPT 297 is useful include disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections. INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The structure of INTERCEPT 297 is analogous to the structures of integral membrane proteins responsible for transmembrane transport of molecules such as sugars, ions, and the like. INTERCEPT 297 is thus involved in one or more transmembrane transport-related disorders such as cystic fibrosis, nerve conduction disorders (e.g., pain and loss or failure of sensation), muscle contraction disorders (e.g., cardiac insufficiency), metal ion uptake disorders (e.g., hemochromatosis), and the like. INTERCEPT 297 polypeptides, nucleic acids, and modulators thereof

can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

### TANGO 276

5 A cDNA clone (designated jthsa006e01) encoding at least a portion of human TANGO 276 protein was isolated from a human fetal spleen cDNA library. The human TANGO 276 protein is predicted by structural analysis to be a secreted protein.

The full length of the cDNA encoding human TANGO 276 protein  
10 (Figure 3; SEQ ID NO: 33) is 2811 nucleotide residues. The ORF of this cDNA, nucleotide residues 58 to 786 of SEQ ID NO: 33 (i.e., SEQ ID NO: 34), encodes a 243-amino acid secreted protein (Figure 3; SEQ ID NO: 35).

The invention thus includes purified human TANGO 276 protein, both in the form of the immature 243 amino acid residue protein (SEQ ID NO: 35)  
15 and in the form of the mature, approximately 223 amino acid residue protein (SEQ ID NO: 37). Mature human TANGO 276 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 276 protein and cleaving the signal sequence therefrom.

20 In addition to full length mature and immature human TANGO 276 proteins, the invention includes fragments, derivatives, and variants of these TANGO 276 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 276 polypeptides of the invention or TANGO 276 proteins of the invention.

25 The invention also includes nucleic acid molecules which encode a TANGO 276 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 33 or some portion thereof, such as the portion which encodes mature TANGO 276 protein, immature TANGO 276 protein, or a domain of TANGO 276 protein. These nucleic  
30 acids are collectively referred to as TANGO 276 nucleic acids of the invention.

TANGO 276 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional

features, as indicated by the conservation of amino acid sequence between human TANGO 276 protein and the murine protein designated M-Sema-F (see Inagaki et al. (1995) *FEBS Lett.* 370:269-272), as shown in Figures 3F to 3H.

A common domain present in TANGO 276 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 276 protein contains a signal sequence corresponding to about amino acid residues 1 to 20 of SEQ ID NO: 35 (SEQ ID NO: 36). The signal sequence is cleaved during processing of the mature protein.

TANGO 276 proteins can exist in a secreted form, such as a mature protein having the amino acid sequence of amino acid residues 21 to 243 of SEQ ID NO: 35 (SEQ ID NO: 37).

TANGO 276 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IV, as predicted by computerized sequence analysis of TANGO 276 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 276 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, or all 8 of the post-translational modification sites listed in Table IV.

Table IV

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 35	Amino Acid Sequence
N-glycosylation site	106 to 109	NQTE
	121 to 124	NASH
cAMP- or cGMP-dependent protein kinase phosphorylation site	43 to 46	RRFS
Protein kinase C phosphorylation site	194 to 196	SLK
Casein kinase II phosphorylation site	34 to 37	SSGE
	57 to 60	TLTE
N-myristoylation site	16 to 21	GLGIGA
	68 to 73	GAREAL
Sema domain	53 to 141	See Fig. 3

A Sema domain occurs in human TANGO 276 protein. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to this Sema domain.

Sema domains occur in semaphorin proteins. Semaphorins are a large family of secreted and transmembrane proteins, some of which function as repellent signals during neural axon guidance. The Sema domain and a variety of semaphorin proteins in which it occurs are described, for example, in Winberg et al. (1998 *Cell* 95:903-916). Sema domains also occur in human hepatocyte growth factor receptor (SwissProt Accession no. P08581) and the similar neuronal and epithelial transmembrane receptor protein (SwissProt Accession no. P51805). The presence of a Sema domain in human TANGO 276 protein indicates that TANGO 276 is involved in one or more physiological processes in which the semaphorins

are involved, has biological activity in common with one or more of the semaphorins, or both.

Human TANGO 276 protein exhibits considerable sequence similarity to murine M-Sema F protein (GenBank Accession no. S79463), as indicated herein in Figures 3F to 3H. Figures 3F to 3H depict an alignment of the amino acid sequences of human TANGO 276 protein (SEQ ID NO: 35) and murine M-Sema F protein (SEQ ID NO: 65). In this alignment (pam120.mat scoring matrix, gap opening penalty = 12, gap extension penalty = 4), the amino acid sequences of the proteins are 76.1% identical. Figures 3I through 3R depict an alignment of the nucleotide sequences of cDNA encoding human TANGO 276 protein (SEQ ID NOs: 33) and murine cDNA encoding M-Sema F protein (SEQ ID NO: 66). In this alignment (pam120.mat scoring matrix, gap opening penalty = 12, gap extension penalty = 4), the nucleic acid sequences of the cDNAs are 79.7% identical. Thus, TANGO 276 is related to murine M-Sema F and shares functional similarities to that protein.

It is known that semaphorins are bi-functional, capable of functioning either as attractive axonal guidance proteins or as repellent axonal guidance proteins (Wong et al. (1997) *Development* 124:3597-3607). Furthermore, semaphorins bind with neuronal cell surface proteins designated plexins, which are expressed on both neuronal cells and cells of the immune system (Comeau et al. (1998) *Immunity* 8:473-482; Jin and Strittmatter (1997) *J. Neurosci.* 17:6256-6263).

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 276 protein includes an approximately 20 (i.e., 18, 19, 20, 21, or 22) amino acid signal peptide (amino acid residues 1 to 20 of SEQ ID NO: 35; SEQ ID NO: 36) preceding the mature TANGO 276 protein (i.e., approximately amino acid residues 21 to 243 of SEQ ID NO: 34; SEQ ID NO: 37). Human TANGO 276 protein is a secreted protein.

Figure 3E depicts a hydrophilicity plot of human TANGO 276 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to about amino acid residues 1 to 20 of SEQ

ID NO: 35 is the signal sequence of human TANGO 276. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 276 protein from about amino acid residue 90 to about amino acid residue 105 appears to be located at or near the surface of the protein, while the region from about amino acid residue 170 to about amino acid residue 180 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 276 protein without modification and prior to cleavage of the signal sequence is about 27.1 kilodaltons. The predicted molecular weight of the mature human TANGO 276 protein without modification and after cleavage of the signal sequence is about 24.8 kilodaltons.

Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding TANGO 276 is expressed in the tissues listed in Table V, wherein "++" indicates a greater level of expression and "+" indicates a lower level of expression.

Table V

Animal	Tissue	Relative Level of Expression
Human	heart	++
	placenta	++
	brain	+
	lung	+
	liver	+
	skin	+
	kidney	+
	pancreas	+

Biological function of TANGO 276 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 276 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally  
5 not expressed. Based on the observation that TANGO 276 is expressed in human heart and placenta tissues, to a lesser extent in brain, lung, liver, skin, kidney, and pancreas tissues, and in fetal spleen tissue, TANGO 276 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO  
10 276 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, heart, placenta, spleen, brain, lung, liver, skin, kidney, and pancreas cells of the animal in which it is normally expressed. Thus, TANGO 276 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity.

Because TANGO 276 exhibits expression in the heart, TANGO 276  
15 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 276 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent,  
20 or alleviate one or more of these disorders.

In another example, TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous  
25 abortion. TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 276 polypeptides, nucleic acids, or modulators thereof, can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection,  
30 toxins, or drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive

encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain. TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to

5 prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 276 polypeptides, nucleic acids, and modulators thereof can be associated with pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial

10 asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's

15 granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors (e.g., bronchogenic carcinoma, bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

20 In another example, TANGO 276 polypeptides, nucleic acids, and modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Najjar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and

25 thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or

30 more of these disorders.

Exemplary skin disorders with which TANGO 276 can be associated include, by way of example, psoriasis, infections, wounds (and healing of wounds),

inflammation, dermatitis, acne, benign and malignant dermatological tumors, and the like. TANGO 276 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to prognosticate, diagnose, treat, and inhibit one or more of these disorders.

- 5 In another example, TANGO 276 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus
- 10 erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced
- 15 tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and
- 20 nephroblastoma). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

- Pancreatic disorders in which TANGO 276 can be involved include pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis),
- 25 pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma).
- 30 TANGO 276 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The presence of the Sema domain in TANGO 276 indicates that this protein is involved in development of neuronal and epithelial tissues and also functions as a repellant protein which guides axonal development. TANGO 276 modulates nerve growth and regeneration and also modulates growth and  
5 regeneration of other epithelial tissues. TANGO 276 is thus involved in a variety of neuronal disorder including, but not limited to, one or more of seizure, epilepsy, (regeneration of) neuronal damage, pain (including, for example, migraine, headache, and other chronic pain), infections of the central nervous system, multiple sclerosis, sleep disorders, psychological disorders, nerve root disorders, and the  
10 like. Presence of a Sema domain in TANGO 276 further indicates that TANGO 276 has one or more physiological roles in common with other proteins (e.g., secreted and transmembrane semaphorins, collapsins, neuropilins, plexins, and the like) in which the Sema domain occurs. Thus, TANGO 276 is implicated in development, maintenance, and regeneration of neuronal connections and networks,  
15 in modulating differentiation of cells of the immune system, in modulating cytokine production by cells of the immune system, in modulating reactivity of cells of the immune system toward cytokines, in modulating initiation and persistence of an inflammatory response, and in modulating proliferation of epithelial cells. Sema domain-containing proteins have also been implicated in development and  
20 progression of small cell lung cancer, in normal brain development, and immune system regulation. This indicates that TANGO 276 is also involved in one or more of these processes and in disorders relating to these processes (e.g., small cell lung cancer, brain development disorders, and immune and auto-immune disorders). TANGO 276 polypeptides, nucleic acids, and modulators thereof can be used to  
25 prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

The observation that TANGO 276 shares identity with the murine semaphorin protein designated M-Sema F suggests that TANGO 276 has activity identical or analogous to the activity of this protein. These observations indicate that TANGO 276 modulates growth, proliferation, survival, differentiation, and  
30 activity of neuronal cells. Thus, TANGO 276 protein is useful, for example, for modulating and guiding neural axon development and for modulating establishment and maintenance of neuronal networks.

### TANGO 292

A cDNA clone (designated jthkf040b11) encoding at least a portion of human TANGO 292 protein was isolated from a human normal embryonic keratinocyte cDNA library. A corresponding gerbil cDNA clone (designated jtiba040e12) was also isolated, and encoded at least a portion of gerbil TANGO 292 protein. The human and TANGO 292 proteins are predicted by structural analysis to be transmembrane proteins.

The full length of the cDNA encoding human TANGO 292 protein (Figure 4; SEQ ID NO: 38) is 2498 nucleotide residues. The ORF of this cDNA, nucleotide residues 205 to 882 of SEQ ID NO: 38 (i.e., SEQ ID NO: 39), encodes a 226-amino acid residue transmembrane protein (Figure 4; SEQ ID NO: 40). The full length of the cDNA encoding gerbil TANGO 292 protein (Figure 4; SEQ ID NO: 81) is 2002 nucleotide residues. The ORF of this cDNA, nucleotide residues 89 to 763 of SEQ ID NO: 81 (i.e., SEQ ID NO: 82), encodes a 225-amino acid transmembrane protein (Figure 4; SEQ ID NO: 83).

The invention thus includes purified human TANGO 292 protein, both in the form of the immature 226 amino acid residue protein (SEQ ID NO: 40) and in the form of the mature, approximately 209 amino acid residue protein (SEQ ID NO: 42). The invention also includes purified gerbil TANGO 292 protein, both in the form of the immature 225-amino acid residue (SEQ ID NO: 83) protein and in the form of the mature, approximately 208-amino acid residue protein (SEQ ID NO: 85). Mature human or gerbil TANGO 292 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 292 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human and gerbil TANGO 292 proteins, the invention includes fragments, derivatives, and variants of these TANGO 292 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 292 polypeptides of the invention or TANGO 292 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 292 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 38 or 81 or some portion thereof, such as the portion which encodes mature human or gerbil  
5 TANGO 292 protein, immature human or gerbil TANGO 292 protein, or a domain of human or gerbil TANGO 292 protein. These nucleic acids are collectively referred to as TANGO 292 nucleic acids of the invention.

TANGO 292 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional  
10 features. This family includes, for example, human and gerbil TANGO 292 proteins and nucleic acid molecules described herein.

A common domain present in TANGO 292 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-  
15 bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more  
20 preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 292 protein contains a signal sequence corresponding to about amino acid residues 1 to 17 of SEQ ID NO: 40 (SEQ ID NO: 41) or to about amino acid residues 1 to 17 of SEQ ID NO: 83 (SEQ ID NO: 84). The signal  
25 sequence is cleaved during processing of the mature protein.

TANGO 292 proteins can include an extracellular domain. The human TANGO 292 protein extracellular domain is located from about amino acid residue 18 to about amino acid residue 113 of SEQ ID NO: 40 (SEQ ID NO: 43). The gerbil TANGO 292 protein extracellular domain includes at least about amino  
30 acid residues 18 to 112 of SEQ ID NO: 83 (SEQ ID NO: 86).

In addition, TANGO 292 include a transmembrane domain. In one embodiment, a human TANGO 292 protein contains a transmembrane domain

corresponding to about amino acid residues 114 to 138 of SEQ ID NO: 40 (SEQ ID NO: 44). Gerbil TANGO 292 protein includes a transmembrane domain corresponding to about amino acid residues 113 to 137 of SEQ ID NO: 83 (SEQ ID NO: 87).

5           The present invention includes TANGO 292 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. The human TANGO 292 cytoplasmic domain is located from about amino acid residue 139 to amino acid residue 226 of SEQ ID NO: 40 (SEQ ID NO: 45). The gerbil TANGO 292 cytoplasmic domain is located from about  
10 amino acid residue 138 to amino acid residue 225 of SEQ ID NO: 83 (SEQ ID NO: 88).

TANGO 292 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VIa as predicted by computerized sequence analysis of  
15 human TANGO 292 protein, or in Table VIb as predicted by computerized sequence analysis of gerbil TANGO 292 protein, using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 292 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of  
20 the invention has at least 1, 2, 4, 6, or all of the post-translational modification sites listed in Table VIa or in Table VIb.

Table VIa

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 40	Amino Acid Sequence
cAMP- or cGMP-dependent protein kinase phosphorylation site	197 to 200	RKHS
Protein kinase C phosphorylation site	37 to 39	TSK
	97 to 99	SAK
	102 to 104	TTK
	196 to 198	TRK
Casein kinase II phosphorylation site	37 to 40	TSKE
	103 to 106	TKSD
	180 to 183	SVED
N-myristoylation site	116 to 121	GLLTGL
Vitamin K-dependent carboxylation domain	56 to 98	See Fig. 4

Table VIb

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 83	Amino Acid Sequence
cAMP- or cGMP-dependent protein kinase phosphorylation site	196 to 199	RKHS
Protein kinase C phosphorylation site	23 to 25	SLK
	37 to 39	SKK
	96 to 98	SVK
	101 to 103	TTR
	155 to 157	TRR
	195 to 197	TRK

Table VIb (Continued)

Casein kinase II phosphorylation site	74 to 77	SYEE
	102 to 105	TRSD
	155 to 157	THEE
	195 to 197	SSSE
N-myristoylation site	33 to 38	GVFASK
	115 to 120	GLLTGL
Vitamin K-dependent carboxylation domain	55 to 92	See Fig. 4

Among the domains that occur in TANGO 292 protein is a vitamin K-dependent carboxylation domain. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to this vitamin K-dependent carboxylation domain.

The vitamin K-dependent carboxylation domain has the following consensus sequence, wherein standard single-letter amino acid codes are used and 'X' refers to any amino acid residue.

$-X_{12}-E-X_3-E-X-C-X_6-(D \text{ or } E \text{ or } N)-X-(L \text{ or } I \text{ or } V \text{ or } M \text{ or } F \text{ or } Y)-X_6-(F \text{ or } Y \text{ or } W)-$

Glutamic acid residues within this consensus region are potential vitamin K-dependent carboxylation sites. Human TANGO 292 has 9 glutamic acid residues in the vitamin K-dependent carboxylation domain located from about amino acid residue 56 to 98 of SEQ ID NO: 40, namely at amino acid residues 58, 66, 68, 71, 72, 77, 78, 81, and 86 of SEQ ID NO: 40, and gerbil TANGO 292 has 10 glutamic acid residues in the vitamin K-dependent carboxylation domain located from about amino acid residue 55 to 92 of SEQ ID NO: 83, namely at amino acid residues 57, 65, 67, 70, 71, 76, 77, 80, 86, and 87 of SEQ ID NO: 83. In one embodiment, the protein of the invention is carboxylated at one or more of these glutamic acid residues. In some proteins in which a vitamin K-dependent carboxylation domain

occurs, many of the glutamic acid residues which occur from the amino terminus of the protein through the conserved aromatic residue at the carboxyl terminal end of the domain are carboxylated. Human TANGO 292 has 13 glutamic acid residues in the region from the amino terminus of (both the immature and mature forms of) the protein and the tryptophan residue at amino acid residue 93 of SEQ ID NO: 40, and also has another glutamic acid residue at position 95 of SEQ ID NO: 40 which can also be carboxylated. In addition, human TANGO 292 protein has four sets of paired (i.e., adjacent) glutamic acid residues, at residues 33-34, 40-41, 71-72, and 77-78 and a pair of glutamic acid residues (66 and 68) which are separated by a single residue. Similarly, gerbil TANGO 292 has 12 glutamic acid residues in the region from the amino terminus of (both the immature and mature forms of) the protein and the tryptophan residue at amino acid residue 92 of SEQ ID NO: 83, and also has another glutamic acid residue at position 94 of SEQ ID NO: 83 which can also be carboxylated. In addition, gerbil TANGO 292 protein has three sets of glutamic acid residues, at residues 70-71, 76-77, and 86-87, and a pair of glutamic acid residues (65 and 67) which are separated by a single residue. The protein of the invention includes proteins which are carboxylated at one or more of the individual or paired glutamic acid residues.

TANGO 292, like other vitamin K-dependent carboxylation domain-containing proteins, is involved in binding, uptake, and response to metal cations such as calcium, to proteins, and to small molecules. Other proteins in which a vitamin K-dependent carboxylation domain occurs include, for example, osteocalcin (bone-Gla protein), matrix Gla protein, various plasma proteins such as prothrombin, coagulation factors VII, IX, and X, proline rich Gla domain-containing proteins PRGP1 and PRGP2, and proteins C, S, and Z. Thus, TANGO 292 is involved in physiological processes in which one or more of these other vitamin K-dependent carboxylation domain-containing proteins is involved.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 292 protein includes an approximately 17 (i.e., 15, 16, 17, 18, or 19) amino acid residue signal peptide (amino acid residues 1 to 17 of SEQ ID NO: 40; SEQ ID NO: 41) preceding the mature TANGO 292 protein (i.e., approximately amino acid residues 18 to 226

of SEQ ID NO: 40; SEQ ID NO: 42). In one embodiment, human TANGO 292 protein includes an extracellular domain (amino acid residues 18 to 113 of SEQ ID NO: 40; SEQ ID NO: 43); a transmembrane domain (amino acid residues 114 to 138 of SEQ ID NO: 40; SEQ ID NO: 44); and a cytoplasmic domain (amino acid residues 139 to 225 of SEQ ID NO: 40; SEQ ID NO: 45). In an alternative embodiment, human TANGO 292 protein includes a cytoplasmic domain (amino acid residues 18 to 113 of SEQ ID NO: 40; SEQ ID NO: 43); a transmembrane domain (amino acid residues 114 to 138 of SEQ ID NO: 40; SEQ ID NO: 44); and an extracellular domain (amino acid residues 139 to 225 of SEQ ID NO: 40; SEQ ID NO: 45).

The SignalP program predicted that gerbil TANGO 292 protein includes an approximately 17 (i.e., 15, 16, 17, 18, or 19) amino acid residue amino acid signal peptide (amino acid residues 1 to 17 of SEQ ID NO: 83; SEQ ID NO: 84) preceding the mature TANGO 292 protein (i.e., approximately amino acid residues 18 to 225 of SEQ ID NO: 83; SEQ ID NO: 85). In one embodiment, gerbil TANGO 292 protein includes an extracellular domain (amino acid residues 18 to 112 of SEQ ID NO: 83; SEQ ID NO: 86); a transmembrane domain (amino acid residues 113 to 137 of SEQ ID NO: 83; SEQ ID NO: 87); and a cytoplasmic domain (amino acid residues 138 to 225 of SEQ ID NO: 83; SEQ ID NO: 88). In an alternative embodiment, gerbil TANGO 292 protein includes a cytoplasmic domain (amino acid residues 18 to 112 of SEQ ID NO: 83; SEQ ID NO: 86); a transmembrane domain (amino acid residues 113 to 137 of SEQ ID NO: 83; SEQ ID NO: 87); and an extracellular domain (amino acid residues 138 to 225 of SEQ ID NO: 83; SEQ ID NO: 88).

Figure 4E depicts a hydrophilicity plot of human TANGO 292 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 17 of SEQ ID NO: 40 is the signal sequence of human TANGO 292. The hydrophobic region which corresponds to amino acid residues 114 to 138 of SEQ ID NO: 40 is the transmembrane domain of human TANGO 292. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a

protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 292 protein from about amino acid residue 90 to about amino acid residue 110 appears to be located at or near the surface of the protein, while the region from about amino acid residue  
5 190 to about amino acid residue 195 appears not to be located at or near the surface.

Figure 4M depicts a hydrophilicity plot of gerbil TANGO 292 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 17 of SEQ ID  
10 NO: 83 is the signal sequence of gerbil TANGO 292. The hydrophobic region which corresponds to amino acid residues 113 to 137 of SEQ ID NO: 40 is the transmembrane domain of gerbil TANGO 292. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a  
15 hydrophobic regions. For example, the region of gerbil TANGO 292 protein from about amino acid residue 90 to about amino acid residue 110 appears to be located at or near the surface of the protein.

An alignment of the human (H) and gerbil (G) ORF sequences encoding TANGO 292 protein is shown in Figures 4I-4K. This alignment was  
20 made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), and indicates about 64.1% identity between these two cDNA sequences. An alignment of the amino acid sequences of gerbil (G) and human (H) TANGO 292 proteins is shown in Figure 4L. In this alignment (made using the ALIGN software  
25 {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are about 77.7% identical and about 80% similar.

The predicted molecular weight of human TANGO 292 protein without modification and prior to cleavage of the signal sequence is about 25.4  
30 kilodaltons. The predicted molecular weight of the mature human TANGO 292 protein without modification and after cleavage of the signal sequence is about 23.6 kilodaltons. The predicted molecular weight of gerbil TANGO 292 protein without

modification and prior to cleavage of the signal sequence is about 25.4 kilodaltons. The predicted molecular weight of the mature human TANGO 292 protein without modification and after cleavage of the signal sequence is about 23.5 kilodaltons.

- Northern analysis experiments indicated that human mRNA
- 5 corresponding to the cDNA encoding TANGO 292 is expressed in the tissues listed in Table VIc, wherein "++" indicates strong expression, "+" indicates lower expression, "+/-" indicates still lower expression, and "-" indicates that expression could not be detected in the corresponding tissue.

Table VIc

Animal	Tissue	Relative Level of Expression
Human	placenta	++
	liver	++
	kidney	++
	lung	+
	pancreas	+
	heart	+/-
	brain	-
	skeletal muscle	-

10

Biological function of TANGO 292 proteins, nucleic acids encoding them, and modulators of these molecules

- TANGO 292 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally
- 15 not expressed. Based on the observation that TANGO 292 is expressed in human embryonic keratinocytes, and in placenta, liver, kidney, lung, pancreas, and heart tissues, TANGO 292 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 292 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited
- 20 to, keratinocytes and cells with which keratinocytes interact in the animal in which TANGO 292 is normally expressed. TANGO 292 is also involved in modulating growth, proliferation, survival, differentiation, and activity of placenta, liver,

kidney, lung, pancreas, and heart cells. Thus, TANGO 292 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 292 polypeptides, nucleic acids, and modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Naijar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 292 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced

tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical  
5 necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 292 polypeptides, nucleic acids, and modulators thereof can  
10 be associated with pulmonary (i.e., lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion, pulmonary edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic  
15 pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), and tumors  
20 (e.g., bronchogenic carcinoma, bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). TANGO 292 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Pancreatic disorders in which TANGO 292 can be involved include  
pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis),  
25 pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma).  
30 TANGO 292 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because TANGO 292 exhibits expression in the heart, TANGO 292 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 292 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 292 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Presence in TANGO 292 of a vitamin K-dependent carboxylation (Gla) domain indicates that TANGO 292 is involved in physiological functions identical or analogous to the functions performed by other proteins having such domains. For example, like other Gla domain-containing proteins, TANGO 292 modulates binding and uptake of calcium and other metal ions by cells which express it and the response of those cells to the presence and uptake of such ions. Human matrix Gla protein, for example, is involved in Keutel syndrome, an autosomal recessive disorder characterized by abnormal cartilage calcification, peripheral pulmonary stenosis, and midfacial hypoplasia (Munroe et al. (1999) *Nat. Genet.* 21:142-144). Other proteins containing a Gla domain include, for example, two human proline-rich Gla proteins designated PRGP1 and PRGP2, human G domain-containing protein Gas6, and several human blood coagulation factors (Kulman et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:9058-9062; Mark et al., (1996) *J. Biol. Chem.* 271:9785-9786; Cancela et al. (1990) *J. Biol. Chem.* 265:15040-15048). These proteins are involved in binding of mineral ions such as calcium, phosphate, and hydroxyapatite, binding of proteins, binding of vitamins and small molecules, and mediation of blood coagulation. Thus, TANGO 292 is involved in numerous physiological processes which are influenced by levels of calcium and other metal ions in body fluids or by the presence of proteins, vitamins, or small molecules. Such processes include, for example, bone uptake, maintenance, and deposition, formation, maintenance, and repair of cartilage, formation and maintenance of extracellular matrices, movement of cells through extracellular matrices, coagulation and dissolution of blood components (e.g., blood cells and proteins), and deposition of materials (e.g., lipids, cells, calcium, and the like) in arterial walls. TANGO 292 polypeptides, nucleic acids, and modulators thereof can

be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

TANGO 292 is involved in disorders which affect the tissues in which it is normally expressed and upon which it normally acts. Thus, TANGO 292 is involved in disorders which involve aberrant binding or aberrant failure to bind of keratinocytes or similar cells with a tissue affected by the disorder. Such disorders include, by way of example and not limitation, osteoporosis, (repair of) traumatic bone injuries, rickets, osteomalacia, Paget's disease, and other bone disorders, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, Keutel syndrome, and other disorders of the joints and cartilage, iron deficiency anemia, hemophilia, inappropriate blood coagulation, stroke, arteriosclerosis, atherosclerosis, aneurysm, and other disorders related to blood and blood vessels, metastasis and other disorders related to inappropriate movement of cells through extracellular matrices, and the like. TANGO 292 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

#### TANGO 325

A cDNA clone (designated jthdc071a12) encoding at least a portion of human TANGO 325 protein was isolated from a human aortic endothelial cell cDNA library. The human TANGO 325 protein is predicted by structural analysis to be a transmembrane protein.

The full length of the cDNA encoding human TANGO 325 protein (Figure 5; SEQ ID NO: 46) is 2169 nucleotide residues. The ORF of this cDNA, nucleotide residues 135 to 2000 of SEQ ID NO: 46 (i.e., SEQ ID NO: 47), encodes a 622-amino acid transmembrane protein (Figure 5; SEQ ID NO: 48).

The invention thus includes purified human TANGO 325 protein, both in the form of the immature 622 amino acid residue protein (SEQ ID NO: 48) and in the form of the mature, approximately 591 amino acid residue protein (SEQ ID NO: 50). Mature human TANGO 325 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized

by generating immature TANGO 325 protein and cleaving the signal sequence therefrom.

In addition to full length mature and immature human TANGO 325 proteins, the invention includes fragments, derivatives, and variants of these  
5 TANGO 325 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 325 polypeptides of the invention or TANGO 325 proteins of the invention.

The invention also includes nucleic acid molecules which encode a TANGO 325 polypeptide of the invention. Such nucleic acids include, for example,  
10 a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 46 or some portion thereof, such as the portion which encodes mature TANGO 325 protein, immature TANGO 325 protein, or a domain of TANGO 325 protein. These nucleic acids are collectively referred to as TANGO 325 nucleic acids of the invention.

TANGO 325 proteins and nucleic acid molecules encoding them  
15 comprise a family of molecules having certain conserved structural and functional features.

A common domain present in TANGO 325 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-  
20 bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more  
25 preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 325 protein contains a signal sequence corresponding to about amino acid residues 1 to 31 of SEQ ID NO: 48 (SEQ ID NO: 49). The signal sequence is cleaved during processing of the mature protein.

30 TANGO 325 proteins can include an extracellular domain. The human TANGO 325 protein extracellular domain is located from about amino acid residue 32 to about amino acid residue 529 of SEQ ID NO: 48 (SEQ ID NO: 51).

In addition, TANGO 325 include a transmembrane domain. In one embodiment, a TANGO 325 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 530 to 547 of SEQ ID NO: 48 (SEQ ID NO: 52).

5           The present invention includes TANGO 325 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. The human TANGO 325 cytoplasmic domain is located from about amino acid residue 548 to amino acid residue 622 of SEQ ID NO: 48 (SEQ ID NO: 53).

10           TANGO 325 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VII, as predicted by computerized sequence analysis of TANGO 325 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 325 with the information in the PROSITE  
15   database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table VII.

Table VII

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 48	Amino Acid Sequence
N-glycosylation site	71 to 74	NISY
	76 to 79	NESE
	215 to 218	NLTK
	266 to 269	NVTR
	317 to 320	NDTF
	331 to 334	NLSF
	336 to 339	NLTA
	400 to 403	NITN
	410 to 413	NVSR
	451 to 454	NITF
	579 to 582	NVTA
cAMP- or cGMP-dependent protein kinase phosphorylation site	231 to 234	RRLS
Protein kinase C phosphorylation site	40 to 42	TGR
	229 to 231	SLR
	326 to 328	SLK
	390 to 392	SMR
	510 to 512	SGK
	575 to 577	SAR
Casein kinase II phosphorylation site	284 to 287	SHND
	442 to 445	SPLE
	447 to 450	TETE
	453 to 456	TFWE

Table VII (Continued)

N-myristoylation site	3 to 8	GLQFSL
	69 to 74	GNNISY
	126 to 131	GIFKGL
	174 to 179	GTFVGM
ATP/GTP-binding site motif A (P-loop)	506 to 513	AASMSGKT
Leucine rich repeat amino terminal domain (LLRNT)	32 to 60	See Fig. 5
Leucine rich repeat (LRR) domain	61 to 84	See Fig. 5
	85 to 108	See Fig. 5
	109 to 132	See Fig. 5
	133 to 156	See Fig. 5
	157 to 180	See Fig. 5
	181 to 204	See Fig. 5
	205 to 228	See Fig. 5
	229 to 252	See Fig. 5
	253 to 276	See Fig. 5
	277 to 300	See Fig. 5
	301 to 324	See Fig. 5
	326 to 349	See Fig. 5
Leucine rich repeat carboxyl terminal domain (LRRCT)	359 to 405	See Fig. 5

Among the domains that occur in TANGO 325 protein are leucine  
5 rich repeat (LRR) domains, including amino terminal and carboxyl terminal LRR  
domains, and a P-loop domain. In one embodiment, the protein of the invention has  
at least one domain that is at least 55%, preferably at least about 65%, more  
preferably at least about 75%, yet more preferably at least about 85%, and most

preferably at least about 95% identical to one of these domains. In another embodiment, the protein has at least one amino terminal LRR domain, at least one carboxyl terminal LRR domain, and a plurality of LRR domains interposed therebetween. In yet another embodiment, the protein has at least one P-loop domain, and a plurality (e.g., 2, 3, 4, or more) of the LRR domains described herein in Table VII.

One or more LRR domains is present in a variety of proteins involved in protein-protein interactions. Such proteins include, for example, proteins involved in signal transduction, cell-to-cell adhesion, cell-to-extracellular matrix adhesion, cell development, DNA repair, RNA processing, and cellular molecular recognition processes. Specialized LRR domains, designated LRR amino terminal (LRRNT) domains and LRR carboxyl terminal (LRRCT) domains often occur near the amino and carboxyl, respectively, ends of a series of LRR domains. TANGO 325 protein has fourteen clustered LRR domains, including (from the amino terminus toward the carboxyl terminus of TANGO 325) an LRRNT domain, twelve LRR domains, and an LRRCT domain. TANGO 325 is thus involved in one or more physiological processes in which these other LRR domain-containing proteins are involved, namely binding of cells with extracellular proteins such as soluble extracellular proteins and cell surface proteins of other cells.

The fact that TANGO 325 has an ATP/GTP-binding domain (i.e., a P-loop domain) within the extracellular domain of the protein indicates that this protein is involved in transmembrane signaling events. Considered in combination with the protein-binding LRR domains present in the extracellular domain of the, the presence of the ATP/GTP-binding domain indicates that TANGO 325 protein is capable of sensing extracellular proteins, including ATP-binding proteins and GTP-binding proteins, and extracellular nucleotides (e.g., ATP, ADP, and AMP). Thus, TANGO 325 protein is involved in translating information (e.g., environmental conditions or signaling molecules provided to the environment by other cells) from the extracellular environment of the cell in which it is expressed to one or more intracellular biochemical systems.

TANGO 325 exhibits amino acid sequence and nucleic acid sequence homology with human Slit-1 protein. An alignment of the amino acid sequences of TANGO 325 and human Slit-1 protein is shown in Figures 5G to 5L. In this alignment (made using the ALIGN software {Myers and Miller (1989) CABIOS, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 35.4% identical (i.e., 35.4% of the residues of TANGO 325 correspond to identical residues in Slit-1). An alignment of the nucleotide sequences of the ORFs encoding TANGO 325 and human Slit-1 protein is shown in Figures 5Mi through 5Mxviii. The two ORFs are 65.7% identical, as assessed using the same software and parameters.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 325 protein includes an approximately 31 (i.e., 29, 30, 31, 32, or 33) amino acid residue signal peptide (amino acid residues 1 to 31 of SEQ ID NO: 48; SEQ ID NO: 49) preceding the mature TANGO 325 protein (i.e., approximately amino acid residues 42 to 622 of SEQ ID NO: 48; SEQ ID NO: 50). In one embodiment, human TANGO 325 protein includes an extracellular domain (amino acid residues 32 to 529 of SEQ ID NO: 48; SEQ ID NO: 51); a transmembrane domain (amino acid residues 530 to 547 of SEQ ID NO: 48; SEQ ID NO: 52); and a cytoplasmic domain (amino acid residues 548 to 622 of SEQ ID NO: 48; SEQ ID NO: 53). In an alternative embodiment, human TANGO 325 protein includes a cytoplasmic domain (amino acid residues 32 to 529 of SEQ ID NO: 48; SEQ ID NO: 51); a transmembrane domain (amino acid residues 530 to 547 of SEQ ID NO: 48; SEQ ID NO: 52); and an extracellular domain (amino acid residues 548 to 622 of SEQ ID NO: 48; SEQ ID NO: 53).

Figure 5F depicts a hydrophilicity plot of human TANGO 325 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 31 of SEQ ID NO: 48 is the signal sequence of human TANGO 325 (SEQ ID NO: 49). The hydrophobic region which corresponds to amino acid residues 530 to 547 of SEQ ID NO: 48 is the transmembrane domain of human TANGO 325 (SEQ ID NO: 52).

As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 325 protein from about amino acid residue 550 to about amino acid residue 565 appears to be located at or near the surface of the protein, while the region from about amino acid residue 168 to about amino acid residue 185 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 325 protein without modification and prior to cleavage of the signal sequence is about 70.3 kilodaltons. The predicted molecular weight of the mature human TANGO 325 protein without modification and after cleavage of the signal sequence is about 66.8 kilodaltons.

Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding TANGO 325 is expressed in the tissues listed in Table VIIA, wherein "+" indicates expression and "-" indicates that expression could not be detected in the corresponding tissue.

Table VIIA

Animal	Tissue	Relative Level of Expression
Human	placenta	+
	liver	+
	kidney	+
	pancreas	+
	heart	+
	brain	-
	skeletal muscle	-
	lung	-

Biological function of TANGO 325 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 325 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally

not expressed. Based on the observation that TANGO 325 is expressed in human aortic endothelial tissue and in placenta, liver, kidney, pancreas, and heart tissues, TANGO 325 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 325 is involved in modulating growth,  
5 proliferation, survival, differentiation, and activity of endothelial cells including, but not limited to, vascular and cardiac (including valvular) endothelial cells of the animal in which it is normally expressed. TANGO 325 also modulates growth, proliferation, survival, differentiation, and activity of placenta, liver, kidney, and pancreas cells. Thus, TANGO 325 has a role in disorders which affect these cells  
10 and their growth, proliferation, survival, differentiation, and activity. TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In one example, TANGO 325 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of  
15 pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 325 polypeptides, nucleic acids, and  
20 modulators thereof, can be used to treat hepatic (i.e., liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Naijar syndromes and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic  
25 and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), and malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

30 In another example, TANGO 325 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (i.e., kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive

glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), and tumors (e.g., renal cell carcinoma and nephroblastoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Pancreatic disorders in which TANGO 325 can be involved include pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), and islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because TANGO 325 exhibits expression in the heart, TANGO 325 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 325 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 325 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

It is known that serum nucleotide levels (e.g., ATP) affect cardiac contractility and vasomotor tone. Presence in TANGO 325 of an ATP/GTP binding domain in the extracellular portion thereof implicates this transmembrane protein in sensing of serum nucleotide levels and transmission of the sensed level by mechanisms not yet fully understood to myocytes underlying the epithelium. Thus, TANGO 325 is involved in disorders such as cardiovascular insufficiency, hypertension, hypotension, shock, and the like.

Leukocytes are known to bind with vascular endothelial surfaces in a reversible manner prior to penetrating the vascular endothelium in route to an underlying tissue. Although a few proteins have previously been implicated in the leukocyte-endothelium binding process, the identities of all of the proteins involved remain unknown. The presence of numerous LRR domains on the exterior portion of TANGO 325 protein implicates this protein in reversible binding of leukocytes to vascular endothelium. Thus, TANGO 325 is involved in physiological processes and disorders which involve leukocyte-endothelium binding. Such processes and disorders include, by way of example, cellular aspects of immune responses, autoimmune responses and disorders, and migration of leukocytes to lymph nodes.

The aortic endothelium, as well as other vascular endothelia, are known to be involved in detection of signals (e.g., metabolites, proteins, and the like) in the blood stream. Mammalian Slit-1 protein is known to be involved in the human endocrine system (Itoh et al. (1998) *Brain Res. Mol. Brain Res.* 62:175-186). Amino acid and nucleic acid sequence similarity of TANGO 325 with human Slit-1 protein, as described herein, indicates that TANGO 325 is involved in sensing physiological signals by the endocrine system. Thus, TANGO 325 is involved in one or more human endocrine disorders such as pituitary disorders (e.g., diabetes insipidus), thyroid disorders (e.g., hyperthyroidism, hypothyroidism, diabetes, goiter, and growth and developmental disorders), adrenal disorders (e.g., Addison's disease, Cushing's syndrome, hyperaldosteronism, and pheochromocytoma), and the like.

Human Slit-1 protein is also known to be involved in guidance of neuronal growth. The sequence similarity of TANGO 325 with Slit-1, as described herein, implicates TANGO 325 in growth, development, maintenance, and

regeneration of neurons. TANGO 325 can thus be used to prevent, diagnose, and treat a variety of neurological disorders.

### TANGO 331

5                   A cDNA clone (designated jthvb042g08) encoding at least a portion of human TANGO 331 protein was isolated from a human mammary epithelium cDNA library. A corresponding cDNA clone (designated jchrc045a03) was isolated from a human heart library. The human TANGO 331 protein is predicted by structural analysis to be a secreted protein.

10                   The full length of the cDNA encoding human TANGO 331 protein (Figure 6; SEQ ID NO: 54) is 1432 nucleotide residues. The ORF of this cDNA, nucleotide residues 114 to 1172 of SEQ ID NO: 54 (i.e., SEQ ID NO: 55), encodes a 353-amino acid secreted protein (Figure 6; SEQ ID NO: 56).

                  The invention thus includes purified human TANGO 331 protein, both in the form of the immature 353 amino acid residue protein (SEQ ID NO: 56) and in the form of the mature, approximately 329 amino acid residue protein (SEQ ID NO: 58). Mature human TANGO 331 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 331 protein and cleaving the signal sequence  
20                   therefrom.

                  In addition to full length mature and immature human TANGO 331 proteins, the invention includes fragments, derivatives, and variants of these TANGO 331 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 331 polypeptides of the  
25                   invention or TANGO 331 proteins of the invention.

                  The invention also includes nucleic acid molecules which encode a TANGO 331 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 54 or some portion thereof, such as the portion which encodes mature TANGO 331 protein, immature TANGO 331 protein, or a domain of TANGO 331 protein. These nucleic  
30                   acids are collectively referred to as TANGO 331 nucleic acids of the invention.

TANGO 331 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 331 protein and the Chinese hamster (*Cricetulus griseus*) protein designated HT and having GenBank Accession number U48852, as shown in Figure 6E, and the conservation of nucleotide sequence between the ORFs encoding human TANGO 331 protein and Chinese hamster protein HT, as shown in Figures 6F through 6J.

A common domain present in TANGO 331 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 331 protein contains a signal sequence corresponding to about amino acid residues 1 to 24 of SEQ ID NO: 56 (SEQ ID NO: 57). The signal sequence is cleaved during processing of the mature protein.

TANGO 331 proteins can include an extracellular domain. The human TANGO 331 protein is a secreted protein, and thus includes an 'extracellular domain' consisting of the entire mature protein (i.e., approximately residues 25 to 353 of SEQ ID NO: 56; SEQ ID NO: 58).

TANGO 331 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VIII, as predicted by computerized sequence analysis of TANGO 331 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 331 with the information in the PROSITE database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4,

6, 10, 15, or 20 or more of the post-translational modification sites listed in Table VIII.

Table VIII

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 56	Amino Acid Sequence
N-glycosylation site	190 to 193	NETH
	251 to 254	NGSY
cAMP- or cGMP-dependent protein kinase phosphorylation site	26 to 29	KKPT
Protein kinase C phosphorylation site	48 to 50	TAK
	123 to 125	TLK
	144 to 146	SQR
	165 to 167	SCR
	187 to 189	SLR
	202 to 204	SCK
	210 to 212	TNR
Casein kinase II phosphorylation site	58 to 61	Tawe
	66 to 69	SKYE
	86 to 89	SDFE
	197 to 200	TACD
	210 to 213	TNRD
	255 to 258	TCEE
	295 to 298	SLAE
	339 to 342	TEGE
	349 to 352	SRED

Table VIII (Continued)

Tyrosine kinase phosphorylation site	303 to 309	RKNENCY
N-myristoylation site	44 to 49	GMVDTA
	54 to 59	GGGNTA
	81 to 86	GLCESS
	150 to 155	GNGHCS
	158 to 163	GSRQGD
	164 to 169	GSCRCH
	252 to 257	GSYTCE
	313 to 318	GSYVCV
Aspartic acid and asparagine hydroxylation site	308 to 319	See Fig. 6
EGF-like domain cystein pattern signature	166 to 177	See Fig. 6
EGF domain	140 to 177	See Fig. 6
	234 to 263	See Fig. 6
	301 to 330	See Fig. 6
Laminin-like EGF domain	153 to 199	See Fig. 6
TNFR/NGFR cysteine-rich region domain	180 to 214	See Fig. 6
Vertebrate metallothionein-like domain	229 to 298	See Fig. 6
Leucine Zipper domain	94 to 115	See Fig. 6

Among the domains that occur in TANGO 331 protein are EGF domains, including a laminin-like EGF domain, a TNFR/NGFR cysteine-rich domain, a metallothionein-like domain, and a leucine zipper domain.

EGF-like domains are about 30 to 40 amino acid residues in length and comprise several conserved cysteine residues in one of several patterns. EGF-like domains occur in a large number of proteins including, for example, human epidermal growth factor (EGF), murine adipocyte differentiation inhibitor, human agrin, human growth factor amphiregulin, human growth factor betacellulin, sea urchin blastula tissue patterning proteins BP10 and Span, cattle tick glycoprotein BM86, human bone morphogenic protein 1, sea urchin suBMP, *Drosophila* tolloid protein, *Caenorhabditis elegans* developmental proteins lin-12 and glp-1, *C. elegans* tissue patterning protein APX-1, human calcium-dependent serine proteinase, human cartilage matrix protein, human cartilage oligomeric matrix protein, human cell surface antigen 114/A10, rat cell surface glycoprotein complex transmembrane subunit ASGP-2, human coagulation associated proteins C, Z, and S, human coagulation factors VII, IX, X, and XII, human complement components C1r, C1s, C6, C7, C8 $\alpha$ , C8 $\beta$ , and C9, human complement-activating components of Ra-reactive factor, *Drosophila* epithelial development protein Crumbs, sea urchin exogastrula-inducing peptides A, C, D, and X, *Drosophila* cadherin-related tumor suppressor protein Fat, human fetal antigen 1 (a neuroendocrine differentiation protein derived from the delta-like protein), human fibrillins 1 and 2, sea urchin fibropellins IA, IB, IC, II, and III, human extracellular matrix proteins fibulin-1 and -2, *Drosophila* cell determination/axon guidance protein Argos, various poxvirus growth factor-related proteins, *Drosophila* developmental protein Gurken, human heparin-binding EGF-like growth factor, human transforming growth factor- $\alpha$ , human growth factors Lin-3 and Spitz, human hepatocyte growth factor activator, human LDL and VLDL receptors, human LDL receptor-related protein, human leukocyte antigen CD97, human cell surface glycoprotein EMR1, human cell surface glycoprotein F4/80, Japanese horseshoe crab limulus clotting factor C, mammalian membrane-bound endopeptidase Meprin A  $\alpha$  subunit, murine milk fat globule-EGF factor 8, human glial growth factors neuregulin GGF-I and GGF-II, mammalian neurexins, human neurogenic proteins Notch, Xotch, Tan-1, and Delta, *C. elegans* differentiation protein Lag-2, *Drosophila* differentiation proteins Serrate and Slit, chordate basement membrane protein Nidogen, *Plasmodium* ookinete 24, 25, and 28 kilodalton surface proteins, human pancreatic secretory granule

membrane glycoprotein GP2, human non-specific cell lysis protein Perforin, human proteoglycans aggrecan, versican, perlecan, brevican, and chondroitin sulfate, human endoplasmic reticulum prostaglandin G/H synthases 1 and 2, human extracellular protein S1-5, human autocrine growth factor Schwannoma-derived growth factor, human E-, P-, and L-selectins, *Arabidopsis thaliana* chlorophyll complex assembly protein serine/threonine-protein kinase homolog, guinea pig sperm-egg fusion proteins PH-30 $\alpha$  and  $\beta$ , murine stromal cell derived protein-1, human teratocarcinoma-derived growth factor, mammalian extracellular protein tenascin, chicken extracellular protein TEN-A, human tenascin-X, *Drosophila* tenascin-like proteins TEN-A and TEN-M, human protein C activator thrombomodulin, human adhesive glycoproteins thrombospondins 1, 2, 3, and 4, human thyroid peroxidases 1 and 2, human transforming growth factor  $\beta$ -1 binding protein, human tyrosine-protein kinase receptors Tek and Tie, human urokinase-type plasminogen activator, human tissue plasminogen activator, human uromodulin, human vitamin K-dependent anticoagulant proteins C and S (and the related human single-chain plasma glycoprotein Z), the sea urchin 63 kilodalton sperm flagellar membrane protein, chicken Nel protein, and the hypothetical C. *Elegans* protein T20G5.3. Although these proteins have a variety of activities and sites of expression, a common characteristic of most of them is that they are involved in protein-to-protein binding in the extracellular space - either to a secreted protein, a component of the extracellular matrix, or to an extracellular portion of an integral membrane protein. Based on this shared characteristic, the presence of multiple EGF-like domains in TANGO 331 indicates that TANGO 331 is involved in binding to proteins extracellularly.

Post-translational hydroxylation of aspartic acid or asparagine to form erythro- $\beta$ -hydroxyaspartic acid or erythro- $\beta$ -hydroxyasparagine occurs in various proteins having one or more EGF-like domains (e.g., blood coagulation protein factors VII, IX, and X, blood coagulation proteins C, S, and Z, the LDL receptor, thrombomodulin, and the like). TANGO 331 has a signature sequence which is characteristic of hydroxylation of the asparagine residue at amino acid residue 310. The invention thus includes TANGO 331 proteins having a hydroxylated asparagine residue at position 310 of SEQ ID NO: 56.

TNFR/NGFR (tumor necrosis factor receptor/nerve growth factor receptor) cysteine-rich region domains are about 30 to 40 amino acid residues in length, and generally exhibit a conserved pattern of six or more cysteine residues. These domains occur in several soluble and transmembrane proteins which are known to be receptors for growth factors or for cytokines. Examples of TNFR/NGFR cysteine-rich region domain-containing proteins are human tumor necrosis factor (TNF) cysteine-rich region domains type I and type II receptors, Shope fibroma virus soluble TNF receptor, human lymphotoxin  $\alpha/\beta$ , human low-affinity nerve growth factor receptor, human CD40L (cytokine) receptor CD40, human CD27L (cytokine) receptor CD27, human CD30L (cytokine) receptor CD30, human T-cell cytokine receptor 4-1BB, human apoptotic FASL protein receptor FAS, human T-cell OX40L (cytokine) receptor OX40, human apoptosis-related receptor Wsl-1, and *Vaccinia* protein A53. Presence of a TNFR/NGFR cysteine-rich region domain in TANGO 331 is an indication that TANGO 331 is involved in one or more physiological processes involving extracellular binding with a cytokine or growth factor. Such processes include, for example, growth, homeostasis, regeneration, and proliferation of cells and tissues, immune (including autoimmune) responses, host defenses against infection, and the like.

Metallothioneins are cysteine-rich proteins which are capable of binding heavy metals such as calcium, zinc, copper, cadmium, cobalt, nickel, and the like. Proteins which have a domain which resembles a metal-binding domain of a metallothionein are also capable of binding such metals. TANGO 331 comprises a metallothionein-like domain, and is capable of binding one or more heavy metals. This is an indication that TANGO 331 is involved in one or more physiological processes which involve metal binding. Such processes include, by way of example and not limitation, nutritional supply of metals to cells on a controlled basis, removal of toxic metal species from body tissues, storage of metals, and the like.

TANGO 331 comprises a leucine zipper region at about amino acid residue 94 to about amino acid residue 115 (i.e., 94 LeaqeehLeawwlqLkseydL 115). Leucine zipper regions are known to be involved in dimerization of proteins. Leucine zipper regions interact with one another, leading to formation of homo- or hetero-dimers between proteins, depending on their identity. The presence in

TANGO 331 of a leucine zipper region is a further indication that this protein is involved in protein-protein interactions.

TANGO 331 shares amino acid and nucleic acid homology with a Chinese hamster protein designated HT, and thus is involved in corresponding physiological processes in humans. An alignment of the amino acid sequences of (human) TANGO 331 and Chinese hamster protein HT is shown in Figure 6E. In this alignment (made using the ALIGN software (Myers and Miller (1989) CABIOS, ver. 2.0); pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 71.9% identical. An alignment of the nucleotide sequences of the ORFs encoding (human) TANGO 331 and Chinese hamster protein HT is shown in Figures 6F through 6J. The two ORFs are 74.5% identical, as assessed using the same software and parameters.

The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 331 protein includes an approximately 24 (i.e., 22, 23, 24, 25, or 26) amino acid residue signal peptide (amino acid residues 1 to 24 of SEQ ID NO: 56; SEQ ID NO: 57) preceding the mature TANGO 331 protein (i.e., approximately amino acid residues 25 to 353 of SEQ ID NO: 56; SEQ ID NO: 58). Mature human TANGO 331 is a secreted protein.

Figure 6D depicts a hydrophilicity plot of human TANGO 331 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to amino acid residues 1 to 24 of SEQ ID NO: 56 is the signal sequence of human TANGO 331 (SEQ ID NO: 57). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 331 protein from about amino acid residue 140 to about amino acid residue 170 appears to be located at or near the surface of the protein, while the region from about amino acid residue 115 to about amino acid residue 130 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 331 protein without modification and prior to cleavage of the signal sequence is about 38.2 kilodaltons. The predicted molecular weight of the mature human TANGO 331 protein without modification and after cleavage of the signal sequence is about 35.6  
5 kilodaltons.

Tissue distribution of TANGO 331 mRNA was determined by Northern blot hybridization. Northern blot hybridizations with the various RNA samples were performed using standard Northern blotting conditions and washing under stringent conditions (i.e., 0.2× SSC at 65°C). The DNA probe used in the  
10 Northern Blot experiments was radioactively labeled with 32P-dCTP using the PRIME-IT™ kit (Stratagene, La Jolla, CA) according to the instructions of the supplier. Filters having human mRNA disposed thereon (MULTITISSUE™ Northern I and MULTITISSUE™ Northern II obtained from Clontech, Palo Alto, CA) were probed in EXPRESSHYB™ hybridization solution (Clontech) and  
15 washed at high stringency according to the manufacturer's recommendations.

Two isoforms of human TANGO 331 were identified using this Northern blot analysis, indicating that TANGO 331 can have a splice variant. One isoform (corresponding to the larger message) can be a transmembrane protein (frizzled-like) and the other (i.e., smaller) isoform can be a secreted form. The two  
20 isoforms exhibit a clear pattern of tissue specificity. On the multiple tissue blot from Clontech, the large transcript is found in almost all tissues, whereas the smaller message is expressed mainly in heart, skeletal muscle, placenta, and pancreas tissues.

TANGO 331 can be expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is  
25 isolated and characterized. Specifically, TANGO 331 can be fused with GST and this fusion polypeptide can be expressed in *E. coli*, e.g., in strain PEB199. Expression of the GST-TANGO 331 fusion protein in PEB199 is induced with IPTG. The recombinant fusion polypeptide can be purified from crude bacterial lysates of the  
30 induced PEB199 strain by affinity chromatography, e.g., using glutathione-substituted beads. Using polyacrylamide gel electrophoretic analysis of the

polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide can be determined.

To express the TANGO 331 gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) can be used. This vector  
5 contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire TANGO 331 protein and an HA tag (Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment can be cloned into the polylinker region of the  
10 vector, thereby placing the expression of the recombinant protein under the control of the CMV promoter.

To construct the plasmid, the TANGO 331 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the TANGO 331 coding  
15 sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the TANGO 331 coding sequence. The PCR amplified fragment and the pcDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is  
20 dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the TANGO 331 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (e.g., one or more of strains HB101, DH5a, SURE, available from Stratagene Cloning Systems, La Jolla, CA), the transformed culture is plated on  
25 ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected using the TANGO 331-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-  
30 precipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods of transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory

Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The expression of the TANGO 331 polypeptide can be detected by radiolabelling ( $^{35}\text{S}$ -methionine or  $^{35}\text{S}$ -cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labelled for 8 hours with  $^{35}\text{S}$ -methionine (or  $^{35}\text{S}$ -cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 millimolar NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 millimolar Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-PAGE.

Alternatively, DNA containing the TANGO 331 coding sequence can be cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the TANGO 331 polypeptide can be detected by radiolabelling and immunoprecipitation using an TANGO 331 specific monoclonal antibody.

The human TANGO 331 gene was mapped using the Genebridge 4 Human Radiation hybrid mapping panel with ATTATTCAGAAGGATGTCCCGTGG (SEQ ID NO: 99) as the forward primer and CCTCCTGATTACCTACAATGGTC (SEQ ID NO: 100) as the reverse primer. The human TANGO 331 gene maps to human 22q11-q13. Flanking markers for this region are WI-4572 and WI-8917. The schizophrenia 4 (sczd4) locus also maps to this region of the human chromosome. Also mapping to this region of the human chromosome are the following genes: transcription factor 20 (tcf20), Benzodiazepine receptor, peripheral type (bzip), Arylsulfatase A (arsa), diaphorase (NADH); cytochrome b-5 reductase (dia1), and Solute carrier family 5 (sodium/glucose transporter), member 1 (slca1). This region is syntenic to mouse chromosome 15. The stargazer (stg), gray tremor (gt), brachyury modifier 2 (Brm2), bronchial hyperresponsiveness 2 (Bhr2), loss of righting induced by ethanol 5 (Lore5), fluctuating asymmetry QTL 8 (Faq8), jerky (Jrk), belted (bt), and

koala (Koa) loci also map to this region of the mouse chromosome, several of which are neuromuscular related.

5 Biological function of TANGO 331 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 331 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 331 is expressed in human mammary epithelial tissue and human heart tissue, TANGO 331 protein is involved in one or more biological processes which occur in mammary epithelial tissue, in other epithelial tissues, and in heart tissue. In particular, TANGO 331 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, epithelial cells (e.g., mammary epithelial cells) of the animal in which it is normally expressed. Thus, TANGO 331 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. TANGO 331 is therefore involved in physiological processes such as maintenance of epithelia, carcinogenesis, modulation and storage of protein factors and metals, and lactation. Furthermore, because TANGO 331 is expressed in human mammary epithelial cells, it also has a role in nutrition of human infants (e.g., providing nutrients such as minerals to infants and providing protein factors not synthesized by infants) and in disorders which affect them. Thus, TANGO 331 is involved in a number of disorders such as breast cancer, insufficient lactation, infant nutritional and growth disorders, and the like. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Because TANGO 331 exhibits expression in the heart, TANGO 331 nucleic acids, proteins, and modulators thereof can be used to treat heart disorders. Examples of heart disorders with which TANGO 331 can be involved include ischemic heart disease, atherosclerosis, hypertension, angina pectoris, hypertrophic cardiomyopathy, and congenital heart disease. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof, can be involved in normal and aberrant functioning of skeletal muscle tissue, and can thus be involved in disorders of such tissue. Examples of skeletal muscle disorders include muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies (e.g., dermatomyositis and polymyositis), myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (e.g., phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmityl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency). TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

In another example, TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, and spontaneous abortion.

Presence in TANGO 331 of numerous EGF-like domains, including the laminin-like EGF-like domain indicates that TANGO 331 is involved in

extracellular binding of proteins, including both other secreted proteins (e.g., growth factors and cytokines) and cell-surface proteins. Binding of TANGO 331 to other secreted proteins modulates their activity, their rate of uptake by cells, and their rate of degradation. Binding of TANGO 331 to cell surface proteins  
5 modulates their activity, including, for example, their ability to bind with other secreted proteins, and transmits a signal to the cell expressing the cell-surface protein. Presence in TANGO 331 of a TNFR/NGFR cysteine-rich region domain is further indicative of the ability of TANGO 331 to bind with growth factors and cytokines. Thus, TANGO 331 is involved in a number of proliferative and immune  
10 disorders including, but not limited to, cancers (e.g., breast cancer), autoimmune disorders, insufficient or inappropriate host responses to infection, acquired immune deficiency syndrome, and the like. TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

15 The fact that TANGO 331 has a metallothionein-like region is indicative of the ability of TANGO 331 to bind with metal ions, including nutritionally required metal ions (e.g., calcium, magnesium, zinc, manganese, cobalt, iron, and the like). Thus, TANGO 331 is involved in binding with essential minerals and in delivering them to their proper body locations. TANGO 331 is also  
20 involved in binding excess or toxic metal ions so that they can be excreted. TANGO 331 is thus involved in disorders involving insufficient or inappropriate localization of metal ions. Such disorders include, but are not limited to, malnutrition and mineral deficiency disorders, hemochromatosis, inappropriate calcification of body tissues, bone disorders such as osteoporosis, and the like.  
25 TANGO 331 polypeptides, nucleic acids, or modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

Mapping of the human TANGO 331 gene to chromosomal region 22q11-q13 is an indication of disorders with which its expression (or non- or aberrant-expression) can be associated. For example, arylsulfatase A is associated  
30 with Metachromatic leukodystrophy. Diaphorase (NADH:cytochrome b-5 reductase) is associated with methemoglobinemia, types I and II. Solute carrier family 5 (sodium/glucose transporter), member 1 is associated with

glucose/galactose malabsorption. The gene designated schizophrenia 4 is associated with schizophrenia and velocardiofacial syndrome, as described in Online Mendelian Inheritance in Man, Johns Hopkins University, Baltimore, MD. MIM Number: 600850:12/7/98. (World Wide Web URL:

- 5 <http://www.ncbi.nlm.nih.gov/omim/>). These mapping data indicate that TANGO 331 polypeptides, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, inhibit, prevent, or alleviate one or more of these disorders.

### TANGO 332

- 10 A cDNA clone (designated jlhab463g12) encoding at least a portion of human TANGO 332 protein was isolated from a human adult brain cDNA library. The human TANGO 332 protein is predicted by structural analysis to be a secreted protein.

- The full length of the cDNA encoding human TANGO 332 protein  
15 (Figure 7; SEQ ID NO: 59) is 2730 nucleotide residues. The ORF of this cDNA, nucleotide residues 173 to 2185 of SEQ ID NO: 59 (i.e., SEQ ID NO: 60), encodes a 671-amino acid transmembrane protein (Figure 7; SEQ ID NO: 61).

- The invention thus includes purified human TANGO 332 protein, both in the form of the immature 671 amino acid residue protein (SEQ ID NO: 61)  
20 and in the form of the mature, approximately 649 amino acid residue protein (SEQ ID NO: 63). Mature human TANGO 332 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 332 protein and cleaving the signal sequence therefrom.

- 25 In addition to full length mature and immature human TANGO 332 proteins, the invention includes fragments, derivatives, and variants of these TANGO 332 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as TANGO 332 polypeptides of the invention or TANGO 332 proteins of the invention.

- 30 The invention also includes nucleic acid molecules which encode a TANGO 332 polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 59 or some

portion thereof, such as the portion which encodes mature TANGO 332 protein, immature TANGO 332 protein, or a domain of TANGO 332 protein. These nucleic acids are collectively referred to as TANGO 332 nucleic acids of the invention.

5 TANGO 332 proteins and nucleic acid molecules encoding them  
comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 332 protein, human brain-enriched hyaluronan-binding factor (BEF), as shown in Figures 7G and 7H, and murine brevican protein, as shown in Figures 7I to 7K. This conservation is further indicated by conservation of nucleotide  
10 sequence between the ORFs encoding human TANGO 332 protein and murine brevican protein, as shown in Figures 7L through 7U.

A common domain present in TANGO 332 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-  
15 bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more  
20 preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 332 protein contains a signal sequence corresponding to about amino acid residues 1 to 22 of SEQ ID NO: 61 (SEQ ID NO: 62). The signal sequence is cleaved during processing of the mature protein.

25 TANGO 332 proteins are secreted proteins. The mature form of human TANGO 332 protein has the amino acid sequence of approximately amino acid residues 23 to 671 of SEQ ID NO: 61.

TANGO 332 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those  
30 described herein in Table IX, as predicted by computerized sequence analysis of TANGO 332 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 332 with the information in the PROSITE

database {rel. 12.2; Feb, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IX.

5

Table IX

Type of Potential Modification Site or Domain	Amino Acid Residues of SEQ ID NO: 61	Amino Acid Sequence
N-glycosylation site	130 to 133	NDSG
	337 to 340	NQTG
Protein kinase C phosphorylation site	67 to 69	SRR
	74 to 76	SPR
	165 to 167	SAR
	212 to 214	TVR
	219 to 221	TPR
	310 to 312	SVR
	319 to 321	SQR
	545 to 547	TPR
Casein kinase II phosphorylation site	615 to 617	SGR
	29 to 32	SSED
	116 to 119	SLTD
	219 to 222	TPRE
	269 to 272	TLEE
	382 to 385	TVTE
	386 to 389	TLEE
	397 to 400	TESE
	419 to 422	STPE
	430 to 433	TLLE
	446 to 449	SEEE
	545 to 548	TPRE
	558 to 561	TLVE

Table IX (Continued)

Tyrosine kinase phosphorylation site	128 to 135	RPNDSGIY
	451 to 459	KALEEEEEKY
N-myristoylation site	47 to 52	GVLGGA
	133 to 138	GIYRCE
	142 to 147	GIDDSS
	174 to 179	GAQEAC
	183 to 188	GAHIAT
	281 to 286	GAEIAT
	288 to 293	GQLYAA
	297 to 302	GLDHCS
	324 to 329	GGLPGV
	403 to 408	GAIYSI
	414 to 419	GGGGSS
	576 to 581	GVPRGE
	586 to 591	GSSEGA
Immunoglobulin-/major histocompatibility protein-like (Ig-/MHC-like) domain	50 to 141	See Fig. 7
Extracellular link domain	156 to 251	See Fig. 7
	257 to 353	See Fig. 7

Among the domains that occur in TANGO 332 protein are an Ig-  
5 /MHC-like domain and a pair of extracellular link domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In other embodiments, the protein has at least one Ig-/MHC-like domain  
10 and one extracellular link domain described herein in Table IX. In other

embodiments, the protein has at least one Ig-/MHC-like domain and at least two extracellular link domains.

Ig-/MHC-like domains are conserved among immunoglobulin (Ig) constant (CL) regions and one of the three extracellular domains of major histocompatibility proteins (MHC). The presence in TANGO 332 of an Ig-/MHC-like domain indicates that the corresponding region of TANGO 332 is structurally similar to this conserved extracellular region.

Extracellular link domains occur in hyaluronan- (HA-)binding proteins. Proteins having this domain include cartilage link protein, proteoglycans such as aggrecan, brevican, neurocan, and versican, CD44 antigen (the primary cell surface receptor for HA), and tumor necrosis factor-inducible protein TSG-6. Presence of a pair of extracellular link domains in TANGO 332 indicates that this protein is also involved in HA-binding, and therefore is involved in physiological processes such as cartilage (and other tissue) organization, extracellular matrix organization, neural growth and branching, and cell-to-cell and cell-to-matrix interactions. Involvement of TANGO 332 in these processes implicates this protein in disorders such as tumor growth and metastasis, movement of cells (e.g., leukocytes) through extracellular matrix, inappropriate inflammation, and the like.

Brevican is a murine nervous system-specific chondroitin sulfate proteoglycan which binds in a calcium-dependent manner with two classes of sulfated glycolipids, namely sulfatides and HNK-1-reactive sulfoglucuronylglycolipids (Miura et al. (1999) *J. Biol. Chem.* 274:11431-11438). A human orthologue, designated BEF ('Brain-Enriched hyaluronan-binding Factor'), of murine brevican is expressed by human glioma cells, but not by brain tumors of non-glial origin (P.C.T. application publication number WO98/31800; Zhang et al. (1998) *J. Neurosci.* 18:2370-2376). Those authors suggested that cleavage of that human orthologue mediates glioma cell invasion *in vivo*.

An alignment of the amino acid sequences of TANGO 332 and BEF protein is shown in Figures 7G and 7H. In this alignment (made using the ALIGN software {Myers and Miller (1989) *CABIOS*, ver. 2.0}; pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 75.7% identical, although it is seen that TANGO 332 includes two domains (one from

about amino acid residue 152 to about residue 208, and the other near the carboxyl terminus of TANGO 332) which do not occur in BEF protein. It is likely that these two regions account for the differences between the physiological roles of TANGO 332 and BEF.

5           An alignment of the amino acid sequences of (human) TANGO 332 and murine brevican protein is shown in Figures 7I through 7K. In this alignment (made using the ALIGN software (Myers and Miller (1989) *CABIOS*, ver. 2.0); pam120.mat scoring matrix; gap opening penalty = 12, gap extension penalty = 4), the proteins are 75.5% identical, although it is seen that murine brevican protein  
10 includes a domain which does not occur in TANGO 332 protein, this domain is present from about amino acid residue 626 to the carboxyl terminus of murine brevican protein. An alignment of the nucleotide sequences of the ORFs encoding (human) TANGO 332 and murine brevican protein is shown in Figures 7L through 7U. The two ORFs are 62.6% identical, as assessed using the same software and  
15 parameters.

TANGO 332 exhibits many of the same properties as BEF. TANGO 332 is also related to murine brevican protein, and thus is involved with corresponding physiological processes (i.e., such as those described above) in humans. For example, TANGO 332 modulates intracellular binding and migration  
20 of cells in a tissue or extracellular matrix. However, the absence from BEF of one of the two extracellular link domains present in TANGO 332 indicates that one or more of the subunit structure, the tissue specificity, and the binding specificity of TANGO 332 and BEF proteins differ. Thus, TANGO 332 is involved in many of the physiological processes and disorders in which BEF protein is involved. Like  
25 murine brevican and other proteoglycans, TANGO 332 acts *in vivo* as a tissue organizing protein, influences growth and maturation of tissues in which it is expressed, modulates growth factor-mediated activities, modulates structural features of tissues (e.g., collagen fibrillogenesis), modulates tumor cell growth and invasivity, and influences neurite growth and branching.

30           The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 332 protein includes an approximately 22 (i.e., 20, 21, 22, 23, or 24) amino acid residue signal

peptide (amino acid residues 1 to 22 of SEQ ID NO: 61; SEQ ID NO: 62) preceding the mature TANGO 332 protein (i.e., approximately amino acid residues 23 to 671 of SEQ ID NO: 61; SEQ ID NO: 63). Human TANGO 332 protein is a secreted protein, as assessed using the secretion assay described herein. Secreted TANGO  
5 332 proteins having approximate sizes of 148 kilodaltons and 100 kilodaltons could be detected using this assay.

Figure 7F depicts a hydrophilicity plot of human TANGO 332 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The  
10 hydrophobic region which corresponds to amino acid residues 1 to 22 of SEQ ID NO: 61 is the signal sequence of human TANGO 332 (SEQ ID NO: 62). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human  
15 TANGO 332 protein from about amino acid residue 445 to about amino acid residue 475 appears to be located at or near the surface of the protein, while the region from about amino acid residue 45 to about amino acid residue 62 appears not to be located at or near the surface.

The predicted molecular weight of human TANGO 332 protein  
20 without modification and prior to cleavage of the signal sequence is about 71.7 kilodaltons. The predicted molecular weight of the mature human TANGO 332 protein without modification and after cleavage of the signal sequence is about 69.5 kilodaltons.

25 Biological function of TANGO 332 proteins, nucleic acids encoding them, and modulators of these molecules

TANGO 332 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 332 is expressed in human  
30 adult brain tissue, TANGO 332 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 332 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells

including, but not limited to, adult brain cells of the animal in which it is normally expressed. Thus, TANGO 332 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, interaction, and activity.

Examples of such disorders include, by way of example and not limitation,  
5 disorders of neural connection establishment or maintenance, impaired cognitive function, dementia, senility, Alzheimer's disease, mental retardation, brain tumors (e.g., gliomas such as astrocytomas, endophytic and exophytic retinoblastomas, ependymomas, gangliogliomas, mixed gliomas, nasal gliomas, optic gliomas, and Schwannomas, and other brain cell tumors such as medulloblastomas, pituitary  
10 adenomas, teratomas, etc.), and the like.

Homology of human TANGO 332 with murine brevican protein and with human brevican homolog BEF indicates that TANGO 332 has physiological functions in humans analogous to the functions of these proteins. Brevican is a member of the aggrecan/versican family of proteoglycans, and has a hyaluronic  
15 acid-binding domain in its amino terminal region and a lectin-like domain in its carboxyl terminal region. Expression of brevican is highly specific to brain tissue, and increases as the mammalian brain develops. Thus, brevican is involved in maintaining the extracellular environment of mature brain tissue and is a constituent of adult brain extracellular matrix. TANGO 332 is involved in modulating cell-to-  
20 cell adhesion, tissue and extracellular matrix invasivity of cells, and the like. Thus, TANGO 332 is involved in disorders in which these physiological processes are relevant. Such disorders include, for example, loss of control of cell growth, tumor metastasis, malformation of neurological connections, inflammation, immune and autoimmune responses, and the like.

25 In addition, presence in TANGO 332 of extracellular link domains indicates that this protein is involved in physiological processes involving structure and function of extracellular matrices and interaction of cells with such matrices and with each other. This is further evidence that TANGO 332 is involved in disorders such as inappropriate inflammation, tumor metastasis, inappropriate  
30 leukocyte extravasation, localization, and reactivity, and the like.

TANGO 332-related molecules can be used to modulate one or more of the activities in which TANGO 332 is involved and can also be used to prevent, diagnose, or treat one or more of the disorders in which TANGO 332 is involved.

- Tables A and B summarize sequence data corresponding to the
5. human proteins herein designated INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332.

Table A

Protein Designation	SEQ ID NOs			Depicted in Figure #	ATCC® Accession #
	cDNA	ORF	Protein		
INTERCEPT 217	1	2	3	1	PTA-147
INTERCEPT 297	9	10	11	2	PTA-147
TANGO 276	33	34	35	3	PTA-150
TANGO 292	38	39	40	4	207230
TANGO 325	46	47	48	5	PTA-147
TANGO 331	54	55	56	6	PTA-147
TANGO 332	59	60	61	7	PTA-151

Table B

Protein Desig.	Signal Sequence	Mature Protein	Extracellular Domain(s)	Transmembrane Domain(s)	Cytoplasmic Domain(s)
SEQ ID NOs					
INTERCEPT 217	1-20	4	5	6	7
INTERCEPT 297	(1-18)	(12)	13	14	(12)
			19-371	19-47	69-88
				110-118	138-144
				162-175	193-215
				234-260	284-292
				313-319	337-371
TANGO 276	1-20	36	37	37	N/A
TANGO 292	1-17	41	42	43	45
TANGO 325	1-31	49	50	51	53
TANGO 331	1-24	57	58	58	N/A
TANGO 332	1-22	62	63	63	N/A
Amino Acid Residues					

Various aspects of the invention are described in further detail in the following subsections.

#### I. Isolated Nucleic Acid Molecules

5           One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a biologically active portion thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the  
10           amplification or mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

15           An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of  
20           the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kilobases, 4 kilobases, 3 kilobases, 2 kilobases, 1 kilobases, 0.5 kilobases, or 0.1 kilobases of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an  
25           "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

30           A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of all or a portion of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or a complement thereof, or which has a nucleotide sequence comprising one of these sequences, can be

isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequences of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92 as a hybridization probe, nucleic acid molecules of the invention can be isolated using  
5 standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide  
10 primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

15 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a portion thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently  
20 complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding a full length polypeptide of the invention for example, a fragment which can be used as a probe or primer or a  
25 fragment encoding a biologically active portion of a polypeptide of the invention. The nucleotide sequence determined from the cloning one gene allows for the generation of probes and primers designed for use in identifying and/or cloning homologs in other cell types, e.g., from other tissues, as well as homologs from other mammals. The probe/primer typically comprises substantially purified  
30 oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 15, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or

400 or more consecutive nucleotides of the sense or anti-sense sequence of one of any of SEQ ID NOs: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or of a naturally occurring mutant of one of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92.

5 Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences encoding the same protein molecule encoded by a selected nucleic acid molecule. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of  
10 a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

A nucleic acid fragment encoding a biologically active portion of a  
15 polypeptide of the invention can be prepared by isolating a portion of one of SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, and 92, expressing the encoded portion of the polypeptide protein (e.g., by recombinant expression *in vitro*), and assessing the activity of the encoded portion of the polypeptide.

The invention further encompasses nucleic acid molecules that differ  
20 from the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence of SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, or 92.

In addition to the nucleotide sequences of SEQ ID NOs: 2, 10, 34,  
25 39, 47, 55, 60, 82, and 92, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus.

30 As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding proteins of the invention from other species (homologs), which have a nucleotide sequence which differs from that of the specific proteins described herein are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologs of a cDNA of the invention can be isolated based on their identity to human nucleic acid molecules using the cDNAs described herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a cDNA encoding a soluble form of a membrane-bound protein of the invention isolated based on its hybridization to a nucleic acid molecule encoding all or part of the membrane-bound form. Likewise, a cDNA encoding a membrane-bound form can be isolated based on its hybridization to a nucleic acid molecule encoding all or part of the soluble form.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a complement thereof. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least

60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or a complement thereof, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention sequence that can exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (e.g., murine and human) may be essential for activity and thus would not be likely targets for alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that

includes an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the amino acid sequence of one of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98.

5 An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, such that one or more amino acid residue substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated  
10 mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with  
15 basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains  
20 (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be  
25 determined.

In a preferred embodiment, a mutant polypeptide that is a variant of a polypeptide of the invention can be assayed for: (1) the ability to form protein:protein interactions with the polypeptide of the invention; (2) the ability to bind a ligand of the polypeptide of the invention (e.g., another protein identified  
30 herein); (3) the ability to bind to a modulator or substrate of the polypeptide of the invention; or (4) the ability to modulate a physiological activity of the protein, such as one of those disclosed herein.

The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a polypeptide of the invention, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' un-translated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N<sub>6</sub>-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N<sub>6</sub>-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N<sub>6</sub>-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic

acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit expression, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.*

15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach (1988) *Nature* 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide of the invention can be designed based upon the nucleotide sequence of a cDNA disclosed herein. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742. Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) *Science* 261:1411-1418.

The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. See generally Helene (1991) *Anticancer Drug Des.* 6(6):569-84; Helene (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) *Bioorganic & Medicinal Chemistry* 4(1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four

natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or anti-gene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), *supra*; or as probes or primers for DNA sequence and hybridization (Hyrup (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675).

In another embodiment, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996), *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, and Finn et al. (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag et al. (1989) *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996)

*Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al. (1975) *Bioorganic Med. Chem. Lett.* 5:1119-11124).

In other embodiments, the oligonucleotide can include other  
5 appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition,  
10 oligonucleotides can be modified with hybridization-triggered cleavage agents (*see, e.g.*, Krol et al. (1988) *Bio/Techniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

15

## II. Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide of the  
20 invention. In one embodiment, the native polypeptide can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide of the invention can be synthesized chemically using standard peptide  
25 synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language  
30 "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular

material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein (e.g., the amino acid sequence shown in any of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

Preferred polypeptides have the amino acid sequence of one of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98. Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).

- 5 The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of  
10 identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions)  $\times$  100). In one embodiment the two sequences are the same length.

- The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example  
15 of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches  
20 can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes,  
25 Gapped BLAST can be utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. *Id.* When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. *See*  
30 <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated into

the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

5           The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

          The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably  
10   biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention). Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the  
15   amino-terminus or the carboxyl-terminus of the polypeptide of the invention.

          One useful fusion protein is a GST fusion protein in which the polypeptide of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

20           In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a polypeptide of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols*  
25   *in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the  
30   protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

          In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide of the invention is fused to

sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (*see, e.g., Ausubel et al., supra*). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence of a polypeptide of the invention (e.g., the signal sequence in one of SEQ ID NO: 3, 4, 11, 12, 35, 36, 40, 41, 48, 49, 56, 57, 61, 62, 83, 84, 93, and 94) can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to

- the described polypeptides having a signal sequence, as well as to the signal sequence itself and to the polypeptide in the absence of the signal sequence (i.e., the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a
- 5 protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods.
- 10 Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

In another embodiment, the signal sequences of the present invention can be used to identify regulatory sequences, e.g., promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, the

15 nucleic acids which flank the signal sequence on its amino-terminal side are likely regulatory sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences and their flanking regions, and these flanking regions can be studied to identify regulatory elements therein.

- 20 The present invention also pertains to variants of the polypeptides of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, e.g., discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally
- 25 occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject
- 30 with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants  
5 is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion  
10 proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (*see, e.g.,* Narang (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science*  
15 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded  
20 PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, re-naturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and  
25 ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening  
30 cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression

vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

An isolated polypeptide of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Figures 1F, 1M, 2D, 3E, 4E, 4M, 5F, 6D, and 7F are hydrophobicity plots of the proteins of the invention. These plots or similar analyses can be used to identify hydrophilic regions.

An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms "antibody" and "antibody substance" as used interchangeably herein refer to immunoglobulin molecules and

immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against (i.e., which bind specifically with) one or more polypeptides of the invention. Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against one or more polypeptides of the invention. Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.

The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies which bind specifically with a protein or polypeptides of the invention can be selected (e.g., partially purified) or purified using chromatographic methods, such as affinity chromatography. For

example, a recombinantly expressed and purified (or partially purified) protein of the invention can be produced as described herein, and covalently or non-covalently coupled with a solid support such as, for example, a chromatography column. The column thus exhibits specific affinity for antibody substances which bind

5 specifically with the protein of the invention, and these antibody substances can be purified from a sample containing antibody substances directed against a large number of different epitopes, thereby generating a substantially purified antibody substance composition, i.e., one that is substantially free of antibody substances which do not bind specifically with the protein. By a substantially purified

10 antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those on the desired protein or polypeptide of the invention, preferably at most 20%, more preferably at most 10%, most preferably at most 5% (by dry weight), of the sample is contaminating antibodies. A purified antibody

15 composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

At an appropriate time after immunization, e.g., when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as

20 the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see

25 generally *Current Protocols in Immunology* (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, NY). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas,

30 a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest.

Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SURFZAP™ Phage Display Kit*, Catalog No. 240612).

Additionally, examples of methods and reagents particularly amenable for use in  
5 generating and screening antibody display library can be found in, for example,  
U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication  
No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO  
92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO  
92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO  
10 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum.  
Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths  
et al. (1993) *EMBO J.* 12:725-734.

Additionally, recombinant antibodies, such as chimeric and  
humanized monoclonal antibodies, comprising both human and non-human  
15 portions, which can be made using standard recombinant DNA techniques, are  
within the scope of the invention. A chimeric antibody is a molecule in which  
different portions of the antibody amino acid sequence are derived from different  
animal species, such as those having a variable region derived from a murine  
monoclonal antibody and a constant region derived from a human immunoglobulin.  
20 (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No.  
4,816,397). Humanized antibodies are antibody molecules which are obtained from  
non-human species, which have one or more complementarity-determining regions  
(CDRs) derived from the non-human species, and which have a framework region  
derived from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent  
25 No. 5,585,089). Such chimeric and humanized monoclonal antibodies can be  
produced by recombinant DNA techniques known in the art, for example using  
methods described in PCT Publication No. WO 87/02671; European Patent  
Application 184,187; European Patent Application 171,496; European Patent  
Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No.  
30 4,816,567; European Patent Application 125,023; Better et al. (1988) *Science*  
240:1041-1043; Liu et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu et  
al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *Proc. Natl. Acad. Sci. USA*

84:214-218; Nishimura et al. (1987) *Cancer Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559); Morrison (1985) *Science* 229:1202-1207; Oi et al. (1986) *Bio/Techniques* 4:214; U.S. Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al.  
5 (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy  
10 and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and  
15 subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal  
20 antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

25 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., 1994, *Bio/technology* 12:899-903).

30 An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an

- antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example,
- 5 determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group
  - 10 complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent
  - 15 materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

- Further, an antibody substance can be conjugated with a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion. Cytotoxins and cytotoxic agents include any agent that is detrimental to cells.
- 20 Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of these compounds.
  - 25 Therapeutic agents include, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, and decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine {BSNU}, lomustine {CCNU}, cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin),
  - 30 anthracyclines (e.g., daunorubicin {formerly daunomycin} and doxorubicin), antibiotics (e.g., dactinomycin {formerly actinomycin}, bleomycin, mithramycin,

and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used to modify a biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety can be a protein or polypeptide which exhibits a desired biological activity. Such proteins include, for example, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; and biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and other growth factors.

Techniques for conjugating a therapeutic moiety with an antibody substance are well known (see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., eds., pp. 243-256, Alan R. Liss, Inc., 1985; Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., pp. 623-653, Marcel Dekker, Inc., 1987; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological and Clinical Applications, Pinchera et al., eds., pp. 475-506, 1985; "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin et al., eds., pp. 303-316, Academic Press, 1985; and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58, 1982). Alternatively, an antibody can be conjugated with a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragment thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of

- (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;
- 5 (iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of
- 10 the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or
- 15 with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a

20 polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:

- (i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as
- 25 ATCC® PTA-147, PTA-150, 207230, or PTA-151;
- (iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of
- 30 the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

(iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

(v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC<sup>®</sup> PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The substantially purified antibodies or fragments thereof can specifically bind with a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain cytoplasmic membrane of a polypeptide of the invention. In a particularly preferred embodiment, the substantially purified  
5 antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind with a secreted sequence or with an extracellular domain of one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. Preferably, the extracellular domain with which  
10 the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 14-18, 37, 43, 51, 58, or 63.

Any of the antibody substances of the invention can be conjugated with a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated with the antibody substances of the  
15 invention include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide)..

The invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use.  
20 Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.

25 Still another aspect of the invention is a method of making an antibody that specifically recognizes one of INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, and TANGO 332. This method comprises immunizing a vertebrate (e.g., a mammal such as a rabbit, goat, or pig) with a polypeptide. The polypeptide used as an immunogen has an amino  
30 acid sequence that comprises a sequence selected from the group consisting of:

(i) SEQ ID NOs: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98;

(ii) the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151;

(iii) a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98;

5 (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, or 93-98, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and

10 (v) an amino acid sequence which is encoded by a nucleic acid molecule, the complement of which hybridizes with a nucleic acid molecule having the sequence of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, or 92, or with a cDNA of a clone deposited as ATCC® PTA-147, PTA-150, 207230, or PTA-151, under conditions of hybridization of 6× SSC (standard saline citrate  
15 buffer) at 45°C and washing in 0.2× SSC, 0.1% SDS at 65°C.

After immunization, a sample is collected from the vertebrate that contains an antibody that specifically recognizes the polypeptide with which the vertebrate was immunized. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, an antibody substance can be further  
20 purified from the sample using techniques well known to those of skill in the art. The method can further comprise making a monoclonal antibody-producing cell from a cell of the vertebrate. Optionally, antibodies can be collected from the antibody-producing cell.

### 25 III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide of the invention (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has  
30 been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated

into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon  
5 introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of  
10 expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or  
15 more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro*  
20 transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990).  
25 Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be  
30 transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce

proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic (e.g., *E. coli*) or  
5 eukaryotic cells (e.g., insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E.*  
10 *coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the  
15 recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their  
20 cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target  
25 recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector  
30 relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7

gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident lambda prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari et al. (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al. (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

Alternatively, the expression vector is a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., *supra*.

- In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-
- 5 limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and
- 10 Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166).
- 15 Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

- The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in
- 20 an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous
- 25 expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under
- 30 the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of

the regulation of gene expression using antisense genes see Weintraub et al. (*Reviews - Trends in Genetics*, Vol. 1(1) 1986).

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms  
5 "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included  
10 within the scope of the term as used herein.

A host cell can be any prokaryotic (e.g., *E. coli*) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the  
15 terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*supra*), and other laboratory  
20 manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for  
25 resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

30 In another embodiment, the expression characteristics of an endogenous nucleic acid within a cell, cell line, or microorganism (e.g., a INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325,

TANGO 331, or TANGO 332 nucleic acid, as described herein) can be modified by inserting a heterologous DNA regulatory element (i.e., one that is heterologous with respect to the endogenous gene) into the genome of the cell, stable cell line, or cloned microorganism. The inserted regulatory element can be operatively linked  
5 with the endogenous gene (e.g., INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332) and thereby control, modulate, or activate the endogenous gene. For example, an endogenous INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene which is normally "transcriptionally silent"  
10 (i.e., a INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene which is normally not expressed, or is normally expressed only at only a very low level) can be activated by inserting a regulatory element which is capable of promoting expression of the gene in the cell, cell line, or microorganism. Alternatively, a transcriptionally silent, endogenous  
15 INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene can be activated by inserting a promiscuous regulatory element that works across cell types.

A heterologous regulatory element can be inserted into a stable cell line or cloned microorganism such that it is operatively linked with and activates  
20 expression of an endogenous INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art (described e.g., in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991).

25 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector  
30 encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide of the invention have been introduced into their genome or homologous recombinant animals in which endogenous encoding a polypeptide of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide of the invention (or a homologue thereof) into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for

example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), and in Wakayama et al., 1999, Proc. Natl. Acad. Sci. USA 96:14984-14989. Similar methods are used for production of other  
5 transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals  
10 carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide of the invention into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene. In a preferred embodiment, the vector is  
15 designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be  
20 altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid  
25 sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (*see, e.g.*, Thomas and Capecchi (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in  
30 which the introduced gene has homologously recombined with the endogenous gene are selected (*see, e.g.*, Li et al. (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras

(see, e.g., Bradley in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication NOS. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

#### IV. Pharmaceutical Compositions

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically

acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention and one or more additional active compounds.

The agent which modulates expression or activity can, for example, be a small molecule. For example, such small molecules include peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the

composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined using the assays described herein. When one or more of these agents is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or

methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.

For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.

Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic

dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional  
5 desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.  
10 Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of  
15 a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or  
20 saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

25 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal  
30 administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers  
5 that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to  
10 those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having one or more monoclonal antibodies incorporated therein or thereon; e.g., liposomes comprising a monoclonal antibody which binds specifically with a virus antigen) can also be used as pharmaceutically acceptable carriers.  
15 These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as  
20 unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect  
25 to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally,  
30 partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be

used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al. ((1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193).

- 5           The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (*see, e.g.,* Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy
- 10   vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
- 15           The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### V. Uses and Methods of the Invention

- The nucleic acid molecules, proteins, protein homologs, and
- 20   antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology); c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic). For example, polypeptides of the invention can
- 25   to used for all of the purposes identified herein in portions of the disclosure relating to individual types of protein of the invention (e.g., INTERCEPT 217 proteins, INTERCEPT 297 proteins, TANGO 276 proteins, TANGO 292 proteins, TANGO 325 proteins, TANGO 331 proteins, and TANGO 332 proteins). The isolated nucleic acid molecules of the invention can be used to express proteins (e.g., via a
- 30   recombinant expression vector in a host cell in gene therapy applications), to detect mRNA (e.g., in a biological sample) or a genetic lesion, and to modulate activity of a polypeptide of the invention. In addition, the polypeptides of the invention can be

used to screen drugs or compounds which modulate activity or expression of a polypeptide of the invention as well as to treat disorders characterized by insufficient or excessive production of a protein of the invention or production of a form of a protein of the invention which has decreased or aberrant activity compared to the wild type protein. In addition, the antibodies of the invention can be used to detect and isolate a protein of the and modulate activity of a protein of the invention.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

#### A. Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a polypeptide of the invention or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al.

(1994). *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop et al. (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds can be presented in solution (e.g., Houghten  
5 (1992) *Bio/Techniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84),  
chips (Fodor (1993) *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409),  
spores (Patent NOS. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al.  
(1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or phage (Scott and Smith (1990)  
*Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla et al. (1990)  
10 *Proc. Natl. Acad. Sci. USA* 87:6378-6382; and Felici (1991) *J. Mol. Biol.* 222:301-  
310).

In one embodiment, an assay is a cell-based assay in which a cell  
which expresses a membrane-bound form of a polypeptide of the invention, or a  
biologically active portion thereof, on the cell surface is contacted with a test  
15 compound and the ability of the test compound to bind to the polypeptide  
determined. The cell, for example, can be a yeast cell or a cell of mammalian  
origin. Determining the ability of the test compound to bind to the polypeptide can  
be accomplished, for example, by coupling the test compound with a radioisotope  
or enzymatic label such that binding of the test compound to the polypeptide or  
20 biologically active portion thereof can be determined by detecting the labeled  
compound in a complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  
 $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct  
counting of radio-emission or by scintillation counting. Alternatively, test  
compounds can be enzymatically labeled with, for example, horseradish peroxidase,  
25 alkaline phosphatase, or luciferase, and the enzymatic label detected by  
determination of conversion of an appropriate substrate to product. In a preferred  
embodiment, the assay comprises contacting a cell which expresses a membrane-  
bound form of a polypeptide of the invention, or a biologically active portion  
thereof, on the cell surface with a known compound which binds the polypeptide to  
30 form an assay mixture, contacting the assay mixture with a test compound, and  
determining the ability of the test compound to interact with the polypeptide,  
wherein determining the ability of the test compound to interact with the

polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or a biologically active portion thereof as compared to the known compound.

In another embodiment, the assay involves assessment of an activity  
5 characteristic of the polypeptide, wherein binding of the test compound with the polypeptide or a biologically active portion thereof alters (i.e., increases or decreases) the activity of the polypeptide.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of a polypeptide of the  
10 invention, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide or a biologically active portion thereof can be accomplished, for  
15 example, by determining the ability of the polypeptide to bind to or interact with a target molecule or to transport molecules across the cytoplasmic membrane.

Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. As used herein, a "target molecule"  
20 is a molecule with which a selected polypeptide (e.g., a polypeptide of the invention binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses the selected protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A target molecule can be a  
25 polypeptide of the invention or some other polypeptide or protein. For example, a target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a polypeptide of the invention) through the cell membrane and into the cell or a second intercellular protein which has catalytic activity or a protein  
30 which facilitates the association of downstream signaling molecules with a polypeptide of the invention. Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by

determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., an mRNA, intracellular  $\text{Ca}^{2+}$ , diacylglycerol, IP3, and the like), detecting catalytic/enzymatic activity of the target on an appropriate  
5 substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a  
10 cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the polypeptide or biologically active portion thereof. Binding of the test compound to the polypeptide can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes  
15 contacting the polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the  
20 ability of the test compound to preferentially bind to the polypeptide or biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g.,  
25 stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished, for example, by determining the ability of the polypeptide to bind to a target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability  
30 of the test compound to modulate the activity of the polypeptide can be accomplished by determining the ability of the polypeptide of the invention to further modulate the target molecule. For example, the catalytic activity, the

enzymatic activity, or both, of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting a polypeptide of the invention or biologically active portion thereof with a known  
5 compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the polypeptide to preferentially bind to or modulate the activity of a target  
10 molecule.

The cell-free assays of the present invention are amenable to use of both a soluble form or the membrane-bound form of a polypeptide of the invention. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it can be desirable to utilize a solubilizing agent such that the  
15 membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-octylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate  
20 (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

In one or more embodiments of the above assay methods of the present invention, it can be desirable to immobilize either the polypeptide of the invention or its target molecule to facilitate separation of complexed from non-  
25 complexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to the polypeptide, or interaction of the polypeptide with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and  
30 micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase fusion proteins or glutathione-S-transferase

fusion proteins can be adsorbed onto glutathione Sepharose beads (Sigma Chemical; St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or A polypeptide of the invention, and the mixture incubated  
5 under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of  
10 the polypeptide of the invention can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the polypeptide of the invention or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target  
15 molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the polypeptide of the invention or target molecules but which do not interfere with binding of the  
20 polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the polypeptide of the invention or target  
25 molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the polypeptide of the invention or target molecule.

In another embodiment, modulators of expression of a polypeptide of the invention are identified in a method in which a cell is contacted with a candidate compound and the expression of the selected mRNA or protein (i.e., the  
30 mRNA or protein corresponding to a polypeptide or nucleic acid of the invention) in the cell is determined. The level of expression of the selected mRNA or protein in the presence of the candidate compound is compared to the level of expression of

the selected mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of expression of the polypeptide of the invention based on this comparison. For example, when expression of the selected mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of the selected mRNA or protein expression. Alternatively, when expression of the selected mRNA or protein is less (i.e., statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the selected mRNA or protein expression. The level of the selected mRNA or protein expression in the cells can be determined by methods described herein.

In yet another aspect of the invention, a polypeptide of the inventions can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Bio/Techniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with the polypeptide of the invention and modulate activity of the polypeptide of the invention. Such binding proteins are also likely to be involved in the propagation of signals by the polypeptide of the inventions as, for example, upstream or downstream elements of a signaling pathway involving the polypeptide of the invention.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

#### B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue

typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

### 1. Chromosome Mapping

5           Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, nucleic acid molecules described herein or fragments thereof, can be used to map the location of the corresponding genes on a chromosome. The mapping of the sequences to chromosomes is an important first  
10   step in correlating these sequences with genes associated with disease.

          Briefly, genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 base pairs in length) from the sequence of a gene of the invention. Computer analysis of the sequence of a gene of the invention can be used to rapidly select primers that do not span more than one exon in the genomic  
15   DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the gene sequences will yield an amplified fragment. For a review of this technique, see D'Eustachio et al. ((1983) *Science* 220:919-924).

20           PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the nucleic acid sequences of the invention to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes. Other  
25   mapping strategies which can similarly be used to map a gene to its chromosome include *in situ* hybridization (described in Fan et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries. Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread  
30   can further be used to provide a precise chromosomal location in one step. For a review of this technique, see Verma et al. (Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York, 1988)).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to non-coding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland et al. (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with a gene of the invention can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Furthermore, the nucleic acid sequences disclosed herein can be used to perform searches against "mapping databases", e.g., BLAST-type search, such that the chromosome position of the gene is identified by sequence homology or identity with known sequence fragments which have been mapped to chromosomes.

A polypeptide and fragments and sequences thereof and antibodies which bind specifically with such polypeptides/fragments can be used to map the location of the gene encoding the polypeptide on a chromosome. This mapping can be performed by specifically detecting the presence of the polypeptide/fragments in

members of a panel of somatic cell hybrids between cells obtained from a first species of animal from which the protein originates and cells obtained from a second species of animal, determining which somatic cell hybrid(s) expresses the polypeptide, and noting the chromosome(s) of the first species of animal that it contains. For examples of this technique (see Pajunen et al., 1988, Cytogenet. Cell Genet. 47:37-41 and Van Keuren et al., 1986, Hum. Genet. 74:34-40).  
Alternatively, the presence of the polypeptide in the somatic cell hybrids can be determined by assaying an activity or property of the polypeptide (e.g., enzymatic activity, as described in Bordelon-Riser et al., 1979, Som. Cell Genet. 5:597-613 and Owerbach et al., 1978, Proc. Natl. Acad. Sci. USA 75:5640-5644).

## 2. Tissue Typing

The nucleic acid sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the nucleic acid sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The nucleic acid sequences of the invention uniquely

represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the non-coding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described  
5 herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the non-coding regions, fewer sequences are necessary to differentiate individuals. The non-coding sequences of SEQ ID NO: 1, 9, 33, 38, 46, 54, 59, and 81 can comfortably provide positive individual identification with a  
10 panel of perhaps 10 to 1,000 primers which each yield a non-coding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO: 2, 10, 34, 39, 47, 55, 60, 82, and 92 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from the nucleic acid sequences described  
15 herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

### 20 3. Use of Partial Gene Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology  
25 can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide  
30 polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e., another DNA

sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to non-coding regions are particularly appropriate for this use as greater numbers of polymorphisms occur in the non-coding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the nucleic acid sequences of the invention or portions thereof, e.g., fragments derived from non-coding regions having a length of at least 20 or 30 bases.

The nucleic acid sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by species and/or by organ type.

15

#### C. Predictive Medicine

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining expression of a polypeptide or nucleic acid of the invention and/or activity of a polypeptide of the invention, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant expression or activity of a polypeptide of the invention. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, mutations in a gene of the invention can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder

25

30

characterized by or associated with aberrant expression or activity of a polypeptide of the invention.

As an alternative to making determinations based on the absolute expression level of a selected gene, determinations can be based on normalized expression levels of the gene. A gene expression level is normalized by correcting the absolute expression level of the gene (e.g., an INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene as described herein) by comparing its expression to expression of a gene for which expression is not believed to be co-regulated with the gene of interest, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene. Such normalization allows comparison of the expression level in one sample, e.g., a patient sample, with the expression level in another sample, e.g., a sample obtained from a patient known not to be afflicted with a disease or condition, or between samples obtained from different sources.

Alternatively, the expression level can be assessed as a relative expression level. To assess a relative expression level for a gene (e.g., an INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO 325, TANGO 331, or TANGO 332 gene, as described herein), the level of expression of the gene is determined for 10 or more samples (preferably 50 or more samples) of different isolates of cells in which the gene is believed to be expressed, prior to assessing the level of expression of the gene in the sample of interest. The mean expression level of the gene detected in the large number of samples is determined, and this value is used as a baseline expression level for the gene. The expression level of the gene assessed in the test sample (i.e., its absolute level of expression) is divided by the mean expression value to yield a relative expression level. Such a method can identify tissues or individuals which are afflicted with a disorder associated with aberrant expression of a gene of the invention.

Preferably, the samples used in the baseline determination are generated either using cells obtained from a tissue or individual known to be afflicted with a disorder (e.g., a disorder associated with aberrant expression of one of the INTERCEPT 217, INTERCEPT 297, TANGO 276, TANGO 292, TANGO

325, TANGO 331, or TANGO 332 genes) or using cells obtained from a tissue or individual known not to be afflicted with the disorder. Alternatively, levels of expression of these genes in tissues or individuals known to be or not to be afflicted with the disorder can be used to assess whether the aberrant expression of the gene  
5 is associated with the disorder (e.g., with onset of the disorder, or as a symptom of the disorder over time).

Another aspect of the invention provides methods for expression of a nucleic acid or polypeptide of the invention or activity of a polypeptide of the invention in an individual to thereby select appropriate therapeutic or prophylactic  
10 agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent).

15 Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of a polypeptide of the invention in clinical trials. These and other agents are described in further detail in the following sections.

20 1. Diagnostic Assays

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting a polypeptide or nucleic  
25 acid (e.g., mRNA, genomic DNA) of the invention such that the presence of a polypeptide or nucleic acid of the invention is detected in the biological sample. A preferred agent for detecting mRNA or genomic DNA encoding a polypeptide of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA encoding a polypeptide of the invention. The nucleic acid probe can  
30 be, for example, a full-length cDNA, such as the nucleic acid of SEQ ID NO: 1, 9, 33, 38, 46, 54, 59, 62, or 81, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically

hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a polypeptide of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of a polypeptide of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a polypeptide of the invention or mRNA or genomic DNA encoding a polypeptide of the invention, such that the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide is detected in the biological sample, and comparing the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the control sample with the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). For example, the kit can comprise a labeled compound or agent capable of detecting the polypeptide or mRNA encoding the polypeptide in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule encoding a polypeptide of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a

protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually  
5 enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide.

10 2. Prognostic Assays

The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, the assays described herein, such as the preceding  
15 diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). Alternatively, the prognostic assays can be utilized to identify a subject  
20 having or at risk for developing such a disease or disorder. Thus, the present invention provides a method in which a test sample is obtained from a subject and a polypeptide or nucleic acid (e.g., mRNA, genomic DNA) of the invention is detected, wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant  
25 expression or activity of the polypeptide. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist,  
30 antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, such methods can be used

to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease activity of the polypeptide). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant expression or activity of a polypeptide of the invention in which a test sample is obtained and the polypeptide or nucleic acid encoding the polypeptide is detected (e.g., wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant expression or activity of the polypeptide).

10           The methods of the invention can also be used to detect genetic lesions or mutations in a gene of the invention, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized aberrant expression or activity of a polypeptide of the invention. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding the polypeptide of the invention, or the mis-expression of the gene encoding the polypeptide of the invention. For example, such genetic lesions or mutations can be detected by ascertaining the existence of at least one of:

15           1) a deletion of one or more nucleotides from the gene; 2) an addition of one or more nucleotides to the gene; 3) a substitution of one or more nucleotides of the gene; 4) a chromosomal rearrangement of the gene; 5) an alteration in the level of a messenger RNA transcript of the gene; 6) an aberrant modification of the gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; 8) a non-wild type level of the protein encoded by the gene; 9) an allelic loss of the gene; and 10) an inappropriate post-translational modification of the protein encoded by the gene.

25           As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a gene.

          In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran et al. (1988) *Science*

30

241:1077-1080; and Nakazawa et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in a gene (see, e.g., Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to the selected gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. PCR and/or LCR can be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self-sustained sequence replication (Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a selected gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, (optionally) amplified, digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al.

(1996) *Human Mutation* 7:244-255; Kozal et al. (1996) *Nature Medicine* 2:753-759). For example, genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the selected gene and detect mutations by comparing the sequence of the sample nucleic acids with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Bio/Techniques* 19:448), including sequencing by mass spectrometry (*see, e.g.*, PCT Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in a selected gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) *Science* 230:1242). In general, the technique of mismatch cleavage entails providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to base pair mismatches between the control and sample strands. RNA/DNA duplexes can be treated with

RNase to digest mismatched regions, and DNA/DNA hybrids can be treated with S1 nuclease to digest mismatched regions.

In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:4397; Saleeba et al. (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called DNA mismatch repair enzymes) in defined systems for detecting and mapping point mutations in cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a selected sequence, e.g., a wild-type sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in genes. For example, single strand conformation polymorphism (SSCP) can be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2766; see also Cotton (1993) *Mutat. Res.* 285:125-144; Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids will be denatured and allowed to re-nature. The secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments can be labeled or detected with labeled probes. The sensitivity of the assay can be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a

preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) *Trends Genet.* 7:5).

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a 'GC clamp' of approximately 40 base pairs of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys. Chem.* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers can be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) *Nature* 324:163); Saiki et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification can be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification can carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; Gibbs et al. (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatching can prevent or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition, it can be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) *Mol. Cell Probes* 6:1). Amplification can also be performed using Taq ligase for

amplification (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5           The methods described herein can be performed, for example, using pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which can be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a gene encoding a polypeptide of the invention. Furthermore, any cell  
10   type or tissue, preferably peripheral blood leukocytes, in which the polypeptide of the invention is expressed can be utilized in the prognostic assays described herein.

### 3.   Pharmacogenomics

          Agents, or modulators which have a stimulatory or inhibitory effect  
15   on activity or expression of a polypeptide of the invention as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant activity of the polypeptide. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's  
20   response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic  
25   treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of a polypeptide of the invention, expression of a nucleic acid of the invention, or mutation content of a gene of the invention in an individual can be determined to thereby select appropriate agent(s)  
30   for therapeutic or prophylactic treatment of the individual.

          Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal

action in affected persons. See, e.g., Linder (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors  
5 altering the way the body acts on drugs are referred to as "altered drug metabolism".

These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials,  
10 sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and  
15 CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations.  
20 For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no  
25 therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

30 Thus, the activity of a polypeptide of the invention, expression of a nucleic acid encoding the polypeptide, or mutation content of a gene encoding the polypeptide in an individual can be determined to thereby select appropriate

agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of activity or expression of the polypeptide, such as a modulator identified by one of the exemplary screening assays described herein.

10 4. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drug compounds) on the expression or activity of a polypeptide of the invention (e.g., the ability to modulate aberrant cell proliferation chemotaxis, and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent, as determined by a screening assay as described herein, to increase gene expression, protein levels, or protein activity, can be monitored in clinical trials of subjects exhibiting decreased gene expression, protein levels, or protein activity. Alternatively, the effectiveness of an agent, as determined by a screening assay, to decrease gene expression, protein levels or protein activity, can be monitored in clinical trials of subjects exhibiting increased gene expression, protein levels, or protein activity. In such clinical trials, expression or activity of a polypeptide of the invention and preferably, that of other polypeptide that have been implicated in for example, a cellular proliferation disorder, can be used as a marker of the immune responsiveness of a particular cell.

25 For example, and not by way of limitation, genes, including those of the invention, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates activity or expression of a polypeptide of the invention (e.g., as identified in a screening assay described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of a gene of the invention and other genes implicated in the disorder. The levels of gene expression (i.e., a

gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of a gene of the invention or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state can be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of the polypeptide or nucleic acid of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of the polypeptide or nucleic acid of the invention in the post-administration samples; (v) comparing the level of the polypeptide or nucleic acid of the invention in the pre-administration sample with the level of the polypeptide or nucleic acid of the invention in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase the expression or activity of the polypeptide to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression or activity of the polypeptide to lower levels than detected, i.e., to decrease the effectiveness of the agent.

#### D. Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant expression or activity of a polypeptide of the invention and/or in which the polypeptide of the invention is involved. Disorders

characterized by aberrant expression or activity of the polypeptides of the invention are described elsewhere in this disclosure.

1. Prophylactic Methods

5 In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a polypeptide of the invention, by administering to the subject an agent which modulates expression or at least one activity of the polypeptide. Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a  
10 polypeptide of the invention can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of aberrance, for example, an  
15 agonist or antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating  
20 expression or activity of a polypeptide of the invention for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of the polypeptide. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a  
25 peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of the polypeptide. Examples of such stimulatory agents include the active polypeptide of the invention and a nucleic acid molecule encoding the polypeptide of the invention that has been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological  
30 activities of the polypeptide of the invention. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or,

alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a polypeptide of the invention. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) expression or activity. In another embodiment, the method involves administering a polypeptide of the invention or a nucleic acid molecule of the invention as therapy to compensate for reduced or aberrant expression or activity of the polypeptide.

Stimulation of activity is desirable in situations in which activity or expression is abnormally low or down-regulated and/or in which increased activity is likely to have a beneficial effect, e.g., in wound healing. Conversely, inhibition of activity is desirable in situations in which activity or expression is abnormally high or up-regulated and/or in which decreased activity is likely to have a beneficial effect.

The contents of all references, patents, and published patent applications cited throughout this application are hereby incorporated by reference.

#### Deposits of Clones

Clones encoding the proteins of the invention were deposited with the American Type Culture Collection (ATCC®, 10801 University Boulevard, Manassas, VA 20110-2209) on April 27, 1999 and May 27, 1999. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Each of these deposits was made merely as a convenience to those of skill in the art. These deposits are not an admission that a deposit is required under 35 U.S.C. §112.

Clones comprising cDNA molecules encoding human INTERCEPT 217, human INTERCEPT 297, human TANGO 325, and human TANGO 331 were deposited with ATCC® on May 28, 1999, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid

harboring a particular cDNA clone. This deposit was assigned Accession Number PTA-147

To distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture is streaked out to single colonies on nutrient medium (e.g., Luria broth plates) supplemented with 100 micrograms per milliliter ampicillin, single colonies grown, and then plasmid DNA is extracted using a standard mini-preparation procedure. Next, a sample of the DNA mini-preparation is digested using a combination of the restriction enzymes *Sall*, *NorI*, and *SmaI*, and the resultant products are resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions. The digest liberates fragments as follows:

1. human INTERCEPT 217 (clone EpT217): 2.9 kilobases
2. human INTERCEPT 297 (clone EpT297): 1.2 kilobases and 0.3 kilobases (human INTERCEPT 297 has a *SmaI* cut site at about base pair 1183).
3. human TANGO 325 (clone EpT325): 2.2 kilobases
4. human TANGO 331 (clone EpT331): 1.4 kilobases

The identity of the strains can be inferred from the fragments liberated.

Human TANGO 276, human TANGO 292, and human TANGO 332 were each deposited as single deposits. Their clone names, deposit dates, and accession numbers are as follows:

1. human TANGO 276: clone EpT276 was deposited with ATCC® on May 28, 1999, and was assigned Accession Number PTA-150.
2. human TANGO 292: clone EpT292 was deposited with ATCC® on April 28, 1999, and was assigned Accession Number 207230.
3. human TANGO 332: clone EpT332 was deposited with ATCC® on May 28, 1999, and was assigned Accession Number PTA-151.

**Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be

5 encompassed by the following claims.

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule having a nucleotide sequence which is at least 40% identical to the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92 or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

b) a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98 or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the fragment comprises at least 8 consecutive amino acid residues of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151; and

e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule consisting of the

nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions.

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid having the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

3. The nucleic acid molecule of claim 1, further comprising vector nucleic acid sequences.

4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

5. A host cell which contains the nucleic acid molecule of claim 1.

6. The host cell of claim 5 which is a mammalian host cell.

7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.

8. An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the fragment comprises at least 8 contiguous amino acids of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151;

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions; and

c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 40% identical to a nucleic acid consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

9. The isolated polypeptide of claim 8 having the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof.

10. The polypeptide of claim 8, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

11. An antibody which selectively binds with the polypeptide of claim 8.

12. A method for producing a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof;

b) a polypeptide comprising a fragment of the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof, wherein the fragment comprises at least 8 contiguous amino acids of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof; and

c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 3-8, 11-32, 35-37, 40-45, 48-53, 56-58, 61-63, 83-88, and 93-98, or the amino acid sequence encoded by a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NO: 1, 2, 9, 10, 33, 34, 38, 39, 46, 47, 54, 55, 59, 60, 81, 82, and 92, or the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers PTA-147, PTA-150, 207230, and PTA-151, or a complement thereof under stringent conditions;

the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

- a) contacting the sample with a compound which selectively binds with a polypeptide of claim 8; and
- b) determining whether the compound binds with the polypeptide in the sample.

14. The method of claim 13, wherein the compound which binds with the polypeptide is an antibody.

15. A kit comprising a compound which selectively binds with a polypeptide of claim 8 and instructions for use.

16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes with the nucleic acid molecule; and
- b) determining whether the nucleic acid probe or primer binds with a nucleic acid molecule in the sample.

17. The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

18. A kit comprising a compound which selectively hybridizes with a nucleic acid molecule of claim 1 and instructions for use.

19. A method for identifying a compound which binds with a polypeptide of claim 8 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
- b) determining whether the polypeptide binds with the test compound.

20. The method of claim 19, wherein the binding of the test compound with the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for an activity characteristic of the polypeptide.

21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds with the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:

- a) contacting a polypeptide of claim 8 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

23. An antibody substance which selectively binds with the polypeptide of claim 8, wherein the antibody substance is made by providing the polypeptide to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.

1 / 109

GTCGACCCACGCGTCCGGGGAGCGGGCTAAGAGTGCCCGCACCGCCTCACAACCTGGGAACGGAGAGTAGGGCCGTC 79  
 GGCTGGCAAGAACC CGCGTCCCTCCTCGGCAAGGGCCATCCGGTGCCACCCCATGTGCGCACTAGACAGAGAGGGTGA 158  
 GTCCCTGAACCTGCAACAGAGCTGCTCTGTACTGTCCCTGGTGGTCCCGCC ATG ACC TGG TTG GTG 5 229  
 L L G T L L C M L R V G L G T P D S E G 25  
 CTG CTG GGG ACA CTG CTC TGC ATG ATG CGC GTT GGG TTA GGC ACC CCG GAC TCC GAG GGT 289  
 F P P R A L H N C P Y K C I C A A D L L 45  
 TTC CCG CCC CGT GCG CTC CAC AAC TGC CCC TAC AAA TGT ATC TGC GCT GCC GAC CTG CTA 349  
 S C T G L G L Q Q D V P A E L P A A T A D 65  
 AGC TGC ACT GGC CTA GGG CTG CAG GAC GAC GTG CCA GCC GAG TTA CCT GCC GCT ACT GCG GAC 409  
 L D L S H N A L Q R L R P G W L A P L F 85  
 CTC GAC CTG AGC CAC AAC GCG CTC CAG CGC CTG CGC CCC GGC TGG TTG GCG CCC CTC TTC 469  
 Q L R A L H L D H N E L D A L G R G V F 105  
 CAG CTG CGC GCC CTC CAC CTA GAC CAC AAC GAA CTA GAT GCG CTG GGT CGC GGC GTC TTC 529  
 V N A S G L R L L D L S S N T L R A L G 125  
 GTC AAC GCC AGC GGC CTG AGG CTG CTC GAT CTA TCA TCT AAC ACG TTG CGG GCG CTT GGC 589

Fig. 1A

2 / 109

```

R H D L D G L G A L E K L L L L F N N R L 145
CGC CAC GAC CTC GAC GGG CTG GGG CTG GAG AAG CTG CTT CTG TTC AAT AAC CGC TTG 649

V H L D E H A F H G L R A L S H L Y L G 165
GTG CAC TTG GAC GAG CAT GCC TTC CAC GGC CTG CGC GCG CTC AGC CAT CTC TAC CTG GGC 709

C N E L A S F S F D H L H G L S A T H L 185
TGC AAC GAA CTC GCC TCG TTC TCC AAC CGG CTG GGA CAC ATC TCC GTA CCT GAG CTG GCC CAC CTG 769

L T L D L S S N R L G H I S V P E L A A 205
CTT ACT CTG GAC CTC TCC TCC AAC CGG CTG GGA CAC ATC TCC GTA CCT GAG CTG GCC GCG 829

L P A F L K N G L Y L H N N P L P C D C 225
CTG CCG GCC TTC CTC AAG AAC GGC CTC TAC TTG CAC AAC AAC CCT TTG CCT TGC GAC TGC 889

R L Y H L L Q R W H Q R G L S A V R D F 245
CGC CTC TAC CAC CTG CTA CAG CGC TGG CAC CAG CGG GGC CTG AGC GCC GTG CGC GAC TTC 949

A R E Y V C L A F K V P A S R V R F Q 265
GCG CGC GAG TAC GTA TGC TTG GCC TTC AAG GTA CCC GCG TCC CGC GTG CGC TTC TTC CAG 1009

H S R V F E N C S A P A L G L K R P E 285
CAC AGC CGC GTC TTT GAG AAC TGC TCG TCG GCC CCA GCT CTT GGC CTA AAG CGG CCG GAA 1069

```

Fig. 1B

3 / 109

```

E H L Y A A L V G R S L R L Y C N T S V P 305
GAG CAC CTG TAC GCG CTG GTG GGT CGG TCC CTG AGG CTT TAC TGC AAC ACC AGC GTC CCG 1129

A M R I A W V S P Q Q CAG CAG CTT CTC AGG GCG CCA P G S R 325
GCC ATG CGC ATT GCC TGG GTT TCG CCG CAG CAG CTT CTC AGG GCG CCA GGA TCC CGC 1189

D G S I A V L A D G S L A I G N V Q E Q 345
GAT GGC AGC ATC GCG GTG CTG GCG GAC GGC AGC TTG GCC ATA GGC AAC GTA CAG GAG CAG 1249

H A G L F V C L A T G P P R R L H H N Q T H 365
CAT GCG GGA CTC TTC GTG TGC TGC ACT GCG CCC GCG CTG CAC CAC AAC CAG ACG CAC 1309

E Y N V S V H F P R P E P E A F N T G F 385
GAG TAC AAC GTG AGC GTG CAC TTT CCG CGC CCA GAG CCC GAG GCT TTC AAC ACA GGC TTC 1369

T T L L G C A V G L V L V L L Y L F A P 405
ACC ACA CTG CTG GGC TGT GCC GTG GGC CTT GTG CTC GTG CTG CTC TAC CTG TTC GCC CCA 1429

P C R C C R R A C P L P P L A P N T Q P 425
CCC TGC CGC TGC TGC CGC CGT GCC TGC CCG CTG CCG CCG CTG GCC CCA AAC ACC CAG CCC 1489

A P R A E P H K S S V L S T T P P D A P 445
GCT CCA AGA GCT GAG CCG CAG AAG TCC TCA GTA CTC AGC ACC ACA CCG CCA GAC GCA CCC 1549

```

Fig. 1C

4 / 109

S P Q G Q A S T S T \* 456  
 AGC CCG CAA GGC CAA GCG TCC ACA AGC ACG TAG 1582  
 TCTTTCTGGAGCCAGGCCGAGGGGCTCAATGGCCCCGCTGCAGCTGGCAGTAGCTGAGGAATTGATCTCTACAACC 1661  
 CTGAGGGCCTGCAGCTGAAGGCTGGCTCTGAGTCCGCCAGCTCCATAGGCTCCGAGGGTCCCATGACAACCTAGACTGC 1740  
 CAGGGCTCCCCACCCAGGCCCCACCCCTCTTGCTGCTGCGCCCTGCTCCCTGCTTCGGTCCAGAGAACTGGCAGATACT 1819  
 GGTGGGAAGCACTGTGCCTGGCCCCCAGCTTCCTGTATGGGCCCTCGAAACACAATGGGCCCTTCTCGCTCACTGGTAGA 1898  
 GACAGGGGTTGTGGTCCCCAACCTGCCCTTCTGCTCTGCCCCCTGCACAGGACCCAAAGGCCCTGCAAGGTGTG 1977  
 CTAGTTCCCTGCTTTCCCGGGACTTCCTAGTGCCCAATGCCCTGTGAGGCTGAGAGACCCAGGCCCTGTGGCTTTCA 2056  
 ACACAGCACAGCTGTGAAGTGGCTGTGTCTTCTACAGCCCTGTGGAGAACCCTGTAGCAGAGCCTCCCATCCACCC 2135  
 TCAGGGGCTGAGGCAGCTCTCGAGGAGTGGTGCTCAAGAGCTGACGAGGGCCACCTCCCCCTTCCCAAGGGGTGGAG 2214  
 GGAGTGGGCCACAGGGAAAGAGGGGCTCTGAAGGAAGATCTGCCCCACACCCCCAGGACAGAAAGAGGAAACAAGC 2293  
 CCGCCCTCTGGTGAAATGGGACTCCCTCCATCCACCAACACCCCAACCTCCTGAAAGCTTCACAACCTTCACGCAGAGTCC 2372  
 GGTGGCAGGCACCAGGCAGGAAGGCTCCTCAAGAGGTTCCCTGGTGTCTGGCCCTAAGCCCCCAGCCAGAGGCCCTGCTC 2451

Fig. 1D

5/109

TCTCTGGCCCTGGGGCATCCACCCGTTGTTCTGAAGGCAGAGCCCATTTCTGTGGGCTCACAAACACACAGTGAAGGGATC 2530  
ATGGCCTGCACCCCTGCTTTTCAGCAGTAAAGCCGAGCCCTGGCGAGCATGGCCGAGCTGGGAGGGCCGAGCCG 2609  
GAACTCCACGTCCCTCGAGAGCAGGAGCCCTCTTAAGGGCTGGCACTGGTCTCAGCCCTAATGGCTGAGGCGGTACCCCTGG 2688  
CTTCATATGCATCTCACTGCTCCCACCTGCAGGGGGGCAGGGAAGGGGGTCTGGAGCCCTTCATGTGTGGGGCCGAG 2767  
CTGGGGCCCCCATGGCCATCCTGGACCTCGCTCCAGAGTTTAATAAAGGTAGCACATGCTTATTGCTAGAAAAA 2846  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGCGGCCGC 2895

Fig. 1E




Fig. 1F

```

10      20      30      40      50      60      70
H MTWLVLLGTLLCMLRVGLGTPDSEGFPPRALHNCYPKICAAADLLSCTGLGLQDVPAELPAATADLDLSH
:. : . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P MN-LDIHCEQLSDARWTELLPQLQYEVVRLLDDCGLTEEHCKDIGS--ALRANPSLTELCLRTNEL--GD
10      20      30      40      50      60
H NALQRLRPGWLAPLFLQRLALHLDHNELDALGRGVFVNA----SGLRLDLLSSNTLRALGRHDL-DGLGA-
.... : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P AGVHLVLQGLQSPTCKIQKLSLQNCSLTEAGCGVLPSTLRSPLTLRELHLSDNPLGDAGRLRLCEGLLDP
70      80      90      100      110      120      130
H ---LEKLLLFNNRLVHLD-EHAFHGLRALSHLYLGCNELASFDFHLHGLSATHLLTLDLSSNRLIGHISV
:::: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P QCHLEKLQLEYCRLTAASCEPLASVLRATRAL----KELTVSNND--IGEAGARVLGQGLAD-----SA
140      150      160      170      180      190
H 210      220      230      240      250      260
H PELAALPAFLKN-GLYLHNNPLPCDCRLYHLLQRWHQRLSARVDFAREYVCLAFKVPASVR---FFQH
::: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
P CQLETLR--LENCGLTPANCKDLCGIVASQASLRELDLGSNGIGDAGIAELCPGLLSPASRLKTLWLWEC
200      210      220      230      240      250      260

```

**Fig. 1G**

270 280 290 300 310 320  
H SRVFENCSSA-PALGLKRPEEHLVALGRSL-----RLYCNTSV-PAMRIAVVSPQQLLRAPGSRDGS  
P DITASGCRDLRCRVLOAKETLREL-SLAGNKLGDGARGLLCESLLQPGCQLESILWVKSCSLTAACQHVSL  
270 280 290 300 310 320 330  
330 340 350 360 370 380 390  
H AVLADGSLAIGNVQEQHAGLFVCLATGPRLLHNNQTHEYNVSVHFPRPEPEAFNTGFTLLGCAVGLVLVL  
P MLTONKHL-----LELQLSSNKLGDGSGIQELCQALSQPGTTLRVLCGLDCEVTNSGCSSLAS--LLANRS  
340 350 360 370 380 390  
400 410 420 430 440 450  
H LYLFAPPCCRRACPLPPLAPNTQAPAPRAEPHK-SSVLSTTPPDAPSPQQAATS-----T  
P LRELDLSNNCVGDPGVLLQLLGSLEQPGCALEQLVLYDTYWTVEEDRLQALEGSKPGLRVIS  
400 410 420 430 440 450

Fig. 1H

```

ccg ttt ctc ttt aac cac ttg cac ggt ctg ggg tta acc cgc ctg cgg      48
Pro Phe Leu Phe Asn His Leu His Gly Leu Thr Arg Leu Arg      15
1      5      10
act ctg gac ctc tcc tcc aac tgg ctg aaa cat atc tcc atc cct gag      96
Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu      30
20      25
ttg gct gca ctg cca act tat ctc aag aac agg ctc tac ctg cac aac      144
Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn      45
35      40
aac ccg ctg ccc tgt gac tgc agc ctc tac cac ctg ctc cgg cgc tgg      192
Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp      55
50      60
cac cag cgg ggc ctg agt gcc ctg cat gat ttt gaa cgc gag tac aca      240
His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr      75
65      70
tgc ttg gtc ttt aag gtg tca gag tcc cga gtg cgc ttt ttt gag cac      288
Cys Leu Val Phe Lys Val Ser Glu Ser Arg Val Arg Phe Phe Glu His      85
80      90
agc cgg gtc ttc aag aac tgc tct gtg gct gca gct cca ggc tta gag      336
Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu      100
100      105

```

Fig. 11

10/109

ctg cct gaa gag cag ctg cac gcg cag gtg ggc cag tcc ctg agg ctc Leu Pro Glu Glu Gln Leu His Ala Gln Val Gly Gln Ser Leu Arg Leu	384
115 120 125	
ttc tgc aac acc agt gtg cct gcc act cgg gtg gcc tgg gtc tcc ccg Phe Cys Asn Thr Ser Val Pro Ala Thr Arg Val Ala Trp Val Ser Pro	432
130 135 140	
aag aat gag ctg ctt gtg gcg cca gcc tct cag gat ggt agc atc gct Lys Asn Glu Leu Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala	480
145 150 155 160	
gtg ttg gct gat ggc agc tta gcc ata ggc agg gtg caa gag cag cac Val Leu Ala Asp Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His	528
165 170 175	
gca ggc gtc ttt gtg tgc ctg gcc agt ggg ccc cgc ctg cac cac aac Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn	576
180 185 190	
cag aca ctt gag tac aat gtg agt gtg caa aag gct cgc ccc gag cca Gln Thr Leu Glu Tyr Asn Val Ser Val Gln Lys Ala Arg Pro Glu Pro	624
195 200 205	
gag act ttc aac aca ggc ttt acc acc ctg ggc tgt att gtg ggc Glu Thr Phe Asn Thr Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly	672
210 215 220	

Fig. 1J

ctg gtg ctg gtg ttg ctc tac ttg ttt gca cca ccc tgt cgt ggc tgc	720
Leu Val Leu Val Leu Leu Tyr Leu Phe Ala Pro Pro Cys Arg Gly Cys	225 230 235 240
tgt cac tgc tgt cag cgg gcc tgc cgc aac cgt tgc tgg ccc cgg gca	768
Cys His Cys Cys Gln Arg Ala Cys Arg Asn Arg Cys Trp Pro Arg Ala	245 250 255
tcc agt cca ctc cag gag ctg agc gca cag tcc tcc atg ctt agc act	816
Ser Ser Pro Leu Leu Gln Glu Leu Ser Ala Gln Ser Ser Met Leu Ser Thr	260 265 270
acg cca cca gat gca ccc agc cgc aag gcc agt gtc cac aag cat gtg	864
Thr Pro Pro Asp Ala Pro Ser Arg Lys Ala Ser Val His Lys His Val	275 280 285
gtc ttc ctg gag ccg ggc aag aag ggc ctc aat ggc cgt gtg cag ctc	912
Val Phe Leu Glu Pro Gly Lys Lys Gly Leu Asn Gly Arg Val Gln Leu	290 295 300
gca gta cct cca gac tcc gat ctg tgc aac ccc atg ggc ttg caa ctc	960
Ala Val Pro Pro Asp Ser Asp Leu Cys Asn Pro Met Gly Leu Gln Leu	305 310 315 320
aa	962

Fig. 1K

12/109




Fig. 1L

```

M      1 .....PFLFNHLHGLGLTRLRLTDLSSNWLKHISI 30
H     151 HAFHGLRALSHLYLGCNELASFSFDHLHGLSATHLLTDLSSNRIGHISV 200
M      31 PELAAALPTYLKNRLYLHNNPLPCDCSLYHLLRRWHQRLSALHDFEREYT 80
H     201 PELAAALPAFLKNGLYLHNNPLPCDCRLYHLLQRWHQRLSAVRDFAREYV 250
M      81 CLVEKVSERVRFFEHSRVFKNCVAAAPGLEPEEQLHAQVGQSLRLFC 130
H     251 CLAFKVPASRVRFQHSRVFENCSSAPALGLKRPEEHLYALVGRSLRLYC 300
M     131 NTSVPATRVAVVSPKNELLVAPASQDGSIAVLADGSLAIGRVQEQHAGVF 180
H     301 NTSVPAMRIAIVSPQQELLRAPGSRDGSIAVLADGSLAIGNVQEQHAGLF 350
M     181 VCLASGPRLHHNQTLNYSVQKARPEPETFNTGFTLLGCI VGLVLVLL 230
H     351 VCLATGPRLHHNQTHEYNVSVHFPRPEAFNTGFTLLGCAVGLVLVLL 400
M     231 YLFAPPCCGCHCCQACRNRWCWPRESSPIQELSA.QSSMLSTTPPDAPS 279
H     401 YLFAPPCCR...CCRRACPLPPLAPNTQAPAPRAEPHKSSVLSTTPPDAPS 446
M     280 RKASVHKHVVFLEPGKKGLNGRVQLAVPPDSDLCPNPMGLQL 320
H     447 PQQASTST..... 455

```

Fig. 1M

14/109

GTCGACCCACGCGTCCGGCGGAACCCAGCGTCCGCCGAC	M	A	W	T	K	Y	Q	L	F	L	10
											69
A G L M L V T G S I N T L S A K W A D N											30
GCC GGG CTC ATG CTT GTT ACC GGC TCC ATC AAC ACG CTC TCG GCA AAA TGG GCG GAC AAT											129
F M A E G C G G G G S K E H S F Q H P F L Q											50
TTC ATG GCC GAG GGC TGT GGA GGG AGC AAG GAG CAC AGC TTC CAG CAT CCC TTC CTC CAG											189
A V G M F L G E F S C L A A F Y L L R C											70
GCA GTG GGC ATG TTC CTG GGA GAA TTC TCC TGC CTG GCT GCT GCC TTC TAC CTC CTC CGA TGC											249
R A A G Q S D S S V D P Q Q P F N P L L											90
AGA GCT GCA GGG CAA TCA GAC TCC AGC GTA GAC CCC CAG CAG CCC TTC AAC CCT CTT CTT											309
F L P P A L C D M T G T S L M Y V A L N											110
TTC CTG CCC CCA GCG CTC TGT GAC ATG ACA GGG ACC AGC CTC ATG TAT GTG GCT CTG AAC											369
M T S A S S F Q M L R G A V I I F T G L											130
ATG ACC AGT GCC TCC AGC TTC CAG ATG CTG CGG GGT GCA GTG ATC ATA TTC ACT GGC CTG											429
F S V A A F L G R R L V L S Q W L G I L A											150
TTC TCG GTG GCC TTC CTG GGC CGG AGG CTG GTG CTG AGC CAG TGG CTG GGC ATC CTA GCC											489

Fig. 2A

15/109

T I A G L V V V G L A D L L L S K H D S Q 170  
 ACC ATC GCG GGG CTG GTG GTC GTG GGC CTG GCT GAC CTC CTG AGC AAG CAC GAC AGT CAG 549  
  
 H K L S E V I T G D L L L I I M A Q I I V 190  
 CAC AAG CTC AGC GAA GTG ATC ACA GGG GAC CTG TTG ATC ATC ATC GGC CAG ATC ATC GTT 609  
  
 A I Q M V L E E K F V Y Y K H N V H P L R 210  
 GCC ATC CAG ATG GTG CTA GAG GAG AAG TTC GTC TAC AAA CAC AAT GTG CAC CCA CTG CGG 669  
  
 A V G T E G L F G F V I L S L L L V P M 230  
 GCA GTT GGC ACT GAG GGC CTC TTT GGC TTT GTG ATC CTC TCC CTG CTG GTG CCC ATG 729  
  
 Y Y I P A G S F S G N P R G T L E D A L 250  
 TAC TAC ATC CCC GCC GGC TCC TTC AGC GGA AAC CCT CGT GGG ACA CTG GAG GAT GCA TTG 789  
  
 D A F C Q V G Q Q P L I A V A L L G N I 270  
 GAC GCC TTC TGC CAG GTG GGC CAG CAG CCG CTC ATT GCC GTG GCA CTG GGC AAC ATC 849  
  
 S S I A F F N F A G I S V T K E L S A T 290  
 AGC AGC ATT GCC TTC TTC AAC TTC GCA GGC ATC AGC GTC ACC AAG GAA CTG AGC GCC ACC 909  
  
 T R M V L D S L R T V V I W A L S L A L 310  
 ACC CGC ATG GTG TTG GAC AGC TTG CGC ACC GTT GTC ATC TGG GCA CTG AGC CTG GCA CTG 969

Fig. 2B

G W E A A F H A L Q I L G F L I L I G T 330  
 GGC TGG GAG GCC TTC CAT GCA CTG CAG ATC CTT GGC TTC CTC ATA CTC CTT ATA GGC ACT 1029  
  
 A L Y N G L H R P L L G R L S R G R P L 350  
 GCC CTC TAC AAT GGG CTA CAC CGT CCG CTG CTG GGC CGC CTG TCC AGG GGC CGG CCC CTG 1089  
  
 A E E S E Q E R L L G G T R T P I N D A 370  
 GCA GAG GAG AGC GAG CAG GAG AGA CTG CTG GGT GGC ACC CGC ACT CCC ATC AAT GAT GCC 1149  
  
 S \* 372  
 AGC TGA 1155  
  
 GGTTCCCTGGAGGCTTCTACTGCCACCCGGGTGCTCCTTCTCCTGAGACTGAGGCCACACAGGCTGGTGGGCCCCGAA 1234  
 TGCCCTATCCCCAAGGCCTCACCCCTGTCCCCCTGCAGAACCCCCAGGGCAGCTGCTGCCACAGAGATAACAACAC 1313  
 CCAAGTCCTCTTTTCTCACTACCACCTGCAGGGTGGTGTACCCAGCCCCACAGCCTGAGTGCAGTGCAGACCTC 1392  
 AGCTCTCTGGACCCCTCCTACAGCACTAGAGCTAAATCATGAAGTTGAATTGTAGGAATTACCACCGTAGTGTATCTG 1471  
 AATCATAAACTAGATTATCATAAAAAAGGGGCGCGC 1518

16/109

Fig. 2C




Fig. 2D

18/109

	M	A	P	H	W	
GTCGACCCACGCGTCCGCGGACAGCTGGCCTGAAGCTCAGAGCCGGGGCGTGGCC	ATG	GCC	CCA	CAC	TGG	5
						72
A V W L L A A A R L W G L G I G A E V W W						25
GCT GTC TGG CTG CTG GCA GCA AGG CTG TGG GGC CTG GGC ATT GGG GCT GAG GTG TGG TGG						132
N L V P R K T V S S G E L A T V V R R F						45
AAC CTT GTG CCG CGT AAG ACA GTG TCT TCT GGG GAG CTG GGC ACG GTA GTA CGG CGG TTC						192
S Q T G I Q D F L T L T E P T G L L						65
TCC CAG ACC GGC ATC CAG GAC TTC CTG ACA CTG ACG CTG ACG GAG CCC ACT GGG CTT CTG						252
Y V G A R E A L F A F S M E A L E L Q G						85
TAC GTG GGC GCC CGA GAG GGC CTG TTT GCC TTC AGC ATG GAG GCC CTG GAG CTG CAA GGA						312
A I S W E A P V E K K T E C I Q K G K N						105
GCG ATC TCC TGG GAG GCC CCC GTG GAG AAG AAG ACT GAG TGT ATC CAG AAA GGG AAG AAC						372
N Q T E C F N F I R F L Q P Y N A S H L						125
AAC CAG ACC GAG TGC TTC AAC TTC ATC CGC TTC CTG CAG CCC TAC AAT GCC TCC CAC CTG						432
Y V C G T Y A F Q P K C T Y V V S A A L						145
TAC GTC TGT GGC ACC TAC GCC TTC CAG CCC AAG TGC ACC TAC GTC GTG AGT GCT GCC CTC						492

Fig. 3A

19/109

L P R C P Q P P A L L T L L L W T R G C G 165  
 CTA CCT CGG TGT CCC CAG CCC CCC GGC CTC CTC CTT CTC TGG ACT CGT GGA TGT GGC 552  
  
 P Q S P A L K H L L I T S L S V L R T C 185  
 CCA CAG AGC CCT GCC CTT AAG CAT CTC CTC ATC ACC TCT CTC TCT TCT GTC CTT AGA ACA TGC 612  
  
 S P S L W S M E S L K M G R A S V P M T 205  
 TCA CCT TCA CTT TGG AGC ATG GAG AGT TTG AAG ATG GGA AGG GCA AGT GTC CCT ATG ACC 672  
  
 Q L R A M L A F L W M V S C T R P H S T 225  
 CAG CTA AGG GCC ATG CTG GCC TTC TTG TGG ATG GTG AGC TGT ACT CGG CCA CAC TCA ACA 732  
  
 T S W A R N P L S C V T W G P T T P \* 244  
 ACT TCC TGG GCA CGG AAC CCA TTA TCC TGC GTA ACA TGG GGC CCC ACC ACT CCA TGA 789  
  
 AGACAGAGTACCTGGCCTTTTGGCTCAACGAACCTCACTTTGTAGGCTCTGCCCTATGTACCTGAGAGTGTGGCAGCTT 868  
 CACGGGGGACGACGACAAGGTCTACTTCTTCTCAGGGAGCGGGCAGTGGAGTCCGACTGCTATGCCGAGCAGGTGGTG 947  
 GCTCGTGTGGCCCGTGTCTGCAAGGGCGATATGGGGGGCGCACGGACCCCTGCAGAGGAAGTGGACCCACGTTCTCTGAAGG 1026  
 CGCGGCTGGCATGCTCTGCCCCGAACTGGCAGCTCTACTTCAACCAGCTGCAGGGCGATGCACACCCCTGCAGGACACCTC 1105

Fig. 3B

20 / 109

CTGGCACAACACCACTTCTTTGGGGTTTTCAAGCACAGTGGGTGACATGTACCTGTGGCCATCTGTGAGTACCAG 1184  
TTGGAAGAGATCCAGCGGGTGTTTGAGGGCCCCCTATAAGGAGTACCATGAGGAAGCCCCAGAAAGTGGACCGCTACACTG 1263  
ACCTGTACCCAGGCCCTGGTTGTGATGGCTGCCAGCCCCGCCATGCCGGGGCCTACCACTGCTTTTCAGAGGAGCAG 1342  
GGGGCGGGCTGGCTGCTGAAGGCTACCTTGTGGCTGTCTGGCAGGCCCGTCGGTGACCTTGGAGGCCCGGGCCCCCCC 1421  
TGGAAAACCTGGGGCTGGTGTGGCTGGCGGTGGTGGCCCTGGGGGCTGTGTGCCCTGGTGTGCTGTGCTGTGCTGTC 1500  
ATTGCCCGCGGCTGCCGGAAGAGCTGGAGAAAGGGCCCAAGGCTACTGAGAGGACCTTGGTGTACCCCCCTGGAGCTG 1579  
CCCAAGGAGCCCAACCACTCCCGCCCTGTCCCTGAACCAAGATGAGAAACTTTGGGATCCTGTGCGTTACTACT 1658  
ATTCAGATGGCTCCCTTAAGATAGTACCTGGGCATGCCCGGTGCCAGCCCCGGTGGGGGGCCCCCTTCGCCACCTCCAGG 1737  
CATCCCAGGCCAGCCTCTGCCCTTCTCCAACCTCGGCTTCACCTGGGGGGTGGCGGGAACCTCAAATGCCAATGGTTACGTG 1816  
CGCTTACAACCTAGGAGGGAGGACCGGGAGGGCTCGGGCACCCCCCTGCCCTGAGCTCGCGGATGAACCTGAGACGCAAAAC 1895  
TGCAGCAACGCCAGCCACTGCCCCGACTCCAACCCCGAGGAGTCATCAGTATGAGGGGAACCCCCACCGCGTCGGCGGGA 1974  
AGCGTGGGAGGTAGCTCCTACTTTTGCACAGGCACCAAGTACCTCAGGGACATGGGCACGGGCACCTGCTGTGCTGG 2053

Fig. 3C

21 / 109

GACAGATACTGCCCCAGCACCCACCCGGCCATGAGGACCTGCTCTGCTCAGCACGGGCACTGCCACTTGGTGTGGCTCAC 2132  
CAGGGCACCCAGCCTCGCAGAAAGGCATCTTCCTCCTCTCTGTGAATCACAGACACGCGGGACCCCGCCAAACTTT 2211  
TCAAGGCAGAAAGTTTCAAGATGTGTGTTTGTCTGTATTTGCACATGTGTTTGTGTGTGTGTGTGTGTGTGCACGC 2290  
GGTGGCGGCTGTGGCATAGCCTTCCTGTTCTGTCAAGTCTTCCCTTGGCCTGGGTCCCTCGTGAGTCATTGGAG 2369  
CTATGAAGGGGAAGGGTCTGTATCACTTTGTCTCTCCTACCCCACTGCCCCGAGTGTGGGCAGCGATGTACATATGG 2448  
AGGTGGGTGGACAGGGTGTGTGCCCCCTTCAGAGGGAGTGCAGGGCTTGGGTGGGCCCTAGTCCCTGCTCCTAGGGCTG 2527  
TGAATGTTTTTCAGGGTGGGGGAGGAGATGGAGCCCTCCTGTGTGTTTGGGGGGAAGGGTGGGTGGGGCTCCCACTTG 2606  
GCCCCGGGTTTCAGTGGTATTTTATCTTGCCTTCTTCCCTGTACAGGGCTGGGAAAGGCTGTGTGAGGGGAGAGAAGGG 2685  
AGAGGGTGGGCCCTGCTGTGGACAATGGCATACTCTCTCCAGCCCTAGGAGAGGGCTCCTAACAGTGTAACCTTATTGT 2764  
GTCCCCCGGTATTTATTGTTGTAAATATTGAGATTTTATATTGA 2811

Fig. 3D




Fig. 3E

[illegible]

**Fig. 3F**

24 / 109

```

360      370      380      390      400      410      420
M QAQWARYTDPVSPRPGSCINNWHRDNGYTSSLELPDNTLNFIKKHPLMEDQVKPRLGRPLLKKNTNF
  ::      ::      ::      ::      ::      ::      ::
H ---WTR-----GCGPQ-----SPAL-----KH-----LLI---TSL
160      170

430      440      450      460      470      480      490
M THVVADRVPGLDGATYTVLFIGTGDGWLKAVSLGPWIHMVEELQVFDQEPVESLVLSQSKKVLFAGRSR
  .      .      .      .      .      .      .
H S-----VLRTCSPSLW-----SMESLKMGRA-----SVPMT
180      190      200

500      510      520      530      540      550      560
M QLVQLSLADCTKYRFCVDCVLARDPYCAWNVNTSRCVATTSGRSGSLVQHVANLDTSKMCNQYGIKKVR
  ::      ::      :      :      :      :      :
H QLRAM-LA-----F-----L-----WMVSCTRPHSTTS-----
210      220

570      580      590      600      610      620      630
M SIPKNITVVSGTDLVLPCHLSSNLAAHAWTFGSQDLPAEQPGSFYDTGLQALVVMAAQSRHSGPYRCYS
  :
H -----W-----

640      650      660      670      680      690      700
M EEQGTRLAAESYLVAVVAGSSVTLEARAPLENLGLVWLAVVALGAVCLVLLVLSLRRRLREELEKGAK
  ::      ::      ::      ::      ::      ::      ::
H -----ARNPLS-----CVT-----
230

```

Fig. 3G

```

710      720      730      740      750      760      770
M ASERTLVYPLELPKEPASPFRPGPETDEKLWDVPVGYYSYSDGSLKIVPGHARCQPGGGPFPSPPPGIPGQP
H -----W-----GPTTP-----
                                     240

780      790      800      810      820      830
M LPSPTRLHLGGGRNSNANGYVRLQLGGEDRGGSGHPLPELADELRRKLQQRQPLPDSNPEESSV
H -----

```

Fig. 3H

```

10      20      30      40      50      60      70
M GGCACGAGGTGGCCGGAGTCAAACGGAGGGCAGCGCCAGGGATTGGAGCTGCACGAAAGAGGGCTGCTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTC-----GACC-----CACG-----CGTC-----CGCG-----GGACAGCTG
10      20

80      90      100     110     120     130     140
M GACTGAAGTTTAGACCCCTGGGTGTCTGCCATGGCCCCACACTGGGCTGTCTGGCTGCTGGCAGAGGGCT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GCCTGAAGCTCAGAGCCGGGGCGTGGCCATGGCCCCACACTGGGCTGTCTGGCTGCTGGCAGCAAGGCT
30      40      50      60      70      80      90

150     160     170     180     190     200     210
M GTGGGGCCTGGGCATCGGGCTGAGATGTGGTGAACCTTGTCGCCCGGAAGACAGTATCTTCTGGGGAG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTGGGGCCTGGGCATTGGGGCTGAGGTGTGGTGAACCTTGTCGCCCGTAAGACAGTGTCTTCTGGGGAG
100     110     120     130     140     150     160

220     230     240     250     260     270     280
M CTGGTCACAGTAGTGAGCGGGTTCTCCAGACAGGCATCCAGGACTTCCTGACACTGACCCCTGACAGAAC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CTGGCCACGGTAGTACGGCGGTTCTCCAGACCGGCATCCAGGACTTCCTGACACTGACGCTGACGGAGC
170     180     190     200     210     220     230

290     300     310     320     330     340     350
M ATTCTGGCCTTTTATATGTGGGGCCCGAGAGGGCGTGTTCCTTCAGTGTAGAGGCTCTGGAGCTGCA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CCACTGGGCTTCTGTACGTGGGGCCCGAGAGGCCCTGTTTGCCTTCAGCATGGAGGCCCTGGAGCTGCA
240     250     260     270     280     290     300

```

Fig. 3I

**Fig. 3J**

**Fig. 3K**

**Fig. 3L**

```

1410      1420      1430      1440      1450      1460      1470
M CACCTATACAGTGTGTTTCATTGGTACAGGAGATGGCTGGCTGCTGAAGGCTGTGAGCCTGGGGCCCTGG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H C--CGTGTCTG-----CAAGGG--C--GATATGGGGGGC-----GCA-----C--GGACCCCTG--
960      970      980      990

1480      1490      1500      1510      1520      1530      1540
M ATCCACATGGTGGAGGAACCTGCAGGTGTTTGACCAGGAGCCAGTGGAAAGTCTGGTGTCTCAGAGCA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----CA-----GAGGAA-----GTG-----GACCACGTTCCCTG-----AAGGC-----GCGG-----CTG-GCA
1000      1010      1020      1030

1550      1560      1570      1580      1590      1600      1610
M AGAAGGTGCTCTTTGCTGGCTCCCGCTCTCAGCTGGTTCAGCTGTCTCTGCGCCGACTGCACAAAGTACCG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H -----TGCTCT-----GC-CCCGAACT-GGCAG-CTCTACT-TCA---ACCAGCTGCA---GG---CG
1040      1050      1060      1070      1080

1620      1630      1640      1650      1660      1670      1680
M TTTCTGTAGACTGTGTCCTGGCCAGGGACCCCTTACTGTGCTGGAATGTCAACACACCGCCGCTGTGTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ATGC-----ACA---CCCTG--CAGGACACCT-----CCTGGCA---CAACACACACCTTCTTTGGG
1090      1100      1110      1120      1130

1690      1700      1710      1720      1730      1740      1750
M GCCACCAACAGTGGTCGCTCGGGGTCCTTTCTGGTCCAAACATGTGGCGAAGTGGACACTTCAAAGATGT
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTTT--TTCAA-----GCACAGTGG-----GGT--GACATGTACCTGTC---GGC-CATCTG---TGA
1140      1150      1160      1170

```

Fig. 3M

```

1760      1770      1780      1790      1800      1810      1820
M  GTAACCAAGTATGGCATTAATAAAGTCAGATCTATTCCCAAGAACATCACCGTTGTGTAGGCACAGACCT
   ::::: ::::: ::::: ::::: ::::: :::::
H  GTA-CCAGT-TGG-----AAG--AGATC-----CAGCG--GGTGTTTGAGG-----
1180      1190      1200      1210

1830      1840      1850      1860      1870      1880      1890
M  GGTCTACCCCTGCCACCTCTCGTCCAAATTGGCCCCATGCCCACTGGACCTTCGGAAGCCAGGACCTGCCT
   ::::: ::::: ::::: ::::: ::::: :::::
H  -----GCC-----CCTATAAGGA--GTACC---ATGA-----GGAAGC-----CCA
1220      1230      1240

1900      1910      1920      1930      1940      1950      1960
M  GCAGAAACACCTGGCTCCTTTCTTTATGACACGGGACTCCAGGCGCTGGTGTATGGCCGACAGTCCC
   :::: :::: :::: :::: :::: :::: ::::
H  GAAGTGGGACC--GCTAC--ACT-----GACCCCTGTAC--CCAGGCCCTGGTGTATGGCTGCCAGCCCC
1250      1260      1270      1280      1290      1300

1970      1980      1990      2000      2010      2020      2030
M  GTCACCTCTGGACCCCTATCGTTGCTATTTCAGAGGAGCAGGGGACAAAGACTGGCTGCAGAAAGCTACCTTGT
   :::: :::: :::: :::: :::: :::: ::::
H  GCCATGCCGGGGCCCTACCACTGCTTTTCAGAGGAGCAGGGGGCGCGCTGGCTGCTGAAGGCTACCTTGT
1310      1320      1330      1340      1350      1360      1370

2040      2050      2060      2070      2080      2090      2100
M  TGCTGTCTGGCCGGCTCGTCGGTGACACTGGAGGCACGGGCTCCCTTGGAAAACCTGGGGCTCGTGTGG
   :::: :::: :::: :::: :::: :::: ::::
H  GGCTGTCTGGCAGGCCCGTCGGTGACCTTGGAGGCCCGGGCCCTGGGAAACCTGGGGCTGGTGTGG
1380      1390      1400      1410      1420      1430      1440

```

Fig. 3N

```

2110      2120      2130      2140      2150      2160      2170
M CTCGCTGTGGTGGCCCTGGGGGCTGTGTGCCTGGTGTCTGTCTTCTATCGCTCCGCGGCGAC
  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H CTGGCGGTGGTGGCCCTGGGGGCTGTGTGCCTGGTGTCTGTCTGTCTATTCGCGCGGCGGC
  1450      1460      1470      1480      1490      1500      1510

2180      2190      2200      2210      2220      2230      2240
M TTCGAGAAGAGCTAGAAAGGGTGCCCAAGGCATCTGAGAGGACACTGGTGTACCCCTTGGAAC TGCCCAA
  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H TGCGGGAAGAGCTGGAGAAAGGGGCCAAGGCTACTGAGAGGACCTTGGTGTACCCCTGGAGCTGCCCAA
  1520      1530      1540      1550      1560      1570      1580

2250      2260      2270      2280      2290      2300      2310
M GGAGCCTGCCAGTCCCCCTTCCGTCTCCGTGCCCCGAAACTGATGAGAAACTTTGGGATCCTGTCTGGGTAC
  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GGAGCCCCACCAGTCCCCCTTCCGGCCCTGTCTCTGAACCAAGATGAGAAACTTTGGGATCCTGTCTGGTTAC
  1590      1600      1610      1620      1630      1640      1650

2320      2330      2340      2350      2360      2370      2380
M TACTATTCGGATGGCTCTCTCAAGATTGTGCCTGGTCACGCCCGGTGCCAGCCTGGGGGTGGGCCCCCTT
  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H TACTATTCAGATGGCTCCCTTAAGATAGTACCTGGGCATGCCCGGTGCCAGCCCGGTGGGGGGCCCCCTT
  1660      1670      1680      1690      1700      1710      1720

2390      2400      2410      2420      2430      2440      2450
M CCCCACCTCCTGGCATACCTGGCCAGCCTCTGCCTTCTCCAACCTCGGCTCCACCTAGGAGGTGGTCGGAA
  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H CGCCACCTCCAGGCATCCAGGCCAGCCTCTGCCTTCTCCAACCTCGGCTTCACCTGGGGGTGGGCGCGAA
  1730      1740      1750      1760      1770      1780      1790

```

Fig. 30

```

2460      2470      2480      2490      2500      2510      2520
M CTCAAATGCCAATGGTTATGTGCGTTTACAGTTGGCGGAGAGACCGAGGAGGATCTGGGCACCCACTG
      :::::::::::::::::::: :::::::::::::::::::: :::::::::::::::::::: ::::::::::::::::::::
H CTCAAATGCCAATGGTTACGTGCGCTTACAACCTAGGAGGGGAGGACCGGGAGGGCTCGGGCACCCCTG
1800      1810      1820      1830      1840      1850      1860

2530      2540      2550      2560      2570      2580      2590
M CCTGAGCTCGCGGATGAATTACGACGGAACTACAACAGCGCCAGCCGCTGCCTGACTCCAACCCAGAGG
      :::::::::::::::::::: :::::::::::::::::::: :::::::::::::::::::: ::::::::::::::::::::
H CCTGAGCTCGCGGATGAACCTGAGACGCAAACTGCAGCAACGCCAGCCACTGCCCGACTCCAACCCCGAGG
1870      1880      1890      1900      1910      1920      1930

2600      2610      2620      2630      2640      2650
M AGTCTTCAGTATGAGGGGACCCCCACCTCATTTGGCGGGGGGGGTCTCATGAGGAGGTGCA-CTCTTAA
      :::::::::::::::::::: :::::::::::::::::::: :::::::::::::::::::: ::::::::::::::::::::
H AGTCATCAGTATGAGGGGAAACCCCC-ACCGCGTTCGGCGGGAAG-----CGTGGGAGGTGTAGCTCCTA-
1940      1950      1960      1970      1980      1990

2660      2670      2680      2690      2700      2710      2720
M CTTTTCACAGGCACCACTACCTCAGGGACATGGCAGGGGCACTTGCTCTGCTGGGACAGACACTGCC
      :::::::::::::::::::: :::::::::::::::::::: :::::::::::::::::::: ::::::::::::::::::::
H CTTTTCACAGGCACCACTACCTCAGGGACATGGCAGGGGCACTTGCTCTGCTGGGACAGATACTGCC
2000      2010      2020      2030      2040      2050      2060

2730      2740      2750      2760      2770      2780      2790
M CATCATTTGCCCGCGCGTGAGGACCTGCTC-----AGCATGGGCACTGCCACTTGGTGTGGCTCACCAGG
      :::::::::::::::::::: :::::::::::::::::::: :::::::::::::::::::: ::::::::::::::::::::
H CAGCACCCACCGGCCATGAGGACCTGCTCTGCTCAGCACGGGCACTGCCACTTGGTGTGGCTCACCAGG
2070      2080      2090      2100      2110      2120      2130

```

Fig. 3P

```

2800      2810      2820      2830      2840      2850      2860
M ACTTCAGCCTCACAGGAGACA-CACCCCTCCTCT--GTGAATTGAGACATGTGGACCCAGAGCCCAA
.. : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GCACAGCCTCGCAGAGGCATCTTCCTCCTCTCTGTGAATCACAGACACGCGGACCCAGCCGCCCAA
2140      2150      2160      2170      2180      2190      2200

2870      2880      2890      2900      2910      2920
M ACTTTGCAAGGAAGAGGTTTCAAGATGTGGCGTGT--ATATGTTGGTATGCATGTGGAA
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ACTTTCAAGGCAGAAAGTTTCAAGATGTGTGTTGTCTGTATTTGCACATGTGTTGTGTGTGTAT
2210      2220      2230      2240      2250      2260      2270

2930      2940      2950      2960      2970      2980      2990
M GAATGTGTGTGTGTGTGTG---TGTGTTGTAACCTTCCCTGTCTCTATCAGCTTCCCTTGCCCTGG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTGTGTGTGCACGCGCGTGTGCGGCTTGTGGCATAGCCTTCCCTGTTTCTGTCAAGTCTTCCCTTGCCCTGG
2280      2290      2300      2310      2320      2330      2340

3000      3010      3020      3030      3040      3050      3060
M GGTCCTCCTGGTTGAGTCTTTGGAGCTATGAAGGGGAAGGGGTATAGCACTTGTCTCTCCTACCCCC
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H G-TCCTCCTGGT-GAGTCATTGGAGCTATGAAGGGGAAGGGG-TCGTATCACTTGTCTCTCCTACCCCC
2350      2360      2370      2380      2390      2400      2410

3070      3080      3090      3100      3110      3120      3130
M AGCTGTCCCAAGCTTTGGGCGAGTGATGTACATACGGGGAAGGAAGACAGGGTGTGTACCCCTTTTG
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H A-CTGCCCCCGAG-TGTCGGGCGAGCGATGTACATATGGAGGTGGGGTGGACAGGGTGTGTGCCCTTCAG
2420      2430      2440      2450      2460      2470      2480

```

Fig. 3Q

**Fig. 3R**

GTCGACCCACGCGTCCGCGGACGCGTGGCGCGCGGGGCCCATCCAGACCCCTGCGGAGAGCGAGGCCCGGAGCGTCGCC 79  
 GAGGTTTGAGGGCGCGGAGACCGAGGGCCTGGCGGCCGGAAGAACCCGCCCAAGAGAGCCCTCTGGCCCGGGGGCTGC 158  
 TGGAACATGTGGGGGGACACAGTTTGTGACAGTTGCCAGACT ATG TTT ACG CTT CTG GTT CTA CTC 8  
 228  
 S Q L P T V T L G F P H C A R G P K A S 28  
 AGC CAA CTG CCC ACA GTT ACC CTG GGG TTT CCT CAT TGC GCA AGA GGT CCA AAG GCT TCT 288  
 K H A G E E V F T S K E E A N F F I H R 48  
 AAG CAT GCG GGA GAA GTG TTT ACA TCA AAA GAA GAA GCA AAC TTT TTC ATA CAT AGA 348  
 R L L Y N R F D L E L F T P G N L E R E 68  
 CGC CTT CTG TAT AAT AGA TTT GAT CTG GAG CTC TTC ACT CCC GGC AAC CTA GAA AGA GAG 408  
 C N E E L C N Y E E A R E I F V D E D K 88  
 TGC AAT GAA GAA CTT TGC AAT TAT GAG GAA GCC AGA GAG ATT TTT GTG GAT GAA GAT AAA 468  
 T I A F W Q E Y S A K G P T T K S D G N 108  
 ACG ATT GCA TTT TGG CAG GAA TAT TCA GCT AAA GGA CCA ACC ACA AAA TCA GAT GGC AAC 528

36/109


Fig. 4A

R E K I D V M G L L T G L I A A G V F L 128  
 AGA GAG AAA ATA GAT GTT ATG GGC CTT CTG ACT GGA TTA ATT GCT GCT GGA GTA TTT TTG 588  
  
 V I F G L L G Y Y L C I T K C N R L Q H 148  
 GTT ATT TTT GGA TTA CTT GGC TAC TAT CTT TGT ATC ACT AAG TGT AAT AGG CTA CAA CAT 648  
  
 P C S S A V Y E R G R H T P S I I F R R 168  
 CCA TGC TCT TCA GCC GTC TAT GAA AGG GGG AGG CAC ACT CCC TCC ATC ATT TTC AGA AGA 708  
  
 P E E A A L S P L P P S V E D A G L P S 188  
 CCT GAG GAG GCT GCC TTG TCT CCA TTG CCG CCT TCT GTG GAG GAT GCA GGA TTA CCT TCT 768  
  
 Y E Q A V A L T R K H S V S P P P Y P 208  
 TAT GAA CAG GCA GTG GCG CTG ACC AGA AAA CAC AGT GTT TCA CCA CCA CCA TAT CCT 828  
  
 G H T K G F R V F K K S M S L P S H \* 227  
 GGG CAC ACA AAA GGA TTT AGG GTA TTT AAA AAA TCT ATG TCT CTC CCA TCT CAC TGA 885  
  
 CTACCTTGTCATTTTGGTATAAGAAAATTGTGTATTGTATAGGCCGGGCATGGTGGCTCATGCCCTGTAATCCAGCAC 964  
 TTTGGGAGGCCAGGAGTTCGAGACCAGCCTGGCCAAACATGGTGAACCCGGTCTCTACTAAAAATTCAAAAATTACCTA 1043  
 GCGGTCATGGGGCATGCCCTGTAGTCCACCTACTTGGGAGGCTGAAGCAGGAGAAATTGCTCGAACCTGGGAGGCAGAGG 1122

37/109

Fig. 4B

**Fig. 4C**



GTCGACCCAC	GGGTCGCGTG	CGTTCTCACC	CCTGGACCAC	CCTGGGAGAA	CAGTTGACCG	60
AAGTTTGTTT	GCGAGTTGCT	GCTGGACT	ATG TTT CTG	CTT CTG	GTA CTC	112
	Met	Phe	Leu	Leu	Val Val Leu	
						5
AGC CAG CTG	CCC AGA CTT	ACC CTC	GCG GTT	CCT CAT	ACA AGA AGC CTA	160
Ser Gln Leu	Pro Arg Leu	Thr Leu	Ala Val	Pro His	Thr Arg Ser Leu	
						20
						15
AAG AAT TCT	GAA CAT GCC	CCA GAA	GGA GTC	TTT GCA	TCA AAA AAA GCA	208
Lys Asn Ser	Glu His Ala	Pro Glu	Gly Val	Phe Ala	Ser Lys Lys Ala	
						40
						35
GCA AGC ATC	TTT ATG	CAC CAC	CGT CGC	CTC CTA	TAC AAT AGA	256
Ala Ser Ile	Phe Met	His Arg	Arg Leu	Leu Tyr	Asn Arg Phe Asp Leu	
						55
						50
GAA CTC TTC	ACT CCC	GGG AAC	CTG GAG	AGA GAG	TGC TAT GAG	304
Glu Leu Phe	Thr Pro	Gly Asn	Leu Glu	Arg Glu	Cys Tyr Glu Glu Phe	
						70
						65
						60
TGT AGT TAT	GAA GAA	GCC AGA	GAG ATC	CTC GGG	GAC AAC GAA GAA ATG	352
Cys Ser Tyr	Glu Glu	Ala Arg	Glu Ile	Leu Gly	Asp Asn Glu Glu Met	
						85
						80
						75

Fig. 4E

ATC ACA TTC TGG CGG GAA TAT TCA GTC AAA GGA CCA ACC ACA AGA TCA Ile Thr Phe Trp Arg Glu Tyr Ser Val Lys Gly Pro Thr Thr Arg Ser 90 95 100	400
GAT GTC AAC AAA GAG AAA ATT GAT GTT ATG GGC CTT CTG ACT GGC TTA Asp Val Asn Lys Glu Lys Ile Asp Val Met Gly Leu Thr Gly Leu 105 110 115 120	448
ATT GCG GCT GGA GTA TTC TTG GTT GTT TTT GGC TTA CTT GGT TAC TAT Ile Ala Ala Gly Val Phe Leu Val Val Phe Gly Leu Leu Gly Tyr Tyr 125 130	496
CTG TGT ATC ACC AAG TGT AAT AGG CAG CCA TAT CAA GGT TCT TCA GCT Leu Cys Ile Thr Lys Cys Asn Arg Gln Pro Tyr Gln Gly Ser Ser Ala 140 145 150	544
GTC TAC ACA AGA AGG ACC AGG CAC ACA CCG TCC ATC ATT TTC AGA ACC Val Tyr Thr Arg Arg Thr Arg His Thr Pro Ser Ile Ile Phe Arg Thr 155 160 165	592
CAT GAG GAA GCT GTC TTG TCT CCA TCG TCA TCC TCA GAG GAC GCG GGA His Glu Glu Ala Val Leu Ser Pro Ser Ser Ser Ser Glu Asp Ala Gly 170 175 180	640

Fig. 4F

42 / 109

CTA CCT TCC TAT GAA CAG GCA GTA GCT CTG ACC AGA AAA CAC AGT GTC	688
Leu Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val	200
185	
190	
TCA CCA CCA CCT CCA TAT CCT GGG CCA GCA AAA GGA TTT AGG GTA TTT	736
Ser Pro Pro Pro Tyr Pro Gly Pro Ala Lys Gly Phe Arg Val Phe	215
205	
210	
AAA AAG TCA ATG TCA CTC CCA TCT CAC TAAGCCCACC TTGCCGCCCTT	783
Lys Lys Ser Met Ser Leu Pro Ser His	225
220	
GCTGTGGTCT GAATAATATG TTCTTCCTGA AACAAACAACA ACAAAAAAAT TTGCCTGTTC	843
AGCTTTTAT GACAAAGCAC AAGGAATAAA GGAACACTAT ATACAGAACA GAATTCACCA	903
CAGCCCCGCT TTCAGCTCTG CCCCCAATG GATTGCTGTC TTGGTAAGAG ACTTCTACCG	963
TGCTTCCTCG AAGTTAAGAA GAAAGTGCCT TTTTGCAATG TAAACTGTAC TGGTTCAAC	1023
ATTCTTGCTA CAGCTAGGTA CCTATAATCC CCACCTTCAG GAGACTTAGG CGGGAGGGAT	1083
GAGAGTTCAA GGCCAGCCTG GGCCCTGTCA GGACGCTGTC TCAAAACAACA GTTTGTTATC	1143
AATAGAATAA TTAGAATTAA CAAACTAGGA TTTTCAGTCT TAAGTCATGA TATTGGATCT	1203
TCTCTTCAGT AAGGTTTCTT TTTGGCTAGA AATACTTCAT AGAATTGAC ATTTTGGTAT	1263
ACATCTGTGG CCTTGATACA ATGACTTTGAT TTTCTGTTTT AATTAGTGCA GAGGATTCAG	1323
CAAATTTGCA GGTCTTCATT TTGTTCCCTC GCTATCCATC GATCATGTTT CAGTGTATTA	1383
AGAGGAGTCA GCCAGGCGTG GTGGCCACACA CCTGTGATCC CAGCACTTAG GGGGCCATAG	1443
GCAGGCAGAT CTCTGTGAGC TGAAGGACAG CCTGGCCCTAC AAAGTCCAGG ACAACCGAGA	1503
CCACACAGAG AAACCTTGTC TTGAAAAACA AAACAACAAAC AAGAGAGAGA GAGAGAGAGA	1563

Fig. 4G

GAGAAAAGAG ATGTCAAGAG GTTTTGT TTATGGGCCT 1623  
CACTTGGAAG AGTGCTTGCC ATGCAATAG AAGGACAGGA GTTCAATCCT CATTACCCAC 1683  
ATTGAAACA AATAACAAGA AAAACAACC AAAAACCAGG AACAAACAAA ATCTTGAGAA 1743  
CTTGAGTGAA TACCGGTAAC CTCAGGGCTA GGCACTGTAA CTGAATCAGG AGCCTCCAGA 1803  
TCCAGGGAAA CGCTGTCTCA ACAATAAAT AAATAAGTAA GTCAGTGAGG TGGTCTTTAA 1863  
ACCCAGCACT TGAGAGCCAA AGGCAGGCAG AGCTCAGTGA GTTGGAGACC AGCCTGGTCT 1923  
ACAAAGCAAG TTCTAAGGGA GCCAGGGCAC AGAGAAACCC TGTCTGAAGG AAAAAAAAAA 1983  
AAAAAAAAAG GCGGGCCGC 2002

Fig. 4H

**Fig. 4I**

**Fig. 4J**

**Fig. 4K**

```

G      1  MELLVLSQLPRLTLAVPH.TRSLKNSEHAPEGVFASKKAASIFMHRRL  49
H      1  MFTLLVLSQLPTVTIGFPHCARGPKASKHAGEEVFTSKEEANFFIHRRL  50
G      50  LYNREFDLELFTPGNLERECYEEFCSEYEEAREILGDNEEMITFWREYSVKG  99
H      51  LYNREFDLELFTPGNLERECNEELCNYYEEAREIFVDEDKTIAFWQEYSAG  100
G      100  PTTTRSDVNKEKIDVMGLLTGLIAAGVFLVFGLLGYLGCITKCNRPYQG  149
H      101  PTTKSDGNREKIDVMGLLTGLIAAGVFLVIFGLLGYLGCITKCNRLQHPC  150
G      150  SSAVYTRRTRHTPSIIFRTHHEEAVLSP.SSSSEDAGLPSYEQAVALTRKH  198
H      151  SSAVY.ERGRHTPSIIFRRPEEAALSPLPPSVEDAGLPSYEQAVALTRKH  199
G      199  SVSPPPPPYPGPAKGFRVFKKMSLPSH  225
H      200  SVSPPPPPYPGHTKGFRVFKKMSLPSH  226

```

Fig. 4L




Fig. 4M

GTCGACCCACGGTCGGAAATGTCGTTCTTCAGATTATAAAGAAAACCTTTACTGAATCAGCTGAGTGTTAATAATA 79  
 CGAATTTCCTTTTCTTGCCCAATTCTGATCTGAACAGAAAATCCAAGAACAGGGAT ATG TGT GGA TTA CAG TTT 6  
 152  
 S L P C L R L F L V V T C Y L L L L L L H 26  
 TCT CTG CCT TGC CTA CGA CTG TTT CTG GTT GTT ACC TGT TAT CTT TTA TTA CTC CAC 212  
 K E I L G C S S V C Q L C T G R Q I N C 46  
 AAA GAA ATA CTT GGA TGT TCG TCT GTT TGT CAG CTC TGC ACT GGG AGA CAA ATT AAC TGC 272  
 R N L G L S S I P K N F P E S T V F L Y 66  
 CGT AAC TTA GGC CTT TCG AGT ATT CCT AAG AAT TTT CCT GAA AGT ACA GTT TTT CTG TAT 332  
 L T G N N I S Y I N E S E L T G L H S L 86  
 CTG ACT GGG AAT AAT ATA TCT TAT ATA AAT GAA AGT GAA TTA ACA GGA CTT CAT TCT CTT 392  
 V A L Y L D N S N I L Y V Y P K A F V Q 106  
 GTA GCA TTG TAT TTG GAT AAT TCT AAC ATT CTG TAT GTA TAT CCA AAA GCC TTT GTT CAA 452  
 L R H L Y F L F L N N N F I K R L D P G 126  
 TTG AGG CAT CTA TAT TTT CTA TTT CTA AAT AAT AAT TTC ATC AAA CGC TTA GAT CCT GGA 512

49/109

Fig. 5A

I	F	K	G	L	L	N	L	R	N	L	Y	L	Q	Y	N	Q	V	S	F	146
ATA	TTT	AAG	GGA	CTT	TTA	AAT	CTT	CGT	AAT	TTA	TAT	TTA	CAG	TAT	AAT	CAG	GTA	TCT	TTT	572
V	P	R	G	V	F	N	D	L	V	S	V	Q	Y	L	N	L	Q	R	N	166
GTT	CCG	AGA	GGA	GTA	TTT	AAT	GAT	CTA	GTT	TCA	GTT	CAG	TAC	TTA	AAT	CTA	CAA	AGG	AAT	632
R	L	T	V	L	G	S	G	T	F	V	G	M	V	A	L	R	I	L	D	186
CGC	CTC	ACT	GTC	CTT	GGG	AGT	GGT	ACC	TTT	GTT	GGT	ATG	GTT	GCT	CTT	CGG	ATA	CTT	GAT	692
L	S	N	N	I	L	L	R	I	S	E	S	G	F	Q	H	L	E	N	L	206
TTA	TCA	AAC	AAT	AAC	ATT	TTG	AGG	ATA	TCA	GAA	TCA	GGC	TTT	CAA	CAT	CTT	GAA	AAC	CTT	752
A	C	L	Y	L	G	S	N	N	L	T	K	V	P	S	N	A	F	E	V	226
GCT	TGT	TTG	TAT	TTA	GGA	AGT	AAT	AAT	TTA	ACA	AAA	GTA	CCA	TCA	AAT	GCC	TTT	GAA	GTA	812
L	K	S	L	R	R	L	S	L	S	H	N	P	I	E	A	I	Q	P	F	246
CTT	AAA	AGT	CTT	AGA	AGA	CTT	TCT	TTG	TCT	CAT	AAT	CCT	ATT	GAA	GCA	ATA	CAG	CCC	TTT	872
A	F	K	G	L	A	N	L	E	Y	L	L	L	K	N	S	R	I	R	N	266
GCA	TTT	AAA	GGA	CTT	GCC	AAT	CTG	GAA	TAC	CTC	CTC	CTG	AAA	AAT	TCA	AGA	ATT	AGG	AAT	932
V	T	R	D	G	F	S	G	I	N	N	L	K	H	L	I	L	S	H	N	286
GTT	ACT	AGG	GAT	GGG	TTT	AGT	GGA	ATT	AAT	AAT	CTT	AAA	CAT	TTG	ATC	TTA	AGT	CAT	AAT	992

50/109

Fig. 5B

D L E N L N S D T F S L L K N L I Y L K 306  
 GAT TTA GAG AAT TTA AAT TCT GAC ACA TTC AGT TTG TTA AAG AAT TTA ATT TAC CTT AAG 1052  
  
 L D R N R I I S I D N D T F E N M G A S 326  
 TTA GAT AGA AAC AGA ATA ATT AGC ATT GAT AAT GAT ACA TTT GAA AAT ATG GGA GCA TCT 1112  
  
 L K I L N L S F N N L T A L H P R V L K 346  
 TTG AAG ATC CTT AAT CTG TCA TTT AAT AAT CTT ACA GCC TTG CAT CCA AGG GTC CTT AAG 1172  
  
 P L S S L I H L Q A N S N P W E C N C K 366  
 CCG TTG TCT TCA TTG ATT CAT CTT CAG GCA AAT TCT AAT CCT TGG GAA TGT AAC TGC AAA 1232  
  
 L L G L R D W L A S S A I T L N I Y C Q 386  
 CTT TTG GGC CTT CGA GAC TGG CTA GCA TCT TCA GCC ATT ACT CTA AAC ATC TAT TGT CAG 1292  
  
 N P P S M R G R A L R Y I N I T N C V T 406  
 AAT CCC CCA TCC ATG CGT GGC AGA GCA TTA CGT TAT ATT AAC ATT ACA AAT TGT GTT ACA 1352  
  
 S S I N V S R A W A V V K S P H I H H K 426  
 TCT TCA ATA AAT GTA TCC AGA GCT TGG GCT GTT GTA AAA TCT CCT CAT ATT CAT CAC AAG 1412  
  
 T T A L M M A W H K V T T N G S P L E N 446  
 ACT ACT GCG CTA ATG ATG GCC TGG CAT AAA GTA ACC ACA AAT GGC AGT CCT CTG GAA AAT 1472

51 / 109

Fig. 5C

T E T E N I T F W E R I P T S P A G R F 466  
 ACT GAG ACT GAG AAC ATT ACT TTC TGG GAA CGA ATT CCT ACT TCA CCT GCT GGT AGA TTT 1532  
 F Q E N A F G N P L E T T A V L P V Q I 486  
 TTT CAA GAG AAT GCC TTT GGT AAT CCA TTA GAG ACT ACA GCA GTG TTA CCT GTG CAA ATA 1592  
 Q L T T S V T L N L E K N S A L P N D A 506  
 CAA CTT ACT ACT TCT GTT ACC TTG AAC TTG GAA AAA AAC AGT GCT CTA CCG AAT GAT GCT 1652  
 A S M S G K T S L I C T Q E V E K L N E 526  
 GCT TCA ATG TCA GGG AAA ACA TCT CTA ATT TGT ACA CAA GAA GTT GAG AAG TTG AAT GAG 1712  
 A F D I L L A A F I L A C V L I I F L I 546  
 GCT TTT GAC ATT TTG CTA GCT TTT TTC ATC TTA GCT TGT TTT TTA ATC ATT TTT TTG ATC 1772  
 Y K V V Q F K Q K L K A S E N S R E N R 566  
 TAC AAA GTT GTT CAG TTT AAA CAA AAA CTA AAG GCA TCA GAA AAC TCA AGG GAA AAT AGA 1832  
 L E Y Y S F Y Q S A R Y N V T A S I C N 586  
 CTT GAA TAC TAC AGC TTT TAT CAG TCA GCA AGG TAT AAT GTA ACT GCC TCA ATT TGT AAC 1892  
 T S P N S L E S P G L E Q I R L H K Q I 606  
 ACT TCC CCA AAT TCT CTA GAA AGT CCT GGC TTG GAG CAG ATT CGA CTT CAT AAA CAA ATT 1952

52/109

Fig. 5D

V P E N E A Q CAG GTC ATT CTT TTT GAA CAT TCT GCT TTA TAA \*  
GTT CCT GAA AAT GAG GCA GAG GTC ATT CTT TTT GAA CAT TCT GCT TTA TAA 623  
CTCAACTAAATATTGTCTATAAGAAACTTCAGTGCCATGGACATGATTAAACTGAAACCCTCCTTATATATAATATATAC 2003  
TTTAGTTGAAATATAATGAATTATATGAGGTTAGCATTATTAAATATGTTTTTAATAAAAAAAAAAAAAAAAAAAGG 2082  
GCGGCCGC 2161  
2169

Fig. 5E




Fig. 5F

55 / 109

```

10      10      20      30      40      50      60
Slit  MRGVGWQLSLSLGLVLA-----ILNKVAPACPAQCS-CSGSTVDCHGLALRSVPRNIPRNTERLDLNG
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
325  MCGLQFSLPCLRLFLVVTCYLLLLHK-EILGCSSVCQLCTGRQINCRNLGLSSIPKNFPPESTVFLYLTG
      10      20      30      40      50      60

      70      80      90      100     110     120     130
Slit  NNITRITKDFAGLRHLRVLQLMENKISTIERGAFOQLKELERLRNLRNHLQLFPPELLFLGTAKLYRLDL
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
325  NNISYINESELTGLHSLVALYLDNSNILYVYPKAFVQLR-----HLY--FLFLNNNFIKRDL-
      70      80      90      100     110     120

      140     150     160     170     180     190     200
Slit  SENQIQAIPRKAFRGAVDIKNLQLDYNQISCIEDGAFRALRDLEVLTLNNNNITRLSVASFNHMPKLRTF
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
325  -----PGI-----FKGLLNLRNLYLQYNQVSFVPRGVFNLDLVSQYLNLRNLTVLGSGTF-----
      130     140     150     160     170

      210     220     230     240     250     260     270
Slit  RLHSNNLYCDCHLAWLSDWLRQRPRVGLYTQCMGPSHLRGNVAEVQKREFVCSGHQSFMAPSCSVLHCP
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
325  -----VGM-----VA-----
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      180

```

Fig. 5G

```

280      290      300      310      320      330      340
Slit AACTCSNNIVDCRGKGLTEIPTNLPEITTEIRLEQNTIKVIPPGAFSPYKLRRLDLSNNQISELAPDAF
325 -----
      :: :: :: :: ::
      -----LRILDLSNNNI-----
      190

350      360      370      380      390      400      410
Slit QGLRSLNSLVLYGNKITELPKSLFEGFLSLQLLLNANKINCLRVDAFODLHNLNLLSLYDNKLQTIAGK
      :: ::
325 --LR-----ISE-----
      :: :: :: :: ::
      -----SGFQHLENLACL-----
      200

420      430      440      450      460      470      480
Slit TFSPLRAIQTMHLAQNPFCIDCHLKWLDYLYHTNPIETSGARCTSPRRLANKRIGQIKSKKFRCSAKEQY
      :: ::
325 -----YLGSN-----
      210

490      500      510      520      530      540      550
Slit FIPGTEDYRSKLSGDCFADLACPEKRCCEGTTVDCSNQKLNKIPEHIPOYTAE LRLNNEFTVLEATGIF
      :: ::
325 -----NLTKVP-----
      220
      -----SNAFEVLKS-----

```

Fig. 5H

**Fig. 51**

58 / 109

```

      840      850      860      870      880      890      900
Slit GNDISVVEGAENDLSALSHLAIGANPLYCDCNMQWLSDWKSEYKEPGIARCAGPGEMADKLLLTTPSK
325 -----SSLIHLQANSNPWECNCKLLGLRDWLAS-----
      350      360      370

      910      920      930      940      950      960      970
Slit KFTCQGPVDVNIILAKCNPCLSNPCKNDGTCNSDPVDFYRCTCPYGFKGQDCDVPIHACISNPCKHGGTCH
325 -----SAITLNI-----Y-----CQNP-----PSMRG-----
      380      390

      980      990      1000      1010      1020      1030      1040
Slit LKEGEEDGFWCICADGFEGENCEVNVDDCEDNDCENNSTCVDGINNYTCLCPPEYTGELCEEKLDFFCAQD
325 -----RALRYI-----NITNCV-----
      400

     1050      1060      1070      1080      1090      1100      1110
Slit LNPCQHDSKCILTPKGFKCDCTPGYVGEHCDIDFDDCQDNKCKNGAHCTDAVNGYTCICPEGYSGLFCEE
325 -----TSSIN-----
      410

```

Fig. 5J

59/109

```

1130      1130      1140      1150      1160      1170      1180
Slit  SPPMVLPRTSPCDNFDCQGAQCIVRINEPICQCLPGYQGEKCEKLVSVNFINKESYLQIPSAKVRPQTN
      .:. . . . .
325  -----VRAWA-----VVK-----SPHIIHKTTALMMMAWHKV-----
      420      430

1190      1200      1210      1220      1230      1240      1250
Slit  ITLQIATDEDSGILLYKGDKDHIAVELYRGRVRASYDTGSHPASAIYSVETINDGNFHVIELLALDQSLN
      .:. . . . .
325  -----TTNGSP-----LENTETENIT-----FWERIPST-----PAGRFFQENAFGNP-LETTAVLPVQIQLT
      440      450      460      470      480

1260      1270      1280      1290      1300      1310      1320
Slit  LSVDDGNPKIITNLSKQSTLNFDSPLYVGGMPGKSNVASLRQAPGQNGTSEHGCIRNLYINSELQDFQKV
      .:. . . . .
325  TSV-----TLNLEKNSALPNDA-----MSGKTSLI-----CT-----QEVEKL
      490      500      510      520

1330      1340      1350      1360      1370      1380      1390
Slit  PMQTGILPGCEPCHKKVCAGHTCQPSSQAGFTCECQEGWMGPLCDQRTNDPCLGNKCVHGTCLPINAFSY
      .:. . . . .
325  NEAFDILLA-----F-----FIL
      530

```

Fig. 5K

```

1400      1410      1420      1430      1440      1450      1460
Slit  SCKLEGGHGVLCDEEEDLFNPCQAICKKHGKCRLLSGLGQPYCECSSGYTGDSCDREISCRGERIRDYYQ
      .:      .:      .:      .:      .:      .:      .:
325 AC-----VL-----IIFLIYKVVFQKQ-----KLKA-----SENS-----RENRL-EYY-
      540      550      560      570

1470      1480      1490      1500      1510      1520
Slit  KQQGYAACQTTK-KVSRLECRGGCAGGCCGGLRSKRKRKYSFECTDGSFVDEVEKVVKCGCTRCVS
      .:      .:      .:      .:      .:      .:
325 ---SF---YQSARYNVTAICNTSPNSLESFGLQIRLHK-----QIVPENEAQVI-LFEHSAL
      580      590      600      610      620

```

Fig. 5L

**Fig. 5Mi**

62 / 109

```

290      300      310      320      330      340      350
Slit AGCGTGCCCGGCGCAGTGCTCTTGCTCGGGCAGCACAGTGGACTGTACGGGGCTGCGCTGCGCAGCGT
325 -----CAGG-----CGT
                               10

360      370      380      390      400      410      420
Slit GCCCAGGAATATCCCCGCAACACCGAGAGACTGGATTAAATGGAATAACATCACAGAATTACGAAG
      :::::::::::
325 --CCGGAAATGTC-----
                               20

430      440      450      460      470      480      490
Slit ACAGATTTTGCTGGTCTTAGACATCTAAGAGTTCTTCAGCTTATGGAGAATAAGATTAGCACCATTGAAA
      :::::::::::
325 -----GTTCTTCAGATTTAAAAAGAAAA-----CCTTTA-----
                               30      40      50

500      510      520      530      540      550      560
Slit GAGGAGCATCCAGGATCTTAAAGAACTAGAGAGACTGCGTTTAAACAGAAATCACCTTCAGCTGTTTCC
      :::::::::::
325 -----CTGAATC-----AGCT-GAGTG-----TTAAT-----AATACG-----AATTTC
                               60      70      80

```

Fig. 5Mii

```

570      580      590      600      610      620      630
Slit  TGAGTTGCTGTTTCTTGGGACTGCGAAGCTATACAGGCTTGATCTCAGTGAAACCAAAATTCAGGCAATC
      :          :          :          :          :          :
325  T-----TTTCTTG--C--CAATTCTGATCTGA-----ACAGA-AAATCCAAGAACAGG-----
      90          100      110          120      130

640      650      660      670      680      690      700
Slit  CCAAGGAAAGCTTCCGTTGGGCGAGTTGACATAAAAAATTGCAACTGGATTACACCAGATCAGCTGTA
      :          :          :          :          :          :
325  -----GATATGTG-----TGGATTACA-----GTT
      :          :          :          :          :          :
      140          150

710      720      730      740      750      760      770
Slit  TTGAAGATGGGCATTCAGGGCTCTCCGGGACCTGGAAGTGCTCACTCTCAACAATAACAACATTACTAG
      :          :          :          :          :          :
325  TT-----CTCT-----GCCT-----TGC-----CTACGA-----
      :          :          :          :          :          :
      160          170

780      790      800      810      820      830      840
Slit  ACTTCTGTGGCAAGTTTCAACCATATATGCCCTAAACTTAGGACTTTTCGACTGCATTCAAACAACCTGTAT
      :          :          :          :          :          :
325  -----CTGTTTCTGGTTGTTACCTGTTA-----TCTTTT-----AT
      180          190          200

```

Fig. 5Miii

**Fig. 5Miv**

65 / 109

```

1130      1140      1150      1160      1170      1180      1190
Slit GTTTGGAACAGAACACAAATCAAAAGTCATCCCTCCTGGAGCTTTCTCACCATAATAAAAGCTTAGACGAAT
   :: : : : : :
325 ---TGTATCTGA-----CTGGGAATAATAATATCTTATATAAATGAAAGT-GAAT
      330      340      350      360      370

1200      1210      1220      1230      1240      1250      1260
Slit TGACCTGAGCAATAATCAGATCTCTGAACCTGCACCAGATGCTTCCCAAGACTACGCTCTCTGAATTCA
   : : : : :
325 TAAC-----AGGACTTC-----ATTCT
      380

1270      1280      1290      1300      1310      1320      1330
Slit CTTGTCCTCTATGGAAATAAAATCACAGAACTCCCAAGTTTATTGAAGGACTGTTTTCCTTACAGC
   : : : : :
325 CTTGT-----AGC-----ATTGTATTGGA-----TAATTCTAACA--
      390      400      410      420

1340      1350      1360      1370      1380      1390      1400
Slit TCCTATTATTGAATGCCAACACAAAGATAAACTGCCCTTCGGGTAGATGCTTTTCAGGATCTCCACAACCTTGAA
   : : : : :
TTCTGTATGTATAT-CCAAA-----GCCTTTG-----TTCAATTGAGG-----CATCTATAT
      430      440      450      460

```

Fig. 5Mv

[illegible]

**Fig. 5Mvi**

**Fig. 5Mvii**

68 / 109

```

1970      1980      1990      2000      2010      2020      2030
Slit AAATACCTTACGAGTAATCGTTTGGAAAATGTGCAGCATAAGATGTTCAAGGGATTGGAAAGCCTCAA
      :::::  :: :::::
325 --ATACTT-----GATTATC-----A
      690

2040      2050      2060      2070      2080      2090      2100
Slit AACTTTGATGTTGAGAAGCAATCGAATAACCTGTGTGGGAATGACAGTTTCATAGGACTCAGTTCTGTG
      :::::  :::::  :::::  :::::  :::::  :::::
325 AAC-----ATAAC--ATTTGAGGATATCAGAATCAG-----
      700      710      720

2110      2120      2130      2140      2150      2160      2170
Slit CGTTTGCTTCTTTGTATGATAATCAAAATTACTACAGTTGCACCGGGCATTGTGATACTCTCCATTCTT
      :::::  :::::
325 -----GCTTTC-----
      730

2180      2190      2200      2210      2220      2230      2240
Slit TATCTACTAAACCTCTTTGGCCAATCCTTTTAACTGTAACCTGCTACCTGGCTTGGTTGGGAGAGTGGCT
      :::::  :::::  :::::  :::::  :::::  :::::
325 -----AACATCTTGA--AAACCTT-----GCTTGTGTTGTAT-----T
      740      750      760

```

Fig. 5Mviii

**Fig. 5Mix**

Slit	CTCTCCAAC	TACAAACAT	TTAACTT	AAGCTT	ATAGACT	TATAGACT	TAACTT	AAGCTT	AAGCTT	TCTTAAT	CAGACGA	2590
325	---	TCCTGAAA	AATCAAGAA	---	TTAGGA	---	ATGTTACTA	GGGATGGG	---	TTTAGT	---	GG
	910	920	930	940	950							
Slit	GCTTCAGCA	AACATGAC	CCAGCTC	CTCACCT	TAACTT	CTTAGT	TACAAACC	GTCTGAGAT	GTATTC	CTCCTCG		2660
325	AATTAATA	ATCTTAA	---	ACATTG	ATCTTAA	---	GTCA	TAATGA	---			
	960	970	980	990								
Slit	CACCTTTG	ATGGATT	AAAGTCT	CTTCGATT	ACTTTCT	CTACATG	GAAATG	ACATTTCT	GTGTG	CGCTGAA		2730
325	---	TTTAGAGA	AATTTAAAT	---	TCTGAC	ACATTCAGT	---	TTGT	TAAAGA	ATT	---	TAATTTACCTTAA
	1000	1010	1020	1030	1040	1050						
Slit	GGTGCTTT	CAATGAT	CTTTCTG	CATTATC	ACATCTAG	CAATTG	GAGCCA	ACCCTCT	TTTACT	GTGTG	ATTGTA	2800
325	G	---	TTAGATAG	AA	---	ACAGAATA	AT	---	TAGCAT	---	---	GATAATGAT
	1060	1070	1080									

**Fig. 5Mx**

```

2810      2820      2830      2840      2850      2860      2870
Slit ACATGCAGTGGTTATCCGACTGGGTGAAGTCGGAATATAAGGAGCCTGGAATTGCTCGTTGTGCTGGTGCC
:::
325 ACAT-----TTGAAAATATGGGAGCAT-----CTTTGAA--GATCC
1090      1100      1110      1120

2880      2890      2900      2910      2920      2930      2940
Slit TGGAGAAATGGCAGATAAACTTTTACTCACAACTCCCTCCAAAAAATTACCTGTCAAGGTCCTGTGGAT
:
325 T-----TAACTCTGTCAT-----
1130

2950      2960      2970      2980      2990      3000      3010
Slit GTCAATATCTAGCTAAGTGTAACCCCTGCCCTATCAAAATCCGTTGTAATAATGATGGCACATGTAATAGTG
: ::::::::::: : :::::
325 -TTAATAATCTTACA-----GCCTTGC--ATCCAAG-----G
1140      1150      1160

3020      3030      3040      3050      3060      3070      3080
Slit ATCCAGTTGACHTTTACCGATGCACCTGTCCCATATGTTTCAAGGGCAGGACTGTGATGTCCCAATTCA
::: : ::::: : :
325 GTCC-----TTAAGCCGT-----TGTC-----TTCATTTG-----ATTCA
1170      1180      1190

```

**Fig. 5Mxi**

72 / 109

```

3090      3100      3110      3120      3130      3140      3150
Slit  TGCCTGCATCAGTAACCCATGTAAACATGGAGGAACCTGCCACTTAAAGGAGGAGAGAAAGATGGATTTC
:      :      :      :      :      :      :
325  T-----CTTCAGG-----CAAATT-----CTAATC-CTT-----GGGAATGTAACCTGCAAAAC
1200      1210      1220      1230

3160      3170      3180      3190      3200      3210      3220
Slit  TGGTGATTTGTGCTGATGGATTGGAAGGAGAGAAAATTGTGAAGTCAACGTTGATGATGTGTGAAGATAATG
:      :      :      :      :      :      :
325  T-----TTTGGGC-----CTTCGA-----CTTCGA-----G
1240

3230      3240      3250      3260      3270      3280      3290
Slit  ACTGTGAAAATAATTCTACATGTGTGCGATGGCATTAAATACTACACATGCCTTTGCCACCCTGAGTATAC
:      :      :      :      :      :      :
325  ACTG-----GC-----TAGCAT-----CTTCA-----GCCATTAC-----
1250      1260      1270

3300      3310      3320      3330      3340      3350      3360
Slit  AGGTGAGTTGTGTGAGGAGAAGCTGGACTTCTGTGCCCCAGGACCCTGAACCCCTGCCAGCACGATTCAAAG
:      :      :      :      :      :      :
325  -----TCTAAACATCTATT-----GTCAGAAATCCCC-----
1280      1290

```

Fig. 5Mxii

3370 3380 3390 3400 3410 3420 3430  
Slit TGCATCCTAACTCCAAAGGGATTCAAATGTGACTGCACACACCAGGTACGTAGGTGAACACTGCGACATCG  
::: :::  
325 --CATCCATGC-----GTGGCAGAGCA---TTACGTT-----  
1300 1310 1320

3440 3450 3460 3470 3480 3490 3500  
Slit ATTTTGACGACTGCCAAGACAACAAGTGTAAAAACGGAGCCACTGCACAGATGCAGTGAACGGCTATAC  
::: :::  
325 ATATTAAC-----ATTACAAATTGTGTTA-----CATCTTCA-----ATAA  
1330 1340 1350 1360

3510 3520 3530 3540 3550 3560 3570  
Slit GTGCATATGCCCCGGAAGGTTACAGTGGCTTGTCTGTGAGTTTCTCCACCCCATGGTCCTCCCTCGTACC  
::: :::  
325 ATGTAT-----CCAGAG-----CTTGGGCT-GTT-----GTAAATCTCCTC--ATATTCAATCACAAGA--C  
1370 1380 1390 1400 1410

3580 3590 3600 3610 3620 3630 3640  
Slit AGCCCTGTGATAATTTTGATTGTCAGAATGGAGCTCAGTGTATCGTCAGAAATAAATGAGCCAAATATGTC  
::: :::  
325 TAC---TGCGCTAAT---GATGGCCTG-----GCATAAAGTAAC--CA-----CAA-ATGGC  
1420 1430 1440 1450

**Fig. 5Mxiii**

```

3650      3660      3670      3680      3690      3700      3710
Slit AGTGTTCCTGGCTATCAGGGAGAAAGTGTGAAAATGGTTAGTGTGAATTTATAACAAAGAGTC
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 AGT-----CCT--CT-----GGAAAATACTGAGAC-----TGAGAACATTACTTCTCTGGGAA--
1460      1470      1480      1490      1500

3720      3730      3740      3750      3760      3770      3780
Slit TTATCTTCAGATTCCCTTCAGCCCAAGGTTCCGGCCTCAGACGGAACATAACACTTCAGATTGCCACAGATGAA
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 -----CGAATTCCTAC-----TTCACCTGCTGGTAGA-TTTTTCAGAGAAATGCCCTTTGGTAA-
1510      1520      1530      1540      1550

3790      3800      3810      3820      3830      3840      3850
Slit GACAGCGGAATCCTCTGTATAAGGGTGACAAAGACCATATCGCGGTAGAACTCTATCGGGGGCGGTGTTTC
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 -----TCCATTA-----GAGACTA-----CA-----GCAGTGTAC-CTGT-----GCAAATAC
1560      1570      1580      1590

3860      3870      3880      3890      3900      3910      3920
Slit GTGCCAGCTATGACACCGGCTCTCATCCAGCTTCTGCCATTACAGTGTGGAGACAAATCAATGATGGAAA
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325 AA-CTTACTA-----CTTCTGTACCTTGAACCT---TGGAAAAAACACAGTGCT-----
1600      1610      1620      1630

```

Fig. 5Mxiv

```
3930      3940      3950      3960      3970      3980      3990
Slit  CTTCCACATTGTGGAAC TACTTGCCCTTGGATCAGAGTCTCTCTTTGTCCGTGGATGGTGGAAACCCCAA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  CTACCG---AATGATGCTGCTT-----CAATGTC-----AGGGAA-----
      1640      1650      1660

4000      4010      4020      4030      4040      4050      4060
Slit  ATCATCACTAACTTGTCAAAGCAGTCCACTCTGAATTTTGACTCTCCACTCTATGTAGGAGGCATGCCAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  AACATCTCTAATTGT-----ACACAAGAAGTTGA-----
      1670      1680      1690

4070      4080      4090      4100      4110      4120      4130
Slit  GGAAGAGTAACGTGGCATCTCTGCGCCAGGCCCTGGGAGAACGGAACAGCTTCCACGGCTGCATCCG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  -GAAAGTTGAATGAGGCTT-----TTGACATTTTG---CTAGCTT-----
      1700      1710      1720      1730

4140      4150      4160      4170      4180      4190      4200
Slit  GAACCTTTACATCAACAGTGAGCTGCAGGACTTCCAGAAGGTGCCGATGCAAAACAGGCATTTTGCCCTGGC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  -----TTTTCATC-----TTAGCTT-----GTG-----TTTAAATCATTTT-----
      1740      1750      1760
```

Fig. 5Mxv

76 / 109

```

4210      4220      4230      4240      4250      4260      4270
Slit  TGTGAGCCATGCCACAAGAAGGTGTGTGCCCATGGCACATGCCAGCCAGCAGCGCTTCACCT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  TTTGATC--TAC-----AAAGTTGTT-----CAGTTTA-----A
      1770      1780      1790

4280      4290      4300      4310      4320      4330      4340
Slit  GCGAGTGCCAGGAAGGATGGATGGGGCCCTCTGTGACCAACGAGCACCAATGACCCCTTGCCTTGGAATAA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  ACAAAACTA--AAGG-----CATCAGAAACT-----CAAGGGAAT
      1800      1810      1820

4350      4360      4370      4380      4390      4400      4410
Slit  ATGCGTACATGGCACCTGCTTGCCCATCAATGCGTTCTCTACAGCTGTAAGTGCTGGAGGGCCATGGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  AGACTTGAATA-CTACAGCTT-----TTATCAGTCAGCAAGGTATA-----ATGTA
      1830      1840      1850      1860      1870

4420      4430      4440      4450      4460      4470      4480
Slit  GGTGTCCTCTGTGATGAAGAGGAGGATCTGTTTAACCCATGCCAGCGCATCAAGTCAAGCACGGGAAGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
325  ACTG-CCTCAAT-TTG-----TAACACTTCCC-----CAAATTCT--CT-AGAAAGT
      1880      1890      1900      1910

```

Fig. 5Mxxvi

77/109

```

4490      4500      4510      4520      4530      4540      4550
Slit GCAGGCTTTCAGGTCTGGGGCAGCCCTACTGTGAATGCAGCAGTGGATACACGGGGACAGCTGTGATCG
      :.:.:.:.:
325 CCTGGCTT-----GGAGCAG-----ATTC-----GACTTCA-TAAACA
      1920      1930      1940

4560      4570      4580      4590      4600      4610      4620
Slit AGAAATCTTGTCTGAGGGGAAAGGATAAGAGATTATTACCAAAGCAGCAGGGCTATGCTGCTTGCCAA
      :.:.:.:.:
325 AATTGT-TC-----C-----TGAAAATGAG-----GCA-CAGGTC-ATTCTTTTGTG---A
      1950      1960      1970      1980

4630      4640      4650      4660      4670      4680      4690
Slit ACAACCAAGAAGGTGTCCCGATTAGAGTGCAGAGGTGGGTGTGCAGGAGGGCAGTGTGTGGACCGCTGA
      :.:.:.:
325 ACATTC-----TGCTTTTATAACTC-----
      1990      2000

4700      4710      4720      4730      4740      4750      4760
Slit GGAGCAAGCGGGAAATACTCTTTTCGAATGCACTGACGGCTCCTCTTGTGGACGAGGTTGAGAAAGT
      :.:.:.:
325 --AACTAA-----ATATTGTCTATAAGAAACT---TCAGTGCCA-----TGGACATGATTAA-----
      2010      2020      2030      2040      2050

```

Fig. 5Mxvii

**Fig. 5Mxviii**

**Fig. 6A**

T Y G G P D C L A C Q G G C S Q R P C S G N 151  
 ACC TAC GGT CCC GAC TGT CTC GCA TGC CAG GGC GGA TCC CAG AGG CCC TGC AGC GGC AAT 566  
 G H C S G D G S R Q G D G S C R C H M G 171  
 GGC CAC TGC AGC GGA GAT GGG AGC AGA CAG GGC GAC GGG TCC TGC CGG TGC CAC ATG GGG 626  
 Y Q G G P L C T D C M D G Y F S S L R N E 191  
 TAC CAG GGC CCG CTG TGC ACT GAC TGC ATG GAC GGC TAC TTC AGC TCG CTC CGG AAC GAG 686  
 T H S I C T A C D E S C K T C S G L T N 211  
 ACC CAC AGC ATC TGC ACA GCC TGT GAC GAG TCC TGC AAG ACG TGC TCG GGC CTG ACC AAC 746  
 R D C G E C E V G W L D E G A C V D V 231  
 AGA GAC TGC GGC GAG TGT GAA GTG GGC TGG GTG CTG GAC GAG GGC GCC TGT GTG GAT GTG 806  
 D E C A A E P P C S A A Q F C K N A N 251  
 GAC GAG TGT GCG GCC GAG CCG CCT CCC TGC AGC GCT GCG CAG TTC TGT AAG AAC GCC AAC 866  
 G S Y T C E E C D S S C V G C T G E G P 271  
 GGC TCC TAC ACG TGC GAA GAG TGT GAC TCC AGC TGT GTG GGC TGC ACA GGC GAA GGC CCA 926  
 G N C K E C I S G Y A R E H G Q C A D V 291  
 GGA AAC TGT AAA GAG TGT ATC TCT GGC TAC GCG AGG GAG CAC GGA CAG TGT GCA GAT GTG 986

80/109

Fig. 6B

D E C S L A E K T C V R K N E N C Y N T 311  
 GAC GAG TGC TCA CTA GCA GAA AAA ACC TGT GTG AGG AAA AAC GAA AAC TGC TAC AAT ACT 1046  
 P G S Y V C V C P D G G C TTC GAA GAA ACG GAA GAT GCC TGT GTG 331  
 CCA GGG AGC TAC GTC TGT GTG TGT CCT GAC GGC GGC GAA GAA GAT GCC TGT GTG 1106  
 P P A E A E A T E G E S P T Q L P S R E 351  
 CCG CCG GCA GAG GCT GAA GCC ACA GAA GAA GAA AGC CCG ACA CAG CTG CCC TCC CGC GAA 1166  
 D L \*  
 GAC CTG TAA 354  
 1175  
 TGTGCCGGACTTACCCTTTAAATTATTCAGAAGGATGTCCCGTGGAATAATGTGGCCCTGAGGATGCCGTCTCCTGCAGT 1254  
 GGACAGCGGGGAGAGGCTGCCTCTCTAACGGTTGATTCTCATTTGTCCCTTAAACAGCTGCATTTCTTGGTTG 81 / 109  
 TTCTTAAACAGACTTGTATATTTTGATACAGTTCTTTTGTAATAAAATTGACCATTTAGGTAATCAAAAAAAAAAAAA 1333  
 AAAAAAGGCGCGCGCTAGAC 1412  
 1432

Fig. 6C




Fig. 6D

**Fig. 6E**

**Fig. 6F**

```
260      270      280      290      300      310      320
C  GGCAACACGGCGTGGGAGGAGAAAGAGTCTGTCCAAGTACGAATTCAGTGAGATTCGGCTCCTGGAGATTA
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H  GGGAAACACGGCTTGGGAGGAAAGACGCTGTCCAAGTACGAGTCCAGCGAGATTCGCCCTGCTGGAGATCC
280      290      300      310      320      330      340

330      340      350      360      370      380      390
C  TGGAGGGCCCTGTGTGACAGCAACGACTTTGAATGCAACCAACT-CTTGGAACAGCATGAGGAGCAGCTAG
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H  TGGAGGGGCTGTGCGAGAGAGCAGCGACTTCGAATGCAATCAGATGCTAGAGGC-GCAGGAGGAGCACCTGG
350      360      370      380      390      400      410

400      410      420      430      440      450      460
C  AGGCCTGGTGGCAGACACTGAAGAAGGAGTGCCCTAACCTATTGAGTGGTCTGTGTACACACACTGAA
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H  AGGCCTGGTGGCTGCAGCTGAAGAGCGAATATCCTGACTTATTCGAGTGGTTTTGTGTGAAGACACTGAA
420      430      440      450      460      470      480

470      480      490      500      510      520      530
C  AGCATGCTGTCTTCCAGGCACCTATGGGCCCAGACTGTTCAGGAATGCCAGGGTGGTCTCAGAGGCCCTGT
   :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
H  AGTGTGCTGTCTCCAGGAACCTACGGTCCCAGACTGTCTCGCATGCCAGGCGGATCCCAGAGGCCCTGC
490      500      510      520      530      540      550
```

Fig. 6G

```

540      550      560      570      580      590      600
C  AGCGGGAATGGCCACTGCGACGGAGATGGCAGACAGGGCGACGGTCTCTGCCAGTGTCACTAGGAT
   ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H  AGCGGGAATGGCCACTGCGACGGAGATGGGAGCAGACAGGGCGACGGTCTCTGCCAGTGTCACTAGGAT
560      570      580      590      600      610      620

610      620      630      640      650      660      670
C  ACAAGGGCCGCTGTGTATCGACTGCATGGATGGCTACTTCAGCTTGCTGAGGAACGAGACCCACAGCTT
   ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H  ACCAGGGCCGCTGTGTACTGACTGCATGGACGGCTACTTCAGCTCGCTCCGGAACGAGACCCACAGCAT
630      640      650      660      670      680      690

680      690      700      710      720      730      740
C  CTGCACAGCCCTGTGATGAGTCCCTGCAAGACATGCTCAGGTCCAACCAAAAGGCTGTGTGGAGTCCGAA
   ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H  CTGCACAGCCCTGTGACGAGTCCCTGCAAGACGCTGCTCGGGCCTGACCAACAGAGACTGCGGGCGAGTGTGAA
700      710      720      730      740      750      760

750      760      770      780      790      800      810
C  GTGGGCTGGACACGTGTGGAGGATGCCCTGTGTGGATGTTGACGAGTGTGCAGAGAGACCCACCCCTGCA
   ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
H  GTGGGCTGGGTGCTGGACGAGGGCGCCCTGTGTGGATGTGGACGAGTGTGCGGCCGAGCCCTCCCTGCA
770      780      790      800      810      820      830

```

Fig. 6H

87 / 109

```

      820      830      840      850      860      870      880
C  GCAATGTACAGTACTGTGAAATGTCAACGGCTCCTACACATGTGAAGAGTGTGATTCTACCTGTGTGGG
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H  GCGCTGGCGCAGTTCTGTAAAGAACGCCAACGGCTCCTACACGTGCGGAAGAGTGTGACTCCAGCTGTGTGGG
      840      850      860      870      880      890      900

      890      900      910      920      930      940      950
C  CTGCACAGGAAAGGCCCCAGCCCAATTGTAAGAGTGTATCTCTGGCTACAGCAAGCAGAAAGGAGAGTGT
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H  CTGCACAGGGGAAGGCCCCAGGAAACTGTAAAGAGTGTATCTCTGGCTACGCGGAGGAGCACGGACAGTGT
      910      920      930      940      950      960      970

      960      970      980      990      1000      1010      1020
C  GCAGATATAGATGAATGCTCATTAGAAACAAGGTGTGTAAGAAGGAAATGAGAACTGCTACAATATCTC
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H  GCAGATGTGGACGAGTGTCTACTAGCAGAAACCTGTGTGAGGAAACGAAACTGCTACAATATCTC
      980      990      1000      1010      1020      1030      1040

      1030      1040      1050      1060      1070      1080      1090
C  CAGGGAGCTTTGTCTGCGTGTGTCCGGAAGGTTTCGAGGAAGACAGAGATGCTTGTGTACAGACAGCAG
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H  CAGGGAGCTACGTTCTGTGTGTCTGACGGCTTCGAAGAA-ACGGAAGATGCCCTGTGTGCCCGCGGCAG
      1050      1060      1070      1080      1090      1100      1110

```

Fig. 6I

```

1100      1110      1120      1130      1140      1150
C AAGCGAAGTGGCAGAGGAAAGT--CCC-ACACAGCCACCCTCCCATGAGGATTGTGACGGGCATCCAG
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H AGGCTGAAGCCACAGAGGAGAAAGCCGACACAGCTGCCCTCCCGCGAAGA-----CCTG
1120      1130      1140      1150      1160      1170
1160      1170      1180      1190      1200      1210      1220
C GTTCAGAAGCTGGACTCTCACCCCTTTAAAGTTATTGAGAGGACATCCTATAGAAAATGTGGCCCATGGAC
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H --TAATGTGCCGGACTT--ACCCTTTAAATATTTCAGAAGGATGTCCCGTGGAAAATGTGCCCTGAGGA
1180      1190      1200      1210      1220      1230

1230      1240      1250      1260      1270      1280      1290
C ATCAACCCCATTTCTCCAGGAAGTTTGG-AGGAAGAAGCTGCCTGTGTTGAAACAGTAGATACTACTT
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H TGCCGTCTC-----CTGCAGTGGACAGCGGGGAGAGGCTGCCCTCTCTAACGGTTGATTCTCATTT
1240      1250      1260      1270      1280      1290      1300
1300      1310      1320      1330      1340      1350      1360
C GGCCCTTAAACGCTGCATTTCTTGGTGGTCTTAAACAGATTTCGTATATTTTGATACTGTTCTTTATA
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H GTCCCTTAAACA-GCTGCATTTCTTGGTGTCTTAAACAGACTTGTATATTTTGATACAGTTCCTTTGTA
1310      1320      1330      1340      1350      1360      1370

1370      1380      1390
C ATAAATATGATCATTTGAAGGTCACCAGGAA-----CA-----
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
H ATAAATATGACCATTTGATAGGTAATCAAAAAAAGGCGGCGCGCTAGAC
1380      1390      1400      1410      1420      1430

```

Fig. 6J

GTCGACCCACGCGTCCTGCGGGCCCCAGCCTCTCCTCAGCTCGCGCAGTCTCCGCCGCGAGTCTCAGCTGCAGCTG 79  
 CAGGACTGAGCCGTGCACCCGGAGGAGACCCCCGGAGGCGGACAACTTCGACGTGCCGCGACCCAAACCCAGCCCT 158  
 M A Q L F L P L L A A L V L A Q 16  
 GGTAGCCTGCAGC ATG GCC CAG CTG TTC CTG CCC CTG CTG GCA GCC CTG GTC CTG GCC CAG 220  
 A P A A L A D V L E G D S S E D R A F R 36  
 GCT CCT GCA GCT TTA GCA GAT GTT CTG GAA GGA GAC AGC TCA GAG GAC CGC GCT TTT CGC 280  
 V R I A G D A P L Q G V L G G A L T I P 56  
 GTG CGC ATC GCG GGC GAC GCG CCA CTG CAG GGC GTG CTC GGC GGC GGC CTC ACC ATC CCT 340  
 C H V H Y L R P P S R R A V L G S P R 76  
 TGC CAC GTC CAC TAC CTG CGG CCA CCG CCG AGC CGC GCT GTG CTG GGC TCT CCG CGG 89/109  
 V K W T F L S R G R E A E V L V A R G V 96  
 GTC AAG TGG ACT TTC CTG TCC CCG GGC CCG GAG GCA GAG GTG CTG GTG GCG CGG GGA GTG 460  
 R V K V N E A A Y R F R V A L P A Y P A S 116  
 CGC GTC AAG GTG AAC GAG GCC TAC CCG TTC CGC GTG GCA CTG CCT GCG TAC CCA GCG TCG 520  
 L T D V S L A L S E L R P N D S G I Y R 136  
 CTC ACC GAC GTC TCC CTG GCG CTG AGC GAG CTG CGC CCC AAC GAC TCA GGT ATC TAT CGC 580

Fig. 7A

C E V Q H G I D D S S D A V E V K V K G 156  
 TGT GAG GTC CAG CAC GGC ATC GAT GAC AGC AGC AGC GGT GTG GAG GTC AAG GTC AAA GGG 640  
 V V F L Y R E G S A R Y A F S F S G A Q 176  
 GTC GTC TTT CTC TAC CGA GAG GGC TCT GCC CGC TAT GCT TTC TCC TTT TCT GGG GCC CAG 700  
 E A C A R I G A H I A T P E Q L Y A A Y 196  
 GAG GCC TGT GCC CGC ATT GGA GCC CAC ATC GCC ACC CCG GAG CAG CTC TAT GCC GCC TAC 760  
 L G G Y E Q C D A G W L S D Q T V R Y P 216  
 CTT GGG GGC TAT GAG CAA TGT GAT GCT GGC TGG CTG TCG GAT CAG ACC GTG AGG TAT CCC 820  
 I Q T P R E A C Y G D M D G F P G V R N 236  
 ATC CAG ACC CCA CGA GAG GCC TGT TAC GGA GAC ATG GAT GGC TTC CCC GGG GTC CGG AAC 880  
 Y G V V D P D L Y D V Y C Y A E D L N 256  
 TAT GGT GTG GAC CCG GAT GAC CTC TAT GAT GTG TAC TGT TAT GCT GAA GAC CTA AAT 940  
 G E L F L G D P P E K L T L E E A R A Y 276  
 GGA GAA CTG TTC CTG GGT GAC CCT CCA GAG AAG CTG ACA TTG GAG GAA GCA CGG GCG TAC 1000  
 C Q E R G A E I A T T G Q L Y A A W D G 296  
 TGC CAG GAG CGG GGT GCA GAG ATT GCC ACC ACG GGC CAA CTG TAT GCA GCC TGG GAT GGT 1060

90/109

Fig. 7B

G L D H C S P G W L A D G S V R Y P I V 316  
 GGC CTG GAC CAC TGC AGC CCA GGG TGG CTA GCT GAT GGC AGT GTG CGC TAC CCC ATC GTC 1120  
 T P S Q R C G G G G L P G V K T L F L F P 336  
 ACA CCC AGC CAG CGC TGT GGT GGG GGC TTG CCT GGT GTC AAG ACT CTC TTC CTC TTC CCC 1180  
 N Q T G F P N K H S R F N V Y C F R D S 356  
 AAC CAG ACT GGC TTC CCC AAT AAG CAC AGC CGC TTC AAC GTC TAC TGC TTC CGA GAC TCG 1240  
 A Q P S A I P E A S N P A S N P A S D G 376  
 GCC CAG CCT TCT GCC ATC CCT GAG GCC TCC AAC CCA GCC TCC AAC CCA GCC TCT GAT GGA 1300  
 L E A I V T V T E T L E E L Q L P Q E A 396  
 CTA GAG GCT ATC GTC ACA GTG ACA GAG ACC CTG GAG GAA CTG CAG CTG CCT CAG GAA GCC 1360  
 T E S E S R G A I Y S I P I M E D G G G 416  
 ACA GAG AGT GAA TCC CGT GGG GCC ATC TAC TCC ATC CCC ATC ATG GAG GAC GGA GGT 1420  
 G S S T P E D P A E A P R T L L E F E T 436  
 GGA AGC TCC ACT CCA GAA GAC CCA GCA GAG GCC CCT AGG ACG CTC CTA GAA TTT GAA ACA 1480  
 Q S M V P P T G F S E E G K A L E E E 456  
 CAA TCC ATG GTA CCG CCC ACG GGG TTC TCA GAA GAG GAA GGT AAG GCA TTG GAG GAA GAA 1540

Fig. 7C

92 / 109

**Fig. 7D**

[illegible]

**Fig. 7E**

94 / 109




Fig. 7F

332	MAQLFLPLLAALVLAQAPAAALADVLEGDSS	EDRAFRVRIAGDAPLQGVLGALTIPCHVHYLRPPPSRRA	10	20	30	40	50	60	70
BEF	MAQLFLPLLAALVLAQAPAAALADVLEGDSS	EDRAFRVRIAGDAPLQGVLGALTIPCHVHYLRPPPSRRA	10	20	30	40	50	60	70
332	VLGSPRVKWTFLSRGREA	EVLVARGVRVKVNEAYRFRVALPAYPASLTDVSLSELRPNDSGIYRCEVQ	80	90	100	110	120	130	140
BEF	VLGSPRVKWTFLSRGREA	EVLVARGVRVKVNEAYRFRVALPAYPASLTDVSLSELRPNDSGIYRCEVQ	80	90	100	110	120	130	140
332	HGIDSSDAVEVKVG	VFLYREGSARYAFSFGAQEACARIGAHIAATPEQLYAAYLGGYEQCDAGWLSD	150	160	170	180	190	200	210
BEF	HGIDSSDAVE	-----	150	160	170	180	190	200	210
332	QTVRYPIQTPREACYGMDG	FGFVGVRNYGVDPDDLVDVYCYAEDLNGELFLGDPPEKLTLEEARAYCQER	220	230	240	250	260	270	280
BEF	Q--RYPIQTPREACYGMDG	FGFVGVRNYGVDPDDLVDVYCYAEDLNGELFLGDPPEKLTLEEARAYCQER	160	170	180	190	200	210	220
332	GAEIATTGQLYAAWDGGLDHC	SPGWLADGSGVRYPVITPSQRCGGGLPGVKTLFLFPNQTFPNKHSRNFV	290	300	310	320	330	340	350
BEF	GAEIATTGQLYAAWDGGLDHC	SPGWLADGSGVRYPVITPSQRCGGGLPGVKTLFLFPNQTFPNKHSRNFV	230	240	250	260	270	280	290

**Fig. 7G**

**Fig. 7H**

[illegible]

**Fig. 7I**

**Fig. 7J**

```

      680      690      700      710      720      730      740
M  GACYKHFSTRRSWEEAESQCRAALGAHLTSICTPEEQDFVNDRYQWIGLNDRTIEGDFLWSDGAPLLY
H  -----SI-----L-----LLF
      660

      750      760      770      780      790      800      810
M  ENWNPCQPD SYFLSGENCVMVWHHDQGWSDVPCNYHLSYTKMGLVSCGPPQLPLAQIFGRPRRLRYAV
H  -----F-----PLQ-----
      670

      820      830      840      850      860      870      880
M  DTVLYRCRDGLAQRNLPLIRCQENGLWEAPQISCVPRRPRGRALRSMDAPEGPRGQLSRHRKAPLTPPSS
H  -----LWVT-----
      670

```

M L

H -

Fig. 7K

100/109

```

10      20      30      40      50
H  GTCG-ACCCA-CG-----CGTCC-----GTCCTGGGCCCCAGCCTCTCCTCAGCTCGCGCAGTC
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
M  GAGGCTCCCGGCGAGCTGGCGCCCCCTGTCTGGGTCCCGCGGCCCGGCC-CTGCTCGCGCCCGCGCA-TC
10      20      30      40      50      60

60      70      80      90      100     110     120
H  TCCGCCCGCAGTCTCAG-CTGCAGCTGCAGGACTGAGCCGTGCACCCGGAGGAGACCCCGGAGGAGCGCA
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
M  GC-GCCGCGAGTCTCGGTCTGCGGTGCGGACGTGACGGCGTGCAGCGGAGGGGACCTC-----GCAA
70      80      90      100     110     120

130     140     150     160     170     180     190
H  CAAACTTCGCAGTGCCCGGACCCCAACCCAGCCCTGGGTAGCCTGCAGCATGGCCAGCTGTTCTCTGCCC
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
M  -GTTCTTC-----CATC-----AGTG---TGCAGAATGATACCACTGCTTCTGTCC
130     140     150     160     170

200     210     220     230     240     250     260
H  CTGCTGGCAGCCCTTGTCTCTGGCCAGGCTCCTGCAGCTTTAGCAGATGTTCTGGAAGAGACAGCTCAG
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
M  CTGCTGGCCGCTCTGGTCTGACCCCAAGCCCTGCCGCCCTCGCTGATGACCTGAAAGAAGACAGCTCGG
180     190     200     210     220     230     240

270     280     290     300     310     320     330
H  AGGACCGCGCTTTTCGCGTGGCGCATCGCGGGCGACGCCCACTGCAGGGCGTGTCTGGCGGCCCTCAC
:  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
M  AGGATCGAGCCCTTCCGCGTGGCGCATCG-GTGC--CGCGCAGCTGCGGGCGTGTGGCGGGTGCCCTGGC
250     260     270     280     290     300

```

Fig. 7L

**Fig. 7M**

```

690      700      710      720      730      740      750
H CCTTTCTGGGGCCAGAGGCCCTGTGCCCGCATTGGAGCCCAACATCGCCACCCGGAGCAGCTCTATGC
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M CCTTCGCTGGAGCCCAAGAACCTGCGCTCGCATAGGAGCCCGAATCGCCACCCGGAGCAGCTCTATGC
660      670      680      690      700      710      720

760      770      780      790      800      810      820
H CGCCTACCTTGGGGCTATGAGCAATGTGATGCTGGCTGGCTGTCGGATCAGACCGTGAGGTATCCCATC
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M TGCCTACCTCGGGCGGCTATGAGCAGTGTGATGACAGGCTGGCTGTCCGACCAAACTGTGAGGTACCCCATC
730      740      750      760      770      780      790

830      840      850      860      870      880      890
H CAGACCCCAAGAGAGGCCCTGTACGGAGACATGGATGGCTTCCCGGGGTCCGGAACCTATGGTGGTGG
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M CAGAACCCCAAGAGAGGCCCTGCTCTGGAGACATGGATGGCTATCCTGGCGTCCGGAACCTACGGAGTGGTGG
800      810      820      830      840      850      860

900      910      920      930      940      950      960
H ACCCGGATGACCTCTATGATGTGTACTGTTATGCTGAAGACCTAAATGGAGAACTGTTCTCTGGTGACCC
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M GTCCTGATGATCTCTATGATGTCTACTGTTATGCCGAAGACCTAAATGGAGAACTGTTCTCTAGGCGCCCC
870      880      890      900      910      920      930

970      980      990      1000      1010      1020      1030
H TCCAGAGAAGCTGACATTGGAGGAAGCACGGGCGTACTGCCAGGAGCGGGGTGCAGAGATTGCCACCCAG
   :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: :::: ::::
M TCCAGCAAGCTGACATGGAGGAGGCTCGGGACTACTGTCTGGAACGTGGTGCACAGATCGCTAGCACA
940      950      960      970      980      990      1000

```

Fig. 7N

Fig. 70

**Fig. 7P**

**Fig. 7Q**

**Fig. 7R**

[illegible]

**Fig. 7S**

**Fig. 7T**

```

2690
H CGCTTTGT-----AAC-----CAAAAAAAAAAAAAA 2700
: : : : :
M CTCCTTGTCCCTCGATNTCGTNAGGGGACACTGTGCTATTTCGATCTTGATTCGAAAGAGTTT TAGGAT
3030 3040 3050 3060 3070 3080 3090

2710
H AAA-----AAATAAAGGCGG--CC-----GC 2730
... : : : : :
M GGAGTACCAGCAAAACCAGGTGGAATAAAGTTGCTGAACCCCAAGAAAAA
3100 3110 3120 3130 3140 3150

```

Fig. 7U

## SEQUENCE LISTING

<110> KIRST, Susan  
 SHARP, John  
 HOLTZMAN, Douglas  
 BARNES, Tom  
 FRASER, Christopher

<120> Novel Genes Encoding Proteins Having Diagnostic,  
 Preventive, Therapeutic, and Other Uses

<130> 210147.0026/11WO

<140> Not Yet Assigned

<141> 2000-06-16

<150> US 09/342,364

<151> 1999-06-29

<160> 100

<170> PatentIn Ver. 2.1

<210> 1

<211> 2895

<212> DNA

<213> Homo sapiens

<400> 1

```

gtcgacccac gcgtccgggg agcgcggcta agagtgccgc accgcctcac aacctgggaa 60
ccggagagta ggggccgtcg gctggcaaga acccgccgtg cctcctcggc aagggccatc 120
cgggtgccacc catgtcgcac tagagcagaa gagggtagt cctgaactgc aacctgcaca 180
gagctgctct gtactgtccc tgggtggtcg cgccatgacc tggttggtgc tgctggggac 240
actgctctgc atgtgcgcg ttgggttagg caccgccgac tccgagggtt tcccgccccg 300
tgcgctccac aactgcccct acaaatgtat ctgcgctgcc gacctgctaa gctgcactgg 360
cctaggggtg caggacgtgc cagccgagtt acctgccgct actgcggacc tcgacctgag 420
ccacaacgcg ctccagcgcc tgcgccccgg ctggttggcg cccctcttcc agctgcgcgc 480
cctgcaccta gaccacaacg aactagatgc gctgggtcgc ggcgtcttcg tcaacgccag 540
cggcctgagg ctgctcgatc tatcatctaa cacgttgccg gcgcttgccc gccacgacct 600
cgacgggctg ggggcgctgg agaagctgct tctgttcaat aaccgcttg tgcaattgga 660
cgagcatgcc ttccacggcc tgcgcgcgct cagccatctc tacctgggct gcaacgaact 720
cgctcggttc tccttcgacc acctgcacgg tctgagcgcc acccactgc ttactctgga 780
cctctcctcc aaccggctgg gacacatctc cgtacctgag ctggccgcgc tgccggcctt 840
cctcaagaac ggctctact tgcacaacaa ccctttgcct tgcgactgcc gcctctacca 900
cctgctacag cgctggcacc agcggggcct gaggcgccgt cgcgactttg cgcgcgagta 960
cgtatgcttg gccttcaagg taccgcgcgc ccgcgtgcgc ttcttcagc acagccgcgt 1020
ctttgagaac tgctcgctcg ccccgactct tggcctaaag cggccggaag agcacctgta 1080
cgcgctggtg ggtcggtccc tgaggcttta ctgcaacacc agcgtccccg ccatgcgcat 1140

```

tgctgggtt tcgccgcagc aggagcttct cagggcgcca ggatcccgcg atggcagcat 1200  
 cgcggtgctg gccgacggca gcttgccat aggcaacgta caggagcagc atgcgggact 1260  
 cttcgtgtgc ctggccactg ggccccgcct gcaccacaac cagacgcacg agtacaacgt 1320  
 gagcgtgcac ttccgcgcgc cagagcccga ggctttcaac acaggcttca ccacactgct 1380  
 gggctgtgcc gtgggcttg tgctcgtgct gctctacctg ttcccccac cctgccgctg 1440  
 ctgccgcgct gcctgcccgc tgccgcgcgt ggcccaaac acccagcccg ctccaagagc 1500  
 tgagccgcac aagtcctcag tactcagcac cacaccgcca gacgcacca gcccgcaagg 1560  
 ccaagcgtcc acaagcacgt agtctttctg gagccaggcc ggaggggcct caatggcccg 1620  
 cgtgcagctg gcagtagctg aggaattcga tctctacaac cctggaggcc tgcagctgaa 1680  
 ggctggctct gagtccgcca gctccatagg ctccgagggt cccatgacaa cctagactgc 1740  
 cagggctccc ccaccaggc cccaccctc ttgctgctcg cctgctccc tgcttcggtc 1800  
 cagagaactg gcagatactg gtgggaagca ctgtgcctgg ccccccagct tcctgtatgg 1860  
 gcctcgaaac acaatgggcc ttctcgtcga ctggtagaga caggggttgt ggtccccaac 1920  
 ctgcttctg ctctgccct gcacaggacc caaaggcccc aggcctgca aggtgtgcta 1980  
 gttcctgctt tccgcggac ttctagtgc ccaaatgccc tgtgaggctg agagaccag 2040  
 gccctgtgg ctttcaacac agcacagctg tggaagtggc tgtgttctc tacagcctgt 2100  
 ggaagaacct ctgtagcaga gcctcccatc caccctcagg ggctgaggca gctctcagg 2160  
 agtgggtgctc aagagctgac gcagggccac ctccccttcc caagggggtg ggaggaggag 2220  
 ggcccacagg gaaaagaagg cggctctgaa ggaagatctc gccacacccc caggacagaa 2280  
 agaggaaaca agcccgcct ctggtgaaat gggactccct ccatccacca acaccaacc 2340  
 tcctgaaagc ttcacaactt cagcagagt ccggtggcag gcaccaggca ggaaaggctc 2400  
 ctcaagaggt tctggtggt ctggcctaag cccagccag aggcctgct ctctctggcc 2460  
 tggggcatcc acccggtgt ctgaaggcag agccattct gtgggctcac aagacacagt 2520  
 gaaggggatc atggcctgca ccctgcttt tcagcagtaa aaagcccga aagcctggcg 2580  
 agcatggccg agctgggagg gccgagccg aactccact ccctcagag caggagcctc 2640  
 ttaagggctg gcactggtct cagcctaag gctgaggcgg taccctggt tcatatgcat 2700  
 ctactgctc cactgcagg ggggcaggga aggggggtct gggagccct catgtgtgg 2760  
 ggccgagctg ggggccccca tggccatcct ggacctcgt gctccagag ttaataaagg 2820  
 tagcacatgc ttattgctag aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2880  
 aaaaagggcg gccgc 2895

&lt;210&gt; 2

&lt;211&gt; 1365

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

atgacctggt tgggtgctgct ggggacactg ctctgcatgc tgccggttg gttaggcacc 60  
 ccggaactccg agggtttccc gcccgcgtgc ctccacaact gccctacaa atgtatctgc 120  
 gctgccgacc tgctaagctg cactggccta gggctgcagg acgtgccagc cgagttacct 180  
 gccgctactg cggacctcga cctgagccac aacgcgctcc agcgcctgcg cccgggctgg 240  
 ttggcgcccc tcttcagct gcgcgccctg cacctagacc acaacgaact agatgcgctg 300  
 ggtcgcggcg tcttcgtcaa cgccagcggc ctgaggctgc tcgatctatc atctaacacg 360  
 ttgcgggcgc ttggccgcca cgacctgac gggctggggg cgctggagaa gctgcttctg 420  
 ttcaataacc gcttggtgca cttggacgag catgccttcc acggcctgcg cgcgctcagc 480  
 catctctacc tgggtgcaa cgaactcgc tcgttctcct tcgaccacct gcacggctc 540  
 agcgccaccc acctgcttac tctggacctc tctccaacc ggctgggaca catctccgta 600

cctgagctgg ccgcgctgcc ggccttcctc aagaacggcc tctacttgca caacaaccct 660  
 ttgccttgcg actgccgcct ctaccacctg ctacagcgct ggcaccagcg gggcctgagc 720  
 gccgtgcgcg actttgcgcg cgagtacgta tgcttggcct tcaaggtagc cgcgtcccgc 780  
 gtgcgcttct tccagcacag ccgcgtcttt gagaactgct cgtcggcccc agctcttggc 840  
 ctaaagcggc cggaagagca cctgtacgcg ctggtgggtc ggtccctgag gctttactgc 900  
 aacaccagcg tcccggccat gcgcattgcc tgggtttcgc cgcagcagga gcttctcagg 960  
 gcgccaggat cccgcgatgg cagcatcgcg gtgctggccg acggcagctt ggccataggc 1020  
 aacgtacagg agcagcatgc gggactcttc gtgtgcctgg ccactgggcc ccgcctgcac 1080  
 cacaaccaga cgcacgagta caacgtgagc gtgcactttc cgcgccaga gcccgaggct 1140  
 ttcaacacag gcttcaccac actgctgggc tgtgccgtgg gccttgtgct cgtgctgctc 1200  
 tacctgttcg cccacacctg ccgctgctgc cgcctgcct gcccgctgcc gccgctggcc 1260  
 ccaaacaccc agcccgtcc aagagctgag ccgcacaagt cctcagtact cagcaccaca 1320  
 ccgccagacg caccagccc gcaaggccaa gcgtccacaa gcacg 1365

&lt;210&gt; 3

&lt;211&gt; 455

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg Val  
 1 5 10 15

Gly Leu Gly Thr Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His  
 20 25 30

Asn Cys Pro Tyr Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr  
 35 40 45

Gly Leu Gly Leu Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala  
 50 55 60

Asp Leu Asp Leu Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp  
 65 70 75 80

Leu Ala Pro Leu Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu  
 85 90 95

Leu Asp Ala Leu Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg  
 100 105 110

Leu Leu Asp Leu Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp  
 115 120 125

Leu Asp Gly Leu Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg  
 130 135 140

Leu Val His Leu Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser  
 145 150 155 160  
 His Leu Tyr Leu Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His  
 165 170 175  
 Leu His Gly Leu Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser  
 180 185 190  
 Asn Arg Leu Gly His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala  
 195 200 205  
 Phe Leu Lys Asn Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp  
 210 215 220  
 Cys Arg Leu Tyr His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser  
 225 230 235 240  
 Ala Val Arg Asp Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val  
 245 250 255  
 Pro Ala Ser Arg Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn  
 260 265 270  
 Cys Ser Ser Ala Pro Ala Leu Gly Leu Lys Arg Pro Glu Glu His Leu  
 275 280 285  
 Tyr Ala Leu Val Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val  
 290 295 300  
 Pro Ala Met Arg Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg  
 305 310 315 320  
 Ala Pro Gly Ser Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser  
 325 330 335  
 Leu Ala Ile Gly Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys  
 340 345 350  
 Leu Ala Thr Gly Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn  
 355 360 365  
 Val Ser Val His Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr Gly  
 370 375 380  
 Phe Thr Thr Leu Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu Leu  
 385 390 395 400

Tyr Leu Phe Ala Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu  
 405 410 415

Pro Pro Leu Ala Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His  
 420 425 430

Lys Ser Ser Val Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln  
 435 440 445

Gly Gln Ala Ser Thr Ser Thr  
 450 455

<210> 4  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg Val  
 1 5 10 15

Gly Leu Gly Thr  
 20

<210> 5  
 <211> 435  
 <212> PRT  
 <213> Homo sapiens

<400> 5  
 Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His Asn Cys Pro Tyr  
 1 5 10 15

Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr Gly Leu Gly Leu  
 20 25 30

Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala Asp Leu Asp Leu  
 35 40 45

Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp Leu Ala Pro Leu  
 50 55 60

Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu Leu Asp Ala Leu  
 65 70 75 80

Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu

	85		90		95
Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp Leu Asp Gly Leu	100		105		110
Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg Leu Val His Leu	115		120		125
Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser His Leu Tyr Leu	130		135		140
Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His Leu His Gly Leu	145		150		155
					160
Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser Asn Arg Leu Gly	165		170		175
His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala Phe Leu Lys Asn	180		185		190
Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp Cys Arg Leu Tyr	195		200		205
His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser Ala Val Arg Asp	210		215		220
Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val Pro Ala Ser Arg	225		230		235
					240
Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn Cys Ser Ser Ala	245		250		255
Pro Ala Leu Gly Leu Lys Arg Pro Glu Glu His Leu Tyr Ala Leu Val	260		265		270
Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val Pro Ala Met Arg	275		280		285
Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg Ala Pro Gly Ser	290		295		300
Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser Leu Ala Ile Gly	305		310		315
					320
Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys Leu Ala Thr Gly	325		330		335
Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn Val Ser Val His					

340                      345                      350  
 Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr Gly Phe Thr Thr Leu  
       355                      360                      365  
 Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu Leu Tyr Leu Phe Ala  
       370                      375                      380  
 Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu Pro Pro Leu Ala  
       385                      390                      395                      400  
 Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His Lys Ser Ser Val  
               405                      410                      415  
 Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln Gly Gln Ala Ser  
               420                      425                      430  
 Thr Ser Thr  
       435  
  
 <210> 6  
 <211> 363  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 6  
 Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala Leu His Asn Cys Pro Tyr  
       1                      5                      10                      15  
 Lys Cys Ile Cys Ala Ala Asp Leu Leu Ser Cys Thr Gly Leu Gly Leu  
               20                      25                      30  
 Gln Asp Val Pro Ala Glu Leu Pro Ala Ala Thr Ala Asp Leu Asp Leu  
               35                      40                      45  
 Ser His Asn Ala Leu Gln Arg Leu Arg Pro Gly Trp Leu Ala Pro Leu  
               50                      55                      60  
 Phe Gln Leu Arg Ala Leu His Leu Asp His Asn Glu Leu Asp Ala Leu  
               65                      70                      75                      80  
 Gly Arg Gly Val Phe Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu  
               85                      90                      95  
 Ser Ser Asn Thr Leu Arg Ala Leu Gly Arg His Asp Leu Asp Gly Leu  
               100                      105                      110

Gly Ala Leu Glu Lys Leu Leu Leu Phe Asn Asn Arg Leu Val His Leu  
 115 120 125  
 Asp Glu His Ala Phe His Gly Leu Arg Ala Leu Ser His Leu Tyr Leu  
 130 135 140  
 Gly Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His Leu His Gly Leu  
 145 150 155 160  
 Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser Asn Arg Leu Gly  
 165 170 175  
 His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala Phe Leu Lys Asn  
 180 185 190  
 Gly Leu Tyr Leu His Asn Asn Pro Leu Pro Cys Asp Cys Arg Leu Tyr  
 195 200 205  
 His Leu Leu Gln Arg Trp His Gln Arg Gly Leu Ser Ala Val Arg Asp  
 210 215 220  
 Phe Ala Arg Glu Tyr Val Cys Leu Ala Phe Lys Val Pro Ala Ser Arg  
 225 230 235 240  
 Val Arg Phe Phe Gln His Ser Arg Val Phe Glu Asn Cys Ser Ser Ala  
 245 250 255  
 Pro Ala Leu Gly Leu Lys Arg Pro Glu Glu His Leu Tyr Ala Leu Val  
 260 265 270  
 Gly Arg Ser Leu Arg Leu Tyr Cys Asn Thr Ser Val Pro Ala Met Arg  
 275 280 285  
 Ile Ala Trp Val Ser Pro Gln Gln Glu Leu Leu Arg Ala Pro Gly Ser  
 290 295 300  
 Arg Asp Gly Ser Ile Ala Val Leu Ala Asp Gly Ser Leu Ala Ile Gly  
 305 310 315 320  
 Asn Val Gln Glu Gln His Ala Gly Leu Phe Val Cys Leu Ala Thr Gly  
 325 330 335  
 Pro Arg Leu His His Asn Gln Thr His Glu Tyr Asn Val Ser Val His  
 340 345 350  
 Phe Pro Arg Pro Glu Pro Glu Ala Phe Asn Thr  
 355 360

<210> 7  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Gly Phe Thr Thr Leu Leu Gly Cys Ala Val Gly Leu Val Leu Val Leu  
 1 5 10 15  
 Leu Tyr Leu Phe  
 20

<210> 8  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Ala Pro Pro Cys Arg Cys Cys Arg Arg Ala Cys Pro Leu Pro Pro Leu  
 1 5 10 15

Ala Pro Asn Thr Gln Pro Ala Pro Arg Ala Glu Pro His Lys Ser Ser  
 20 25 30

Val Leu Ser Thr Thr Pro Pro Asp Ala Pro Ser Pro Gln Gly Gln Ala  
 35 40 45

Ser Thr Ser Thr  
 50

<210> 9  
 <211> 1518  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gtcgacccac gcgtccggcg aaccccagcg tccgccgaca tggcctggac caagtaccag 60  
 ctgttcctgg ccgggctcat gcttggtacc ggctccatca acacgctctc ggcaaaatgg 120  
 gcggacaatt tcatggccga gggctgtgga gggagcaagg agcacagctt ccagcatccc 180  
 ttctccagg cagtgggcat gttcctggga gaattctcct gcctggctgc cttctacctc 240  
 ctccgatgca gagctgcagg gcaatcagac tccagcgtag acccccagca gcccttcaac 300  
 cctcttcttt tcctgcccc agcgtctgtg gacatgacag ggaccagcct catgtatgtg 360  
 gctctgaaca tgaccagtgc ctccagcttc cagatgctgc ggggtgcagt gatcatattc 420  
 actggcctgt tctcgtggc ctctcgtggc cggaggctgg tgctgagcca gtggctgggc 480  
 atcctagcca ccacgcggg gctggtggtc gtgggcctgg ctgacctcct gagcaagcac 540

gacagtcagc acaagctcag cgaagtgatc acaggggacc tgttgatcat catggcccag 600  
 atcatcggtt ccatccagat ggtgctagag gagaagttcg tctacaaaca caatgtgcac 660  
 ccaactgctgg cagttggcac tgagggcctc tttggctttg tgatcctctc cctgctgctg 720  
 gtgcccattg actacatccc cgccggctcc ttcagcggaa accctcgtgg gacactggag 780  
 gatgcattgg acgccttctg ccagggtggc cagcagccgc tcattgccgt ggactgctg 840  
 ggcaacatca gcagcattgc cttcttcaac ttcgcaggca tcagcgtcac caaggaaactg 900  
 agcgccacca cccgcatggt gttggacagc ttgcgcaccg ttgtcatctg ggactgagc 960  
 ctggcactgg gctgggaggc cttccatgca ctgcagatcc ttggcttctt catactcctt 1020  
 ataggcactg cctctacaa tgggctacac cgcccgctgc tgggcccgtt gtccaggggc 1080  
 cggcccctgg cagaggagag cgagcaggag agactgctgg gtggcaccgg cactcccatc 1140  
 aatgatgcca gctgaggttc cctggaggct tctactgcca cccgggtgct ccttctccct 1200  
 gagactgagg ccacacaggc tgggtggccc cgaatgccct atccccaagg cctcaccttg 1260  
 tcccctcctt gcagaacccc cagggcagct gctgccacag aagataacaa caccacaagtc 1320  
 ctctttttct cactaccacc tgcagggtgg tgttaccag cccccaacag cctgagtga 1380  
 gtggcagacc tcagctctct ggaccctcc tacagcacta gagctaaatc atgaagtga 1440  
 attgtaggaa tttaccaccg tagtgtatct gaatacaaaa ctagattatc ataaaaaaaa 1500  
 aaaaaaaagg gcggccgc 1518

&lt;210&gt; 10

&lt;211&gt; 1113

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

atggcctgga ccaagtacca gctgttcttg gccgggctca tgettgttac cggctccatc 60  
 aacacgctct cggcaaaatg ggccgacaat ttcattggccg agggctgtgg agggagcaag 120  
 gagcacagct tccagcatcc cttcctccag gcagtgggca tgttcttggg agaattctcc 180  
 tgcttggttg cttctacact cctccgatgc agagctgcag ggcaatcaga ctccagcgta 240  
 gacccccagc agcccttcaa cctcttctt ttcctgcccc cagcgtcttg tgacatgaca 300  
 gggaccagcc tcattgtatg ggctctgaac atgaccagt cctccagctt ccagatgctg 360  
 cggggtgcag tgatcatatt cactggcctg ttctcggttg ccttcttggg ccggaggctg 420  
 gtgctgagcc agtggctggg cactctagcc accatcgccg ggctggtggt cgtgggcctg 480  
 gctgacctcc tgagcaagca cgacagtcag cacaagctca gcgaagtgat cacaggggac 540  
 ctgttgatca tcatggccca gatcatcgtt gccatccaga tgggtgctaga ggagaagttc 600  
 gtctacaaac acaatgtgca cccactgcgg gcagttggca ctgagggcct ctttggcttt 660  
 gtgatcctct cctgctgct ggtgcccatt tactacatcc ccgccggctc cttcagcgga 720  
 aaccctcgtg ggacactgga ggatgcattg gacgccttct gccagggtgg ccagcagccg 780  
 ctcattgccg tggcactgct gggcaacatc agcagcattg cttcttcaa cttcgcaggc 840  
 atcagcgtca ccaaggaaact gagcgccacc acccgcatgg tgttggacag cttgcgcacc 900  
 gttgtcatct gggcactgag cctggcactg ggctgggagg ccttccatgc actgcagatc 960  
 cttggcttcc tcatactcct tataggcact gccctctaca atgggctaca ccgtccgctg 1020  
 ctgggccgcc tgtccagggg ccggcccctg gcagaggaga gcgagcagga gagactgctg 1080  
 ggtggcacc gcactcccat caatgatgcc agc 1113

&lt;210&gt; 11

&lt;211&gt; 371

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

Met Ala Trp Thr Lys Tyr Gln Leu Phe Leu Ala Gly Leu Met Leu Val  
 1 5 10 15

Thr Gly Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met  
 20 25 30

Ala Glu Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro Phe  
 35 40 45

Leu Gln Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala Ala  
 50 55 60

Phe Tyr Leu Leu Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val  
 65 70 75 80

Asp Pro Gln Gln Pro Phe Asn Pro Leu Leu Phe Leu Pro Pro Ala Leu  
 85 90 95

Cys Asp Met Thr Gly Thr Ser Leu Met Tyr Val Ala Leu Asn Met Thr  
 100 105 110

Ser Ala Ser Ser Phe Gln Met Leu Arg Gly Ala Val Ile Ile Phe Thr  
 115 120 125

Gly Leu Phe Ser Val Ala Phe Leu Gly Arg Arg Leu Val Leu Ser Gln  
 130 135 140

Trp Leu Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu  
 145 150 155 160

Ala Asp Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu Val  
 165 170 175

Ile Thr Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala Ile  
 180 185 190

Gln Met Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro  
 195 200 205

Leu Arg Ala Val Gly Thr Glu Gly Leu Phe Gly Phe Val Ile Leu Ser  
 210 215 220

Leu Leu Leu Val Pro Met Tyr Tyr Ile Pro Ala Gly Ser Phe Ser Gly  
 225 230 235 240

```
<210> 12
<211> 18
<212> PRT
<213> Homo sapiens
```

Thr Gly

<400> 13

Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met Ala Glu  
 1 5 10 15  
 Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro Phe Leu Gln  
 20 25 30  
 Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala Ala Phe Tyr  
 35 40 45  
 Leu Leu Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val Asp Pro  
 50 55 60  
 Gln Gln Pro Phe Asn Pro Leu Leu Phe Leu Pro Pro Ala Leu Cys Asp  
 65 70 75 80  
 Met Thr Gly Thr Ser Leu Met Tyr Val Ala Leu Asn Met Thr Ser Ala  
 85 90 95  
 Ser Ser Phe Gln Met Leu Arg Gly Ala Val Ile Ile Phe Thr Gly Leu  
 100 105 110  
 Phe Ser Val Ala Phe Leu Gly Arg Arg Leu Val Leu Ser Gln Trp Leu  
 115 120 125  
 Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu Ala Asp  
 130 135 140  
 Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu Val Ile Thr  
 145 150 155 160  
 Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala Ile Gln Met  
 165 170 175  
 Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro Leu Arg  
 180 185 190  
 Ala Val Gly Thr Glu Gly Leu Phe Gly Phe Val Ile Leu Ser Leu Leu  
 195 200 205  
 Leu Val Pro Met Tyr Tyr Ile Pro Ala Gly Ser Phe Ser Gly Asn Pro  
 210 215 220  
 Arg Gly Thr Leu Glu Asp Ala Leu Asp Ala Phe Cys Gln Val Gly Gln  
 225 230 235 240  
 Gln Pro Leu Ile Ala Val Ala Leu Leu Gly Asn Ile Ser Ser Ile Ala  
 245 250 255

Phe Phe Asn Phe Ala Gly Ile Ser Val Thr Lys Glu Leu Ser Ala Thr  
 260 265 270

Thr Arg Met Val Leu Asp Ser Leu Arg Thr Val Val Ile Trp Ala Leu  
 275 280 285

Ser Leu Ala Leu Gly Trp Glu Ala Phe His Ala Leu Gln Ile Leu Gly  
 290 295 300

Phe Leu Ile Leu Leu Ile Gly Thr Ala Leu Tyr Asn Gly Leu His Arg  
 305 310 315 320

Pro Leu Leu Gly Arg Leu Ser Arg Gly Arg Pro Leu Ala Glu Glu Ser  
 325 330 335

Glu Gln Glu Arg Leu Leu Gly Gly Thr Arg Thr Pro Ile Asn Asp Ala  
 340 345 350

Ser

<210> 14  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 14  
 Ser Ile Asn Thr Leu Ser Ala Lys Trp Ala Asp Asn Phe Met Ala Glu  
 1 5 10 15

Gly Cys Gly Gly Ser Lys Glu His Ser Phe Gln His Pro  
 20 25

<210> 15  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 15  
 Asn Met Thr Ser Ala Ser Ser Phe Gln  
 1 5

<210> 16  
 <211> 14  
 <212> PRT

<213> Homo sapiens

<400> 16

Asp Leu Leu Ser Lys His Asp Ser Gln His Lys Leu Ser Glu  
1 5 10

<210> 17

<211> 27

<212> PRT

<213> Homo sapiens

<400> 17

Pro Ala Gly Ser Phe Ser Gly Asn Pro Arg Gly Thr Leu Glu Asp Ala  
1 5 10 15

Leu Asp Ala Phe Cys Gln Val Gly Gln Gln Pro  
20 25

<210> 18

<211> 7

<212> PRT

<213> Homo sapiens

<400> 18

Glu Ala Phe His Ala Leu Gln  
1 5

<210> 19

<211> 21

<212> PRT

<213> Homo sapiens

<400> 19

Phe Leu Gln Ala Val Gly Met Phe Leu Gly Glu Phe Ser Cys Leu Ala  
1 5 10 15

Ala Phe Tyr Leu Leu  
20

<210> 20

<211> 21

<212> PRT

<213> Homo sapiens

&lt;400&gt; 20

Leu Leu Phe Leu Pro Pro Ala Leu Cys Asp Met Thr Gly Thr Ser Leu  
 1 5 10 15

Met Tyr Val Ala Leu  
 20

&lt;210&gt; 21

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

Met Leu Arg Gly Ala Val Ile Ile Phe Thr Gly Leu Phe Ser Val Ala  
 1 5 10 15

Phe Leu Gly

&lt;210&gt; 22

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

Trp Leu Gly Ile Leu Ala Thr Ile Ala Gly Leu Val Val Val Gly Leu  
 1 5 10 15

Ala

&lt;210&gt; 23

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

Val Ile Thr Gly Asp Leu Leu Ile Ile Met Ala Gln Ile Ile Val Ala  
 1 5 10 15

Ile

&lt;210&gt; 24

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

Gly Leu Phe Gly Phe Val Ile Leu Ser Leu Leu Val Pro Met Tyr

1

5

10

15

Tyr Ile

&lt;210&gt; 25

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

Leu Ile Ala Val Ala Leu Leu Gly Asn Ile Ser Ser Ile Ala Phe Phe

1

5

10

15

Asn Phe Ala Gly Ile Ser Val

20

&lt;210&gt; 26

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

Met Val Leu Asp Ser Leu Arg Thr Val Val Ile Trp Ala Leu Ser Leu

1

5

10

15

Ala Leu Gly Trp

20

&lt;210&gt; 27

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

Ile Leu Gly Phe Leu Ile Leu Leu Ile Gly Thr Ala Leu Tyr Asn Gly

1

5

10

15

Leu

<210> 28  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 28  
 Arg Cys Arg Ala Ala Gly Gln Ser Asp Ser Ser Val Asp Pro Gln Gln  
     1                    5                    10                    15

Pro Phe Asn Pro  
                     20

<210> 29  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<400> 29  
 Arg Arg Leu Val Leu Ser Gln  
     1                    5

<210> 30  
 <211> 23  
 <212> PRT  
 <213> Homo sapiens

<400> 30  
 Gln Met Val Leu Glu Glu Lys Phe Val Tyr Lys His Asn Val His Pro  
     1                    5                    10                    15

Leu Arg Ala Val Gly Thr Glu  
                     20

<210> 31  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 31  
 Thr Lys Glu Leu Ser Ala Thr Thr Arg  
     1                    5

<210> 32  
 <211> 35  
 <212> PRT  
 <213> Homo sapiens

<400> 32  
 His Arg Pro Leu Leu Gly Arg Leu Ser Arg Gly Arg Pro Leu Ala Glu  
 1 5 10 15  
 Glu Ser Glu Gln Glu Arg Leu Leu Gly Gly Thr Arg Thr Pro Ile Asn  
 20 25 30  
 Asp Ala Ser  
 35

<210> 33  
 <211> 2811  
 <212> DNA  
 <213> Homo sapiens

<400> 33  
 gtcgacccac gcgtccgcgg gacagctggc ctgaagctca gagccggggc gtgcgccatg 60  
 gcccacact gggctgtctg gctgctggca gcaaggctgt ggggcctggg cattggggct 120  
 gaggtgtggt ggaaccttgt gccgcgtaag acagtgtctt ctggggagct ggccacggta 180  
 gtacggcggg tctcccagac cgcatccag gacttcctga cactgacgct gacggagccc 240  
 actgggcttc tgtacgtggg cggccgagag gccctgtttg ccttcagcat ggaggccctg 300  
 gagctgcaag gagcgatctc ctgggaggcc cccgtggaga agaagactga gtgtatccag 360  
 aaagggaaga acaaccagac cgagtgtctc aacttcaccc gcttctctga gccctacaat 420  
 gcctcccacc tgtacgtctg tggcacctac gccttcacgc ccaagtgcac ctacgtcgtg 480  
 agtgcctgcc tctacctcgt gtgtcccccag ccccccgcgc tctcaccct tctctggact 540  
 cgtggatgtg gccacagag ccctgccctt aagcatctcc tcatcacctc tctctctgtc 600  
 cttagaacat gctcaccttc actttggagc atggagagtt tgaagatggg aagggaagt 660  
 gtccctatga ccagctaag ggccatgctg gccttcttgt ggatggtgag ctgtactcgg 720  
 ccacactcaa caacttcctg ggcacggaac ccattatcct gcgtaacatg gggccccacc 780  
 actccatgaa gacagagtac ctggcctttt ggctcaacga acctcacttt gtaggctctg 840  
 cctatgtacc tgagagtgtg ggcagcttca cgggggacga cgacaaggct tacttcttct 900  
 tcagggagcg ggcagtggag tccgactgct atgccgagca ggtggtggct cgtgtggccc 960  
 gtgtctgcaa gggcgatatg gggggcgcac ggaccctgca gaggaagtgg accacgttcc 1020  
 tgaaggcgcg gctggcatgc tctgccccga actggcagct ctacttcaac cagctgcagg 1080  
 cgatgcacac cctgcaggac acctcctggc acaacaccac cttctttggg gtttttcaag 1140  
 cacagtgggg tgacatgtac ctgtcgcca tctgtgagta ccagttggaa gagatccagc 1200  
 ggggtgtttga gggcccctat aaggagtacc atgaggaagc ccagaagtgg gaccgctaca 1260  
 ctgacctgt acccaggccc tgggtgtgat ggctgccag ccccgccatg ccggggccta 1320  
 ccactgcttt tcagaggagc agggggcgcg gctggctgct gaaggctacc ttgtggctgt 1380  
 cgtggcaggc ccgtcggtga ccttgaggc ccgggcccc ctggaaaacc tggggctggt 1440  
 gtggctggcg gtggtggccc tgggggctgt gtgcctggtg ctgctgctgc tgggtgctgc 1500

```

attgcgccgg cggtgcggg aagagctgga gaaaggggcc aaggctactg agaggacctt 1560
ggtgtacccc ctggagctgc ccaaggagcc caccagtccc cccttccggc cctgtcctga 1620
accagatgag aaactttggg atcctgtcgg ttactactat tcagatggct cccttaagat 1680
agtacctggg catgcccggt gccagcccg tggggggccc ccttcgccac ctccaggcat 1740
cccaggccag cctctgcctt ctccaactcg gcttcacctg gggggtgggc ggaactcaaa 1800
tgccaatggt tacgtgcgct tacaactagg aggggaggac cggggagggc tcgggcaccc 1860
cctgcctgag ctgcggatg aactgagacg caaactgcag caacgccagc cactgcccga 1920
ctccaacccc gaggagtcag cagtatgagg ggaaccccca ccgcgtcggc gggaagcgtg 1980
ggaggtgtag ctctacttt tgacagga ccagctacct cagggacatg gcacgggcac 2040
ctgctctgtc tgggacagat actgccagc accaccgg ccatgaggac ctgctctgct 2100
cagcacgggc actgccactt ggtgtggctc accagggcac cagcctcgca gaaggcatct 2160
tcctcctctc tgtgaatcac agacacgagg gaccccgcc gccaaaactt ttcaaggcag 2220
aagtttcaag atgtgtgttt gtctgtattt gcacatgtgt ttgtgtgtgt gtgtatgtgt 2280
gtgtgcacgc gcgtgcgcgc ttgtggcata gccttcctgt ttctgtcaag tcttccttg 2340
gcctgggtcc tcctggtgag tcattggagc tatgaagggg aagggtcgt atcactttgt 2400
ctctcctacc cccactgccc cgagtgtcgg gcagcgatgt acatatggag gtgggtgga 2460
cagggtgctg tgccccttca gagggagtgc agggcttggg gtgggcctag tcctgctct 2520
agggctgtga atgtttcag ggtgggggga gggagatgga gcctcctgtg tgtttgggg 2580
gaagggtggg tggggcctcc cacttggccc cggggttcag tggatttta tactgcctt 2640
cttctgttac agggctggga aaggctgtgt gaggggagag aagggagagg gtgggcctgc 2700
tgtggacaat ggcatactct ctccagccc taggaggagg gctcctaaca gtgtaactta 2760
ttgtgtcccc gcgtatttat ttgttgtaaa tatttgagat ttttatattg a 2811

```

<210> 34  
<211> 729  
<212> DNA  
<213> Homo sapiens

```

<400> 34
atggcccccac actgggctgt ctggctgctg gcagcaaggc tgtggggcct gggcattggg 60
gctgaggtgt ggtggaacct tgtgccgct aagacagtgt cttctgggga gctggccacg 120
gtagtacggc ggttctccca gaccggcatc caggacttcc tgacactgac gctgacggag 180
ccactgggc ttctgtacgt gggcgccga gagccctgt ttgccttcag catggaggcc 240
ctggagctgc aaggagcgat ctctgggag gccccgtgg agaagaagac tgagtgtatc 300
cagaaaggga agaacaacca gaccgagtgc ttcaacttca tccgcttcct gcagccctac 360
aatgcctccc acctgtacgt ctgtggcacc tacgccttcc agcccaagtg cacctacgtc 420
gtgagtgtg cctcctacc tcggtgtccc cagcccccg ccctcctcac ccttctctg 480
actcgtggat gtggcccaca gagccctgcc ctttaagcatc tcctcatcac ctctctctc 540
gtccttagaa catgctcacc ttacttttg agcatggaga gtttgaagat ggggaaggga 600
agtgtcccta tgaccagct aagggccatg ctggccttct tgtggatggt gagctgtact 660
cggccacact caacaacttc ctgggcacgg aaccatttat cctgcgtaac atggggcccc 720
accactcca
729

```

<210> 35  
<211> 243  
<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Arg Leu Trp Gly  
 1 5 10 15

Leu Gly Ile Gly Ala Glu Val Trp Trp Asn Leu Val Pro Arg Lys Thr  
 20 25 30

Val Ser Ser Gly Glu Leu Ala Thr Val Val Arg Arg Phe Ser Gln Thr  
 35 40 45

Gly Ile Gln Asp Phe Leu Thr Leu Thr Leu Thr Glu Pro Thr Gly Leu  
 50 55 60

Leu Tyr Val Gly Ala Arg Glu Ala Leu Phe Ala Phe Ser Met Glu Ala  
 65 70 75 80

Leu Glu Leu Gln Gly Ala Ile Ser Trp Glu Ala Pro Val Glu Lys Lys  
 85 90 95

Thr Glu Cys Ile Gln Lys Gly Lys Asn Asn Gln Thr Glu Cys Phe Asn  
 100 105 110

Phe Ile Arg Phe Leu Gln Pro Tyr Asn Ala Ser His Leu Tyr Val Cys  
 115 120 125

Gly Thr Tyr Ala Phe Gln Pro Lys Cys Thr Tyr Val Val Ser Ala Ala  
 130 135 140

Leu Leu Pro Arg Cys Pro Gln Pro Pro Ala Leu Leu Thr Leu Leu Trp  
 145 150 155 160

Thr Arg Gly Cys Gly Pro Gln Ser Pro Ala Leu Lys His Leu Leu Ile  
 165 170 175

Thr Ser Leu Ser Val Leu Arg Thr Cys Ser Pro Ser Leu Trp Ser Met  
 180 185 190

Glu Ser Leu Lys Met Gly Arg Ala Ser Val Pro Met Thr Gln Leu Arg  
 195 200 205

Ala Met Leu Ala Phe Leu Trp Met Val Ser Cys Thr Arg Pro His Ser  
 210 215 220

Thr Thr Ser Trp Ala Arg Asn Pro Leu Ser Cys Val Thr Trp Gly Pro  
 225 230 235 240

Thr Thr Pro

<210> 36  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 36  
 Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Arg Leu Trp Gly  
 1 5 10 15

Leu Gly Ile Gly  
 20

<210> 37  
 <211> 223  
 <212> PRT  
 <213> Homo sapiens

<400> 37  
 Ala Glu Val Trp Trp Asn Leu Val Pro Arg Lys Thr Val Ser Ser Gly  
 1 5 10 15

Glu Leu Ala Thr Val Val Arg Arg Phe Ser Gln Thr Gly Ile Gln Asp  
 20 25 30

Phe Leu Thr Leu Thr Leu Thr Glu Pro Thr Gly Leu Leu Tyr Val Gly  
 35 40 45

Ala Arg Glu Ala Leu Phe Ala Phe Ser Met Glu Ala Leu Glu Leu Gln  
 50 55 60

Gly Ala Ile Ser Trp Glu Ala Pro Val Glu Lys Lys Thr Glu Cys Ile  
 65 70 75 80

Gln Lys Gly Lys Asn Asn Gln Thr Glu Cys Phe Asn Phe Ile Arg Phe  
 85 90 95

Leu Gln Pro Tyr Asn Ala Ser His Leu Tyr Val Cys Gly Thr Tyr Ala  
 100 105 110

Phe Gln Pro Lys Cys Thr Tyr Val Val Ser Ala Ala Leu Leu Pro Arg  
 115 120 125

Cys Pro Gln Pro Pro Ala Leu Leu Thr Leu Leu Trp Thr Arg Gly Cys

130                      135                      140  
 Gly Pro Gln Ser Pro Ala Leu Lys His Leu Leu Ile Thr Ser Leu Ser  
 145                      150                      155                      160  
 Val Leu Arg Thr Cys Ser Pro Ser Leu Trp Ser Met Glu Ser Leu Lys  
                     165                      170                      175  
 Met Gly Arg Ala Ser Val Pro Met Thr Gln Leu Arg Ala Met Leu Ala  
                     180                      185                      190  
 Phe Leu Trp Met Val Ser Cys Thr Arg Pro His Ser Thr Thr Ser Trp  
                     195                      200                      205  
 Ala Arg Asn Pro Leu Ser Cys Val Thr Trp Gly Pro Thr Thr Pro  
                     210                      215                      220

&lt;210&gt; 38

&lt;211&gt; 2498

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

gtcgaccac gcgtccgcgg acgcgtgggc gcgcgggggc catccagacc ctgcggagag 60  
 cgaggcccg agcgtcgccg aggtttgagg gcgccggaga ccgagggcct ggccggccgaa 120  
 ggaaccgccc caagaagagc ctctggcccc ggggctgctg gaacatgtgc ggggggacac 180  
 agtttgtttg acagttgccca gactatgttt acgcttctgg ttctactcag ccaactgccc 240  
 acagttaccc tggggtttcc tcattgcgca agaggtccaa aggcttctaa gcatgcggga 300  
 gaagaagtgt ttacatcaaa agaagaagca aactttttca tacatagacg ccttctgtat 360  
 aatagatttg atctggagct cttcactccc ggcaacctag aaagagagtg caatgaagaa 420  
 ctttgcaatt atgaggaagc cagagagatt tttgtggatg aagataaaac gattgcattt 480  
 tggcaggaat attcagctaa aggaccaacc acaaaatcag atggcaacag agagaaaata 540  
 gatgttatgg gccttctgac tggattaatt gctgctggag tatttttggt tatttttggg 600  
 ttacttggct actatctttg tatcactaag tgtaataggc tacaacatcc atgctcttca 660  
 gccgtctatg aaagggggag gcacactccc tccatcattt tcagaagacc tgaggaggct 720  
 gccttgtctc cattgcccgc ttctgtggag gatgcaggat taccttctta tgaacaggca 780  
 gtggcgctga ccagaaaaca cagtgtttca ccaccaccac catatccttg gcacacaaaa 840  
 ggatttaggg tatttaaaaa atctatgtct ctcccactc actgactacc ttgtcatttt 900  
 ggtataagaa atttgtgtta tttgataagg cgggcatggt ggctcatgcc tgtaatccca 960  
 gcactttggg aggccaggag ttcgagacca gcctggccaa catggtgaaa cccggtctct 1020  
 actaaaaatt caaaaattac ctaggcgtca tggggcatgc ctgtagtccc acctacttgg 1080  
 gaggtgaag caggagaatt gctcgaaact gggaggcaga ggttgcaagta agctgagatc 1140  
 acgccactgc attccagcct gggcgacaga gcaagactcc atctcaaaaa taaaataaaa 1200  
 aaagaaagaa agaaaagaag aagaaaagag aagaaggaga aggagatgaa ggaggaggag 1260  
 gaggagaagg agaagaagaa gaagaagaag accacaaaag acatgactat ccaacttttt 1320  
 atgacaaact gcaaggaata aaggaagaat aagtccatgt actgtaccac agaagttctg 1380  
 tctgcatctt ggacctgaac ttgatcatta tcagcttgat aagagacttt ttgactctat 1440

```

atccttgacg ttaagaagaa agcacttttt tgtaatgttt gttttaatgg ttcaaaaaaa 1500
atctttctta taaagagcat aggtagaatt agtgaactct ttggatcctt tgtacagata 1560
aaggttatag atttcttgtg ttgaatatta aaaaagcaag gatgtctaac cattaagatt 1620
atccaaagtc aggctgggag cagtggctca cgctgtaat ccagcactt tgggagggat 1680
agggtggcgg atcacctgag gtcaggagtt tgagaccage ctggccaaca tggcaaaacc 1740
ccgtctctac aaaaatacaa aagaaattag ccagacatga tggcggtgac ctctaattcc 1800
agctactggg gaggctgagg tgggagaatc gcttgaactc gggaggtgga ggttgtagtg 1860
aggcgagatt gtgccattgc actccaacct gggcgacaga gtgagactcc atctcaaaaa 1920
aaaaaaaaaa aaaaagatta tccaaaaaga tattggacct actctttctt aggatttttt 1980
tggcgggggg ttagaaatac ttcacagaat ttgacatttc agtataaatc tgtgacctta 2040
atataatcac ttggttttat atgttaaatt attgcacagc agtcatacata ttttgacagag 2100
tttagttctt aactcttgct gtcagtcatg ttttattata ggtagtgggg tcagtagttt 2160
tcttcttcta aaaaatacta ttgctatga agttagtctt tcagaagata caagtttgca 2220
atgaaaagga ttgcaaggg ttgttatgct atcaataaaa cagacctaaa atctaggaga 2280
cactagaact taatgaagtt gcccctgtta ctgattagta aatactccca tcttcgttgc 2340
aaaattatct ctctgtataa ctacatatga ttattttgaa atttgtaaaa ctccataagt 2400
aatagtttga gaatgtggaa aaagtaattt gcttttctgc tcttaaaata atattgatta 2460
atgttaccag aaaaaaaaaa aaaaaaagg gcggccgc 2498

```

<210> 39  
 <211> 678  
 <212> DNA  
 <213> Homo sapiens

```

<400> 39
atgtttacgc ttctggttct actcagccaa ctgcccacag ttaccctggg gtttctctcat 60
tgcgcaagag gtccaaaggc ttctaagcat gcgggagaag aagtgtttac atcaaaagaa 120
gaagcaaaact ttttcataca tagacgcctt ctgtataata gatttgatct ggagctcttc 180
actcccggca acctagaaag agagtgaat gaagaacttt gcaattatga ggaagccaga 240
gagatttttg tggatgaaga taaaacgatt gcattttggc aggaatatc agctaaagga 300
ccaaccacaa aatcagatgg caacagagag aaaatagatg ttatgggcct tctgactgga 360
ttaattgctg ctggagtatt tttggttatt tttggattac ttggctacta tctttgtatc 420
actaagtgtg ataggctaca acatccatgc tcttcagccg tctatgaaag ggggaggcac 480
actccctcca tcattttcag aagacctgag gaggtgcct tgtctccatt gccgccttct 540
gtggaggatg caggattacc ttcttatgaa caggcagtgg cgctgaccag aaaacacagt 600
gtttcaccac caccaccata tcttgggcac aaaaaggat ttaggttatt taaaaaatct 660
atgtctctcc catctcac 678

```

<210> 40  
 <211> 226  
 <212> PRT  
 <213> Homo sapiens

```

<400> 40
Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr Leu
  1             5             10             15

```

Gly Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly  
 20 25 30  
 Glu Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg  
 35 40 45  
 Arg Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn  
 50 55 60  
 Leu Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg  
 65 70 75 80  
 Glu Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr  
 85 90 95  
 Ser Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile  
 100 105 110  
 Asp Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu  
 115 120 125  
 Val Ile Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn  
 130 135 140  
 Arg Leu Gln His Pro Cys Ser Ser Ala Val Tyr Glu Arg Gly Arg His  
 145 150 155 160  
 Thr Pro Ser Ile Ile Phe Arg Arg Pro Glu Glu Ala Ala Leu Ser Pro  
 165 170 175  
 Leu Pro Pro Ser Val Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala  
 180 185 190  
 Val Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Tyr Pro  
 195 200 205  
 Gly His Thr Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro  
 210 215 220  
 Ser His  
 225

<210> 41  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 41

Met Phe Thr Leu Leu Val Leu Leu Ser Gln Leu Pro Thr Val Thr Leu  
 1 5 10 15

Gly

&lt;210&gt; 42

&lt;211&gt; 209

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly Glu  
 1 5 10 15

Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg Arg  
 20 25 30

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu  
 35 40 45

Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg Glu  
 50 55 60

Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr Ser  
 65 70 75 80

Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile Asp  
 85 90 95

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val  
 100 105 110

Ile Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg  
 115 120 125

Leu Gln His Pro Cys Ser Ser Ala Val Tyr Glu Arg Gly Arg His Thr  
 130 135 140

Pro Ser Ile Ile Phe Arg Arg Pro Glu Glu Ala Ala Leu Ser Pro Leu  
 145 150 155 160

Pro Pro Ser Val Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val  
 165 170 175

Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Tyr Pro Gly  
 180 185 190

His Thr Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser  
 195 200 205

His

<210> 43

<211> 96

<212> PRT

<213> Homo sapiens

<400> 43

Phe Pro His Cys Ala Arg Gly Pro Lys Ala Ser Lys His Ala Gly Glu  
 1 5 10 15

Glu Val Phe Thr Ser Lys Glu Glu Ala Asn Phe Phe Ile His Arg Arg  
 20 25 30

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu  
 35 40 45

Glu Arg Glu Cys Asn Glu Glu Leu Cys Asn Tyr Glu Glu Ala Arg Glu  
 50 55 60

Ile Phe Val Asp Glu Asp Lys Thr Ile Ala Phe Trp Gln Glu Tyr Ser  
 65 70 75 80

Ala Lys Gly Pro Thr Thr Lys Ser Asp Gly Asn Arg Glu Lys Ile Asp  
 85 90 95

<210> 44

<211> 25

<212> PRT

<213> Homo sapiens

<400> 44

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val  
 1 5 10 15

Ile Phe Gly Leu Leu Gly Tyr Tyr Leu

20

25

<210> 45  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 45

Cys Ile Thr Lys Cys Asn Arg Leu Gln His Pro Cys Ser Ser Ala Val  
 1 5 10 15

Tyr Glu Arg Gly Arg His Thr Pro Ser Ile Ile Phe Arg Arg Pro Glu  
 20 25 30

Glu Ala Ala Leu Ser Pro Leu Pro Pro Ser Val Glu Asp Ala Gly Leu  
 35 40 45

Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val Ser  
 50 55 60

Pro Pro Pro Pro Tyr Pro Gly His Thr Lys Gly Phe Arg Val Phe Lys  
 65 70 75 80

Lys Ser Met Ser Leu Pro Ser His  
 85

<210> 46  
 <211> 2169  
 <212> DNA  
 <213> Homo sapiens

&lt;400&gt; 46

gtcgacccac gcgtccggaa atgtcgttct tcagatttaa aaagaaaacc tttactgaat 60  
 cagctgagtg ttaataatac gaatttcctt ttcttgccaa ttctgatctg aacagaaaat 120  
 ccaagaacag ggatagtgtt ggattacagt ttctctgcc ttgcctacga ctgtttctgg 180  
 ttgttacctg ttatctttta ttattactcc acaaagaaat acttggatgt tcgtctgttt 240  
 gtcagctctg cactgggaga caaattaact gccgtaactt aggcctttcg agtattccta 300  
 agaattttcc tgaaagtaca gtttttctgt atctgactgg gaataatata tcttatataa 360  
 atgaaagtga attaacagga cttcattctc ttgtagcatt gtatttggat aattctaaca 420  
 ttctgtatgt atatccaaaa gcctttgttc aattgaggca tctatatatt ctatttctaa 480  
 ataataattt catcaaagc ttagatcctg gaatatttaa gggactttta aatcttcgta 540  
 atttatattt acagtataat caggatatct ttgttccgag aggagtattt atgatctag 600  
 tttcagttca gtacttaaat ctacaaagga atcgccctac tgtccttggg agtggtagct 660  
 ttgttggtat ggttgctctt cggatacttg atttatcaaa caataacatt ttgaggatat 720  
 cagaatcagg ctttcaacat cttgaaaacc ttgcttgttt gtatttagga agtaataatt 780  
 taacaaaagt accatcaaat gcctttgaag tacttaaaag tcttagaaga ctttctttgt 840

28

```

ctcataatcc tattgaagca atacagccct ttgcatttaa aggacttgcc aatctggaat 900
acctcctcct gaaaaattca agaattagga atgttactag ggatggggtt agtgggaatta 960
ataatcttaa acatttgatc ttaagtcata atgatttaga gaatttaaat tctgacacat 1020
tcagtttggt aaagaattta atttacctta agttagatag aaacagaata attagcattg 1080
ataatgatac atttgaaaat atgggagcat ctttgaagat ccttaatctg tcatttaata 1140
atcttacagc cttgcatcca agggtcctta agccgttgtc ttcattgatt catcttcagg 1200
caaattctaa tccttgggaa tgtaactgca aacttttggg ccttcgagac tggctagcat 1260
cttcagccat tactctaaac atctattgtc agaatccccc atccatgcgt ggcagagcat 1320
tacgttatat taacattaca aattgtgtta catcttcaat aaatgtatcc agagcttggg 1380
ctgttgtaaa atctcctcat attcatcaca agactactgc gctaattgat gcctggcata 1440
aagtaaccac aaatggcagt cctctggaaa atactgagac tgagaacatt actttctggg 1500
aacgaattcc tacttcacct gctggttagat tttttcaaga gaatgccttt ggtaatccat 1560
tagagactac agcagtgtta cctgtgcaaa tacaacttac tacttctgtt accttgaact 1620
tggaaaaaaa cagtgtctta ccgaatgatg ctgcttcaat gtcagggaaa acatctctaa 1680
tttgtagaca agaagttgag aagttgaatg aggcttttga cattttgcta gcttttttca 1740
tcttagcttg tgttttaatc attttttga tctacaaagt tgttcagttt aaacaaaaac 1800
taaaggcatc agaaaactca agggaaaata gacttgaata ctacagcttt tatcagtcag 1860
caaggtataa tgtaactgcc tcaatttgta acacttcccc aaattctcta gaaagtcctg 1920
gcttgagaca gattcgactt cataaacaat ttgttcctga aaatgaggca caggtcattc 1980
tttttgaaca ttctgcttta taactcaact aaatattgtc tataagaaac ttcagtgcc 2040
tggacatgat ttaactgaa acctccttat ataattatat actttagttg gaaatataat 2100
gaattatatg aggttagcat tattaaaata tgtttttaat aaaaaaaaaa aaaaaaaaaa 2160
ggcggccgc

```

&lt;210&gt; 47

&lt;211&gt; 1866

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

```

atgtgtggat tacagtttct tctgccttgc ctacgactgt ttctggttgt tacctgttat 60
cttttattat tactccacaa agaaatactt ggatgttcgt ctgtttgtca gctctgcact 120
gggagacaaa ttaactgccg taacttaggc ctttcgagta ttctaagaa ttttcctgaa 180
agtacagttt ttctgtatct gactgggaat aatatactt atataaatga aagtgaatta 240
acaggacttc attctcttgt agcattgtat ttggataatt ctaacattct gtatgtatat 300
ccaaaagcct ttgttcaatt gaggcattca tattttctat ttctaaataa taatttcac 360
aaacgcttag atccttgaat atttaaggga cttttaaatc ttcgtaattt atatttacag 420
tataatcagg tatcttttgt tccgagagga gtatttaatg atctagtttc agttcagtac 480
ttaaatctac aaaggaatcg cctcactgtc cttgggagtg gtacctttgt tggtaggtt 540
gctcttcgga tacttgattt atcaacaat aacattttga ggatatcaga atcaggcttt 600
caacatcttg aaaaccttgc ttgtttgtat tttaggaagta ataatttaac aaaagtacca 660
tcaaagcct ttgaagtact taaaagtctt agaagacttt ctttgtctca taatcctatt 720
gaagcaatc agccctttgc atttaaagga cttgccaatc tggaatacct cctcctgaaa 780
aattcaagaa tttagaatgt tactagggat gggtttagtg gaatttaata tcttaaacat 840
ttgatcttaa gtcataatga ttttagagaat ttaaattctg acacattcag tttgttaaag 900
aatttaattt accttaagtt agatagaaac agaataatta gcattgataa tgatacattt 960
gaaaatatgg gagcatcttt gaagatcctt aatctgtcat ttaataatct tacagccttg 1020

```

catccaaggg tccttaagcc gttgtcttca ttgattcatc ttcaggcaaa ttctaatacct 1080  
 tgggaatgta actgcaaact tttgggcctt cgagactggc tagcatcttc agccattact 1140  
 ctaaacaatct attgtcagaa tccccatcc atgctgggca gagcattacg ttatattaac 1200  
 attacaaatt gtgttacatc ttcaataaat gtatccagag cttgggctgt tgtaaaatct 1260  
 cctcatattc atcacaagac tactgcgcta atgatggcct ggcataaagt aaccacaaat 1320  
 ggcagtcctc tggaaaatac tgagactgag aacattactt tctgggaacg aattcctact 1380  
 tcacctgctg gtagattttt tcaagagaat gcctttggta atccattaga gactacagca 1440  
 gtgttacctg tgcaaatata acttactact tctgttacct tgaacttga aaaaaacagt 1500  
 gctctaccga atgatgctgc ttcaatgtca gggaaaacat ctctaatttg tacacaagaa 1560  
 gttgagaagt tgaatgaggc ttttgacatt ttgctagctt ttttcatctt agcttgtgtt 1620  
 ttaatcattt ttttgatcta caaagtgtt cagtttaaac aaaaactaaa ggcacagaa 1680  
 aactcaaggg aaaatagact tgaatactac agcttttatc agtcagcaag gtataatgta 1740  
 actgcctcaa tttgtaacac ttcccaaat tctctagaaa gtcctggcct ggagcagatt 1800  
 cgacttcata aacaaattgt tcctgaaaat gaggcacagg tcattctttt tgaacattct 1860  
 gcttta 1866

&lt;210&gt; 48

&lt;211&gt; 622

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val  
 1 5 10 15

Val Thr Cys Tyr Leu Leu Leu Leu His Lys Glu Ile Leu Gly Cys  
 20 25 30

Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg Asn  
 35 40 45

Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val Phe  
 50 55 60

Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu Leu  
 65 70 75 80

Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn Ile  
 85 90 95

Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr Phe  
 100 105 110

Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile Phe  
 115 120 125

Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln Val

130	135	140
Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln Tyr		
145	150	155 160
Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr Phe		
	165	170 175
Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn Ile		
	180	185 190
Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala Cys		
	195	200 205
Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala Phe		
	210	215 220
Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro Ile		
	225	230 235 240
Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu Tyr		
	245	250 255
Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly Phe		
	260	265 270
Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp Leu		
	275	280 285
Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile Tyr		
	290	295 300
Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr Phe		
	305	310 315 320
Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn Asn		
	325	330 335
Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu Ile		
	340	345 350
His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu Leu		
	355	360 365
Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile Tyr		
	370	375 380
Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile Asn		

385                      390                      395                      400  
 Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp Ala  
                                  405                      410                      415  
 Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met Met  
                                  420                      425                      430  
 Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr Glu  
                                  435                      440                      445  
 Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala Gly  
                                  450                      455                      460  
 Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr Ala  
                                  465                      470                      475                      480  
 Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn Leu  
                                  485                      490                      495  
 Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly Lys  
                                  500                      505                      510  
 Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala Phe  
                                  515                      520                      525  
 Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile Phe  
                                  530                      535                      540  
 Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser Glu  
                                  545                      550                      555                      560  
 Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser Ala  
                                  565                      570                      575  
 Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser Leu  
                                  580                      585                      590  
 Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val Pro  
                                  595                      600                      605  
 Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu  
                                  610                      615                      620

<210> 49  
 <211> 31  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

Met Cys Gly Leu Gln Phe Ser Leu Pro Cys Leu Arg Leu Phe Leu Val  
 1 5 10 15

Val Thr Cys Tyr Leu Leu Leu Leu Leu His Lys Glu Ile Leu Gly  
 20 25 30

&lt;210&gt; 50

&lt;211&gt; 591

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

Cys Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg  
 1 5 10 15

Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val  
 20 25 30

Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu  
 35 40 45

Leu Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn  
 50 55 60

Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr  
 65 70 75 80

Phe Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile  
 85 90 95

Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln  
 100 105 110

Val Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln  
 115 120 125

Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr  
 130 135 140

Phe Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn  
 145 150 155 160

Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala  
 165 170 175

Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala  
 180 185 190  
 Phe Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro  
 195 200 205  
 Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu  
 210 215 220  
 Tyr Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly  
 225 230 235 240  
 Phe Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp  
 245 250 255  
 Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile  
 260 265 270  
 Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr  
 275 280 285  
 Phe Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn  
 290 295 300  
 Asn Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu  
 305 310 315 320  
 Ile His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu  
 325 330 335  
 Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile  
 340 345 350  
 Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile  
 355 360 365  
 Asn Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp  
 370 375 380  
 Ala Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met  
 385 390 395 400  
 Met Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr  
 405 410 415  
 Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala  
 420 425 430

Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr  
 435 440 445

Ala Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn  
 450 455 460

Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly  
 465 470 475 480

Lys Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala  
 485 490 495

Phe Asp Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile  
 500 505 510

Phe Leu Ile Tyr Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser  
 515 520 525

Glu Asn Ser Arg Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser  
 530 535 540

Ala Arg Tyr Asn Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser  
 545 550 555 560

Leu Glu Ser Pro Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val  
 565 570 575

Pro Glu Asn Glu Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu  
 580 585 590

<210> 51

<211> 498

<212> PRT

<213> Homo sapiens

<400> 51

Cys Ser Ser Val Cys Gln Leu Cys Thr Gly Arg Gln Ile Asn Cys Arg  
 1 5 10 15

Asn Leu Gly Leu Ser Ser Ile Pro Lys Asn Phe Pro Glu Ser Thr Val  
 20 25 30

Phe Leu Tyr Leu Thr Gly Asn Asn Ile Ser Tyr Ile Asn Glu Ser Glu  
 35 40 45

Leu Thr Gly Leu His Ser Leu Val Ala Leu Tyr Leu Asp Asn Ser Asn

50	55	60
Ile Leu Tyr Val Tyr Pro Lys Ala Phe Val Gln Leu Arg His Leu Tyr		
65	70	75 80
Phe Leu Phe Leu Asn Asn Asn Phe Ile Lys Arg Leu Asp Pro Gly Ile		
	85	90 95
Phe Lys Gly Leu Leu Asn Leu Arg Asn Leu Tyr Leu Gln Tyr Asn Gln		
	100	105 110
Val Ser Phe Val Pro Arg Gly Val Phe Asn Asp Leu Val Ser Val Gln		
	115	120 125
Tyr Leu Asn Leu Gln Arg Asn Arg Leu Thr Val Leu Gly Ser Gly Thr		
	130	135 140
Phe Val Gly Met Val Ala Leu Arg Ile Leu Asp Leu Ser Asn Asn Asn		
145	150	155 160
Ile Leu Arg Ile Ser Glu Ser Gly Phe Gln His Leu Glu Asn Leu Ala		
	165	170 175
Cys Leu Tyr Leu Gly Ser Asn Asn Leu Thr Lys Val Pro Ser Asn Ala		
	180	185 190
Phe Glu Val Leu Lys Ser Leu Arg Arg Leu Ser Leu Ser His Asn Pro		
	195	200 205
Ile Glu Ala Ile Gln Pro Phe Ala Phe Lys Gly Leu Ala Asn Leu Glu		
	210	215 220
Tyr Leu Leu Leu Lys Asn Ser Arg Ile Arg Asn Val Thr Arg Asp Gly		
225	230	235 240
Phe Ser Gly Ile Asn Asn Leu Lys His Leu Ile Leu Ser His Asn Asp		
	245	250 255
Leu Glu Asn Leu Asn Ser Asp Thr Phe Ser Leu Leu Lys Asn Leu Ile		
	260	265 270
Tyr Leu Lys Leu Asp Arg Asn Arg Ile Ile Ser Ile Asp Asn Asp Thr		
	275	280 285
Phe Glu Asn Met Gly Ala Ser Leu Lys Ile Leu Asn Leu Ser Phe Asn		
290	295	300
Asn Leu Thr Ala Leu His Pro Arg Val Leu Lys Pro Leu Ser Ser Leu		

305                      310                      315                      320  
 Ile His Leu Gln Ala Asn Ser Asn Pro Trp Glu Cys Asn Cys Lys Leu  
                                  325                      330                      335  
 Leu Gly Leu Arg Asp Trp Leu Ala Ser Ser Ala Ile Thr Leu Asn Ile  
                                  340                      345                      350  
 Tyr Cys Gln Asn Pro Pro Ser Met Arg Gly Arg Ala Leu Arg Tyr Ile  
                                  355                      360                      365  
 Asn Ile Thr Asn Cys Val Thr Ser Ser Ile Asn Val Ser Arg Ala Trp  
                                  370                      375                      380  
 Ala Val Val Lys Ser Pro His Ile His His Lys Thr Thr Ala Leu Met  
 385                                   390                      395                      400  
 Met Ala Trp His Lys Val Thr Thr Asn Gly Ser Pro Leu Glu Asn Thr  
                                  405                      410                      415  
 Glu Thr Glu Asn Ile Thr Phe Trp Glu Arg Ile Pro Thr Ser Pro Ala  
                                  420                      425                      430  
 Gly Arg Phe Phe Gln Glu Asn Ala Phe Gly Asn Pro Leu Glu Thr Thr  
                                  435                      440                      445  
 Ala Val Leu Pro Val Gln Ile Gln Leu Thr Thr Ser Val Thr Leu Asn  
                                  450                      455                      460  
 Leu Glu Lys Asn Ser Ala Leu Pro Asn Asp Ala Ala Ser Met Ser Gly  
 465                                   470                      475                      480  
 Lys Thr Ser Leu Ile Cys Thr Gln Glu Val Glu Lys Leu Asn Glu Ala  
                                  485                      490                      495  
 Phe Asp

&lt;210&gt; 52

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

Ile Leu Leu Ala Phe Phe Ile Leu Ala Cys Val Leu Ile Ile Phe Leu  
   1                                  5                                  10                                  15

Ile Tyr

&lt;210&gt; 53

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 53

Lys Val Val Gln Phe Lys Gln Lys Leu Lys Ala Ser Glu Asn Ser Arg  
 1 5 10 15

Glu Asn Arg Leu Glu Tyr Tyr Ser Phe Tyr Gln Ser Ala Arg Tyr Asn  
 20 25 30

Val Thr Ala Ser Ile Cys Asn Thr Ser Pro Asn Ser Leu Glu Ser Pro  
 35 40 45

Gly Leu Glu Gln Ile Arg Leu His Lys Gln Ile Val Pro Glu Asn Glu  
 50 55 60

Ala Gln Val Ile Leu Phe Glu His Ser Ala Leu  
 65 70 75

&lt;210&gt; 54

&lt;211&gt; 1432

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

acgcgtccgc acanggccgg cgcggtctggg agcgggtggg cggccgggag gccggagcag 60  
 cacggcccgca ggacctggag ctccggctgc gtcttcccgc agcgctaccc gccatgcgcc 120  
 tgccgcgccc ggccgcgctg gggctcctgc cgcttctgct gctgctgccg cccgcgcccg 180  
 aggccgccaa gaagccgacg ccctgccacc ggtgccgggg gctggtggac aagttaacc 240  
 aggggatggt ggacaccgca aagaagaact ttggcgggcg gaacacggct tggaggaaa 300  
 agacgctgtc caagtacgag tccagcgaga ttgcctgct ggagatcctg gaggggctgt 360  
 gcgagagcag cgacttcgaa tgcaatcaga tgctagaggc gcaggaggag cacctggagg 420  
 cctggtggct gcagctgaag agcgaatcct ctgacttatt cgagtgggtt tgtgtgaaga 480  
 cactgaaagt gtgctgctct ccaggaacct acggctccga ctgtctcgca tgccagggcg 540  
 gatcccagag gccctgcagc gggaatggcc actgcagcgg agatgggagc agacagggcg 600  
 acgggtcctg ccggtgccac atggggtacc agggcccgt gtgactgac tgcagggacg 660  
 gctacttcag ctgcctccg aacgagaccc acagcatctg cacagcctgt gacgagtcct 720  
 gcaagacgtg ctcgggcctg accaagagag actgcggcga gtgtgaagtg ggctgggtgc 780  
 tggacgaggg cgctgtgtg gatgtggacg agtgtgcggc cgagccgcct ccctgcagcg 840  
 ctgcgcagtt ctgtaagaac gccaacggct cctacacgtg cgaagagtgt gactccagct 900  
 gtgtgggctg cacaggggaa ggcccaggaa actgtaaaga gtgtatctct ggctacgcga 960

```

gggagcacgg acagtgtgca gatgtggacg agtgctcact agcagaaaaa acctgtgtga 1020
ggaaaaacga aaactgctac aatactccag ggagctacgt ctgtgtgtgt cctgacggct 1080
tcgaagaaac ggaagatgcc tgtgtgccgc cggcagaggc tgaagccaca gaaggagaaa 1140
gcccgcacaca gctgccctcc cgcgaagacc tgtaatgtgc cggacttacc ctttaaatta 1200
ttcagaagga tgtcccgtgg aaaatgtggc cctgaggatg ccgtctcctg cagtggacag 1260
cggcggggag aggctgcctg ctctctaacg gttgattctc atttgtccct taaacagctg 1320
catttcttgg ttgttcttaa acagacttgt atattttgat acagttcttt gtaataaaat 1380
tgaccattgt aggtaatcaa aaaaaaaaaa aaaaaaaggg cggccgctag ac 1432

```

&lt;210&gt; 55

&lt;211&gt; 1059

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

```

atgcgcctgc cgcgcggggc cgcgctgggg ctctgcccgc ttctgctgct gctgccgccc 60
gcgcgggagg ccgccaagaa gccgacgcc tgccaccggg gccgggggct ggtggacaag 120
tttaaccagg ggatggtgga caccgcaaag aagaactttg gcggcgggaa cacggcttgg 180
gaggaaaaga cgctgtccaa gtacgagtcc agcgagattc gcctgctgga gatcctggag 240
gggctgtgcg agagcagcga ctctgaatgc aatcagatgc tagaggcgca ggaggagcac 300
ctggaggcct ggtggtctga gctgaagagc gaatatcctg acttattcga gtggttttgt 360
gtgaagacac tgaagatgtg ctgctctcca ggaacctacg gtcccgactg tctcgcatgc 420
cagggcggat ccagagggcc ctgcagcggg aatggccact gcagcggaga tgggagcaga 480
cagggcgacg ggtcctgccg gtgccacatg ggggtaccagg gcccgctgtg cactgactgc 540
atggacggct acttcagctc gctccggaac gagaccacac gcactctgcac agcctgtgac 600
gagtcctgca agacgtgctc gggcctgacc aacagagact gcggcgagtg tgaagtgggc 660
tgggtgctgg acgagggcgc ctgtgtggat gtggacgagt gtgcggccga gccgcctccc 720
tgcagcgctg cgcagttctg taagaacgcc aacggctcct acacgtgcga agagtgtgac 780
tccagctgtg tgggtgcac aggggaaggc ccaggaaact gtaaagagtg tatctctggc 840
tacgcgaggg agcacggaca gtgtgcagat gtggacgagt gctcactagc agaaaaaacc 900
tgtgtgagga aaaaacgaaa ctgctacaat actccaggga gctacgtctg tgtgtgtcct 960
gacggcttcg aagaacgga agatgcctgt gtgccgccgg cagaggctga agccacagaa 1020
ggagaaagcc cgacacagct gccctccgcg gaagacctg 1059

```

&lt;210&gt; 56

&lt;211&gt; 353

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 56

```

Met Arg Leu Pro Arg Arg Ala Ala Leu Gly Leu Leu Pro Leu Leu Leu
  1             5             10             15

```

```

Leu Leu Pro Pro Ala Pro Glu Ala Ala Lys Lys Pro Thr Pro Cys His
  20             25             30

```

Arg Cys Arg Gly Leu Val Asp Lys Phe Asn Gln Gly Met Val Asp Thr  
 35 40 45  
 Ala Lys Lys Asn Phe Gly Gly Gly Asn Thr Ala Trp Glu Glu Lys Thr  
 50 55 60  
 Leu Ser Lys Tyr Glu Ser Ser Glu Ile Arg Leu Leu Glu Ile Leu Glu  
 65 70 75 80  
 Gly Leu Cys Glu Ser Ser Asp Phe Glu Cys Asn Gln Met Leu Glu Ala  
 85 90 95  
 Gln Glu Glu His Leu Glu Ala Trp Trp Leu Gln Leu Lys Ser Glu Tyr  
 100 105 110  
 Pro Asp Leu Phe Glu Trp Phe Cys Val Lys Thr Leu Lys Val Cys Cys  
 115 120 125  
 Ser Pro Gly Thr Tyr Gly Pro Asp Cys Leu Ala Cys Gln Gly Gly Ser  
 130 135 140  
 Gln Arg Pro Cys Ser Gly Asn Gly His Cys Ser Gly Asp Gly Ser Arg  
 145 150 155 160  
 Gln Gly Asp Gly Ser Cys Arg Cys His Met Gly Tyr Gln Gly Pro Leu  
 165 170 175  
 Cys Thr Asp Cys Met Asp Gly Tyr Phe Ser Ser Leu Arg Asn Glu Thr  
 180 185 190  
 His Ser Ile Cys Thr Ala Cys Asp Glu Ser Cys Lys Thr Cys Ser Gly  
 195 200 205  
 Leu Thr Asn Arg Asp Cys Gly Glu Cys Glu Val Gly Trp Val Leu Asp  
 210 215 220  
 Glu Gly Ala Cys Val Asp Val Asp Glu Cys Ala Ala Glu Pro Pro Pro  
 225 230 235 240  
 Cys Ser Ala Ala Gln Phe Cys Lys Asn Ala Asn Gly Ser Tyr Thr Cys  
 245 250 255  
 Glu Glu Cys Asp Ser Ser Cys Val Gly Cys Thr Gly Glu Gly Pro Gly  
 260 265 270  
 Asn Cys Lys Glu Cys Ile Ser Gly Tyr Ala Arg Glu His Gly Gln Cys  
 275 280 285

Ala Asp Val Asp Glu Cys Ser Leu Ala Glu Lys Thr Cys Val Arg Lys  
 290 295 300

Asn Glu Asn Cys Tyr Asn Thr Pro Gly Ser Tyr Val Cys Val Cys Pro  
 305 310 315 320

Asp Gly Phe Glu Glu Thr Glu Asp Ala Cys Val Pro Pro Ala Glu Ala  
 325 330 335

Glu Ala Thr Glu Gly Glu Ser Pro Thr Gln Leu Pro Ser Arg Glu Asp  
 340 345 350

Leu

<210> 57

<211> 24

<212> PRT

<213> Homo sapiens

<400> 57

Met Arg Leu Pro Arg Arg Ala Ala Leu Gly Leu Leu Pro Leu Leu Leu  
 1 5 10 15

Leu Leu Pro Pro Ala Pro Glu Ala  
 20

<210> 58

<211> 329

<212> PRT

<213> Homo sapiens

<400> 58

Ala Lys Lys Pro Thr Pro Cys His Arg Cys Arg Gly Leu Val Asp Lys  
 1 5 10 15

Phe Asn Gln Gly Met Val Asp Thr Ala Lys Lys Asn Phe Gly Gly Gly  
 20 25 30

Asn Thr Ala Trp Glu Glu Lys Thr Leu Ser Lys Tyr Glu Ser Ser Glu  
 35 40 45

Ile Arg Leu Leu Glu Ile Leu Glu Gly Leu Cys Glu Ser Ser Asp Phe  
 50 55 60

Glu Cys Asn Gln Met Leu Glu Ala Gln Glu Glu His Leu Glu Ala Trp

65		70		75		80									
Trp	Leu	Gln	Leu	Lys	Ser	Glu	Tyr	Pro	Asp	Leu	Phe	Glu	Trp	Phe	Cys
				85					90					95	
Val	Lys	Thr	Leu	Lys	Val	Cys	Cys	Ser	Pro	Gly	Thr	Tyr	Gly	Pro	Asp
			100					105					110		
Cys	Leu	Ala	Cys	Gln	Gly	Gly	Ser	Gln	Arg	Pro	Cys	Ser	Gly	Asn	Gly
		115					120						125		
His	Cys	Ser	Gly	Asp	Gly	Ser	Arg	Gln	Gly	Asp	Gly	Ser	Cys	Arg	Cys
		130					135						140		
His	Met	Gly	Tyr	Gln	Gly	Pro	Leu	Cys	Thr	Asp	Cys	Met	Asp	Gly	Tyr
	145				150					155				160	
Phe	Ser	Ser	Leu	Arg	Asn	Glu	Thr	His	Ser	Ile	Cys	Thr	Ala	Cys	Asp
			165						170					175	
Glu	Ser	Cys	Lys	Thr	Cys	Ser	Gly	Leu	Thr	Asn	Arg	Asp	Cys	Gly	Glu
			180					185					190		
Cys	Glu	Val	Gly	Trp	Val	Leu	Asp	Glu	Gly	Ala	Cys	Val	Asp	Val	Asp
		195					200					205			
Glu	Cys	Ala	Ala	Glu	Pro	Pro	Pro	Cys	Ser	Ala	Ala	Gln	Phe	Cys	Lys
		210					215					220			
Asn	Ala	Asn	Gly	Ser	Tyr	Thr	Cys	Glu	Glu	Cys	Asp	Ser	Ser	Cys	Val
	225				230					235				240	
Gly	Cys	Thr	Gly	Glu	Gly	Pro	Gly	Asn	Cys	Lys	Glu	Cys	Ile	Ser	Gly
			245						250					255	
Tyr	Ala	Arg	Glu	His	Gly	Gln	Cys	Ala	Asp	Val	Asp	Glu	Cys	Ser	Leu
		260						265						270	
Ala	Glu	Lys	Thr	Cys	Val	Arg	Lys	Asn	Glu	Asn	Cys	Tyr	Asn	Thr	Pro
		275						280					285		
Gly	Ser	Tyr	Val	Cys	Val	Cys	Pro	Asp	Gly	Phe	Glu	Glu	Thr	Glu	Asp
		290					295					300			
Ala	Cys	Val	Pro	Pro	Ala	Glu	Ala	Glu	Ala	Thr	Glu	Gly	Glu	Ser	Pro
	305				310					315				320	
Thr	Gln	Leu	Pro	Ser	Arg	Glu	Asp	Leu							

325

<210> 59  
 <211> 2730  
 <212> DNA  
 <213> Homo sapiens

<400> 59  
 gtcgacccac gcgtccgtcc tgcggcccca gcctctcttc acgctcgcgc agtctccgcc 60  
 gcagtctcag ctgcagctgc aggactgagc cgtgcacccg gaggagaccc ccggaggagg 120  
 cgacaaactt cgcagtgcgc cgacccaacc ccagccctgg gtagcctgca gcatggccca 180  
 gctgttctctg cccctgctgg cagccctggc cctggcccg gctcctgcag ctttagcaga 240  
 tggtctggaa ggagacagct cagaggaccg cgcttttcgc gtgcgcacgc cgggcgacgc 300  
 gccactgcag ggcgtgctcg gcggcgccct caccatccct tgccacgtcc actacctgcg 360  
 gccaccgccg agccgccggg ctgtgctggg ctctcccgcg gtcaagtga ctttctgtc 420  
 ccggggccgg gaggcagagg tgctggtggc gcggggagtg cgcgtcaagg tgaacgaggc 480  
 ctaccgggtc cgcgtggcac tgcctgcgta ccagcgtcg ctacccgacg tctccctggc 540  
 gctgagcgag ctgcgcccc aagactcagg tatctatcgc tgtgaggtcc agcacggcat 600  
 cgatgacagc agcgacgctg tggaggtaa ggtcaaagg gtcgtctttc tctaccgaga 660  
 gggctctgcc cgctatgctt tctcttttc tggggcccg gaggcctgtg cccgcattgg 720  
 agcccacatc gccaccccg agcagctcta tgccgcctac cttgggggct atgagcaatg 780  
 tgatgctggc tggctgtcgg atcagaccgt gaggtatccc atccagaccc cagcagaggc 840  
 ctgttacgga gacatggatg gcttccccgg ggtccggaac tatggtgtgg tggacccgga 900  
 tgacctctat gatgtgtact gttatgtga agacctaat ggagaactgt tcctgggtga 960  
 cctccagag aagctgacat tggaggaagc acgggcgtac tgccaggagc ggggtgcaga 1020  
 gattgccacc acgggccaac tgtatgcagc ctgggatggg ggccctggacc actgcagccc 1080  
 aggggtggta gctgatggca gtgtgcgcta ccccatcgtc acaccagacc agcgtgtgg 1140  
 tgggggcttg cctggtgtca agactctctt cctcttcccc aaccagactg gcttcccca 1200  
 taagcacagc cgcttcaacg tctactgctt ccgagactcg gccagcctt ctgccatccc 1260  
 tgaggcctcc aaccagcct ccaaccagc ctctgatgga cttagaggta tcgtcacagt 1320  
 gacagagacc ctggagggaac tgcagctgcc tcaggaagcc acagagagtg aatcccgtgg 1380  
 ggccatctac tccatcccca tcatggagga cggaggaggt ggaagctcca ctccagaaga 1440  
 cccagcagag gccctagga cgctcctaga atttgaaca caatccatgg taccgcccac 1500  
 ggggttctca gaagaggaag gtaaggcatt ggaggaagaa gagaatatg aagatgaaga 1560  
 agagaaagag gaggaagaag aagaggagga ggtggaggat gaggctctgt gggcatggcc 1620  
 cagcgagctc agcagcccg gccctgaggc ctctctcccc actgagccag cagcccagga 1680  
 gaagtcactc tcccaggcgc cagcaagggc agtcctgcag cctggtgcat caccacttcc 1740  
 tgatggagag tcagaagctt ccaggcctcc aagggtccat ggaccaccta ctgagactct 1800  
 gccactccc agggagaggg acctagcatc cccatcacct tccactctgg ttgaggcaag 1860  
 agaggtgggg gaggaactg gtggtcctga gctatctggg gtccctcgag gagagagcga 1920  
 ggagacagga agctccgagg gtgccccttc cctgcttcca gccacacggg cccctgaggg 1980  
 taccaggag ctggaggccc cctctgaaga taattctgga agaactgcc cagcagggac 2040  
 ctcagtgcag gccagccag tgcgtccac tgacagcgcc agccgaggtg gagtggccgt 2100  
 ggtccccgca tcaggtaat ctgcccaagg ctcaactgcc ctctctatcc tactcctttt 2160  
 cttccccctg cagctctggg tcacctgacc tgtagtcctt taaccacca tcatcccaaa 2220  
 ctctcctgtc ctttgcttc attctcttac ccacctctac ctatgggtct ccaatctcgg 2280  
 atatccacct tgtgggtatc tcagctctcc gcgtctttac cctgtgatcc cagccccgcc 2340

```

actgaccatc tgtgaccctt cctgcccatt gggccctcca cctgtggctc acatctcgcc 2400
agccccacag agcatcctca ggctctcca aggtcctca tcacctattg cagccttcag 2460
ggctcggcct attttccact actcccttca tccgcctgtg tgccgtcccc tttagctgcc 2520
tcctattgat ctgaggaag cctgggagtc ccttctcacc cctcaacctc cggagtccag 2580
gagaacccgt acccccacag agccttaagc aactacttct gtgaagtatt ttttgactgt 2640
ttcatggaaa acaagccttg gaaataaatc tctattaaac cgctttgtaa ccaaaaaaaaa 2700
aaaaaaaaaa aaaaaaaaaa gggcgccgcg 2730

```

&lt;210&gt; 60

&lt;211&gt; 2013

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

```

atggcccagc tgttctgccc cctgctggca gccctggctc tggcccaggc tcctgcagct 60
ttagcagatg ttctggaagg agacagctca gaggaccgcg cttttcgcgt gcgcacgcg 120
ggcgacgcgc cactgcaggg cgtgctcggc ggcgcctca ccaccccttg ccacgtccac 180
tacctgcggc caccgcggag ccgcgggct gtgctgggct ctccgcgggt caagtggact 240
ttcctgtccc ggggcccggg ggagagggtg ctggtggcgc ggggagtgcg cgtcaagggtg 300
aacgaggcct accggttccg cgtggcactg cctgcgtacc cagcgtcgtc caccgacgtc 360
tccttgccgc tgagcgagct gcgcccacac gactcaggta tctatcgctg tgaggtccag 420
cacggcatcg atgacagcag cgacgctgtg gaggtaagg tcaaagggtg cgtctttctc 480
taccgagagg gctctgcccg ctatgctttc tctttttctg gggcccagga ggctgtgcc 540
cgcattggag cccacatcgc caccgcggag cagctctatg ccgcctacct tgggggctat 600
gagcaatgtg atgctggctg gctgtcggat cagaccgtga ggtatcccat ccagacccca 660
cgagaggcct gttacggaga catggatggc tccccgggg tccggaacta tgggtgtgtg 720
gacccggtatg acctctatga tgtgtactgt tatgctgaag acctaaatgg agaactgttc 780
ctgggtgacc ctccagagaa gctgacattg gaggaagcac gggcgtactg ccaggagcgg 840
ggtgcagaga ttgccaccac gggccaactg tatgcagcct gggatggtgg cctggaccac 900
tgacgcccag ggtggctagc tgatggcagt gtgcgtacc ccacgtcac acccagccag 960
cgctgtggtg ggggcttgcc tgggtgcaag actctcttcc tcttcccaa ccagactggc 1020
ttcccaata agcacagccg cttcaacgtc tactgcttcc gagactcggc ccagccttct 1080
gccatccctg aggcctccaa cccagcctcc aaccagcct ctgatggact agaggctatc 1140
gtcacagtga cagagacctt ggaggaactg cagctgcctc aggaagccac agagagtga 1200
tcccgtggg ccacttactc catccccatc atggaggacg gaggaggtg aagctccact 1260
ccagaagacc cagcagaggc ccctaggacg ctcttagaat ttgaaacaca atccatggtg 1320
ccgcccacgg ggttctcaga agaggaaggt aaggcattgg aggaagaaga gaaatatgaa 1380
gatgaagaag agaaagagga ggaagaagaa gaggaggagg tggaggatga ggctctgtg 1440
gcatggccca gcgagctcag cagccggg cctgaggcct ctctccccc tgagccagca 1500
gcccaggaga agtcactctc ccaggcgcca gcaaggcgag tcctgcagcc tgggtcatca 1560
ccacttcctg atggagagtc agaagcttcc aggcctcaa ggtccatgg accacctact 1620
gagactctgc ccactcccag ggagaggaac ctatcatccc catcaccttc cactctggtt 1680
gaggcaagag aggtggggga ggcaactggg ggtcctgagc tatctgggg cctcagagga 1740
gagagcgagg agacaggaag ctccgagggt gcccttccc tgcttcagc cacacgggcc 1800
cctgagggtg ccaggagct ggaggcccc tctgaagata attctggaag aactgcccc 1860
gcagggacct cagtgcaggc ccagccagt ctgcccactg acagcgccag ccgaggtgga 1920
gtggccgtg tccccgcac aggttaattct gcccaaggct caactgcct ctctatccta 1980

```

ctccttttct tccccctgca gctctgggtc acc

2013

&lt;210&gt; 61

&lt;211&gt; 671

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln  
 1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu Asp  
 20 25 30

Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln Gly Val  
 35 40 45

Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr Leu Arg Pro  
 50 55 60

Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg Val Lys Trp Thr  
 65 70 75 80

Phe Leu Ser Arg Gly Arg Glu Ala Glu Val Leu Val Ala Arg Gly Val  
 85 90 95

Arg Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala  
 100 105 110

Tyr Pro Ala Ser Leu Thr Asp Val Ser Leu Ala Leu Ser Glu Leu Arg  
 115 120 125

Pro Asn Asp Ser Gly Ile Tyr Arg Cys Glu Val Gln His Gly Ile Asp  
 130 135 140

Asp Ser Ser Asp Ala Val Glu Val Lys Val Lys Gly Val Val Phe Leu  
 145 150 155 160

Tyr Arg Glu Gly Ser Ala Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln  
 165 170 175

Glu Ala Cys Ala Arg Ile Gly Ala His Ile Ala Thr Pro Glu Gln Leu  
 180 185 190

Tyr Ala Ala Tyr Leu Gly Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu  
 195 200 205

Ser Asp Gln Thr Val Arg Tyr Pro Ile Gln Thr Pro Arg Glu Ala Cys  
 210 215 220

Tyr Gly Asp Met Asp Gly Phe Pro Gly Val Arg Asn Tyr Gly Val Val  
 225 230 235 240

Asp Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn  
 245 250 255

Gly Glu Leu Phe Leu Gly Asp Pro Pro Glu Lys Leu Thr Leu Glu Glu  
 260 265 270

Ala Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu Ile Ala Thr Thr Gly  
 275 280 285

Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp His Cys Ser Pro Gly  
 290 295 300

Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Val Thr Pro Ser Gln  
 305 310 315 320

Arg Cys Gly Gly Gly Leu Pro Gly Val Lys Thr Leu Phe Leu Phe Pro  
 325 330 335

Asn Gln Thr Gly Phe Pro Asn Lys His Ser Arg Phe Asn Val Tyr Cys  
 340 345 350

Phe Arg Asp Ser Ala Gln Pro Ser Ala Ile Pro Glu Ala Ser Asn Pro  
 355 360 365

Ala Ser Asn Pro Ala Ser Asp Gly Leu Glu Ala Ile Val Thr Val Thr  
 370 375 380

Glu Thr Leu Glu Glu Leu Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu  
 385 390 395 400

Ser Arg Gly Ala Ile Tyr Ser Ile Pro Ile Met Glu Asp Gly Gly Gly  
 405 410 415

Gly Ser Ser Thr Pro Glu Asp Pro Ala Glu Ala Pro Arg Thr Leu Leu  
 420 425 430

Glu Phe Glu Thr Gln Ser Met Val Pro Pro Thr Gly Phe Ser Glu Glu  
 435 440 445

Glu Gly Lys Ala Leu Glu Glu Glu Glu Lys Tyr Glu Asp Glu Glu Glu  
 450 455 460

Lys Glu Glu Glu Glu Glu Glu Glu Val Glu Asp Glu Ala Leu Trp  
465 470 475 480

Ala Trp Pro Ser Glu Leu Ser Ser Pro Gly Pro Glu Ala Ser Leu Pro  
485 490 495

Thr Glu Pro Ala Ala Gln Glu Lys Ser Leu Ser Gln Ala Pro Ala Arg  
500 505 510

Ala Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp Gly Glu Ser Glu  
515 520 525

Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr Glu Thr Leu Pro  
530 535 540

Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser Pro Ser Thr Leu Val  
545 550 555 560

Glu Ala Arg Glu Val Gly Glu Ala Thr Gly Gly Pro Glu Leu Ser Gly  
565 570 575

Val Pro Arg Gly Glu Ser Glu Glu Thr Gly Ser Ser Glu Gly Ala Pro  
580 585 590

Ser Leu Leu Pro Ala Thr Arg Ala Pro Glu Gly Thr Arg Glu Leu Glu  
595 600 605

Ala Pro Ser Glu Asp Asn Ser Gly Arg Thr Ala Pro Ala Gly Thr Ser  
610 615 620

Val Gln Ala Gln Pro Val Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly  
625 630 635 640

Val Ala Val Val Pro Ala Ser Gly Asn Ser Ala Gln Gly Ser Thr Ala  
645 650 655

Leu Ser Ile Leu Leu Leu Phe Phe Pro Leu Gln Leu Trp Val Thr  
660 665 670

<210> 62

<211> 22

<212> PRT

<213> Homo sapiens

<400> 62

Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln  
1 5 10 15

Ala Pro Ala Ala Leu Ala

20

&lt;210&gt; 63

&lt;211&gt; 649

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 63

Asp Val Leu Glu Gly Asp Ser Ser Glu Asp Arg Ala Phe Arg Val Arg  
 1 5 10 15

Ile Ala Gly Asp Ala Pro Leu Gln Gly Val Leu Gly Gly Ala Leu Thr  
 20 25 30

Ile Pro Cys His Val His Tyr Leu Arg Pro Pro Pro Ser Arg Arg Ala  
 35 40 45

Val Leu Gly Ser Pro Arg Val Lys Trp Thr Phe Leu Ser Arg Gly Arg  
 50 55 60

Glu Ala Glu Val Leu Val Ala Arg Gly Val Arg Val Lys Val Asn Glu  
 65 70 75 80

Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala Tyr Pro Ala Ser Leu Thr  
 85 90 95

Asp Val Ser Leu Ala Leu Ser Glu Leu Arg Pro Asn Asp Ser Gly Ile  
 100 105 110

Tyr Arg Cys Glu Val Gln His Gly Ile Asp Asp Ser Ser Asp Ala Val  
 115 120 125

Glu Val Lys Val Lys Gly Val Val Phe Leu Tyr Arg Glu Gly Ser Ala  
 130 135 140

Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln Glu Ala Cys Ala Arg Ile  
 145 150 155 160

Gly Ala His Ile Ala Thr Pro Glu Gln Leu Tyr Ala Ala Tyr Leu Gly  
 165 170 175

Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu Ser Asp Gln Thr Val Arg  
 180 185 190

Tyr Pro Ile Gln Thr Pro Arg Glu Ala Cys Tyr Gly Asp Met Asp Gly

195	200	205
Phe Pro Gly Val Arg Asn Tyr Gly Val Val Asp Pro Asp Asp Leu Tyr		
210	215	220
Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn Gly Glu Leu Phe Leu Gly		
225	230	235 240
Asp Pro Pro Glu Lys Leu Thr Leu Glu Glu Ala Arg Ala Tyr Cys Gln		
245	250	255
Glu Arg Gly Ala Glu Ile Ala Thr Thr Gly Gln Leu Tyr Ala Ala Trp		
260	265	270
Asp Gly Gly Leu Asp His Cys Ser Pro Gly Trp Leu Ala Asp Gly Ser		
275	280	285
Val Arg Tyr Pro Ile Val Thr Pro Ser Gln Arg Cys Gly Gly Gly Leu		
290	295	300
Pro Gly Val Lys Thr Leu Phe Leu Phe Pro Asn Gln Thr Gly Phe Pro		
305	310	315 320
Asn Lys His Ser Arg Phe Asn Val Tyr Cys Phe Arg Asp Ser Ala Gln		
325	330	335
Pro Ser Ala Ile Pro Glu Ala Ser Asn Pro Ala Ser Asn Pro Ala Ser		
340	345	350
Asp Gly Leu Glu Ala Ile Val Thr Val Thr Glu Thr Leu Glu Glu Leu		
355	360	365
Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu Ser Arg Gly Ala Ile Tyr		
370	375	380
Ser Ile Pro Ile Met Glu Asp Gly Gly Gly Ser Ser Thr Pro Glu		
385	390	395 400
Asp Pro Ala Glu Ala Pro Arg Thr Leu Leu Glu Phe Glu Thr Gln Ser		
405	410	415
Met Val Pro Pro Thr Gly Phe Ser Glu Glu Glu Gly Lys Ala Leu Glu		
420	425	430
Glu Glu Glu Lys Tyr Glu Asp Glu Glu Glu Lys Glu Glu Glu Glu		
435	440	445
Glu Glu Glu Val Glu Asp Glu Ala Leu Trp Ala Trp Pro Ser Glu Leu		

450                      455                      460  
 Ser Ser Pro Gly Pro Glu Ala Ser Leu Pro Thr Glu Pro Ala Ala Gln  
 465                      470                      475                      480  
 Glu Lys Ser Leu Ser Gln Ala Pro Ala Arg Ala Val Leu Gln Pro Gly  
                     485                      490                      495  
 Ala Ser Pro Leu Pro Asp Gly Glu Ser Glu Ala Ser Arg Pro Pro Arg  
                     500                      505                      510  
 Val His Gly Pro Pro Thr Glu Thr Leu Pro Thr Pro Arg Glu Arg Asn  
                     515                      520                      525  
 Leu Ala Ser Pro Ser Pro Ser Thr Leu Val Glu Ala Arg Glu Val Gly  
                     530                      535                      540  
 Glu Ala Thr Gly Gly Pro Glu Leu Ser Gly Val Pro Arg Gly Glu Ser  
 545                      550                      555                      560  
 Glu Glu Thr Gly Ser Ser Glu Gly Ala Pro Ser Leu Leu Pro Ala Thr  
                     565                      570                      575  
 Arg Ala Pro Glu Gly Thr Arg Glu Leu Glu Ala Pro Ser Glu Asp Asn  
                     580                      585                      590  
 Ser Gly Arg Thr Ala Pro Ala Gly Thr Ser Val Gln Ala Gln Pro Val  
                     595                      600                      605  
 Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly Val Ala Val Val Pro Ala  
                     610                      615                      620  
 Ser Gly Asn Ser Ala Gln Gly Ser Thr Ala Leu Ser Ile Leu Leu Leu  
 625                      630                      635                      640  
 Phe Phe Pro Leu Gln Leu Trp Val Thr  
                     645

<210> 64  
 <211> 456  
 <212> PRT  
 <213> Sus scrofa

<400> 64  
 Met Asn Leu Asp Ile His Cys Glu Gln Leu Ser Asp Ala Arg Trp Thr  
   1                      5                      10                      15

Glu Leu Leu Pro Leu Leu Gln Gln Tyr Glu Val Val Arg Leu Asp Asp  
 20 25 30

Cys Gly Leu Thr Glu Glu His Cys Lys Asp Ile Gly Ser Ala Leu Arg  
 35 40 45

Ala Asn Pro Ser Leu Thr Glu Leu Cys Leu Arg Thr Asn Glu Leu Gly  
 50 55 60

Asp Ala Gly Val His Leu Val Leu Gln Gly Leu Gln Ser Pro Thr Cys  
 65 70 75 80

Lys Ile Gln Lys Leu Ser Leu Gln Asn Cys Ser Leu Thr Glu Ala Gly  
 85 90 95

Cys Gly Val Leu Pro Ser Thr Leu Arg Ser Leu Pro Thr Leu Arg Glu  
 100 105 110

Leu His Leu Ser Asp Asn Pro Leu Gly Asp Ala Gly Leu Arg Leu Leu  
 115 120 125

Cys Glu Gly Leu Leu Asp Pro Gln Cys His Leu Glu Lys Leu Gln Leu  
 130 135 140

Glu Tyr Cys Arg Leu Thr Ala Ala Ser Cys Glu Pro Leu Ala Ser Val  
 145 150 155 160

Leu Arg Ala Thr Arg Ala Leu Lys Glu Leu Thr Val Ser Asn Asn Asp  
 165 170 175

Ile Gly Glu Ala Gly Ala Arg Val Leu Gly Gln Gly Leu Ala Asp Ser  
 180 185 190

Ala Cys Gln Leu Glu Thr Leu Arg Leu Glu Asn Cys Gly Leu Thr Pro  
 195 200 205

Ala Asn Cys Lys Asp Leu Cys Gly Ile Val Ala Ser Gln Ala Ser Leu  
 210 215 220

Arg Glu Leu Asp Leu Gly Ser Asn Gly Leu Gly Asp Ala Gly Ile Ala  
 225 230 235 240

Glu Leu Cys Pro Gly Leu Leu Ser Pro Ala Ser Arg Leu Lys Thr Leu  
 245 250 255

Trp Leu Trp Glu Cys Asp Ile Thr Ala Ser Gly Cys Arg Asp Leu Cys  
 260 265 270

Arg Val Leu Gln Ala Lys Glu Thr Leu Lys Glu Leu Ser Leu Ala Gly  
 275 280 285

Asn Lys Leu Gly Asp Glu Gly Ala Arg Leu Leu Cys Glu Ser Leu Leu  
 290 295 300

Gln Pro Gly Cys Gln Leu Glu Ser Leu Trp Val Lys Ser Cys Ser Leu  
 305 310 315 320

Thr Ala Ala Cys Cys Gln His Val Ser Leu Met Leu Thr Gln Asn Lys  
 325 330 335

His Leu Leu Glu Leu Gln Leu Ser Ser Asn Lys Leu Gly Asp Ser Gly  
 340 345 350

Ile Gln Glu Leu Cys Gln Ala Leu Ser Gln Pro Gly Thr Thr Leu Arg  
 355 360 365

Val Leu Cys Leu Gly Asp Cys Glu Val Thr Asn Ser Gly Cys Ser Ser  
 370 375 380

Leu Ala Ser Leu Leu Leu Ala Asn Arg Ser Leu Arg Glu Leu Asp Leu  
 385 390 395 400

Ser Asn Asn Cys Val Gly Asp Pro Gly Val Leu Gln Leu Leu Gly Ser  
 405 410 415

Leu Glu Gln Pro Gly Cys Ala Leu Glu Gln Leu Val Leu Tyr Asp Thr  
 420 425 430

Tyr Trp Thr Glu Glu Val Glu Asp Arg Leu Gln Ala Leu Glu Gly Ser  
 435 440 445

Lys Pro Gly Leu Arg Val Ile Ser  
 450 455

<210> 65  
 <211> 834  
 <212> PRT  
 <213> Mus sp.

<400> 65  
 Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Gly Leu Trp Gly  
 1 5 10 15

Leu Gly Ile Gly Ala Glu Met Trp Trp Asn Leu Val Pro Arg Lys Thr  
 20 25 30

Val Ser Ser Gly Glu Leu Val Thr Val Val Arg Arg Phe Ser Gln Thr  
 35 40 45  
 Gly Ile Gln Asp Phe Leu Thr Leu Thr Leu Thr Glu His Ser Gly Leu  
 50 55 60  
 Leu Tyr Val Gly Ala Arg Glu Ala Leu Phe Ala Phe Ser Val Glu Ala  
 65 70 75 80  
 Leu Glu Leu Gln Gly Ala Ile Ser Trp Glu Ala Pro Ala Glu Lys Lys  
 85 90 95  
 Ile Glu Cys Thr Gln Lys Gly Lys Ser Asn Gln Thr Glu Cys Phe Asn  
 100 105 110  
 Phe Ile Arg Phe Leu Gln Pro Tyr Asn Ser Ser His Leu Tyr Val Cys  
 115 120 125  
 Gly Thr Tyr Ala Phe Gln Pro Lys Cys Thr Tyr Ile Asn Met Leu Thr  
 130 135 140  
 Phe Thr Leu Asp Arg Ala Glu Phe Glu Asp Gly Lys Gly Lys Cys Pro  
 145 150 155 160  
 Tyr Asp Pro Ala Lys Gly His Thr Gly Leu Leu Val Asp Gly Glu Leu  
 165 170 175  
 Tyr Ser Ala Thr Leu Asn Asn Phe Leu Gly Thr Glu Pro Val Ile Leu  
 180 185 190  
 Arg Tyr Met Gly Thr His His Ser Ile Lys Thr Glu Tyr Leu Ala Phe  
 195 200 205  
 Trp Leu Asn Glu Pro His Phe Val Gly Ser Ala Phe Val Pro Glu Ser  
 210 215 220  
 Val Gly Ser Phe Thr Gly Asp Asp Asp Lys Ile Tyr Phe Phe Phe Ser  
 225 230 235 240  
 Glu Arg Ala Val Glu Tyr Asp Cys Tyr Ser Glu Gln Val Val Ala Arg  
 245 250 255  
 Val Ala Arg Val Cys Lys Gly Asp Met Gly Gly Ala Arg Thr Leu Gln  
 260 265 270  
 Lys Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Val Cys Ser Ala Pro  
 275 280 285

Asp Trp Lys Val Tyr Phe Asn Gln Leu Lys Ala Val His Thr Leu Arg  
 290 295 300  
 Gly Ala Ser Trp His Asn Thr Thr Phe Phe Gly Val Phe Gln Ala Arg  
 305 310 315 320  
 Trp Gly Asp Met Asp Leu Ser Ala Val Cys Glu Tyr Gln Leu Glu Gln  
 325 330 335  
 Ile Gln Gln Val Phe Glu Gly Pro Tyr Lys Glu Tyr Ser Glu Gln Ala  
 340 345 350  
 Gln Lys Trp Ala Arg Tyr Thr Asp Pro Val Pro Ser Pro Arg Pro Gly  
 355 360 365  
 Ser Cys Ile Asn Asn Trp His Arg Asp Asn Gly Tyr Thr Ser Ser Leu  
 370 375 380  
 Glu Leu Pro Asp Asn Thr Leu Asn Phe Ile Lys Lys His Pro Leu Met  
 385 390 395 400  
 Glu Asp Gln Val Lys Pro Arg Leu Gly Arg Pro Leu Leu Val Lys Lys  
 405 410 415  
 Asn Thr Asn Phe Thr His Val Val Ala Asp Arg Val Pro Gly Leu Asp  
 420 425 430  
 Gly Ala Thr Tyr Thr Val Leu Phe Ile Gly Thr Gly Asp Gly Trp Leu  
 435 440 445  
 Leu Lys Ala Val Ser Leu Gly Pro Trp Ile His Met Val Glu Glu Leu  
 450 455 460  
 Gln Val Phe Asp Gln Glu Pro Val Glu Ser Leu Val Leu Ser Gln Ser  
 465 470 475 480  
 Lys Lys Val Leu Phe Ala Gly Ser Arg Ser Gln Leu Val Gln Leu Ser  
 485 490 495  
 Leu Ala Asp Cys Thr Lys Tyr Arg Phe Cys Val Asp Cys Val Leu Ala  
 500 505 510  
 Arg Asp Pro Tyr Cys Ala Trp Asn Val Asn Thr Ser Arg Cys Val Ala  
 515 520 525  
 Thr Thr Ser Gly Arg Ser Gly Ser Phe Leu Val Gln His Val Ala Asn  
 530 535 540

Leu Asp Thr Ser Lys Met Cys Asn Gln Tyr Gly Ile Lys Lys Val Arg  
 545 550 555 560  
 Ser Ile Pro Lys Asn Ile Thr Val Val Ser Gly Thr Asp Leu Val Leu  
 565 570 575  
 Pro Cys His Leu Ser Ser Asn Leu Ala His Ala His Trp Thr Phe Gly  
 580 585 590  
 Ser Gln Asp Leu Pro Ala Glu Gln Pro Gly Ser Phe Leu Tyr Asp Thr  
 595 600 605  
 Gly Leu Gln Ala Leu Val Val Met Ala Ala Gln Ser Arg His Ser Gly  
 610 615 620  
 Pro Tyr Arg Cys Tyr Ser Glu Glu Gln Gly Thr Arg Leu Ala Ala Glu  
 625 630 635 640  
 Ser Tyr Leu Val Ala Val Val Ala Gly Ser Ser Val Thr Leu Glu Ala  
 645 650 655  
 Arg Ala Pro Leu Glu Asn Leu Gly Leu Val Trp Leu Ala Val Val Ala  
 660 665 670  
 Leu Gly Ala Val Cys Leu Val Leu Leu Leu Leu Val Leu Ser Leu Arg  
 675 680 685  
 Arg Arg Leu Arg Glu Glu Leu Glu Lys Gly Ala Lys Ala Ser Glu Arg  
 690 695 700  
 Thr Leu Val Tyr Pro Leu Glu Leu Pro Lys Glu Pro Ala Ser Pro Pro  
 705 710 715 720  
 Phe Arg Pro Gly Pro Glu Thr Asp Glu Lys Leu Trp Asp Pro Val Gly  
 725 730 735  
 Tyr Tyr Tyr Ser Asp Gly Ser Leu Lys Ile Val Pro Gly His Ala Arg  
 740 745 750  
 Cys Gln Pro Gly Gly Gly Pro Pro Ser Pro Pro Pro Gly Ile Pro Gly  
 755 760 765  
 Gln Pro Leu Pro Ser Pro Thr Arg Leu His Leu Gly Gly Gly Arg Asn  
 770 775 780  
 Ser Asn Ala Asn Gly Tyr Val Arg Leu Gln Leu Gly Gly Glu Asp Arg  
 785 790 795 800

Gly Gly Ser Gly His Pro Leu Pro Glu Leu Ala Asp Glu Leu Arg Arg  
 805 810 815

Lys Leu Gln Gln Arg Gln Pro Leu Pro Asp Ser Asn Pro Glu Glu Ser  
 820 825 830

Ser Val

<210> 66

<211> 3503

<212> DNA

<213> Mus sp.

<400> 66

```

ggcacgaggt ggccggagtc aaacgcgagg gcagcgccag ggattggagc tgcacgaaag 60
agggctgctg gactgaagtt tagaccctgg gtgtctgcca tggcccaca ctgggctgtc 120
tggctgctgg cagcagggct gtggggcctg ggcacgagg ctgagatgtg gtggaacctt 180
gtgccccgga agacagtatc ttctggggag ctggtcacag tagtgaggcg gttctccag 240
acaggcatcc aggacttctt gacactgacc ctgacagaac attctggcct tttatatgtg 300
ggggcccag aggcgctgtt tgccttcagt gtagaggctc tggagctgca aggagcgtc 360
tcttgggagg ctccagctga gaagaaaatt gaatgtacc agaaagggaa gagcaaccag 420
accgaatgct tcaacttcat ccgcttcctt cagccataca attcctccca tctgtatgtc 480
tgccgacact atgccttcca gcccaagtgc acctacatca acatgtcac gttcaccttg 540
gaccgtgcag aatttgagga tgggaagggt aaatgccat atgaccacg taagggtcac 600
accggactcc ttgtggacgg tgagctgtac tcagccacac tcaataactt cctgggcaca 660
gagccgggta tccttcgata catggggacc caccactcca tcaagacaga gtacctggt 720
ttttggtga atgaaccca cttttagggc tctgcctttg tccctgagag tgtgggaagc 780
ttcacgggag acgatgacaa gatctacttc ttcttcagt agcgggcagt ggagtatgac 840
tgctattccg agcaggtggt ggctcgtgtg gcgagagtct gtaagggtga catgggggga 900
gcacggagcg tgcagaagaa atggacgacg ttctgaagg ctccggttgg gtgtcagcc 960
cctgactgga aggtctactt caaccagctg aaggcggtgc acaccctgcg gggcgctct 1020
tggcacaaca ccaccttctt cggggtttt caagcgcgat ggggcgatat ggacctgtct 1080
gcagtttgtg agtaccagt ggaacagatc cagcaagtgt ttgagggtcc ctacaaggag 1140
tacagtgagc aagcccagaa gtgggcccgc tatactgacc cggtagccag ccctcggcct 1200
ggttcgtgta tcaacaactg gcaccgagac aatggctaca ccagttccct ggaactgccg 1260
gacaacaccc tcaacttcat caagaagcac ccctgatgg aggaccaggt gaagcctcgg 1320
ttgggcccgc ccctacttgt gaagaagaac actaacttca cacacgtggt ggccgacagg 1380
gtcccagggc ttgatggtgc cacctataca gtgttgttca ttggtacagg agatggctgg 1440
ctgctgaagg ctgtgagcct ggggcccctg atccacatgg tggaggaaact gcagggtgtt 1500
gaccaggagc cagtggaaag tctggtgctg tctcagagca agaagggtct ctttctgtgc 1560
tcccgtcttc agctggttca gctgtctctg gccgactgca caaagtaccg tttctgtgta 1620
gactgtgtcc tggccaggga cccttactgt gcctggaatg tcaacaccag ccgtgtgtg 1680
gccaccacca gtggtcgtc ggggtccttt ctggtccaac atgtggcgaa cttggacact 1740
tcaaagatgt gtaaccagta tggcattaaa aaagtcagat ctattcccaa gaacatcacc 1800
gttgtgtcag gcacagacct ggtcctacce tgccacctct cgtccaattt ggcccatgcc 1860

```

```

cactggacct tcggaagcca ggacctgcct gcagaacaac ctggctcctt tctttatgac 1920
acgggactcc aggcgctggt ggtgatggcc gcacagtccc gtcactctgg accctatcgt 1980
tgctattcag aggagcaggg gacaagactg gctgcagaaa gctaccttgt tgctgtcgtg 2040
gccggctcgt cggtgacact ggaggcacgg gctcccttgg aaaacctggg gctcgtgtgg 2100
ctcgtgtggt tggccctggg ggctgtgtgc ctggtgtgc tgctgtggt cctatcgtc 2160
cgccggcgac ttcgagaaga gctagaaaag ggtgccaaag catctgagag gacactggtg 2220
tacccttgg aactgcccac ggagcctgcc agtccccctt tccgtcctgg ccccgaaact 2280
gatgagaaac tttgggatcc tgcgggtac tactattcgg atggctctct caagattgtg 2340
cctggtcacg cccggtgcc gctgggggt gggeccctt cccacacctc tggcatacct 2400
ggccagcctc tgccttctcc aactcggctc cacctaggag gtggtcggaa ctcaaatgcc 2460
aatggttatg tgcgtttaca gttgggcgga gaggaccgag gaggatctgg gcacccactg 2520
cctgagctcg cggatgaatt acgacggaaa ctacaacagc gccagccgct gcctgactcc 2580
aaccagagg agtcttcagt atgaggggac ccccccacct cattggcggg ggggggtctc 2640
atgggaggtg cactcttaac tttgcacag gcaccagcta cctcaggac atggcagggg 2700
cacttgcctc gcctgggaca gacactgccc atcatttgc cggccgtgag gacctgtca 2760
gcctgggac tgccacttgg tgtggctcac caggacttca gcctcacagg agacacacc 2820
tcctctgtga atttgagaca tgtgggaccc cagcagccaa aactttgcaa ggaagaggtt 2880
tcaagatgtg ggcgtgtttg tgcataatg tgttggtatg catgtggaag aatgtgtgtg 2940
tgtgtgtgtg tgtgtgttaa ctttcctgtc tctatcacgt cttcccttgg cctggggtcc 3000
tcctggttga gtctttggag ctatgaaggg gaaggggtc atagcacttt gcttctccta 3060
ccccagctg tcccaagctt tggggcagtg atgtacatac ggggaaggga aggacagggt 3120
gttgtacccc ttttggggga gtgcgggact cgggggtggg cctagccctg ctctagggc 3180
tgtgaatgtt ttcagggcgg ggggtggggg tggagatgga acctcctgct tcagggggag 3240
gggtgggcag ggcctcccac ttgcctccg ggttcggtg tattttatat ttgcgtctt 3300
ctgacagggc tgggaagggt tgttggggga ggggaaggag gaggtgggca tgctatggat 3360
actggcctat cctctccctg ctctgggaaa agggctaaca gtgtaactta ttgtgtcccc 3420
acatatttat ttgttgtaaa tatttgagta tttttatatt gacaaataaa atggagaaaa 3480
tgaaatttaa aaaaaaaaaa aaa 3503

```

&lt;210&gt; 67

&lt;211&gt; 1529

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 67

Met Arg Gly Val Gly Trp Gln Met Leu Ser Leu Ser Leu Gly Leu Val  
1 5 10 15

Leu Ala Ile Leu Asn Lys Val Ala Pro Gln Ala Cys Pro Ala Gln Cys  
20 25 30

Ser Cys Ser Gly Ser Thr Val Asp Cys His Gly Leu Ala Leu Arg Ser  
35 40 45

Val Pro Arg Asn Ile Pro Arg Asn Thr Glu Arg Leu Asp Leu Asn Gly  
50 55 60

Asn Asn Ile Thr Arg Ile Thr Lys Thr Asp Phe Ala Gly Leu Arg His  
 65 70 75 80  
 Leu Arg Val Leu Gln Leu Met Glu Asn Lys Ile Ser Thr Ile Glu Arg  
 85 90 95  
 Gly Ala Phe Gln Asp Leu Lys Glu Leu Glu Arg Leu Arg Leu Asn Arg  
 100 105 110  
 Asn His Leu Gln Leu Phe Pro Glu Leu Leu Phe Leu Gly Thr Ala Lys  
 115 120 125  
 Leu Tyr Arg Leu Asp Leu Ser Glu Asn Gln Ile Gln Ala Ile Pro Arg  
 130 135 140  
 Lys Ala Phe Arg Gly Ala Val Asp Ile Lys Asn Leu Gln Leu Asp Tyr  
 145 150 155 160  
 Asn Gln Ile Ser Cys Ile Glu Asp Gly Ala Phe Arg Ala Leu Arg Asp  
 165 170 175  
 Leu Glu Val Leu Thr Leu Asn Asn Asn Asn Ile Thr Arg Leu Ser Val  
 180 185 190  
 Ala Ser Phe Asn His Met Pro Lys Leu Arg Thr Phe Arg Leu His Ser  
 195 200 205  
 Asn Asn Leu Tyr Cys Asp Cys His Leu Ala Trp Leu Ser Asp Trp Leu  
 210 215 220  
 Arg Gln Arg Pro Arg Val Gly Leu Tyr Thr Gln Cys Met Gly Pro Ser  
 225 230 235 240  
 His Leu Arg Gly His Asn Val Ala Glu Val Gln Lys Arg Glu Phe Val  
 245 250 255  
 Cys Ser Gly His Gln Ser Phe Met Ala Pro Ser Cys Ser Val Leu His  
 260 265 270  
 Cys Pro Ala Ala Cys Thr Cys Ser Asn Asn Ile Val Asp Cys Arg Gly  
 275 280 285  
 Lys Gly Leu Thr Glu Ile Pro Thr Asn Leu Pro Glu Thr Ile Thr Glu  
 290 295 300  
 Ile Arg Leu Glu Gln Asn Thr Ile Lys Val Ile Pro Pro Gly Ala Phe  
 305 310 315 320

Ser Pro Tyr Lys Lys Leu Arg Arg Ile Asp Leu Ser Asn Asn Gln Ile  
 325 330 335  
 Ser Glu Leu Ala Pro Asp Ala Phe Gln Gly Leu Arg Ser Leu Asn Ser  
 340 345 350  
 Leu Val Leu Tyr Gly Asn Lys Ile Thr Glu Leu Pro Lys Ser Leu Phe  
 355 360 365  
 Glu Gly Leu Phe Ser Leu Gln Leu Leu Leu Leu Asn Ala Asn Lys Ile  
 370 375 380  
 Asn Cys Leu Arg Val Asp Ala Phe Gln Asp Leu His Asn Leu Asn Leu  
 385 390 395 400  
 Leu Ser Leu Tyr Asp Asn Lys Leu Gln Thr Ile Ala Lys Gly Thr Phe  
 405 410 415  
 Ser Pro Leu Arg Ala Ile Gln Thr Met His Leu Ala Gln Asn Pro Phe  
 420 425 430  
 Ile Cys Asp Cys His Leu Lys Trp Leu Ala Asp Tyr Leu His Thr Asn  
 435 440 445  
 Pro Ile Glu Thr Ser Gly Ala Arg Cys Thr Ser Pro Arg Arg Leu Ala  
 450 455 460  
 Asn Lys Arg Ile Gly Gln Ile Lys Ser Lys Lys Phe Arg Cys Ser Ala  
 465 470 475 480  
 Lys Glu Gln Tyr Phe Ile Pro Gly Thr Glu Asp Tyr Arg Ser Lys Leu  
 485 490 495  
 Ser Gly Asp Cys Phe Ala Asp Leu Ala Cys Pro Glu Lys Cys Arg Cys  
 500 505 510  
 Glu Gly Thr Thr Val Asp Cys Ser Asn Gln Lys Leu Asn Lys Ile Pro  
 515 520 525  
 Glu His Ile Pro Gln Tyr Thr Ala Glu Leu Arg Leu Asn Asn Asn Glu  
 530 535 540  
 Phe Thr Val Leu Glu Ala Thr Gly Ile Phe Lys Lys Leu Pro Gln Leu  
 545 550 555 560  
 Arg Lys Ile Asn Phe Ser Asn Asn Lys Ile Thr Asp Ile Glu Glu Gly  
 565 570 575

Ala Phe Glu Gly Ala Ser Gly Val Asn Glu Ile Leu Leu Thr Ser Asn  
 580 585 590  
 Arg Leu Glu Asn Val Gln His Lys Met Phe Lys Gly Leu Glu Ser Leu  
 595 600 605  
 Lys Thr Leu Met Leu Arg Ser Asn Arg Ile Thr Cys Val Gly Asn Asp  
 610 615 620  
 Ser Phe Ile Gly Leu Ser Ser Val Arg Leu Leu Ser Leu Tyr Asp Asn  
 625 630 635 640  
 Gln Ile Thr Thr Val Ala Pro Gly Ala Phe Asp Thr Leu His Ser Leu  
 645 650 655  
 Ser Thr Leu Asn Leu Leu Ala Asn Pro Phe Asn Cys Asn Cys Tyr Leu  
 660 665 670  
 Ala Trp Leu Gly Glu Trp Leu Arg Lys Lys Arg Ile Val Thr Gly Asn  
 675 680 685  
 Pro Arg Cys Gln Lys Pro Tyr Phe Leu Lys Glu Ile Pro Ile Gln Asp  
 690 695 700  
 Val Ala Ile Gln Asp Phe Thr Cys Asp Asp Gly Asn Asp Asp Asn Ser  
 705 710 715 720  
 Cys Ser Pro Leu Ser Arg Cys Pro Thr Glu Cys Thr Cys Leu Asp Thr  
 725 730 735  
 Val Val Arg Cys Ser Asn Lys Gly Leu Lys Val Leu Pro Lys Gly Ile  
 740 745 750  
 Pro Arg Asp Val Thr Glu Leu Tyr Leu Asp Gly Asn Gln Phe Thr Leu  
 755 760 765  
 Val Pro Lys Glu Leu Ser Asn Tyr Lys His Leu Thr Leu Ile Asp Leu  
 770 775 780  
 Ser Asn Asn Arg Ile Ser Thr Leu Ser Asn Gln Ser Phe Ser Asn Met  
 785 790 795 800  
 Thr Gln Leu Leu Thr Leu Ile Leu Ser Tyr Asn Arg Leu Arg Cys Ile  
 805 810 815  
 Pro Pro Arg Thr Phe Asp Gly Leu Lys Ser Leu Arg Leu Leu Ser Leu  
 820 825 830

His Gly Asn Asp Ile Ser Val Val Pro Glu Gly Ala Phe Asn Asp Leu  
 835 840 845  
 Ser Ala Leu Ser His Leu Ala Ile Gly Ala Asn Pro Leu Tyr Cys Asp  
 850 855 860  
 Cys Asn Met Gln Trp Leu Ser Asp Trp Val Lys Ser Glu Tyr Lys Glu  
 865 870 875 880  
 Pro Gly Ile Ala Arg Cys Ala Gly Pro Gly Glu Met Ala Asp Lys Leu  
 885 890 895  
 Leu Leu Thr Thr Pro Ser Lys Lys Phe Thr Cys Gln Gly Pro Val Asp  
 900 905 910  
 Val Asn Ile Leu Ala Lys Cys Asn Pro Cys Leu Ser Asn Pro Cys Lys  
 915 920 925  
 Asn Asp Gly Thr Cys Asn Ser Asp Pro Val Asp Phe Tyr Arg Cys Thr  
 930 935 940  
 Cys Pro Tyr Gly Phe Lys Gly Gln Asp Cys Asp Val Pro Ile His Ala  
 945 950 955 960  
 Cys Ile Ser Asn Pro Cys Lys His Gly Gly Thr Cys His Leu Lys Glu  
 965 970 975  
 Gly Glu Glu Asp Gly Phe Trp Cys Ile Cys Ala Asp Gly Phe Glu Gly  
 980 985 990  
 Glu Asn Cys Glu Val Asn Val Asp Asp Cys Glu Asp Asn Asp Cys Glu  
 995 1000 1005  
 Asn Asn Ser Thr Cys Val Asp Gly Ile Asn Asn Tyr Thr Cys Leu Cys  
 1010 1015 1020  
 Pro Pro Glu Tyr Thr Gly Glu Leu Cys Glu Glu Lys Leu Asp Phe Cys  
 1025 1030 1035 1040  
 Ala Gln Asp Leu Asn Pro Cys Gln His Asp Ser Lys Cys Ile Leu Thr  
 1045 1050 1055  
 Pro Lys Gly Phe Lys Cys Asp Cys Thr Pro Gly Tyr Val Gly Glu His  
 1060 1065 1070  
 Cys Asp Ile Asp Phe Asp Asp Cys Gln Asp Asn Lys Cys Lys Asn Gly  
 1075 1080 1085

Ala His Cys Thr Asp Ala Val Asn Gly Tyr Thr Cys Ile Cys Pro Glu  
 1090 1095 1100

Gly Tyr Ser Gly Leu Phe Cys Glu Phe Ser Pro Pro Met Val Leu Pro  
 1105 1110 1115 1120

Arg Thr Ser Pro Cys Asp Asn Phe Asp Cys Gln Asn Gly Ala Gln Cys  
 1125 1130 1135

Ile Val Arg Ile Asn Glu Pro Ile Cys Gln Cys Leu Pro Gly Tyr Gln  
 1140 1145 1150

Gly Glu Lys Cys Glu Lys Leu Val Ser Val Asn Phe Ile Asn Lys Glu  
 1155 1160 1165

Ser Tyr Leu Gln Ile Pro Ser Ala Lys Val Arg Pro Gln Thr Asn Ile  
 1170 1175 1180

Thr Leu Gln Ile Ala Thr Asp Glu Asp Ser Gly Ile Leu Leu Tyr Lys  
 1185 1190 1195 1200

Gly Asp Lys Asp His Ile Ala Val Glu Leu Tyr Arg Gly Arg Val Arg  
 1205 1210 1215

Ala Ser Tyr Asp Thr Gly Ser His Pro Ala Ser Ala Ile Tyr Ser Val  
 1220 1225 1230

Glu Thr Ile Asn Asp Gly Asn Phe His Ile Val Glu Leu Leu Ala Leu  
 1235 1240 1245

Asp Gln Ser Leu Ser Leu Ser Val Asp Gly Gly Asn Pro Lys Ile Ile  
 1250 1255 1260

Thr Asn Leu Ser Lys Gln Ser Thr Leu Asn Phe Asp Ser Pro Leu Tyr  
 1265 1270 1275 1280

Val Gly Gly Met Pro Gly Lys Ser Asn Val Ala Ser Leu Arg Gln Ala  
 1285 1290 1295

Pro Gly Gln Asn Gly Thr Ser Phe His Gly Cys Ile Arg Asn Leu Tyr  
 1300 1305 1310

Ile Asn Ser Glu Leu Gln Asp Phe Gln Lys Val Pro Met Gln Thr Gly  
 1315 1320 1325

Ile Leu Pro Gly Cys Glu Pro Cys His Lys Lys Val Cys Ala His Gly  
 1330 1335 1340

Thr Cys Gln Pro Ser Ser Gln Ala Gly Phe Thr Cys Glu Cys Gln Glu  
 1345 1350 1355 1360  
 Gly Trp Met Gly Pro Leu Cys Asp Gln Arg Thr Asn Asp Pro Cys Leu  
 1365 1370 1375  
 Gly Asn Lys Cys Val His Gly Thr Cys Leu Pro Ile Asn Ala Phe Ser  
 1380 1385 1390  
 Tyr Ser Cys Lys Cys Leu Glu Gly His Gly Gly Val Leu Cys Asp Glu  
 1395 1400 1405  
 Glu Glu Asp Leu Phe Asn Pro Cys Gln Ala Ile Lys Cys Lys His Gly  
 1410 1415 1420  
 Lys Cys Arg Leu Ser Gly Leu Gly Gln Pro Tyr Cys Glu Cys Ser Ser  
 1425 1430 1435 1440  
 Gly Tyr Thr Gly Asp Ser Cys Asp Arg Glu Ile Ser Cys Arg Gly Glu  
 1445 1450 1455  
 Arg Ile Arg Asp Tyr Tyr Gln Lys Gln Gln Gly Tyr Ala Ala Cys Gln  
 1460 1465 1470  
 Thr Thr Lys Lys Val Ser Arg Leu Glu Cys Arg Gly Gly Cys Ala Gly  
 1475 1480 1485  
 Gly Gln Cys Cys Gly Pro Leu Arg Ser Lys Arg Arg Lys Tyr Ser Phe  
 1490 1495 1500  
 Glu Cys Thr Asp Gly Ser Ser Phe Val Asp Glu Val Glu Lys Val Val  
 1505 1510 1515 1520  
 Lys Cys Gly Cys Thr Arg Cys Val Ser  
 1525

&lt;210&gt; 68

&lt;211&gt; 4900

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 68

cagagcaggg tggagagggc ggtgggaggc gtgtgcctga gtgggctcta ctgccttggt 60  
 ccatattatt ttgtgcacat ttccctggc actctgggtt gctagccccg ccgggcactg 120  
 ggcctcagac actgcgcggt tccctcggag cagcaagcta aagaaagccc ccagtgcg 180  
 cgaggaagga ggcggcgggg aaagatgcgc ggcgttggtt ggcagatgct gtccctgtcg 240  
 ctgggggttag tgctggcgat cctgaacaag gtggcaccgc aggcgtgccc ggcgcagtgc 300

tcttgctcgg gcagcacagt ggactgtcac gggctggcgc tgcgcagcgt gccagggaat 360  
 atcccccgca acaccgagag actggattta aatggaaata acatcacaag aattacgaag 420  
 acagattttg ctggctcttag acatctaaga gttcttcagc ttatggagaa taagattagc 480  
 accattgaaa gaggagcatt ccaggatctt aaagaactag agagactgcg tttaaacaga 540  
 aatcaccttc agctgtttcc tgagttgctg tttcttggga ctgcgaagct atacaggctt 600  
 gatctcagtg aaaaccaaatt tcaggcaatc ccaaggaaaag ctttccgtgg gccagttgac 660  
 ataaaaaatt tgcaactgga ttacaaccag atcagctgta ttgaagatgg gccattcagg 720  
 gctctccggg acctggaagt gctcactctc aacaataaca acattactag actttctgtg 780  
 gcaagtttca accatatgcc taaacttagg acttttcgac tgcattcaaa caacctgtat 840  
 tgtgactgcc acctggcctg gctctccgac tggtctcgcc aaaggcctcg ggttggtctg 900  
 tacactcagt gtatgggccc ctcccacctg agaggccata atgtagccga ggttcaaaaa 960  
 cgagaatttg tctgcagtgg tcaccagtca tttatggctc cttctttagt tgttttgcac 1020  
 tgccctgccg cctgtacctg tagcaacaat atcgtagact gtcgtgggaa aggtctcact 1080  
 gagatcccca caaatcttcc agagaccatc acagaaatac gtttgggaaca gaacacaatc 1140  
 aaagtcatcc ctccctggagc tttctcacca tataaaaaagc ttagacgaat tgacctgagc 1200  
 aataatcaga tctctgaact tgcaccagat gctttccaag gactacgctc tctgaattca 1260  
 cttgtcctct atggaaataa aatcacagaa ctccccaaaa gtttatttga aggactgttt 1320  
 tccttacagc tcctattatt gaatgccaac aagataaact gccttcgggt agatgctttt 1380  
 caggatctcc acaacttgaa ccttctctcc ctatatgaca acaagcttca gaccatcgcc 1440  
 aaggggacct tttcacctct tggggccatt caaactatgc atttgccca gaacctttt 1500  
 atttgtgact gccatctcaa gtggctagcg gattatctcc ataccaaccc gattgagacc 1560  
 agtggtgccc gttgcaccag ccccgccgc ctggcaaaca aaagaattgg acagatcaaa 1620  
 agcaagaaat tccgtgttc agctaaagaa cagtatttca ttccaggtag agaagattat 1680  
 cgatcaaaat taagtggaga ctgctttgcg gatctggctt gccctgaaaa gtgtcgctgt 1740  
 gaaggaacca cagtagattg ctctaataa aagctcaaca aaatcccga gcacattccc 1800  
 cagtagactg cagagttgcg tctcaataa aatgaattta ccgtgttgga agccacagga 1860  
 atctttaaga aacttctca attacgtaaa ataaacttta gcaacaataa gatcacagat 1920  
 attgaggagg gagcatttga aggagcatct ggtgtaaatg aaatacttct tacgagtaat 1980  
 cgtttgaaa atgtgcagca taagatgttc aagggtattg aaagcctcaa aactttgatg 2040  
 ttgagaagca atcgaataac ctgtgtgggg aatgacagtt tcataggact cagtctctgt 2100  
 cgtttgcttt ctttgtatga taatcaaatt actacagttg caccaggggc atttgatact 2160  
 ctccattctt tatctactct aaacctcttg gccaatcctt ttaactgtaa ctgctacctg 2220  
 gcttggttg gagagtggct gagaaagaag agaattgtca cgggaaatcc tagatgtcaa 2280  
 aaaccatact tcctgaaaga aatacccatc caggatgtgg ccattcagga cttcacttgt 2340  
 gatgacggaa atgatgacaa tagttgctcc ccactttctc gctgtcctac tgaatgtact 2400  
 tgcttgata cagtcgtccg atgtagcaac aagggtttga aggtcttgcc gaaaggattt 2460  
 ccaagagatg tcacagagtt gtatctggat ggaaaccaat ttacactggg tcccaaggaa 2520  
 ctctccaact acaaacattt aacacttata gacttaagta acaacagaat aagcacgctt 2580  
 tctaatacaga gcttcagcaa catgacccag ctccctcacct taattcttag ttacaaccgt 2640  
 ctgagatgta ttccctctcg cacctttgat ggattaaaagt ctcttcgatt actttctcta 2700  
 catggaaatg acatttctgt tgtgcctgaa ggtgctttca atgatctttc tgcattatca 2760  
 catctagcaa ttggagccaa ccctctttac tgtgattgta acatgcagtg gtatccgac 2820  
 tgggtgaagt cggaatataa ggagcctgga attgctcgtt gtgctggtcc tggagaaatg 2880  
 gcagataaac ttttactcac aactccctcc aaaaaattta cctgtcaagg tcctgtggat 2940  
 gtcaatatcc tagctaagtg taacccctgc ctatcaaata cgtgtaaaaa tgatggcaca 3000  
 tgtaatagtg atccagttga cttttaccga tgcacctgtc catatgggtt caaggggcag 3060  
 gactgtgatg tcccaattca tgccctgcatc agtaacccat gtaaacaatg aggaacttgc 3120  
 cacttaaagg aaggagaaga agatggattc tgggtgattt gtgctgatgg atttgaagga 3180

```

gaaaattgtg aagtcaacgt tgatgattgt gaagataatg actgtgaaaa taattctaca 3240
tgtgtc gatg gcattaataa ctacacatgc ctttgcccac ctgagtatac aggtgagttg 3300
tgtgaggaga agctggactt ctgtgcccag gacctgaacc cctgccagca cgattcaaag 3360
tgcacccata ctccaaaggg attcaaatgt gactgcacac cagggtacgt aggtgaacac 3420
tgcgacatcg attttgacga ctgccaagac aacaagtgtg aaaacggagc ccactgcaca 3480
gatgcagtga acggctatac gtgcatatgc cccgaagggt acagtggctt gttctgtgag 3540
ttttctccac ccattggctc ccctcgtacc agcccctgtg ataattttga ttgtcagaat 3600
ggagctcagt gtatcgtcag aataaatgag ccaatatgtc agtgtttgcc tggctatcag 3660
ggagaaaagt gtgaaaaatt ggtagtgtg aattttataa acaaagagtc ttatcttcag 3720
attccttcag ccaagggttc gcctcagacg aacataaacac ttcagattgc cacagatgaa 3780
gacagcggaa tcctcctgta taagggtgac aaagaccata tcgcggtaga actctatcgg 3840
gggctgtgtc gtgccagcta tgacaccggc tctcatccag cttctgccat ttacagtgtg 3900
gagacaatca atgatggaaa cttccacatt gtggaactac ttgccttggg tcagagtctc 3960
tctttgtccg tggatgggtg gaaccccaaa atcatcacta acttgtcaaa gcagtccact 4020
ctgaattttg actctccact ctatgtagga ggcattgccag ggaagagtaa cgtggcatct 4080
ctgcgccagg cccctgggca gaacggaacc agcttccacg gctgcattcc gaacctttac 4140
atcaacagtg agctgcagga cttccagaag gtgccgatgc aaacaggcat tttgcctggc 4200
tgtgagccat gccacaagaa ggtgtgtgcc catggcacat gccagcccag cagccaggca 4260
ggcttcacct gcgagtggca ggaaggatgg atggggcccc tctgtgacca acggaccaat 4320
gaccttgcct ttggaataa atgcgtacat ggcacctgct tgcccatcaa tgcgttctcc 4380
tacagctgta agtgcttggg gggccatgga ggtgtcctct gtgatgaaga ggaggatctg 4440
tttaacccat gccaggcgat caagtgaag caccgggaag gcaggcttcc aggtctgggg 4500
cagccctact gtgaatgcag cagtggatac acgggggaca gctgtgatcg agaaatctct 4560
tgtcgagggg aaaggataag agattattac caaaagcagc agggctatgc tgcttgccaa 4620
acaaccaaga aggtgtcccc attagagtgc agaggtgggt gtgcaggagg gcagtgtgtg 4680
ggaccgctga ggagcaagcg gcggaatac tctttcgaat gcactgacgg ctccctcttt 4740
gtggacgagg ttgagaaagt ggtgaagtgc ggctgtacga ggtgtgtgtc ctaaacacac 4800
tcccggcagc tctgtctttg gaaaagggtg tatacttctt gacctgtgg gactaatgaa 4860
tgcttcacag tggaaatatt tgaaatatat tgtaaaatac 4900

```

&lt;210&gt; 69

&lt;211&gt; 348

&lt;212&gt; PRT

<213> *Cricetulus griseus*

&lt;400&gt; 69

```

Met His Leu Pro Pro Ala Ala Ala Val Gly Leu Leu Leu Leu Leu
  1              5              10             15

```

```

Pro Pro Pro Ala Arg Val Ala Ser Arg Lys Pro Thr Met Cys Gln Arg
      20              25              30

```

```

Cys Arg Ala Leu Val Asp Lys Phe Asn Gln Gly Met Ala Asn Thr Ala
  35              40              45

```

```

Arg Lys Asn Phe Gly Gly Gly Asn Thr Ala Trp Glu Glu Lys Ser Leu
  50              55              60

```

65

Ser Lys Tyr Glu Phe Ser Glu Ile Arg Leu Leu Glu Ile Met Glu Gly  
 65 70 75 80  
 Leu Cys Asp Ser Asn Asp Phe Glu Cys Asn Gln Leu Leu Glu Gln His  
 85 90 95  
 Glu Glu Gln Leu Glu Ala Trp Trp Gln Thr Leu Lys Lys Glu Cys Pro  
 100 105 110  
 Asn Leu Phe Glu Trp Phe Cys Val His Thr Leu Lys Ala Cys Cys Leu  
 115 120 125  
 Pro Gly Thr Tyr Gly Pro Asp Cys Gln Glu Cys Gln Gly Gly Ser Gln  
 130 135 140  
 Arg Pro Cys Ser Gly Asn Gly His Cys Asp Gly Asp Gly Ser Arg Gln  
 145 150 155 160  
 Gly Asp Gly Ser Cys Gln Cys His Val Gly Tyr Lys Gly Pro Leu Cys  
 165 170 175  
 Ile Asp Cys Met Asp Gly Tyr Phe Ser Leu Leu Arg Asn Glu Thr His  
 180 185 190  
 Ser Phe Cys Thr Ala Cys Asp Glu Ser Cys Lys Thr Cys Ser Gly Pro  
 195 200 205  
 Thr Asn Lys Gly Cys Val Glu Cys Glu Val Gly Trp Thr Arg Val Glu  
 210 215 220  
 Asp Ala Cys Val Asp Val Asp Glu Cys Ala Ala Glu Thr Pro Pro Cys  
 225 230 235 240  
 Ser Asn Val Gln Tyr Cys Glu Asn Val Asn Gly Ser Tyr Thr Cys Glu  
 245 250 255  
 Glu Cys Asp Ser Thr Cys Val Gly Cys Thr Gly Lys Gly Pro Ala Asn  
 260 265 270  
 Cys Lys Glu Cys Ile Ser Gly Tyr Ser Lys Gln Lys Gly Glu Cys Ala  
 275 280 285  
 Asp Ile Asp Glu Cys Ser Leu Glu Thr Lys Val Cys Lys Lys Glu Asn  
 290 295 300  
 Glu Asn Cys Tyr Asn Thr Pro Gly Ser Phe Val Cys Val Cys Pro Glu  
 305 310 315 320

Gly Phe Glu Glu Asp Arg Arg Cys Leu Cys Thr Asp Ser Arg Arg Arg  
 325 330 335

Ser Gly Arg Gly Lys Ser His Thr Ala Thr Leu Pro  
 340 345

<210> 70

<211> 1399

<212> DNA

<213> *Cricetulus griseus*

<400> 70

```

gtagccgggg gaacggccgg cgcgcttgcc ggtgggcgga ggcgagactc cacagcagtt 60
ctctgccggt cgcccgcgag tgcacccgcc atgcacctgc cgcccgctgc cgcagtcggg 120
ctgctactgc tgctgctgcc gcctcccgcg cgcgtggcct cccggaagcc gacaatgtgc 180
cagaggtgcc gggcgctggt ggacaagttc aaccagggga tggccaacac ggccagggaag 240
aatttcggcg gcggaacac ggcgtgggag gagaagagtc tgtccaagta cgaattcagt 300
gagattcggc tcctggagat tatggagggc ctgtgtgaca gcaacgactt tgaatgcaac 360
caactcttgg aacagcatga ggagcagcta gaggcctggt ggcagacact gaagaaggag 420
tgccctaacc tatttgagtg gttctgtgta cacacactga aagcatgctg tcttccaggc 480
acctatgggc cagactgtca ggaatgccag ggtgggtctc agaggccttg tagcggaat 540
ggccactgcg acggagatgg cagcagacag ggcgacgggt cctgccagtg tcacgtagga 600
tacaaggggc cgtgtgtat cgactgcatg gatggctact tcagcttgct gaggaacgag 660
accacagct tctgcacagc ctgtgatgag tcctgcaaga catgctcagg tccaaccaac 720
aaaggctgtg tggagtgcga agtgggctgg acacgtgtgg aggatgcctg tgtggatgtt 780
gacgagtggt cagcagagac cccaccctgc agcaatgtac agtactgtga aaatgtcaac 840
ggctcctaca catgtgaaga gtgtgattct acctgtgtgg gctgcacagg aaaaggcca 900
gccaattgta aagagtgtat ctctggctac agcaagcaga aaggagagtg tgcagatata 960
gatgaatgct cattagaaac aaaggtgtgt aagaaggaaa atgagaactg ctacaatact 1020
ccagggagct ttgtctgcgt gtgtccggaa ggtttcgagg aagacagaag atgcttgtgt 1080
acagacagca gaaggcgaag tggcagagga aagtcccaca cagccaccct cccatgagga 1140
tttgtgacgg gcatccaggt tcagaagctg gactctcacc cttttaagtt attgagagga 1200
catcctatag aaaatgtggc ccatggacat caacccatt tctccaggaa gttttggagg 1260
aagaagctgc ctgctttgaa acagtagata ctcacttggc cctttaaaac gctgcatttc 1320
ttggtggttc ttaaacagat tcgtatattt tgatactgtt ctttataata aaattgatca 1380
ttgaaggtca ccaggaaca                                     1399
  
```

<210> 71

<211> 528

<212> PRT

<213> *Homo sapiens*

<400> 71

Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln  
 1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu Asp  
                   20                  25                  30  
 Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln Gly Val  
                   35                  40                  45  
 Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr Leu Arg Pro  
                   50                  55                  60  
 Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg Val Lys Trp Thr  
                   65                  70                  75                  80  
 Phe Leu Ser Arg Gly Arg Glu Ala Glu Val Leu Val Ala Arg Gly Val  
                   85                  90                  95  
 Arg Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala  
                   100                  105                  110  
 Tyr Pro Ala Ser Leu Thr Asp Val Ser Leu Ala Leu Ser Glu Leu Arg  
                   115                  120                  125  
 Pro Asn Asp Ser Gly Ile Tyr Arg Cys Glu Val Gln His Gly Ile Asp  
                   130                  135                  140  
 Asp Ser Ser Asp Ala Val Glu Ser Ser Gln Arg Tyr Pro Ile Gln Thr  
                   145                  150                  155                  160  
 Pro Arg Glu Ala Cys Tyr Gly Asp Met Asp Gly Phe Pro Gly Val Arg  
                   165                  170                  175  
 Asn Tyr Gly Val Val Asp Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr  
                   180                  185                  190  
 Ala Glu Asp Leu Asn Gly Glu Leu Phe Leu Gly Asp Pro Pro Glu Lys  
                   195                  200                  205  
 Leu Thr Leu Glu Glu Ala Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu  
                   210                  215                  220  
 Ile Ala Thr Thr Gly Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp  
                   225                  230                  235                  240  
 His Cys Ser Pro Gly Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile  
                   245                  250                  255  
 Val Thr Pro Ser Gln Arg Cys Gly Gly Gly Leu Pro Gly Val Lys Thr  
                   260                  265                  270

Leu Phe Leu Phe Pro Asn Gln Thr Gly Phe Pro Asn Lys His Ser Arg  
 275 280 285  
 Phe Asn Val Tyr Cys Phe Arg Asp Ser Ala Gln Leu Leu Pro Ser Leu  
 290 295 300  
 Arg Pro Pro Thr Gln Pro Pro Thr Gln Leu Asp Gly Leu Glu Ala Ile  
 305 310 315 320  
 Val Thr Val Thr Glu Thr Leu Glu Glu Leu Gln Leu Pro Gln Glu Ala  
 325 330 335  
 Thr Glu Ser Glu Ser Arg Gly Ala Ile Tyr Ser Ile Pro Ile Met Glu  
 340 345 350  
 Asp Gly Gly Gly Gly Ser Ser Thr Pro Glu Asp Pro Ala Glu Ala Pro  
 355 360 365  
 Arg Thr Leu Leu Glu Phe Glu Thr Gln Ser Met Val Pro Pro Thr Gly  
 370 375 380  
 Phe Ser Glu Glu Glu Gly Lys Ala Leu Glu Glu Glu Glu Lys Tyr Glu  
 385 390 395 400  
 Asp Glu Glu Glu Lys Glu Glu Glu Glu Glu Glu Glu Val Glu Asp  
 405 410 415  
 Glu Ala Leu Trp Ala Trp Pro Ser Glu Leu Ser Ser Pro Gly Pro Glu  
 420 425 430  
 Ala Ser Leu Pro Thr Glu Pro Ala Ala Gln Glu Glu Ser Leu Ser Gln  
 435 440 445  
 Ala Pro Ala Arg Ala Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp  
 450 455 460  
 Gly Glu Ser Glu Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr  
 465 470 475 480  
 Glu Thr Leu Pro Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser Pro  
 485 490 495  
 Ser Thr Leu Val Glu Ala Arg Glu Val Gly Glu Ala Thr Gly Gly Pro  
 500 505 510  
 Glu Leu Ser Gly Val Pro Arg Gly Gly Ala Arg Thr Gln Phe Ala Leu  
 515 520 525

<210> 72  
 <211> 883  
 <212> PRT  
 <213> Mus sp.

<400> 72

Met Ile Pro Leu Leu Leu Ser Leu Leu Ala Ala Leu Val Leu Thr Gln  
 1 5 10 15

Ala Pro Ala Ala Leu Ala Asp Asp Leu Lys Glu Asp Ser Ser Glu Asp  
 20 25 30

Arg Ala Phe Arg Val Arg Ile Gly Ala Ala Gln Leu Arg Gly Val Leu  
 35 40 45

Gly Gly Ala Leu Ala Ile Pro Cys His Val His His Leu Arg Pro Pro  
 50 55 60

Arg Ser Arg Arg Ala Ala Pro Gly Phe Pro Arg Val Lys Trp Thr Phe  
 65 70 75 80

Leu Ser Gly Asp Arg Glu Val Glu Val Leu Val Ala Arg Gly Leu Arg  
 85 90 95

Val Lys Val Asn Glu Ala Tyr Arg Phe Arg Val Ala Leu Pro Ala Tyr  
 100 105 110

Pro Ala Ser Leu Thr Asp Val Ser Leu Val Leu Ser Glu Leu Arg Pro  
 115 120 125

Asn Asp Ser Gly Val Tyr Arg Cys Glu Val Gln His Gly Ile Asp Asp  
 130 135 140

Ser Ser Asp Ala Val Glu Val Lys Val Lys Gly Val Val Phe Leu Tyr  
 145 150 155 160

Arg Glu Gly Ser Ala Arg Tyr Ala Phe Ser Phe Ala Gly Ala Gln Glu  
 165 170 175

Ala Cys Ala Arg Ile Gly Ala Arg Ile Ala Thr Pro Glu Gln Leu Tyr  
 180 185 190

Ala Ala Tyr Leu Gly Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu Ser

70

195	200	205
Asp Gln Thr Val Arg Tyr Pro Ile Gln Asn Pro Arg Glu Ala Cys Ser		
210	215	220
Gly Asp Met Asp Gly Tyr Pro Gly Val Arg Asn Tyr Gly Val Val Gly		
225	230	235 240
Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn Gly		
245	250	255
Glu Leu Phe Leu Gly Ala Pro Pro Ser Lys Leu Thr Trp Glu Glu Ala		
260	265	270
Arg Asp Tyr Cys Leu Glu Arg Gly Ala Gln Ile Ala Ser Thr Gly Gln		
275	280	285
Leu Tyr Ala Ala Trp Asn Gly Gly Leu Asp Arg Cys Ser Pro Gly Trp		
290	295	300
Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Ile Thr Pro Ser Gln Arg		
305	310	315 320
Cys Gly Gly Gly Leu Pro Gly Val Lys Thr Leu Phe Leu Phe Pro Asn		
325	330	335
Gln Thr Gly Phe Pro Ser Lys Gln Asn Arg Phe Asn Val Tyr Cys Phe		
340	345	350
Arg Asp Ser Ala His Pro Ser Ala Ser Ser Glu Ala Ser Ser Pro Ala		
355	360	365
Ser Asp Gly Leu Glu Ala Ile Val Thr Val Thr Glu Lys Leu Glu Glu		
370	375	380
Leu Gln Leu Pro Gln Glu Ala Met Glu Ser Glu Ser Arg Gly Ala Ile		
385	390	395 400
Tyr Ser Ile Pro Ile Ser Glu Asp Gly Gly Gly Gly Ser Ser Thr Pro		
405	410	415
Glu Asp Pro Ala Glu Ala Pro Arg Thr Pro Leu Glu Ser Glu Thr Gln		
420	425	430
Ser Ile Ala Pro Pro Thr Glu Ser Ser Glu Glu Glu Gly Val Ala Leu		
435	440	445
Glu Glu Glu Glu Arg Phe Lys Asp Leu Glu Ala Leu Glu Glu Glu Lys		

450                      455                      460  
 Glu Gln Glu Asp Leu Trp Val Trp Pro Arg Glu Leu Ser Ser Pro Leu  
 465                      470                      475                      480  
 Pro Thr Gly Ser Glu Thr Glu His Ser Leu Ser Gln Val Ser Pro Pro  
                     485                      490                      495  
 Ala Gln Ala Val Leu Gln Leu Asp Ala Ser Pro Ser Pro Gly Pro Pro  
                     500                      505                      510  
 Arg Phe Arg Gly Pro Pro Ala Glu Thr Leu Leu Pro Pro Arg Glu Trp  
                     515                      520                      525  
 Ser Ala Thr Ser Thr Pro Gly Gly Ala Arg Glu Val Gly Gly Glu Thr  
                     530                      535                      540  
 Gly Ser Pro Glu Leu Ser Gly Val Pro Arg Glu Ser Glu Glu Ala Gly  
 545                      550                      555                      560  
 Ser Ser Ser Leu Glu Asp Gly Pro Ser Leu Leu Pro Ala Thr Trp Ala  
                     565                      570                      575  
 Pro Val Gly Pro Arg Glu Leu Glu Thr Pro Ser Glu Glu Lys Ser Gly  
                     580                      585                      590  
 Arg Thr Val Leu Ala Gly Thr Ser Val Gln Ala Gln Pro Val Leu Pro  
                     595                      600                      605  
 Thr Asp Ser Ala Ser His Gly Gly Val Ala Val Ala Pro Ser Ser Gly  
                     610                      615                      620  
 Asp Cys Ile Pro Ser Pro Cys His Asn Gly Gly Thr Cys Leu Glu Glu  
 625                      630                      635                      640  
 Lys Glu Gly Phe Arg Cys Leu Cys Leu Pro Gly Tyr Gly Gly Asp Leu  
                     645                      650                      655  
 Cys Asp Val Gly Leu His Phe Cys Ser Pro Gly Trp Glu Ala Phe Gln  
                     660                      665                      670  
 Gly Ala Cys Tyr Lys His Phe Ser Thr Arg Arg Ser Trp Glu Glu Ala  
                     675                      680                      685  
 Glu Ser Gln Cys Arg Ala Leu Gly Ala His Leu Thr Ser Ile Cys Thr  
                     690                      695                      700  
 Pro Glu Glu Gln Asp Phe Val Asn Asp Arg Tyr Arg Glu Tyr Gln Trp

705                      710                      715                      720  
 Ile Gly Leu Asn Asp Arg Thr Ile Glu Gly Asp Phe Leu Trp Ser Asp  
                          725                      730                      735  
 Gly Ala Pro Leu Leu Tyr Glu Asn Trp Asn Pro Gly Gln Pro Asp Ser  
                          740                      745                      750  
 Tyr Phe Leu Ser Gly Glu Asn Cys Val Val Met Val Trp His Asp Gln  
                          755                      760                      765  
 Gly Gln Trp Ser Asp Val Pro Cys Asn Tyr His Leu Ser Tyr Thr Cys  
                          770                      775                      780  
 Lys Met Gly Leu Val Ser Cys Gly Pro Pro Pro Gln Leu Pro Leu Ala  
 785                      790                      795                      800  
 Gln Ile Phe Gly Arg Pro Arg Leu Arg Tyr Ala Val Asp Thr Val Leu  
                          805                      810                      815  
 Arg Tyr Arg Cys Arg Asp Gly Leu Ala Gln Arg Asn Leu Pro Leu Ile  
                          820                      825                      830  
 Arg Cys Gln Glu Asn Gly Leu Trp Glu Ala Pro Gln Ile Ser Cys Val  
                          835                      840                      845  
 Pro Arg Arg Pro Gly Arg Ala Leu Arg Ser Met Asp Ala Pro Glu Gly  
                          850                      855                      860  
 Pro Arg Gly Gln Leu Ser Arg His Arg Lys Ala Pro Leu Thr Pro Pro  
 865                      870                      875                      880  
 Ser Ser Leu

&lt;210&gt; 73

&lt;211&gt; 3153

&lt;212&gt; DNA

&lt;213&gt; Mus sp.

&lt;400&gt; 73

gaggctcccg gcgagctggc gcccctgtct gggctccgcg cggccggccc tgctcgcgcc 60  
 cgcgcacgc gccgcagtct cggctctgcgg ctgcgggacg tgacggcgtg cgcggagggg 120  
 acctcgcaag ttcttccatc agtgtgcaga atgataccac tgcttctgtc cctgctggcc 180  
 gctctgggtc tgacccaagc ccctgccgcc ctgcgtgatg acctgaaaga agacagctcg 240  
 gaggatcgag ccttcgcgt gcgcacggt gccgcgcagc tgcggggcgt gctgggcggt 300  
 gccctggcca tcccatgcca cgtccaccac ctgcggccgc cgcgcagccg ccgggcccgc 360

```

ccgggttttc cccgggtcaa gtggaccttc ctgtccgggg accgggaggt agagggtctg 420
gtggctcgcg ggctgcgct caaggtaaac gaagcctacc ggttccgctg ggcgctgcct 480
gcctaccccg catcgctcac ggatgtgtct ctagtattga gcgaactgcg gcccaatgat 540
tccgggggtct atcgctgcga ggtccagcac ggtatcgacg acagcagtga tgctgtggag 600
gtcaagggtca aaggggtcgt ctctctctac agagaggggt ctgcgcgcta tgctttctcc 660
ttcgctggag cccaggaagc ctgcgctcgc ataggagccc gaatcgccac cccggagcag 720
ctctatgtcg cctacctcgg cggctatgag cagtgtgatg caggctggct gtccgaccaa 780
actgtgaggt accccatcca gaaccacga gaggcctgct ctggagacat ggatggctat 840
cctggcgtgc ggaactacgg agtgggtgggt cctgatgatc tctatgatgt ctactgttat 900
gccgaagacc taaatggaga actgttccta ggcgcccctc ccagcaagct gacatgggag 960
gaggctcggg actactgtct ggaacgtggt gcacagatcg ctacacagc ccagctgtac 1020
gcagcctgga atggtggcct ggacagatgt agccctggct ggctggctga tggcagcgtg 1080
cgctatccca tcatcacacc cagccaacgc tgtgggggcg gcctgccagg agtcaagacc 1140
ctcttctctt tcccaacca gactggcttc cccagcaagc agaaccgctt caatgtctac 1200
tgcttccgag actctgccc tccctctgct tctctgagg cctctagccc agcctcagat 1260
ggacttgagg ccattgtcac agtgacagaa aagctggagg aactgcagct gcctcaggaa 1320
gcgatggaga gcgagtctcg tggggccatc tactccatcc ccatctcaga agatggggga 1380
ggaggaagct ccacccaga agaccagca gagccccca ggactccgct agaatcgga 1440
acccaatcca ttgcaccacc taccgagtc tcalaagagg aaggcgtagc cctggaggaa 1500
gaagaagat tcaaagactt ggaggctctg gaggaagaga aggagcagga ggacctgtg 1560
gtgtggccca gagagctcag cagccctctc cctactggct cagaaacaga gcattcactc 1620
tcccaggtgt cccaccagc ccaggcagtt ctacagctgg atgcgtcacc ttctcctggg 1680
cctccaaggt tccgtggacc gcctgcagag actttgctcc ccccgaggga gtggagcgcc 1740
acatctactc ctggtggggc aagagaagta gggggggaaa ctgggagccc tgagctctct 1800
ggggttcctc gagagagcga ggaggcaggg agctccagct tggaggatgg cccttcccta 1860
cttccagcta catgggccc tgtgggtccc agggagctgg agacccctc agaagagaag 1920
tctggaagaa ctgtcctggc aggcacctca gtgcaggccc agccagtgtg gccaccgac 1980
agtgccagcc acggtggagt ggctgtggct ccctcatcag gtgactgtat cccagcccc 2040
tgccacaatg gtgggacatg cttggaggag aaggagggtt tccgctgcct atgtttgcca 2100
ggctatgggg gggacctgtg cgatgttggc cttcatttct gcagccctgg ctgggaggcc 2160
ttccaggagg cctgtctaaa gcacttttcc acacgaagga gttgggagga ggcagaaagt 2220
cagtgccgag cgctaggtgc tcatctgacc agcatctgca ccctgagga gcaagacttt 2280
gtcaatgatc gataccggga gtaccagtgg attgggtcga atgacaggac catcgagggt 2340
gacttcttgt ggtcagatgg tgcccctctg ctctatgaaa actggaacct tgggcagcct 2400
gacagctact tctgtctgg ggagaactgt gtggtcatgg tgtggcatga ccagggacag 2460
tggagtgatg tgccctgcaa ctaccatcta tctacacct gcaagatggg gcttgtgtcc 2520
tgtgggctc caccacagct acccctggct caaatatttg gtcgcccctg gctgcgtac 2580
gcggtggata ctgtgcttcg atatcgatgc cgagacgggc tggctcagcg caacctgccg 2640
ttgatccgct gccaggagaa tgggctttgg gaggcccctc agatttctg tgtaccccg 2700
aggcctggcc gtgctctgcg ctccatggac gcccagaag gaccacggg acagctctcg 2760
aggcacagga aggcaccgtt gacaccgccc tccagtctct agggagcctg gaagactgtc 2820
gccccagca ggacctctc acatcaactg ccagtgtctc tccccatgat agggggtgac 2880
gtgagagggg tgggactgaa attcagagga cagcgctcga aggggtttct gggaaacact 2940
tgggtggctc cggccctca cacaagggcc tcaggtttta cccggtaagt ccctaagtc 3000
ctcaactgcc ctctcatgtc agctgcctcc ttgtccctcg atntcgtgagg gggacactgt 3060
gctattcgat cttgattgtc gaagagtttt taggatggag taccagcaaa accaggtgga 3120
aataaagttg tctgaacca aagaaaaaa aaa 3153

```

<210> 74  
<400> 74  
000

<210> 75  
<400> 75  
000

<210> 76  
<400> 76  
000

<210> 77  
<400> 77  
000

<210> 78  
<400> 78  
000

<210> 79  
<400> 79  
000

<210> 80  
<400> 80  
000

<210> 81  
<211> 2002  
<212> DNA  
<213> Gerbil

<400> 81  
gtcgaaccac gcgtccgctg cgttctcacc cctggaccac cctgggagaa cagttgaccg 60  
aagtttgttt ggcagttget gctggactat gtttctgctt ctggtggtac tcagccagct 120  
gcccagactt accctcgagg ttccctcatac aagaagccta aagaattctg aacatgcccc 180  
agaaggagtc tttgcatcaa aaaaagcagc aagcatcttt atgcaccgtc gcctcctata 240  
caatagattt gatttagaac tcttcaactcc cgggaacctg gagagagagt gctatgagga 300  
gttctgtagt tatgaagaag ccagagagat cctcggggac aacgaagaaa tgatcacatt 360

```

ctggcgggaa tattcagtca aaggaccaac cacaagatca gatgtcaaca aagagaaaaat 420
tgatgttatg ggccttctga ctggcttaat tgcggctgga gtattcttgg ttgtttttgg 480
cttacttggt tactatctgt gtatcaccaa gtgtaatagg cagccatatac aaggttcttc 540
agctgtctac acaagaagga ccaggcacac accgtccatc attttcagaa cccatgagga 600
agctgtcttg tctccatcgt catcctcaga ggacgcggga ctaccttctt atgaacaggc 660
agtagctctg accagaaaac acagtgtctc accaccacct ccatatcctg ggccagcaaa 720
aggatttagg gtatttaaaa agtcaatgtc actcccatct cactaagccc accttgccgc 780
cttgctgtgg tctgaataat atgttcttcc tgaaacaaca acaacaaaaa aatttgccctg 840
ttcagctttt tatgacaaaag cacaaggaat aaaggaacac tatatacaga acagaattca 900
ccacagcccc gctttcagct ctgcccccaa ctggattgct gtcttggtta gagacttcta 960
ccgtgctttc tcgaagttaa gaagaaagtg cctttttgca atgtaaaactg tactggttca 1020
aacattcttg ctacagctag gtacctataa tccccacctt caggagactt aggcgggagg 1080
gatgagagtt caaggccagc ctggggccctg tcaggacgct gtctcaaaac aaagtgtgtt 1140
atcaatagaa taattagaat taacaaacta ggattttcag tcttaagtca tgatattgga 1200
tcttctcttc agtaagggtt ctttttggct agaaatactt catagaattt gacattttgg 1260
tatacatctg tggccttgat acaatgactt gattttctgt ttaattagt gcagaggatt 1320
cagcaaattt gcaggcttct attttgctcc ctgcctatcc atcgatcatg tttcagtgtg 1380
ttaagaggag tcagccaggc gtggtggccc acacctgtga tcccagcact taggggggca 1440
taggcaggca gatctctgtg agctgaagga cagcctggcc tacaaagtcc aggacaaccg 1500
agaccacaca gaaaaacctt gtcttgaaaa acaaaacaaa aacaagagag agagagagag 1560
agagagaaaa gagatgtcaa gaggtttttg tttttttttt tttaaattac tatttatggg 1620
cctcacttgg aaaaagtgtt gccatgcaaa tagaaggaca ggagttcaat cctcattacc 1680
cacatttgaa acaataaaca agaaaaacaa accaaaaaac caaaacaaac aaaaatcttg 1740
gaacttgagt gaataccggt aacctcaggg ctaggcactg taactgaatc aggagcctcc 1800
agatccaggg aaacgtgtc tcaacaaata aataaataag taagtcatg aggtggtctt 1860
taaaccagc acttgagagc caaaggcagg cagagctcag tgagttggag accagcctgg 1920
tctacaaagc aagttctaag ggagccaggg cacagagaaa ccctgtctga aggaaaaaaa 1980
aaaaaaaaaa aagggcggcc gc
2002

```

<210> 82  
<211> 675  
<212> DNA  
<213> Gerbil

```

<400> 82
atgtttctgc ttctggtggt actcagccag ctgcccagac ttaccctcgc ggttctcat 60
acaagaagcc taaagaattc tgaacatgcc ccagaaggag tctttgcatc aaaaaaagca 120
gcaagcatct ttatgcaccg tcgcctccta tacaatagat ttgatttaga actcttctact 180
cccgggaacc tggagagaga gtgctatgag gagttctgta gttatgaaga agccagagag 240
atcctcgggg acaacgaaga aatgatcaca ttctggcggg aatattcagt caaaggacca 300
accacaagat cagatgtcaa caaagagaaa attgatgtta tgggccttct gactggctta 360
attgcggctg gagtattctt ggttggtttt ggcttacttg gttactatct gtgtatcacc 420
aagtgtataa ggcagccata tcaaggttct tcagctgtct acacaagaag gaccaggcac 480
acaccgtcca tcattttcag aacccatgag gaagctgtct tgtctccatc gtcatectca 540
gaggacggg gactaccttc ctatgaacag gcagtagctc tgaccagaaa acacagtgtc 600
tcaccaccac ctccatctcc tgggccagca aaaggattta gggattttaa aaagtcaatg 660
tcaactcccat ctcac
675

```

<210> 83  
 <211> 225  
 <212> PRT  
 <213> Gerbil

<400> 83

Met Phe Leu Leu Val Val Leu Ser Gln Leu Pro Arg Leu Thr Leu  
 1 5 10 15

Ala Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu  
 20 25 30

Gly Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg  
 35 40 45

Leu Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu  
 50 55 60

Glu Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu  
 65 70 75 80

Ile Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser  
 85 90 95

Val Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp  
 100 105 110

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val  
 115 120 125

Val Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg  
 130 135 140

Gln Pro Tyr Gln Gly Ser Ser Ala Val Tyr Thr Arg Arg Thr Arg His  
 145 150 155 160

Thr Pro Ser Ile Ile Phe Arg Thr His Glu Glu Ala Val Leu Ser Pro  
 165 170 175

Ser Ser Ser Ser Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val  
 180 185 190

Ala Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Tyr Pro Gly  
 195 200 205

Pro Ala Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser

210

215

220

His  
225<210> 84  
<211> 17  
<212> PRT  
<213> Gerbil<400> 84  
Met Phe Leu Leu Leu Val Val Leu Ser Gln Leu Pro Arg Leu Thr Leu  
1 5 10 15

Ala

<210> 85  
<211> 208  
<212> PRT  
<213> Gerbil<400> 85  
Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu Gly  
1 5 10 15Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg Leu  
20 25 30Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu Glu  
35 40 45Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu Ile  
50 55 60Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser Val  
65 70 75 80Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp Val  
85 90 95Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val Val  
100 105 110Phe Gly Leu Leu Gly Tyr Tyr Leu Cys Ile Thr Lys Cys Asn Arg Gln  
115 120 125

78

Pro Tyr Gln Gly Ser Ser Ala Val Tyr Thr Arg Arg Thr Arg His Thr  
130 135 140

Pro Ser Ile Ile Phe Arg Thr His Glu Glu Ala Val Leu Ser Pro Ser  
145 150 155 160

Ser Ser Ser Glu Asp Ala Gly Leu Pro Ser Tyr Glu Gln Ala Val Ala  
165 170 175

Leu Thr Arg Lys His Ser Val Ser Pro Pro Pro Tyr Pro Gly Pro  
180 185 190

Ala Lys Gly Phe Arg Val Phe Lys Lys Ser Met Ser Leu Pro Ser His  
195 200 205

<210> 86

<211> 95

<212> PRT

<213> Gerbil

<400> 86

Val Pro His Thr Arg Ser Leu Lys Asn Ser Glu His Ala Pro Glu Gly  
1 5 10 15

Val Phe Ala Ser Lys Lys Ala Ala Ser Ile Phe Met His Arg Arg Leu  
20 25 30

Leu Tyr Asn Arg Phe Asp Leu Glu Leu Phe Thr Pro Gly Asn Leu Glu  
35 40 45

Arg Glu Cys Tyr Glu Glu Phe Cys Ser Tyr Glu Glu Ala Arg Glu Ile  
50 55 60

Leu Gly Asp Asn Glu Glu Met Ile Thr Phe Trp Arg Glu Tyr Ser Val  
65 70 75 80

Lys Gly Pro Thr Thr Arg Ser Asp Val Asn Lys Glu Lys Ile Asp  
85 90 95

<210> 87

<211> 25

<212> PRT

&lt;213&gt; Gerbil

&lt;400&gt; 87

Val Met Gly Leu Leu Thr Gly Leu Ile Ala Ala Gly Val Phe Leu Val  
 1 5 10 15

Val Phe Gly Leu Leu Gly Tyr Tyr Leu  
 20 25

&lt;210&gt; 88

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Gerbil

&lt;400&gt; 88

Cys Ile Thr Lys Cys Asn Arg Gln Pro Tyr Gln Gly Ser Ser Ala Val  
 1 5 10 15

Tyr Thr Arg Arg Thr Arg His Thr Pro Ser Ile Ile Phe Arg Thr His  
 20 25 30

Glu Glu Ala Val Leu Ser Pro Ser Ser Ser Ser Glu Asp Ala Gly Leu  
 35 40 45

Pro Ser Tyr Glu Gln Ala Val Ala Leu Thr Arg Lys His Ser Val Ser  
 50 55 60

Pro Pro Pro Pro Tyr Pro Gly Pro Ala Lys Gly Phe Arg Val Phe Lys  
 65 70 75 80

Lys Ser Met Ser Leu Pro Ser His  
 85

&lt;210&gt; 89

&lt;400&gt; 89

000

&lt;210&gt; 90

&lt;400&gt; 90

000

&lt;210&gt; 91

&lt;400&gt; 91

000

<210> 92  
 <211> 962  
 <212> DNA  
 <213> Mus sp.

<400> 92  
 ccgtttctct ttaaccactt gcacggtctg gggttaaccc gcctgcggac tctggacctc 60  
 tcctccaact ggctgaaaca tatctccatc cctgagttgg ctgcactgcc aacttatctc 120  
 aagaacaggc tctacctgca caacaaccgc ctgccctgtg actgcagcct ctaccacctg 180  
 ctccggcgct ggcaccagcg gggcctgagt gccctgcatg attttgaacg cgagtacaça 240  
 tgettgtct ttaaggtgtc agagtcccg gtgcgctttt ttgagcacag ccgggtcttc 300  
 aagaactgct ctgtggctgc agctccaggc ttagagctgc ctgaagagca gctgcacgcg 360  
 caggtggggc agtccctgag gctcttctgc aacaccagtg tgcctgccac tcgggtggcc 420  
 tgggtctccc cgaagaatga gctgcttggt gcgccagcct ctccagatgg tagcatcgct 480  
 gtgttggtg atggcagctt agccataggc aggggtgcaag agcagcacgc aggcgtcttt 540  
 gtgtgcctgg ccagtgggcc ccgcctgcac cacaaccaga cacttgagta caatgtgagt 600  
 gtgcaaaagg ctgcgcccg gccagagact ttcaacacag gctttaccac cctgctgggc 660  
 tgtattgtgg gcctggtgct ggtgtgtgct tacttggttg caccaccctg tcgtggctgc 720  
 tgtcactgct gtcagcgggc ctgccgcaac cgctgctggc cccgggcctc cagtccactc 780  
 caggagctga gcgcacagtc ctccatgctt agcactacgc caccagatgc acccagccgc 840  
 aaggccagtg tccacaagca tgtggtcttc ctggagccgg gcaagaaggg cctcaatggc 900  
 cgtgtgcagc tcgcagtacc tccagactcc gatctgtgca accccatggg cttgcaactc 960  
 aa 962

<210> 93  
 <211> 320  
 <212> PRT  
 <213> Mus sp.

<400> 93  
 Pro Phe Leu Phe Asn His Leu His Gly Leu Gly Leu Thr Arg Leu Arg  
 1 5 10 15  
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu  
 20 25 30  
 Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn  
 35 40 45  
 Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp  
 50 55 60  
 His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr  
 65 70 75 80

82

<210> 94  
 <211> 16  
 <212> PRT  
 <213> Mus sp.

<400> 94  
 Pro Phe Leu Phe Asn His Leu His Gly Leu Gly Leu Thr Arg Leu Arg  
 1 5 10 15

<210> 95  
 <211> 304  
 <212> PRT  
 <213> Mus sp.

<400> 95  
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu  
 1 5 10 15

Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn  
 20 25 30

Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp  
 35 40 45

His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr  
 50 55 60

Cys Leu Val Phe Lys Val Ser Glu Ser Arg Val Arg Phe Phe Glu His  
 65 70 75 80

Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu  
 85 90 95

Leu Pro Glu Glu Gln Leu His Ala Gln Val Gly Gln Ser Leu Arg Leu  
 100 105 110

Phe Cys Asn Thr Ser Val Pro Ala Thr Arg Val Ala Trp Val Ser Pro  
 115 120 125

Lys Asn Glu Leu Leu Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala  
 130 135 140

Val Leu Ala Asp Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His  
 145 150 155 160

Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn

	165		170		175
Gln Thr Leu Glu Tyr Asn Val Ser Val Gln Lys Ala Arg Pro Glu Pro					
	180		185		190
Glu Thr Phe Asn Thr Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly					
	195		200		205
Leu Val Leu Val Leu Leu Tyr Leu Phe Ala Pro Pro Cys Arg Gly Cys					
	210		215		220
Cys His Cys Cys Gln Arg Ala Cys Arg Asn Arg Cys Trp Pro Arg Ala					
	225		230		235
					240
Ser Ser Pro Leu Gln Glu Leu Ser Ala Gln Ser Ser Met Leu Ser Thr					
	245		250		255
Thr Pro Pro Asp Ala Pro Ser Arg Lys Ala Ser Val His Lys His Val					
	260		265		270
Val Phe Leu Glu Pro Gly Lys Lys Gly Leu Asn Gly Arg Val Gln Leu					
	275		280		285
Ala Val Pro Pro Asp Ser Asp Leu Cys Asn Pro Met Gly Leu Gln Leu					
	290		295		300

<210> 96  
 <211> 197  
 <212> PRT  
 <213> Mus sp.

<400> 96  
 Thr Leu Asp Leu Ser Ser Asn Trp Leu Lys His Ile Ser Ile Pro Glu  
 1 5 10 15  
 Leu Ala Ala Leu Pro Thr Tyr Leu Lys Asn Arg Leu Tyr Leu His Asn  
 20 25 30  
 Asn Pro Leu Pro Cys Asp Cys Ser Leu Tyr His Leu Leu Arg Arg Trp  
 35 40 45  
 His Gln Arg Gly Leu Ser Ala Leu His Asp Phe Glu Arg Glu Tyr Thr  
 50 55 60

Cys Leu Val Phe Lys Val Ser Glu Ser Arg Val Arg Phe Phe Glu His  
 65 70 75 80

Ser Arg Val Phe Lys Asn Cys Ser Val Ala Ala Ala Pro Gly Leu Glu  
 85 90 95

Leu Pro Glu Glu Gln Leu His Ala Gln Val Gly Gln Ser Leu Arg Leu  
 100 105 110

Phe Cys Asn Thr Ser Val Pro Ala Thr Arg Val Ala Trp Val Ser Pro  
 115 120 125

Lys Asn Glu Leu Leu Val Ala Pro Ala Ser Gln Asp Gly Ser Ile Ala  
 130 135 140

Val Leu Ala Asp Gly Ser Leu Ala Ile Gly Arg Val Gln Glu Gln His  
 145 150 155 160

Ala Gly Val Phe Val Cys Leu Ala Ser Gly Pro Arg Leu His His Asn  
 165 170 175

Gln Thr Leu Glu Tyr Asn Val Ser Val Gln Lys Ala Arg Pro Glu Pro  
 180 185 190

Glu Thr Phe Asn Thr  
 195

<210> 97

<211> 20

<212> PRT

<213> Mus sp.

<400> 97

Gly Phe Thr Thr Leu Leu Gly Cys Ile Val Gly Leu Val Leu Val Leu  
 1 5 10 15

Leu Tyr Leu Phe  
 20

<210> 98

<211> 87

<212> PRT

<213> Mus sp.

<400> 98

Ala Pro Pro Cys Arg Gly Cys Cys His Cys Cys Gln Arg Ala Cys Arg

<400> 100  
cctcctgatt acctacaatg gtc 23

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**